{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "152fc90a",
   "metadata": {},
   "source": [
    "## Questions for Ahmad:\n",
    "\n",
    "- What is the best way to store and process large amounts of text data?\n",
    "    - how to amalgamate the different stored files\n",
    "    - what should my approach be (work on work corpus first?) because different data have different royalty rates\n",
    "    \n",
    "- Goal is to study royaltyrate (a continuous variable) from text data\n",
    "- Validate current methods (NER & Text summarisation) to extract relavent features and then predict royalty rate\n",
    "    - NER on BERT : **location (LOC)**, **organizations (ORG)**, person (PER) and Miscellaneous (MISC) (https://huggingface.co/dslim/bert-base-NER)\n",
    "    - Legal BERT: (https://huggingface.co/nlpaueb/legal-bert-base-uncased)\n",
    "    - Text Summarisation: 16k token count limit, seems plenty (https://huggingface.co/nsi319/legal-led-base-16384)\n",
    "    - topic segmentation/clustering\n",
    "- Otherwise, what steps would you suggest? \n",
    "    - traditional models?\n",
    "    - specific forms of data cleaning (lack of legal domain)\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "02d2f672",
   "metadata": {},
   "source": [
    "- **Summarisation:**\n",
    "    - document is organised in chunks, which can already provide us with a good structure/flow\n",
    "    - \n",
    "\n",
    "- **NER:**\n",
    "    - extract informations like \n",
    "        - 1) lisensor 2) lisensee 3) date of trasaction\n",
    "\n",
    "- **Features for Predicting Royalty Rates**:\n",
    "    - Sales Periods: Differentiate rates based on the stage of the product (Beta Testing, Initial Launch, Secondary Launch, Extension Periods).\n",
    "    - Net Sales: Net Sales can directly influence the royalty rate based on brackets (1st 1 million, 2nd 1 million, above 2 million).\n",
    "    - Minimum Amounts: These are the royalty floors for various periods.\n",
    "    - Patent Status: Depending on the jurisdiction and IP considerations, the royalty rate can change (e.g., 50% reduction).\n",
    "    - Sub-licensing: If sublicensing occurs, royalty needs to be considered.\n",
    "    - Competing or Next-Generation Products: Could lead to renegotiation or changes in royalty rates. "
   ]
  },
  {
   "cell_type": "markdown",
   "id": "347d6059",
   "metadata": {},
   "source": [
    "**Summarised Royalty rate segment:**\n",
    "The paragraph details the royalty agreement between a Licensor and Licensee for Covered Products. The Licensee must pay royalties to the Licensor starting from the Covered Product Launch Date, with rates and terms described in specific sections. There are various phases such as Beta Testing, Initial Launch, Secondary Launch, and Extension Periods, each with its own Minimum Amount of royalty. Net Sales Brackets are defined with rates of 20%, 15%, and 10%. Sales in jurisdictions without patent recognition are subject to a 50% reduced royalty rate. Royalties are to be paid quarterly in US dollars. The Licensee must maintain records for verification and has the right to sublicense. If the Licensor develops a competing product, the Licensee has a right of first negotiation. If the Licensee fails to maintain the Minimum Amounts, they may rectify this in the last report of the applicable period to maintain their license rights.\n",
    "\n",
    "**Extracted Features of Interest:**\n",
    "- Sales Periods:\n",
    "\n",
    "        Beta Testing\n",
    "        Initial Launch\n",
    "        Secondary Launch\n",
    "        Extension Periods\n",
    "        \n",
    "- **Net Sales:**\n",
    "\n",
    "        Defined with rates based on Net Sales Brackets\n",
    "        20% for the 1st 1 million\n",
    "        15% for the 2nd 1 million\n",
    "        10% for above 2 million\n",
    "        \n",
    "- **Minimum Amounts:**\n",
    "\n",
    "        Different for each phase (though exact amounts are not provided in the summary)\n",
    "- **Patent Status:**\n",
    "\n",
    "        Sales in jurisdictions without patent recognition are subject to a 50% reduced royalty rate.\n",
    "- **Sub-licensing:**\n",
    "\n",
    "        The Licensee has the right to sublicense.\n",
    "- **Competing or Next-Generation Products:**\n",
    "\n",
    "        If the Licensor develops a competing product, the Licensee has a right of first negotiation  ."
   ]
  },
  {
   "cell_type": "markdown",
   "id": "8c06567c",
   "metadata": {},
   "source": [
    "### Concerns\n",
    "\n",
    "- each agreement is structured differently\n",
    "- large amounts of data (which can be good but not sure if my processing can handle them)\n",
    "- many different segments, lack knowledge on which features to keep or pay attention to\n",
    "\n",
    "### Notes:\n",
    "\n",
    "- Bin the royaltyrate\n",
    "\n",
    "- EDA of corpus (tokens)\n",
    "- ReGeX\n",
    "- function to read in data (tokens)\n",
    "- vector databases\n",
    "\n",
    "- LLM (langchain)\n",
    "- Claude 2 (feature engineering) \n",
    "\n",
    "ahmad.ammari@unimelb.edu.au"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "3911da35",
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "from docx import Document"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "f90745fe",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Top of Form\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "                                                                    EXHIBIT 10.2\n",
      "\n",
      "                                LICENSE AGREEMENT\n",
      "                                -----------------\n",
      "\n",
      "         This LICENSE AGREEMENT (\"Agreement\") is made this 30th day of March,\n",
      "2006 by and between AzurTec, Inc. (\"AzurTec\" or the \"Licensor\"), a Pennsylvania\n",
      "corporation, and PhotoMedex, Inc. (\"PHMD\" or the \"Licensee\"), a Delaware\n",
      "corporation.\n",
      "\n",
      "                                   WITNESSETH:\n",
      "                                   ----------\n",
      "\n",
      "         WHEREAS, PHMD and AzurTec are parties to that certain Investment\n",
      "Agreement (the \"Investment Agreement\"), that certain Security Agreement (the\n",
      "\"Security Agreement\") and that certain Development Agreement (the \"Development\n",
      "Agreement\"), as amended, all of even date herewith;\n",
      "\n",
      "         WHEREAS, pursuant to the Investment Agreement, PHMD and AzurTec have\n",
      "agreed to enter into this License Agreement.\n",
      "\n",
      "         NOW, THEREFORE, in consideration of the premises and covenants herein\n",
      "contained and intending to be legally bound hereby, the parties hereto agree as\n",
      "follows:\n",
      "\n",
      "         1.       Definitions. Unless otherwise defined herein, capitalized\n",
      "                  -----------\n",
      "terms used herein shall have the meanings set forth in the Investment Agreement.\n",
      "\n",
      "                  (a)      \"Adjunctive Use\" is defined in Section 2(c).\n",
      "\n",
      "                  (b)      \"AzurTec IP\" shall mean the intellectual property\n",
      "rights owned by AzurTec and described on Schedule 1(b) attached hereto and made\n",
      "a part hereof.\n",
      "\n",
      "                  (c)      \"Beta-Testing Period\" is defined in Section 3(b)(i).\n",
      "\n",
      "                  (d)      \"Covered Product Launch Date\" is defined in\n",
      "Section 3(b)(i).\n",
      "\n",
      "                  (e)      \"Covered Products\" shall mean Licensors existing MLS\n",
      "System and any and all modifications or improvements thereof, whether developed\n",
      "by Licensor or Licensee, and any further or related technology which is covered\n",
      "in whole or in part by any issued, unexpired claim or a pending claim contained\n",
      "in the Patent Rights.\n",
      "\n",
      "                  (f)      \"Development Agreement\" is defined in the foregoing\n",
      "preamble.\n",
      "\n",
      "                  (g)      \"Extension Period\" is defined in Section 3(b)(ii).\n",
      "\n",
      "                  (h)      \"Grantee\" is defined in Section 2(d).\n",
      "\n",
      "                  (i)      \"Indemnitor\" and \"Indemnitee\" shall have the meanings\n",
      "so ascribed in Section 7(d) hereof.\n",
      "\n",
      "\n",
      "\n",
      "                  (j)      \"Initial Launch Period\" is defined in\n",
      "Section 3(b)(ii).\n",
      "\n",
      "                  (k)      \"Investment Agreement\" is defined in the foregoing\n",
      "preamble.\n",
      "\n",
      "                  (l)      \"License\" is defined in the foregoing preamble.\n",
      "\n",
      "                  (m)      \"Licensee Affiliate\" shall mean any person or entity\n",
      "directly or indirectly controlling, controlled by or under common control with\n",
      "Licensee, including any person that is an officer, director or employee of any\n",
      "such entity. As used in this definition, \"controlling\" (including, with its\n",
      "correlative meanings, \"controlled by\" and \"under common control with\") means\n",
      "possession, directly or indirectly, of the power to have decisive influence on\n",
      "the voting of the Board of Directors or the decisions of the entitys management\n",
      "regardless of the quantity of stock or other equity interests owned in the\n",
      "entity.\n",
      "\n",
      "                  (n)      \"Minimum Amount\" is defined in Section 3(b)(iii)\n",
      "hereof.\n",
      "\n",
      "                  (o)      \"Net Sales\" means gross revenues actually received by\n",
      "Licensee or any Licensee Affiliate on account of the sale of a Covered Product\n",
      "to any customer of Licensee or of any Licensee Affiliate, including unaffiliated\n",
      "distributors of Licensee or any Licensee Affiliate, less the following amounts:\n",
      "\n",
      "                           (i)      reasonable and customary trade discounts and\n",
      "rebates, sales returns or allowances, costs of freight, insurance, and excise\n",
      "taxes (including without limitation value-added taxes) actually paid by Licensee\n",
      "or any Licensee Affiliate, reasonable and customary commissions actually paid to\n",
      "any person who is not a Licensee Affiliate, and reasonable costs and expenses of\n",
      "collection; and\n",
      "\n",
      "                           (ii)     the cost of that number of demonstration\n",
      "items of Covered Products that is reasonable and customary in the industry and\n",
      "that are transferred at no consideration to customers or potential customers,\n",
      "and revenues from sales of Covered Products by Licensee to Licensee Affiliates\n",
      "for resale to customers, to the same extent that such sales would or would not\n",
      "be recognized under generally accepted accounting principles;\n",
      "\n",
      "provided, however, that if Licensee or any Licensee Affiliate receives on a\n",
      "customers behalf an irrevocable letter of credit securing the customers\n",
      "purchase of a Covered Product from Licensee or any Licensee Affiliate and\n",
      "Licensee or such Licensee Affiliate discounts such letter of credit, then\n",
      "Licensee or such Licensee Affiliate shall upon such discounting be deemed to\n",
      "have received payment for Covered Products, and no deduction shall be allowed to\n",
      "Licensee or such Licensee Affiliate from Net Sales for any cost it may incur in\n",
      "discounting such letter of credit.\n",
      "\n",
      "                  (p)      \"Next-Generation Product\" is defined in Section 2(b).\n",
      "\n",
      "                  (q)      \"Patent Rights\" shall mean, collectively, all rights\n",
      "in and to US patent application serial no. 11/073845, and any subsequently filed\n",
      "US or foreign patent application(s) claiming priority to application serial no.\n",
      "11/073845, including without limitation, PCT applications and associated\n",
      "national phase applications and US utility patent applications claiming priority\n",
      "to such patent application, and each patent that issues or reissues from any of\n",
      "these patent applications.\n",
      "\n",
      "\n",
      "\n",
      "                  (r)      \"Quarter\" or \"Quarterly\" refers to the first, second,\n",
      "third or fourth consecutive three-month period within the Initial Launch Period,\n",
      "the Secondary Launch Period or any Extension Period.\n",
      "\n",
      "                  (s)      \"Secondary Launch Period\" is defined in\n",
      "Section 3(b)(ii).\n",
      "\n",
      "                  (t)      \"Security Agreement\" is defined in the foregoing\n",
      "preamble.\n",
      "\n",
      "                  (u)      \"Stand-Alone Use\" is defined in Section 2(c).\n",
      "\n",
      "         2.       Grant of Exclusive License.\n",
      "                  --------------------------\n",
      "\n",
      "                  (a)      Licensor hereby grants to Licensee a worldwide,\n",
      "royalty-bearing license in and to the AzurTec IP for use solely for applications\n",
      "related to ex-vivo biopsy tissue, and subject to the further limitations on use\n",
      "hereinafter set forth (the \"Licensed Rights\"). Pursuant to the License granted\n",
      "hereunder, Licensee shall have the rights to use, sell, make or have made and\n",
      "otherwise commercialize and exploit (including the right to advertise) the\n",
      "Licensed Rights over any and all medical, surgical or veterinary fields of use,\n",
      "all at its sole discretion. In the event that Licensee desires to assign this\n",
      "Agreement, it shall first obtain the written consent of Licensor, which consent\n",
      "Licensor shall not be unreasonably withheld or delayed. In the event that\n",
      "Licensee desires to sub-license any of its rights hereunder, it shall do so in\n",
      "accordance with Section 2(d). Licensee shall use its commercially reasonable\n",
      "efforts to bring one or more Covered Products to market through a diligent\n",
      "program for exploitation of the Licensed Rights and to continue active, diligent\n",
      "marketing efforts for one or more Covered Products throughout the life of this\n",
      "Agreement.\n",
      "\n",
      "                  (b)      During the term of this Agreement, neither Licensor\n",
      "nor any of its affiliates shall develop, use, market or sell any products which\n",
      "draw on technology which directly competes with Covered Products.\n",
      "Notwithstanding the foregoing of this Section 2(b), Licensor shall have the\n",
      "right, subject to Section 3(h), to commercialize a Covered Product which\n",
      "determines the presence or absence of cancerous cells in situ (a\n",
      "\"Next-Generation Product\"), and such right shall not be included in the Licensed\n",
      "Rights. Conversely, during the term of this Agreement, neither Licensee nor its\n",
      "affiliates shall market or sell any products which directly compete with Covered\n",
      "Products.\n",
      "\n",
      "                  (c)      Notwithstanding Section 2(a), and subject to Section\n",
      "2(b), Licensor reserves to itself the right to use the AzurTec IP, including\n",
      "without limitation the Patent Rights, for research conducted in furtherance or\n",
      "improvement of the AzurTec IP or in the conduct of clinical trials in\n",
      "furtherance of the AzurTec IP. Licensor and Licensee acknowledge that, under the\n",
      "terms of the Development Agreement, as amended, Licensor has agreed to fund and\n",
      "Licensee has agreed to conduct clinical trials to establish the right to market\n",
      "the use of Covered Products in the\n",
      "\n",
      "\n",
      "\n",
      "United States not only on an ex vivo adjunctive basis with instruments\n",
      "corroborating negative findings in tissue excised from the patient (the\n",
      "\"Adjunctive Use\"), but also on an ex vivo stand-alone basis without the\n",
      "necessity of such corroboration on negative findings as well as for the\n",
      "detection of squamous carcinomas in addition to basal carcinomas (the\n",
      "\"Stand-Alone Use\"). Licensee shall promptly disclose to Licensor any and all\n",
      "improvements or modifications to the Covered Products developed by or for\n",
      "Licensee during the term of this Agreement, all of which improvements and\n",
      "modifications, if developed at Licensors expense, shall be the property of\n",
      "Licensor included in the license of rights hereunder, and if such improvements\n",
      "or modifications were developed at Licensees expense, then they shall be the\n",
      "property of Licensee but shall be licensed back to Licensor on a worldwide,\n",
      "royalty-free, perpetual basis.\n",
      "\n",
      "                  (d)      If Licensee proposes to grant any third party (a\n",
      "\"Grantee\") rights (e.g. a sub-license) in the Licensed Rights under this\n",
      "License, Licensee shall:\n",
      "\n",
      "                           (i)      disclose to Licensor the identity of the\n",
      "proposed Grantee on or before the date on which such rights are proposed to be\n",
      "granted, and request Licensors written consent for the same, which consent\n",
      "Licensor shall not unreasonably withhold or delay; and\n",
      "\n",
      "                           (ii)     include in any agreement or document\n",
      "purporting to grant any such rights provisions which (A) set forth in language\n",
      "substantially identical to that set forth in this Agreement the existence and\n",
      "scope of Licensors rights in the Licensed Rights, including without limitation\n",
      "the right to receive royalties and reports of sales of Covered Products; and (B)\n",
      "require the Grantee, as a condition to any further assignment or sublicense by\n",
      "it of the rights proposed to be transferred by Licensee, to comply with the\n",
      "requirements of this Section 2(d).\n",
      "\n",
      "         If Licensee assigns or sub-licenses rights hereunder, Licensee shall\n",
      "not thereby be released from any of its obligations to Licensor hereunder,\n",
      "including without limitation the obligation to ensure that any permitted\n",
      "assignee or sub-licensee pays royalties and makes reports to Licensor as herein\n",
      "required. Any such permitted assignment or sub-license shall automatically\n",
      "terminate and be of no further force or effect if Licensor terminates this\n",
      "Agreement as hereinafter provided. In addition to royalties payable hereunder\n",
      "based on Net Sales, Licensee shall pay to Licensor an amount equal to 20% of the\n",
      "amount or amounts paid to Licensee or any Licensee Affiliate in connection with\n",
      "any permitted assignment or sub-license of the Licensed Rights, when and as\n",
      "Licensee or such Licensee Affiliate is paid by the assignee or sub-licensee and\n",
      "such payment shall be treated as a prepaid royalty to Licensor.\n",
      "\n",
      "                  (e)      Licensee shall have sole discretion to determine and\n",
      "implement marketing strategies for the Covered Products, subject only to the\n",
      "restrictions herein set forth. Licensee shall also have discretion to modify or\n",
      "improve the Covered Products, subject to the written consent of Licensor, which\n",
      "consent Licensor will not unreasonably withhold or delay.\n",
      "\n",
      "                  (f)      In the event that Licensor, as a result of its\n",
      "research and development work on the AzurTec IP for use of a Covered Product for\n",
      "in situ detection of cancerous cells, proposes to introduce a product for in\n",
      "situ detection, whether directly or indirectly, or through a business\n",
      "combination with a third party or any other means, then before introducing such\n",
      "product, Licensee shall have the first right of negotiation for such rights, as\n",
      "set forth in Section 3(h).\n",
      "\n",
      "\n",
      "\n",
      "         3.       Royalty.\n",
      "                  -------\n",
      "\n",
      "                  (a)      In exchange for the License described in Section 2,\n",
      "Licensee shall pay to Licensor, or its nominees or distributees, a royalty on\n",
      "sales made by Licensee of Covered Products. Such obligation to pay royalty shall\n",
      "begin on the Covered Product Launch Date and continue for the term of this\n",
      "License, as set forth in Section 4. The royalty rate shall be as set forth in\n",
      "Section 3(b)(iv) or as adjusted by other provisions hereof, and the rate shall\n",
      "be applied to the Net Sales.\n",
      "\n",
      "                  (b)      The royalty shall be subject to the following terms\n",
      "and conditions:\n",
      "\n",
      "                           (i)      From the date that the US Food and Drug\n",
      "Administration (\"FDA\") gives permission to Licensor or to Licensee to market\n",
      "Covered Products in the United States for Adjunctive Use, Licensee shall have 6\n",
      "months in which to conduct beta testing of the Covered Products for marketing\n",
      "for Adjunctive Use (the \"Beta Testing Period\"). The Covered Product Launch Date\n",
      "shall begin on the earlier of (A) the first day of the month which follows the\n",
      "month in which falls the end of the six-month beta testing period, (B) that date\n",
      "that beta testing is completed.\n",
      "\n",
      "                           (ii)     Beginning on the Covered Product Launch\n",
      "Date, Licensee shall have 18 months in which to launch the Covered Product for\n",
      "Adjunctive Use, as well as for Stand-Alone Use if this use should become\n",
      "marketable (the \"Initial Launch Period\"), and following the Initial Launch\n",
      "Period will be a further period of 12 months in which the launch may be\n",
      "furthered (the \"Secondary Launch Period\"). Following the Secondary Launch Period\n",
      "will be further periods of 24 months each (the \"Extension Periods\") in which the\n",
      "Covered Product may be marketed, each Extension Period having a first year\n",
      "comprising the first 12 months, and a second year comprising the second 12\n",
      "months.\n",
      "\n",
      "                           (iii)    For each of the periods described in\n",
      "subparagraph (ii) above, Licensee is to pay to Licensor a minimum amount (the\n",
      "\"Minimum Amount\") of royalty in order to maintain its rights under this License.\n",
      "The Minimum Amounts are as follows:\n",
      "\n",
      "           Period                             Minimum Amount\n",
      "           -------------------------------    ----------------------------------\n",
      "           Beta Testing Period                None\n",
      "\n",
      "           Initial Launch Period              $100,000\n",
      "\n",
      "           Secondary Launch Period            $250,000,  if Stand-Alone  Use is\n",
      "                                              cleared by the midpoint of the\n",
      "                                              period;  $125,000 if it is not.\n",
      "\n",
      "           First & Later Extension Periods    For each year in an Extension\n",
      "                                              Period,  the greater of (a)\n",
      "                                              $75,000 or (b) royalty  payable on\n",
      "                                              50% of the actual Net Sales of the\n",
      "                                              prior 12 months.\n",
      "\n",
      "\n",
      "\n",
      "In order to maintain its rights under this License, Licensee shall be required\n",
      "to pay to Licensor the Minimum Amount for each applicable period. If the amount\n",
      "of royalty paid, or deemed paid, over a period to which a Minimum Amount applies\n",
      "is less than the applicable Minimum Amount, then Licensee shall be permitted in\n",
      "the last report applicable to such period to pay an amount equal to the deficit\n",
      "from the Minimum Amount, and thus shall maintain its rights under this\n",
      "Agreement. In the case of a Minimum Amount that applies to an Extension Period,\n",
      "Licensee shall be required to pay the Minimum Amount applicable to such period,\n",
      "and upon satisfaction of such requirement, Licensee may, without notice to\n",
      "Licensor, continue this License, or, upon notice to Licensor at least 60 days\n",
      "prior to the end of such period, elect to terminate this Agreement.\n",
      "\n",
      "                           (iv)     The following royalty rates shall apply to\n",
      "Net Sales within any period to which a Minimum Amount applies:\n",
      "\n",
      "           Net Sales Bracket             Royalty Rate\n",
      "           --------------------------    ------------\n",
      "           1st $1 million Net Sales           20%\n",
      "\n",
      "           2nd $1 million Net Sales           15%\n",
      "\n",
      "           Net Sales above $2 million         10%\n",
      "\n",
      "                  (c)      Sales of a Covered Product into a jurisdiction that\n",
      "does not recognize, or no longer recognizes, a patent claim deriving from the\n",
      "AzurTec IP and covering such product, or in which no patent application for the\n",
      "Covered Product was made, shall bear royalty at 50% of the rates set forth in\n",
      "Section 3(b)(iv); provided, however, that this provision shall not apply if an\n",
      "application has been filed in such jurisdiction but is still pending, or if the\n",
      "failure to apply for patent protection constitutes a breach of Licensees\n",
      "obligations under Section 5 of this Agreement.\n",
      "\n",
      "                  (d)      Royalties shall be payable in US dollars within 45\n",
      "days following the close of a Quarter, and shall be accompanied by a Quarterly\n",
      "report detailing Net Sales of Covered Product. Licensee shall also submit a\n",
      "Quarterly report of sales for which royalty must be paid in favor of Licensor.\n",
      "The reports shall be in form reasonably acceptable to the parties, and shall\n",
      "indicate the number of Covered Products sold during the preceding Quarter and\n",
      "the Net Sales (including the net proceeds received thereon), the royalty rate\n",
      "and the royalty due upon such Net Sales.\n",
      "\n",
      "\n",
      "\n",
      "                  (e)      Licensee shall keep true and accurate records, files\n",
      "and books of account containing all the data necessary for the full computation\n",
      "and verification of the royalty to be paid and the information to be given in\n",
      "the report herein provided for, and also permit (subject to execution of\n",
      "appropriate confidentiality agreements) Licensor to examine Licensees records\n",
      "relating solely to sales of the Covered Products from time to time, upon\n",
      "reasonable prior written notice and during business hours, to the extent\n",
      "necessary for Licensor to verify the royalty due and payable hereunder. Licensor\n",
      "shall have two (2) years in which to examine Licensees records underlying its\n",
      "Quarterly reports, after which time such reports, if unexamined, shall be deemed\n",
      "accepted by Licensor. In the event that an audit of Licensees records\n",
      "determines that further royalties were due to Licensor, then Licensee shall\n",
      "promptly pay the deficiency to Licensor as well as interest at the statutory\n",
      "rate applicable in Pennsylvania to such payment. Notwithstanding the foregoing,\n",
      "to the extent that Licensor has as of the date of this License amounts due and\n",
      "owing to Licensee or amounts due and owing and actually encumbering the Licensed\n",
      "Rights, Licensee shall be entitled to offset from its royalties to Licensor\n",
      "until the amount due and owing to Licensee or encumbering the AzurTec IP has\n",
      "been settled (or the encumbrance otherwise removed).\n",
      "\n",
      "                  (f)      In the event that a Covered Product is sold in\n",
      "combination with other products that are not Covered Products, then the royalty\n",
      "rate shall be applied to that portion of the Net Sales price of the combination\n",
      "product that is attributable to the Covered Product, where the amount of the Net\n",
      "Sales price so attributable shall be calculated to be a fraction thereof, the\n",
      "numerator of which is the fully burdened cost of the Covered Product and the\n",
      "denominator of which is the fully burdened cost of the combination product.\n",
      "\n",
      "                  (g)      In the event that Licensee sub-licenses to a third\n",
      "party any part of a patent that is within the AzurTec IP, then sales made by\n",
      "such sub-licensee in respect of Covered Product shall be treated as Net Sales\n",
      "made by Licensee of Covered Product and bear royalty in favor of Licensor. Net\n",
      "Sales made in a currency other than US dollars shall be converted into US\n",
      "dollars in accordance with generally accepted accounting principles in the\n",
      "United States.\n",
      "\n",
      "                  (h)      In the event that Licensor develops, or would license\n",
      "the technology and rights to develop, a Next-Generation Product that is a\n",
      "patentable improvement of or involves AzurTec IP in detecting cancerous cells in\n",
      "situ and, in either case, is or would be competitive with the Covered Product\n",
      "and/or Licensor proposes to introduce such competitive product to the health\n",
      "care market, then Licensor shall provide Licensee with written notice thereof\n",
      "and hereby grants Licensee the first right of negotiation with respect to each\n",
      "such invention. Licensee shall within thirty (30) days after receipt of such\n",
      "notice notify Licensor in writing either that (i) Licensee is interested in\n",
      "negotiating to add such invention to this License, or (ii) Licensee has no\n",
      "interest in such invention and therefore rejects such right of negotiation with\n",
      "respect thereto. If Licensee notifies Licensor within thirty (30) days that\n",
      "Licensee desires to negotiate to incorporate such invention into this License,\n",
      "the parties shall negotiate in good faith for up to sixty (60) days after such\n",
      "notification regarding the terms pursuant to which Licensor would license its\n",
      "rights in such invention to Licensee. Failure by Licensee to give notice of its\n",
      "interest or lack of interest in negotiating for such rights with respect to such\n",
      "invention within thirty (30) days after receipt of written notice from Licensor\n",
      "as described in the first sentence of this Section 3(h) shall be deemed to\n",
      "constitute a waiver by Licensee of its right of first negotiation with respect\n",
      "to such invention. In addition, failure of the parties to agree on the terms of\n",
      "incorporating\n",
      "\n",
      "\n",
      "\n",
      "the invention into this License within such sixty (60) day negotiation period\n",
      "shall be deemed to constitute rejection by Licensee of such right of negotiation\n",
      "with respect to such invention. If Licensee waives or otherwise fails to\n",
      "exercise its right of first negotiation with respect to such invention, or if\n",
      "the parties fail to agree on the terms of a commercial license within such sixty\n",
      "(60) day negotiation period, then Licensor shall be free to negotiate and/or\n",
      "enter into a license arrangement with any third party with respect to such\n",
      "invention on terms that are not substantially more favorable to such third party\n",
      "than terms proposed by Licensee in a written offer delivered to Licensor during\n",
      "the aforesaid 60 day negotiation period, and Licensee shall have no further\n",
      "rights with respect thereto; provided, however, that Licensor shall not enter\n",
      "into any such arrangement with any third party prior to the end of the Secondary\n",
      "Launch Period and if Licensor enters into such an arrangement after such date,\n",
      "and if the product that incorporates the applicable invention competes with the\n",
      "Covered Products, then the royalty rates set forth in Section 3(b)(iv) above\n",
      "shall be reduced by 50%; and Licensees obligation to pay Minimum Amounts of\n",
      "royalties shall terminate. Licensee shall further have the right to terminate\n",
      "this License under Section 4(c). Moreover, Licensee shall have the right to pay\n",
      "up to 30% of the consideration offered for a license to the Next-Generation\n",
      "Product by means of its capital stock in AzurTec, valued at its then fair market\n",
      "value.\n",
      "\n",
      "         4.       Term and Termination.\n",
      "                  --------------------\n",
      "\n",
      "                  (a)      In the event that no patent shall have been issued\n",
      "with substantially the claims that are in the Patent Rights by the end of the\n",
      "first year of the first Extension Period, then the royalty rates set forth in\n",
      "Section 3(b)(iv) and the Minimum Amounts set forth in Section 3(b)(iii) shall be\n",
      "reduced by 50% until such time as a patent shall have issued as aforesaid, at\n",
      "which time the 50% reductions will be reversed and the original rates will be\n",
      "restored. Moreover, in the event that a patent shall not have issued with\n",
      "substantially the claims that are in the Patent Rights by the end of the first\n",
      "year of the first Extension Period, Licensee shall have the right to terminate\n",
      "this Agreement upon notice given within 30 days after the end of the first year\n",
      "or second year within any Extension Period, but such right of Licensee to\n",
      "terminate shall lapse if and when a patent shall have issued with substantially\n",
      "the claims that are in its Patent Rights.\n",
      "\n",
      "                  (b)      Notwithstanding Section 4(a), at the end of each\n",
      "Extension Period and provided Licensor shall not have breached any of its\n",
      "obligations under this License Agreement, the Investment Agreement or the\n",
      "Development Agreement, Licensor may elect to terminate this License upon 180\n",
      "days prior written notice of the same to Licensee and upon payment to Licensee\n",
      "of the sum set forth in confidential Schedule 4(b).\n",
      "\n",
      "                  (c)      In the event that Licensee is not licensed under\n",
      "Section 3(h) in the Next- Generation Product, then Licensee shall have the right\n",
      "to terminate this Agreement on 180 days prior written notice of the same to\n",
      "Licensee, in which case Licensor shall pay to Licensee the sum set forth on\n",
      "confidential Schedule 4(c).\n",
      "\n",
      "                  (d)      If Licensee fails to make any payment due and payable\n",
      "to Licensor hereunder, Licensor shall have the right to terminate this Agreement\n",
      "effective on fifteen (15) days notice, unless Licensee shall make all such\n",
      "payments to Licensor within said fifteen (15) day period. Upon the expiration of\n",
      "the fifteen (15) day period, if Licensee shall not have made all such payments\n",
      "to Licensor, the rights, privileges and license granted hereunder and under the\n",
      "Development Agreement shall at the option of Licensor automatically terminate.\n",
      "\n",
      "\n",
      "\n",
      "                  (e)      Upon any material breach or default of this Agreement\n",
      "or of the Development Agreement by Licensee, other than those occurrences set\n",
      "out in paragraph (d) above, which shall always take precedence in that order\n",
      "over any material breach or default referred to in this paragraph (e), Licensor\n",
      "shall have the right to terminate this Agreement and the Development Agreement\n",
      "and the rights, privileges and license granted hereunder and thereunder\n",
      "effective on thirty (30) days notice to Licensee. Such termination shall become\n",
      "automatically effective at the option of Licensor unless Licensee shall have\n",
      "cured any such material breach or default prior to the expiration of the thirty\n",
      "(30) day period.\n",
      "\n",
      "                  (f)      Upon termination of this Agreement by Licensor\n",
      "pursuant to paragraphs (b), (d) or (e) above, Licensee shall promptly return all\n",
      "AzurTec IP and related documentation to Licensor, including without limitation\n",
      "any and all modifications or improvements developed by Licensee, and shall have\n",
      "no further rights therein or thereto.\n",
      "\n",
      "                  (g)      Upon termination of this Agreement for any reason,\n",
      "nothing herein shall be construed to release either party from any obligation\n",
      "that matured prior to the effective date of such termination, and except as\n",
      "herein expressly provided, neither party shall be prevented from pursuing any\n",
      "and all other remedies available to it at law or in equity or otherwise under\n",
      "the terms of this Agreement.\n",
      "\n",
      "         5.       Maintenance, Prosecution and Defense.\n",
      "                  ------------------------------------\n",
      "\n",
      "                  (a)      Licensee shall be responsible for all patent\n",
      "maintenance fees and expenses accruing by reason of the AzurTec IP from the date\n",
      "of this License. Licensee shall be responsible for prosecution of any patent\n",
      "applications within the AzurTec IP, subject to notice to and comment from\n",
      "Licensor, and shall thus be responsible for fees and expenses which it may\n",
      "choose to incur in the prosecution of any patent applications within the AzurTec\n",
      "IP. Notwithstanding the foregoing, Licensor shall be solely responsible for\n",
      "prosecution, and expenses therefor, of patent applications, if any, for use of\n",
      "AzurTec IP with respect to in situ applications, which Licensor shall use\n",
      "commercially reasonable efforts to diligently and timely pursue, including\n",
      "without limitation not only method patents but also apparatus patents.\n",
      "\n",
      "                  (b)      In the event Licensee or Licensor becomes aware of\n",
      "any possible infringement of the AzurTec IP, it shall promptly notify the other\n",
      "party of such potential infringement. Thereafter, the parties shall confer with\n",
      "each other and shall proceed as follows.\n",
      "\n",
      "                           (i)      Licensee may elect to bring a patent\n",
      "infringement action at its expense, acting in Licensors name, and shall control\n",
      "such action, and Licensor shall cooperate with Licensee in such action at no\n",
      "charge to Licensee. If Licensee prevails, it shall first recover its out of\n",
      "pocket expenses from such damages and shall retain 75% of any remaining damages\n",
      "(including for lost profits from its lost sales) from such action, with 25%\n",
      "being allotted to Licensor for its cooperation.\n",
      "\n",
      "\n",
      "\n",
      "                           (ii)     If Licensee elects not to bring such an\n",
      "infringement action under Section 5(b)(i), then Licensor may bring such an\n",
      "action, acting in its own name and with Licensees cooperation at no charge to\n",
      "Licensor, and if Licensor prevails, it shall first recover its out of pocket\n",
      "expenses from such damages and shall retain 75% of any remaining damages from\n",
      "such action, with 25% being allotted to Licensor for its cooperation.\n",
      "\n",
      "         6.       Confidentiality and Public Announcements.\n",
      "                  ----------------------------------------\n",
      "\n",
      "                  (a)      In the course of performing this Agreement, one party\n",
      "may disclose to the other or receive information from the other relating to the\n",
      "subject matter of this Agreement, which information shall be considered to be\n",
      "the disclosing partys Confidential Information. Each party shall protect and\n",
      "keep confidential and shall not use, publish or otherwise disclose to any third\n",
      "party, except as permitted by this Agreement or with the other partys written\n",
      "consent, the other partys Confidential Information. The recipient of\n",
      "Confidential Information shall exercise reasonable care to prevent its\n",
      "disclosure to any third party and shall limit internal dissemination of\n",
      "Confidential Information within the recipients own organization to individuals\n",
      "whose duties justify the need to know such information, and then only provided\n",
      "that there is a clear understanding by such individuals of their obligation to\n",
      "maintain the trade secret status of such information and to restrict its use\n",
      "solely to the purpose specified herein. Licensee shall protect all portions of\n",
      "the Patent Rights, Covered Products and AzurTec IP under this provision as\n",
      "Confidential Information of Licensor. The parties acknowledge that Licensees\n",
      "distributors names and practices are specifically incorporated in this Section\n",
      "6 as confidential and proprietary information of Licensee, subject only to the\n",
      "following limitations. For the purposes of this Agreement, Confidential\n",
      "Information shall not include such information that: (i) was known to the\n",
      "receiving party at the time of disclosure without obligations of\n",
      "confidentiality; (ii) was generally available to the public or was otherwise\n",
      "part of the public domain at the time of disclosure or became generally\n",
      "available to the public or otherwise part of the public domain after disclosure\n",
      "other than through any act or omission of the receiving party in breach of this\n",
      "Agreement; or (iii) became known to the receiving party after disclosure from a\n",
      "source that had a lawful right to disclose such information to others. The\n",
      "parties agree that all of the provisions of all existing confidentiality\n",
      "agreements relating in any way to the Patent Rights and AzurTec IP shall\n",
      "continue in effect in accordance with their terms.\n",
      "\n",
      "                  (b)      Neither Licensor nor Licensee shall make any public\n",
      "announcement concerning the Covered Product or this Agreement without the\n",
      "others prior written consent.\n",
      "\n",
      "         7.       Indemnification.\n",
      "                  ---------------\n",
      "\n",
      "                  (a)      Licensee agrees to indemnify and hold Licensor\n",
      "harmless from and against: (i) any and all loss, liability, damage or deficiency\n",
      "asserted by a third party and resulting from any misrepresentation, breach of\n",
      "warranty or representation, or non-fulfillment of any covenant or agreement on\n",
      "the part of Licensee under the terms of this Agreement or any document or\n",
      "instrument executed by Licensee in connection herewith; (ii) any and all\n",
      "third-party claims for\n",
      "\n",
      "\n",
      "\n",
      "product liability relating to Covered Products; (iii) any and all loss,\n",
      "liability, damage or deficiency resulting from any misrepresentation, breach of\n",
      "representation or warranty or non-fulfillment of any covenant or agreement on\n",
      "the part of Licensee under the terms of this Agreement or any document or\n",
      "instrument executed by Licensee in connection herewith; and (iv) any and all\n",
      "actions, suits, proceedings, claims, demands, assessments, judgments, costs and\n",
      "expenses, including, without limitation, reasonable attorneys fees, incident to\n",
      "the foregoing subparagraphs (i), (ii) and (iii) and only the foregoing\n",
      "subparagraphs (and on appeal therefrom), regardless of whether or not Licensor\n",
      "prevails in such matter.\n",
      "\n",
      "                  (b)      Licensor agrees to indemnify and hold Licensee\n",
      "harmless from and against: (i) any and all loss, liability, damage or deficiency\n",
      "asserted by a third party and resulting from any misrepresentation, breach of\n",
      "warranty or representation, or non-fulfillment of any covenant or agreement on\n",
      "the part of Licensor under the terms of this Agreement or any document or\n",
      "instrument executed by Licensor in connection herewith; (ii) any and all\n",
      "third-party claims for product liability relating to Covered Products, to the\n",
      "extent such claims relate to any Covered Products directly manufactured or\n",
      "produced by Licensor (even if in contravention of the terms of this Agreement);\n",
      "(iii) any and all loss, liability, damage or deficiency resulting from any\n",
      "misrepresentation, breach of representation or warranty or non-fulfillment of\n",
      "any covenant or agreement on the part of Licensor under the terms of this\n",
      "Agreement or any document or instrument executed by Licensor in connection\n",
      "herewith; and (iv) any and all actions, suits, proceedings, claims, demands,\n",
      "assessments, judgments, costs and expenses, including, without limitation,\n",
      "reasonable attorneys fees, incident to the foregoing subparagraphs (i), (ii)\n",
      "and (iii) and only the foregoing subparagraphs (and on appeal therefrom),\n",
      "regardless of whether or not Licensee prevails in such matter.\n",
      "\n",
      "                  (c)      Notwithstanding Section 7(b), Licensee shall have the\n",
      "right to recover by set-off any and all amounts for which Licensee is entitled\n",
      "to indemnification under this Agreement from Licensor against all payments due\n",
      "or which may become due hereunder, in the order of their maturity or in any\n",
      "other order that Licensee shall elect, until the cumulative amount so set off\n",
      "shall equal the total amount due to Licensee, and in such manner of\n",
      "apportionment among the parties as is, in the reasonable exercise of Licensees\n",
      "discretion, equitable in the circumstances.\n",
      "\n",
      "                  (d)      The party to this Agreement entitled to\n",
      "indemnification under this Section 7 (hereinafter for purposes of this Section 7\n",
      "referred to as \"Indemnitee\") shall notify the party required to indemnify\n",
      "pursuant to this Section 7 (hereinafter for purposes of this Section 7 referred\n",
      "to as \"Indemnitor\") within 15 days after the Indemnitees receipt of notice from\n",
      "any third party of any claim, demand, suit or proceeding with respect to which\n",
      "indemnification may be sought under the terms of this Agreement. Indemnitor\n",
      "shall be entitled, at its expense, to contest or otherwise defend against any\n",
      "such claim, demand, suit or proceeding through representatives and counsel of\n",
      "its own choice, in which event Indemnitee shall, upon Indemnitors request,\n",
      "cooperate in connection with such defense or contest by the preparation and\n",
      "furnishing of evidence and by making employees available to testify, at no cost\n",
      "to Indemnitor except for the reimbursement of costs and expenses incurred by\n",
      "Indemnitee in connection therewith. Nothing set forth herein shall preclude\n",
      "Indemnitee from participating in the defense of such claim, demand, suit or\n",
      "proceeding on its own behalf and at its own expense, in which case Indemnitor\n",
      "\n",
      "\n",
      "\n",
      "shall cooperate with Indemnitee to the same extent contemplated by the foregoing\n",
      "sentence. If Indemnitor fails to protest or defend any such claim, demand, suit\n",
      "or proceeding within 30 days after receipt of the notice specified in the first\n",
      "sentence of this Section 7(d), Indemnitee shall have the right following such\n",
      "30-day period, in the good faith exercise of its reasonable discretion, to\n",
      "settle, defend or pay the same, in which event Indemnitors indemnification\n",
      "shall extend to and include the amount of such settlement or payment and/or the\n",
      "costs and legal expenses of such defense. The failure to notify Indemnitor\n",
      "promptly as set forth above of any such claim, demand, suit or proceeding shall\n",
      "not relieve Indemnitors liability to indemnify Indemnitee under this Section 7,\n",
      "except to the extent such delay has prejudiced the Indemnitors ability to\n",
      "defend the claim.\n",
      "\n",
      "                  (e)      Except for litigation between Licensor and Licensee,\n",
      "each of the parties hereto shall fully cooperate with the other in the defense\n",
      "or prosecution of any existing or future litigation or proceeding against or by\n",
      "such other party relating to or arising out of the business sold hereunder prior\n",
      "to or after the effective date of this License. The party receiving cooperation\n",
      "shall pay the expenses, including legal fees and disbursements, of the\n",
      "cooperating party and its officers, directors and employees reasonably incurred\n",
      "in connection with such litigation.\n",
      "\n",
      "         8.       Waivers; Modification. No course of dealing between Licensor\n",
      "                  ---------------------\n",
      "and Licensee, nor any failure to exercise, nor any delay in exercising, on the\n",
      "part of Licensee or Licensor, any right, power or privilege hereunder shall\n",
      "operate as a waiver thereof; nor shall any single or partial exercise of any\n",
      "right, power or privilege hereunder or thereunder preclude any other or further\n",
      "exercise thereof or the exercise of any other right, power or privilege. This\n",
      "Agreement cannot be altered, amended or modified in any way, except by a writing\n",
      "signed by the parties hereto.\n",
      "\n",
      "         9.       Severability. The provisions of this Agreement are severable,\n",
      "                  ------------\n",
      "and if any clause or provision shall be held invalid and unenforceable in whole\n",
      "or in part in any jurisdiction, then such invalidity or unenforceability shall\n",
      "affect only such clause or provision, or part thereof, in such jurisdiction, and\n",
      "shall not in any manner affect such clause or provision in any other\n",
      "jurisdiction, or any other clause or provision of this Agreement in any\n",
      "jurisdiction.\n",
      "\n",
      "         10.      Cumulative Remedies. All of Licensees and Licensors\n",
      "                  -------------------\n",
      "respective rights and remedies with respect to the AzurTec IP, whether\n",
      "established hereby or otherwise by law or other agreements between the parties\n",
      "hereto shall be cumulative and may be exercised singularly or concurrently. In\n",
      "the event of a breach of the foregoing provisions, the non-defaulting party\n",
      "shall be entitled to equitable and injunctive relief in addition to any other\n",
      "available remedies.\n",
      "\n",
      "         11.      Notices. All notices for purposes under this Agreement shall\n",
      "                  -------\n",
      "be sent either by registered mail (and such notice shall be deemed to be\n",
      "properly served upon proof of posting by registered mail) or by recognized\n",
      "overnight courier, when addressed as follows:\n",
      "\n",
      "     If to Licensor:            AzurTec, Inc.\n",
      "                                12 Penns Trail\n",
      "                                Newtown, PA 18940\n",
      "                                Attn: President\n",
      "\n",
      "\n",
      "\n",
      "     With copy to:              Duane Morris LLP\n",
      "                                30 South 17th Street\n",
      "                                Philadelphia, PA 19103\n",
      "                                Attn: Kate Shay, Esq.\n",
      "\n",
      "     If to Licensee:            PhotoMedex, Inc.\n",
      "                                147 Keystone Drive\n",
      "                                Montgomeryville, PA 18936\n",
      "                                Attn: President\n",
      "\n",
      "     With copy to:              Jenkens & Gilchrist, LLP\n",
      "                                12100 Wilshire Blvd, 15th Floor\n",
      "                                Los Angeles, CA 90025\n",
      "                                Attn: Jeffrey P. Berg, Esq.\n",
      "\n",
      "or to such other address as either party shall designate in writing to the other\n",
      "party.\n",
      "\n",
      "         12.      Binding Effect; Benefits; Independence. This Agreement shall\n",
      "                  --------------------------------------\n",
      "be binding upon and inure to the benefit of the parties hereto and their\n",
      "respective successors and assigns. Except as specifically provided otherwise\n",
      "herein, Licensee may not assign, sell, hypothecate, or otherwise transfer any\n",
      "interest in or obligation under this Agreement. Neither party shall be deemed to\n",
      "be the agent or partner of the other. The parties to this Agreement are\n",
      "independent of each other.\n",
      "\n",
      "         13.      Further Assurances. Each of the parties agrees to execute and\n",
      "                  ------------------\n",
      "deliver to the other such further agreements, instruments and documents, and to\n",
      "perform such further acts, as shall be reasonably requested from time to time in\n",
      "order to carry out the purposes of this Agreement and the transactions\n",
      "contemplated hereby.\n",
      "\n",
      "         14.      Governing Law; Choice of Forum. This Agreement shall be\n",
      "                  ------------------------------\n",
      "interpreted and the rights and liabilities of the parties hereto determined in\n",
      "accordance with the internal laws (as opposed to the conflict of laws\n",
      "provisions) of the Commonwealth of Pennsylvania. Any legal action or proceeding\n",
      "with respect to this License Agreement may be brought in the courts of the\n",
      "Commonwealth of Pennsylvania or of the US located in Philadelphia County,\n",
      "Philadelphia, and by execution, and delivery of this License Agreement, each of\n",
      "the Licensor and the Licensee consents, for itself and in respect of its\n",
      "property, to the exclusive jurisdiction of those courts.\n",
      "\n",
      "         15.      Waiver of Jury Trial. EACH OF THE PARTIES HERETO IRREVOCABLY\n",
      "                  --------------------\n",
      "WAIVES ITS RIGHTS TO A TRIAL BY JURY OF ANY CLAIM OR CAUSE OF ACTION BASED UPON\n",
      "OR ARISING OUT OF OR RELATED TO THIS LICENSE AGREEMENT OR THE TRANSACTIONS\n",
      "CONTEMPLATED HEREBY, IN ANY ACTION, PROCEEDING, OR OTHER LITIGATION OF ANY TYPE\n",
      "BROUGHT BY ONE PARTY AGAINST THE OTHER PARTY, WHETHER WITH RESPECT TO CONTRACT\n",
      "CLAIMS, TORT CLAIMS, OR OTHERWISE. THE LICENSOR AND LICENSEE EACH AGREE THAT ANY\n",
      "SUCH CLAIM OR CAUSE OF ACTION SHALL BE TRIED BY A COURT TRIAL WITHOUT A JURY.\n",
      "\n",
      "\n",
      "\n",
      "         16.      Whole Agreement. This Agreement, including by incorporation by\n",
      "                  ---------------\n",
      "reference the Investment Agreement, the Security Agreement and the Development\n",
      "Agreement, as amended, contains all of the understandings, representations,\n",
      "warranties and obligations between Licensor and Licensee to the subject matter\n",
      "hereof, and no party shall be bound by any prior agreement, oral or in writing,\n",
      "or by any representations, conditions, definitions, or warranties with respect\n",
      "to the subject matter of this Agreement other than as expressly provided herein\n",
      "or as otherwise expressly noted elsewhere. This Agreement shall inure solely to\n",
      "the benefit of and shall be binding upon the permitted successors and assigns of\n",
      "the parties hereto. The captions in this Agreement are for convenience only and\n",
      "shall not be considered a part of or affect the construction or interpretation\n",
      "of any provision hereof. This License Agreement may be authenticated in any\n",
      "number of separate counterparts, each of which shall collectively and separately\n",
      "constitute one and the same agreement. This Agreement may be authenticated by\n",
      "manual signature, facsimile, or, if approved in writing by the other party,\n",
      "electronic means, all of which shall be equally valid. A telecopy of any such\n",
      "executed counterpart shall be deemed valid as an original.\n",
      "\n",
      "IN WITNESS WHEREOF, the Licensor and Licensee have duly executed this License\n",
      "Agreement as of the date first written above.\n",
      "\n",
      "         AZURTEC, INC.                           PHOTOMEDEX, INC.\n",
      "\n",
      "\n",
      "         By:    /s/ Neil B. Sukonik              By:    /s/ Jeffrey F. ODonnell\n",
      "                -------------------                     ------------------------\n",
      "                Neil B. Sukonik                         Jeffrey F. ODonnell\n",
      "         Title: President                        Title: President & CEO\n",
      "\n",
      "\n",
      "\n",
      "Bottom of Form\n",
      "© Copyright 2000 - 2016 RoyaltyStat.\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "def read_txt(file_path):\n",
    "    with open(file_path, 'r', encoding='utf-8') as file:\n",
    "        text = file.read()\n",
    "    return text\n",
    "\n",
    "file_path = '/home/kprasath/DS/NLPInternship/txt_data/ref_1_txt/8683.txt'\n",
    "text = read_txt(file_path)\n",
    "\n",
    "print(text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "9edf2f2a",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Top of Form\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "                             ANDA OWNERSHIP TRANSFER\n",
      "                          AND PRODUCT LICENSE AGREEMENT\n",
      "\n",
      "         This license agreement (the \"Agreement\")  dated as of May 17, 2006 (the\n",
      "\"Effective Date\") is entered into by and between Nostrum  Pharmaceuticals,  Inc.\n",
      "(\"Nostrum\"), a Delaware corporation, and Synovics Laboratories,  Inc. (\"Synovics\n",
      "Labs\"), a Nevada corporation.\n",
      "\n",
      "WHEREAS,\n",
      "\n",
      "         A. Nostrum has  developed,  and is in the process of  developing,  time\n",
      "release and other technology for pharmaceutical products.\n",
      "\n",
      "         B. Synovics Labs is researching, developing,  manufacturing,  marketing\n",
      "and selling pharmaceutical products.\n",
      "\n",
      "         C. Synovics Labs desires to license from Nostrum the exclusive right to\n",
      "develop,  manufacture,  market and sell the Product (as hereinafter  defined) in\n",
      "the United  States of  America,  and  Nostrum  desires to grant such  license to\n",
      "Synovics Labs, all on the terms and conditions hereinafter set forth.\n",
      "\n",
      "         NOW,  THEREFORE,  in  consideration  of the  premises,  and the  mutual\n",
      "agreements hereinafter set forth, the parties hereby agree as follows:\n",
      "\n",
      "                             ARTICLE 1 - DEFINITIONS\n",
      "\n",
      "         The  capitalized  terms set forth  below  (whether  in the  singular or\n",
      "plural) shall have the meanings indicated for the purposes of this Agreement.\n",
      "\n",
      "                  \"Affiliate\" means any Person which controls,  is controlled by\n",
      "         or is under common  control with Synovics Labs or Nostrum,  as the case\n",
      "         may be. The term \"control\" means the ownership, directly or indirectly,\n",
      "         of more than fifty percent (50%) of the voting stock or equity interest\n",
      "         of the subject Person, or the right to receive over fifty percent (50%)\n",
      "         of the profits or earnings of such Person.  Such other  relationship as\n",
      "         in fact gives a Person the power or ability to control the  management,\n",
      "         business  and  affairs of the  subject  Person  shall also be deemed to\n",
      "         constitute control.\n",
      "\n",
      "                  \"Biobatch\"  means a  batch  suitable  for  use in the  Pivotal\n",
      "         Study.\n",
      "\n",
      "                  \"cGMP\" means  current  good  manufacturing  practices  for the\n",
      "         methods to be used in, and the  facilities and controls to be used for,\n",
      "         the manufacture,  storage and handling of the Product, all as set forth\n",
      "         from  time-to-time  by the FDA pursuant to the federal  Food,  Drug and\n",
      "         Cosmetic  Act and the  rules  and  regulations\n",
      "\n",
      "                                       1\n",
      "\n",
      "\n",
      "         promulgated thereunder (including  specifically,  Title 21, part 211 of\n",
      "         the Code of Federal Regulations of the United States).\n",
      "\n",
      "                  \"FDA\" means the United States Food and Drug  Administration or\n",
      "         any successor agency of the United States government.\n",
      "\n",
      "                  \"Future  Strength\"  shall mean a to be  determined  additional\n",
      "         strength of extended release  metformin  formulation  using the Nostrum\n",
      "         Technology  that  may be  developed  and  filed as a  separate  ANDA in\n",
      "         Synovics discretion.\n",
      "\n",
      "                  \"TRANSFERED  FILING\" shall mean  Nostrums ANDA No. 76-756 for\n",
      "         the  Product  and  supplements   thereto,   including  all  pending  or\n",
      "         in-process   registrations  issued  by  United  States  Food  and  Drug\n",
      "         Administration related to the Products.\n",
      "\n",
      "                  \"Litigation  Expenses\"  shall  mean  out-of-pocket  costs  and\n",
      "         expenses  incurred by Synovics Labs (i) connection  with the defense of\n",
      "         any claim,  suit or other legal action  alleging that the Product being\n",
      "         marketed  and  sold  by  Synovics  Labs  hereunder  infringes  upon  or\n",
      "         misappropriates  a third party  patent or other  intellectual  property\n",
      "         right or (ii) in connection with the resolution of any such claim, suit\n",
      "         or other legal action, including any judgment or award against Synovics\n",
      "         Labs or any of its Affiliates or subcontractors and any amounts paid in\n",
      "         settlement (including license fees and royalties).\n",
      "\n",
      "                  \"Nostrum  Technology\"  means  all  of  Nostrums   proprietary\n",
      "         information,  know-how, materials and technology related to the Product\n",
      "         (including  without  limitation,  manufacturing  information)  and  any\n",
      "         related patent  applications  or patents owned or controlled by Nostrum\n",
      "         or its  Affiliates  to the  extent  they cover the  Product  and Future\n",
      "         Strength or any such information,  know-how, materials or technology as\n",
      "         applied  to  the  Product  and  Future  Strength,  including  patent  #\n",
      "         6,416,786.\n",
      "\n",
      "                  \"Net Sales\" means, with respect to the Product for any period,\n",
      "         the amounts  actually  received by Synovics Labs or its Affiliates from\n",
      "         unaffiliated  third  parties  (whether an end-user,  a  distributor  or\n",
      "         otherwise) for the sale of Products in the Territory,  and exclusive of\n",
      "         intercompany transfers or sales between and among Synovics Labs and its\n",
      "         Affiliates,  less the following  reasonable  and  customary  deductions\n",
      "         (without duplication) from such gross amounts:\n",
      "\n",
      "                  (i)      normal  and  customary   trade,   cash  and  quantity\n",
      "                           discounts, allowances and credits;\n",
      "\n",
      "                  (ii)     credits or  allowances  actually  granted for damaged\n",
      "                           goods,   returns  or   rejections   of  Product   and\n",
      "                           retroactive price reductions;\n",
      "\n",
      "                                       2\n",
      "\n",
      "\n",
      "                  (iii)    sales or  similar  taxes  (including  duties or other\n",
      "                           governmental charges levied on, absorbed or otherwise\n",
      "                           imposed  on the sale of  Product  including,  without\n",
      "                           limitation,  value added taxes or other  governmental\n",
      "                           charges  otherwise  measured by the  billing  amount,\n",
      "                           when included in billing); and\n",
      "\n",
      "                  (iv)     all  charge  back  payments,  discounts  and  rebates\n",
      "                           (whether  mandated or  otherwise)  granted to managed\n",
      "                           health care  organizations  or to federal,  state and\n",
      "                           local governments, their agencies, and purchasers and\n",
      "                           reimbursers or to trade customers,  including but not\n",
      "                           limited to, wholesalers and chain and pharmacy buying\n",
      "                           groups  and  charge  back  payments,   discounts  and\n",
      "                           rebates  (whether  mandated or otherwise)  charged by\n",
      "                           national or local government; and\n",
      "\n",
      "                  (v)      commissions  paid to third  parties and sales  agents\n",
      "                           other than  Synovics  Labs sales  personnel  and sale\n",
      "                           representatives.\n",
      "\n",
      "                  (vi)     freight,  postage,   shipping,   customs  duties  and\n",
      "                           insurance charges, when included in billing.\n",
      "\n",
      "                  \"Person\" means any natural person, corporation, unincorporated\n",
      "         organization,  partnership,  association,  joint stock  company,  joint\n",
      "         venture, limited liability company, trust or government,  or any agency\n",
      "         or political subdivision of any government, or any other entity.\n",
      "\n",
      "                  \"Pivotal    Study\"    means   the   pivotal    pharmacokinetic\n",
      "         biostudy(ies)  conducted by a fully licensed biostudy facility mutually\n",
      "         satisfactory to Synovics Labs and Nostrum which is reasonably  expected\n",
      "         to demonstrate,  to the  satisfaction of the FDA, the intended AB rated\n",
      "         bioequivalence of the Product with the Reference Product  sufficient to\n",
      "         enable Synovics Labs to submit to the FDA an acceptable Abbreviated New\n",
      "         Drug  Application  (\"ANDA\") for the  manufacture and commercial sale of\n",
      "         the Product.\n",
      "\n",
      "                  \"Prestudy\" means a pharmacokinetic  biostudy which is intended\n",
      "         to indicate  likelihood of demonstrating  bioequivalence of the Product\n",
      "         with the Reference  Product,  typically carried out in a smaller number\n",
      "         of volunteers than those required by FDA for pivotal biostudies.\n",
      "\n",
      "                  \"Product\"  means  the  AB  rated,   generic  500mg  equivalent\n",
      "         (Metformin ER Tablet) of the branded product Glucophage-XR,.\n",
      "\n",
      "                  \"ANDA\"  shall  mean  an  abbreviated   new  drug   application\n",
      "         submitted to the FDA covering the Product.\n",
      "\n",
      "                  \"Territory\"  means  the  United  States  of  America  and  its\n",
      "         territories, possessions and commonwealths (including Puerto Rico).\n",
      "\n",
      "                                       3\n",
      "\n",
      "\n",
      "                          ARTICLE 2 - GRANT OF LICENSE\n",
      "\n",
      "         2.1      LICENSE  GRANT.  Nostrum  hereby grants to Synovics  Labs, and\n",
      "Synovics  Labs  accepts,  ownership  of the  Transfered  Filing and an exclusive\n",
      "license under the Nostrum  Technology to develop,  make, have made, use, import,\n",
      "offer  for  sale,  market  and sell the  Product  and a  Future  Product  in the\n",
      "Territory.\n",
      "\n",
      "         2.2      RETAINED  RIGHTS.  Subject to the licenses granted to Synovics\n",
      "Labs  hereunder,  Nostrum shall remain the sole owner of any Nostrum  Technology\n",
      "which  Nostrum  shall have  furnished to Synovics  Labs in  connection  with the\n",
      "performance of Nostrums  obligations pursuant to this Agreement.  Nostrum shall\n",
      "retain all right, title and interest to use or license the Nostrum Technology in\n",
      "connection with any product, formulation or process except the Product.\n",
      "\n",
      "                          ARTICLE 3 - RESEARCH PROGRAM\n",
      "\n",
      "         3.1      NOSTRUMS OBLIGATIONS.\n",
      "\n",
      "                  (a)      (i) As of the  Effective  Date,  With  respect to the\n",
      "Future Strength, Nostrum has completed work necessary to develop a bioequivalent\n",
      "Product (as  compared to the  Reference  Product)  suitable for use in the Pilot\n",
      "Study,  and to develop a reliable and efficient  manufacturing  process suitable\n",
      "for producing  commercial scale quantities of the Product meeting the applicable\n",
      "specifications,  necessary  for filing an ANDA for the  Product.  Nostrum  shall\n",
      "provide  to  Synovics  Labs  access  to  all of the  results  of the  Prestudies\n",
      "completed by Nostrum  with  respect to the Product.  Such access shall be during\n",
      "normal  business  hours and shall include the right to make copies,  at Synovics\n",
      "Labs expense, of all relevant records,  data and results of the Prestudies.  In\n",
      "the event  that any  modifications  or  adjustments  to the  formulation  of the\n",
      "Product are necessary to achieve  bioequivalence  for the Product as compared to\n",
      "the  Reference  Product,  or to  develop  a  commercially  viable  manufacturing\n",
      "process,  Nostrum  shall use  diligent  efforts  to  complete  such work and all\n",
      "analysis and testing in connection therewith.\n",
      "\n",
      "                           (ii)     As of the  Effective  date,  with respect to\n",
      "the 500 mg strength, Nostrum has filed an ANDA - the Transfered Filing.\n",
      "\n",
      "                  (b)      Nostrum  shall provide to Synovics Labs access to all\n",
      "information and copies of all records relating to the Product, including without\n",
      "limitation  information relating to formulation  development,  manufacturing and\n",
      "scale-up  (including  procedures  and batch  records),  Product  specifications,\n",
      "stability  testing,  analytical  procedures  and methods,  dissolution  testing,\n",
      "preclinical  and clinical  testing  (including food effect studies) and all data\n",
      "generated  by Nostrum  relating  thereto.  Such  access  shall be during  normal\n",
      "business  hours and shall  include the right to make copies,  at Synovics  Labs\n",
      "expense, of all such records.\n",
      "\n",
      "                                       4\n",
      "\n",
      "\n",
      "                  (c)      Nostrum  will  cooperate  with  Synovics  Labs in all\n",
      "phases  of the  work to be  performed  under  Section  3.2,  including,  without\n",
      "limitation,  the scale up, any Pivotal Study,  process validation,  any ANDA and\n",
      "stability testing relating to the Product performed  pursuant to this Agreement,\n",
      "at any time. Until such time as Synovics Labs has received ANDA approval for the\n",
      "Product in the Territory, Nostrum shall also make available to Synovics Labs the\n",
      "Nostrum personnel  directly involved with the Product to advise and consult with\n",
      "regard to the development and manufacture of the Product.  In addition,  Nostrum\n",
      "agrees that Nostrums President,  Dr. Nirmal Mulye, will be personally available\n",
      "to consult and advise during all aspects of the  development of the ANDA for the\n",
      "Product.  Synovics Labs shall reimburse Nostrum for its reasonable out-of-pocket\n",
      "expenses  incurred in performance of the  obligations  set forth in this Section\n",
      "3.1(c).\n",
      "\n",
      "                  (d)      Nostrum shall use diligent efforts in the performance\n",
      "of its obligations  under this Section 3.1, as well as any other  obligations to\n",
      "be performed  by Nostrum on Synovics  Labs behalf under this Article 3. Nostrum\n",
      "shall  use  diligent  efforts  to comply  with all  applicable  laws,  rules and\n",
      "regulations in the performance of such activities,  including without limitation\n",
      "good  laboratory  practices,  good clinical  practices and cGMPs,  to the extent\n",
      "applicable.\n",
      "\n",
      "         3.2      SYNOVICS LABS OBLIGATIONS.\n",
      "\n",
      "                  (a)      With   respect  to  the  Future   Strength   and  any\n",
      "modifications  of the  formulation  for both the strengths,  Synovics Labs shall\n",
      "promptly commence and diligently  conduct all work preparatory to, and necessary\n",
      "for, the performance of a Pivotal Study for the Product. Synovics Labs shall use\n",
      "diligent  efforts to complete  such  Pivotal  Study as promptly as  practicable.\n",
      "Synovics  Labs shall have the right,  in its sole  discretion,  to contract with\n",
      "Nostrum or use third party  contractors  to conduct the Pivotal Study under this\n",
      "Section 3.2(a).  Synovics Labs obligation to conduct the Pivotal Study shall be\n",
      "contingent upon successful  manufacture and release of finished  product for use\n",
      "in the Pivotal Study.\n",
      "\n",
      "                  (b)      With   respect  to  the  Future   Strength   and  any\n",
      "modifications  of the formulation for both the strengths,  in the event that the\n",
      "Pivotal Study demonstrates bioequivalence for the Product in accordance with FDA\n",
      "regulations,  Synovics Labs in cooperation with Nostrum shall promptly  prepare,\n",
      "submit and  diligently  prosecute an ANDA for such  Product.  Synovics Labs will\n",
      "keep Nostrum fully informed with respect to such  activities,  and Nostrum shall\n",
      "have the right to be present at all meetings with FDA regarding the Product,  at\n",
      "its own expense.\n",
      "\n",
      "                  The ownership of Transfered Filing shall be transferred to and\n",
      "in the name of Synovics Labs.  Synovics Labs shall be  responsible,  at Synovics\n",
      "Labs expense,  for conducting the  post-clinical  and stability  testing of the\n",
      "Product necessary for the approval thereof and for obtaining of all governmental\n",
      "approvals  for  the  manufacture  and  commercial  sale  of the  Product  in the\n",
      "Territory.  Synovics  Labs shall use  diligent  efforts to cause such ANDA to be\n",
      "approved. Synovics Labs will have full and complete ownership thereof.\n",
      "\n",
      "                                       5\n",
      "\n",
      "\n",
      "                  (c)      Synovics Labs shall be responsible  for all costs and\n",
      "expenses  incurred by it in connection  with the  performance of its obligations\n",
      "under this Section 3.2.\n",
      "\n",
      "         3.3      DILIGENCE.  Following  Synovics  Labs receipt of FDA approval\n",
      "with  respect  to the  manufacture  and  commercial  sale of the  Product in the\n",
      "Territory,  Synovics  Labs shall use diligent  efforts to  manufacture,  market,\n",
      "distribute and sell the Product in the Territory. Such diligent efforts shall be\n",
      "commensurate with the efforts expended by Synovics Labs in the commercialization\n",
      "of its other  products of similar  value,  stage of  development  and commercial\n",
      "potential.\n",
      "\n",
      "         3.4      EXCUSED   PERFORMANCE.   All  of  Synovics   Labs   diligence\n",
      "obligations with respect to the development and commercialization of the Product\n",
      "under this Agreement are expressly  conditioned  upon the continuing  absence of\n",
      "any  adverse  condition  or event  relating  to the  safety or  efficacy  of the\n",
      "Product,   or  lack  of  regulatory   approval,   which   warrants  a  delay  in\n",
      "commercialization of the Product.\n",
      "\n",
      "         3.5      OWNERSHIP  OF RESULTS.  Subject to the  provisions  of Section\n",
      "9.5,  all data and  results  obtained  or  generated  by or on  behalf of either\n",
      "Nostrum or Synovics Labs in  performance  of the Prestudy,  the Pivotal Study or\n",
      "other development  activities related to the Product to be performed pursuant to\n",
      "this  Agreement  (the  \"Results\")  shall be the sole and  exclusive  property of\n",
      "Synovics Labs and shall be treated as Synovics  Labs  Confidential  Information\n",
      "pursuant  to Article 5 hereof.  Nostrum  undertakes  to execute,  without  undue\n",
      "delay,  any and all  documents  deemed  necessary to perfect  this right,  on an\n",
      "as-needed, as-requested basis.\n",
      "\n",
      "         3.6      MANUFACTURE/SUPPLY.  Synovics  Labs  shall  have the  right to\n",
      "contract directly with a suitable third party to manufacture and supply Synovics\n",
      "Labs  requirements  for  commercial  supplies  of the  Product.  Alternatively,\n",
      "Synovics Labs may elect to have the Product  manufactured and supplied by itself\n",
      "or  one  of its  Affiliates;  provided  that  the  cost  of  goods  for  Product\n",
      "manufactured by Synovics Labs or such Affiliate is competitive  with the cost of\n",
      "goods for the Product as manufactured  by a qualified third party  manufacturer.\n",
      "Upon request,  Nostrum shall  cooperate with Synovics Labs in  transferring  and\n",
      "implementing the Nostrum  Technology  related to manufacture of the Product from\n",
      "one site of  manufacture  for the  Product  to another  in  accordance  with FDA\n",
      "guidelines  applicable to the proposed  transfer.  Synovics Labs shall reimburse\n",
      "Nostrum  within  thirty  (30)  days  of  Synovics  Labs  receipt  of  Nostrums\n",
      "invoice(s) for all reasonable  out-of-pocket expenses which Nostrum may incur in\n",
      "connection with the performance of its obligations pursuant to this Section 3.6.\n",
      "\n",
      "                                       6\n",
      "\n",
      "\n",
      "                              ARTICLE 4 - PAYMENTS\n",
      "\n",
      "         4.1      INITIAL PAYMENT. In partial consideration for the transfer of\n",
      "ownership  of the  Transfered  Filing  and  license  granted  to  Synovics  Labs\n",
      "hereunder,  Synovics  Labs shall pay  Nostrum  One  hundred  and fifty  thousand\n",
      "dollars ($150,000) USD within fifteen (15) days of the Effective Date.\n",
      "\n",
      "         4.2      MILESTONE PAYMENTS.  In further  consideration for the license\n",
      "granted to  Synovics  Labs  hereunder,  Synovics  Labs  hereby  agrees to pay to\n",
      "Nostrum One hundred and fifty thousand  dollars  ($150,000) USD upon the receipt\n",
      "of  approval  for  Transfered  Filing  by the FDA  within  thirty  (30)  days of\n",
      "achieving the indicated milestone\n",
      "\n",
      "         4.3      ROYALTIES. Synovics Labs agrees to pay to Nostrum royalties on\n",
      "Net Sales of Product in the Territory equal to Twenty Percent (20%) of Net sales\n",
      "up to a maximum of One million five hundred thousand ($1,500,000).\n",
      "\n",
      "         4.4      MANNER OF  PAYMENT.  Within  thirty  (30) days after the first\n",
      "commercial sale of the Product in the Territory by Synovics Labs,  Synovics Labs\n",
      "shall provide Nostrum with written notice to that effect.  Thereafter,  Synovics\n",
      "Labs shall furnish to Nostrum within sixty (60) days following the close of each\n",
      "calendar  quarter,  a written  report for the calendar  quarter  showing the Net\n",
      "Sales and Gross  Profits from the sale of the Product sold by Synovics  Labs and\n",
      "its Affiliates in the Territory  during such calendar  quarter and the royalties\n",
      "payable under this Agreement for such calendar quarter.  Simultaneously with the\n",
      "submission of such written report,  Synovics Labs shall pay to Nostrum,  for the\n",
      "account of Synovics Labs or the applicable Affiliate,  as the case may be, a sum\n",
      "equal to the  aggregate  royalty due for such  calendar  quarter  calculated  in\n",
      "accordance  with this Agreement  (reconciled  for any previous  overpayments  or\n",
      "underpayments). All payments to Nostrum hereunder shall be made by wire transfer\n",
      "of immediately available funds to the account designated in writing by Nostrum.\n",
      "\n",
      "         4.5      RECORDKEEPING/AUDITS.\n",
      "\n",
      "                  (a)      Synovics  Labs,  and to  the  extent  applicable  its\n",
      "Affiliates,  shall keep complete and accurate  records in  sufficient  detail to\n",
      "enable the  royalties  payable  hereunder  to be  determined.  Upon the  written\n",
      "request of Nostrum and not more than twice in each calendar year, Synovics Labs,\n",
      "and to the extent responsible for the manufacture of the Product its Affiliates,\n",
      "shall permit an  independent  certified  public  accounting  firm of  nationally\n",
      "recognized standing,  which is bound by a confidentiality  agreement in favor of\n",
      "Synovics Labs to have access, at Nostrums expense, during normal business hours\n",
      "to such  records  of  Synovics  Labs and such  Affiliates  as may be  reasonably\n",
      "necessary to verify the accuracy of the royalty reports hereunder for any twelve\n",
      "(12) month  period(s).  Nostrum  shall  provide such notice at least thirty (30)\n",
      "days prior to the intended audit.  Nostrum shall have no right to audit any such\n",
      "records  with  respect to any twelve  (12) month  period  which  ended more than\n",
      "ninety-six  (96) months prior to the date of such request.  The accounting  firm\n",
      "shall only disclose to Nostrum the relevant Net Sales, Gross Profits and cost of\n",
      "goods sold  information and whether the royalty reports are correct or incorrect\n",
      "and the specific  details  concerning any  discrepancies.  No other  information\n",
      "shall be shared by the  accounting  firm with\n",
      "\n",
      "                                       7\n",
      "\n",
      "\n",
      "Nostrum.  Nostrums  audit  rights  under this  Section  4.5 shall  survive  the\n",
      "expiration or termination of this Agreement for a period of one (1) year.\n",
      "\n",
      "                  (b)      The cost of each audit  conducted  under this Section\n",
      "4.5 shall be borne by  Nostrum  unless  such  audit  correctly  determines  that\n",
      "Synovics Labs underpaid the royalties due to Nostrum hereunder by more than five\n",
      "percent (5% ) in any five month period in which case, Synovics Labs shall pay to\n",
      "Nostrum the  deficiency  (as Synovics  Labs is required to do  regardless of the\n",
      "amount  thereof or the  results,  requirement  or pendency of any audit)  within\n",
      "fifteen  (15) days of the date that a final  audit  report is issued,  and shall\n",
      "also bear the cost of such audit.  In the event that such audit  determines that\n",
      "Synovics Labs  overpaid the  royalties  due to Nostrum,  Nostrum shall refund to\n",
      "Synovics  Labs the amount of such  overpayment  within  fifteen (15) days of the\n",
      "date that a final audit report is issued.\n",
      "\n",
      "                  (c)      Nostrum shall treat all financial information subject\n",
      "to review under this Agreement in accordance with the confidentiality provisions\n",
      "of this  Agreement,  and  shall  cause  its  accounting  firm to  enter  into an\n",
      "acceptable  confidentiality agreement with Synovics Labs obligating it to retain\n",
      "all such financial  information in confidence  pursuant to such  confidentiality\n",
      "agreement.\n",
      "\n",
      "         Section 4.6    WITHHOLDING. If at any time, any jurisdiction within the\n",
      "Territory  requires the  withholding of income taxes or other taxes imposed upon\n",
      "payments set forth in this Article 4, Synovics Labs shall make such  withholding\n",
      "payments as required and subtract  such  withholding  payments from the payments\n",
      "set forth in this Article 4 or if  applicable,  Nostrum will promptly  reimburse\n",
      "Synovics Labs or its  designee(s) of the amount of such payments.  Synovics Labs\n",
      "shall provide Nostrum with  documentation of such  withholding and payment.  Any\n",
      "withholdings  paid when due  hereunder  shall be for the  account of Nostrum and\n",
      "shall not be  included  in the  calculation  of Net Sales or Gross  Profits,  as\n",
      "applicable.  In addition, if any deficiency in the amount or failure to make any\n",
      "such withholding  payment is caused,  in whole or in part, by any intentional or\n",
      "negligent action or inaction on the part of Nostrum, Nostrum shall be liable for\n",
      "any fine, assessment or penalty imposed by any taxing authority in the Territory\n",
      "for such  deficiency  in the amount of any such  withholding  or such failure to\n",
      "make such  withholding  payment.  If  Synovics  Labs is required to pay any such\n",
      "deficiency, or any fine, assessment or penalty for any such deficiency,  Nostrum\n",
      "shall promptly  reimburse  Synovics Labs for any such payments for which Nostrum\n",
      "is liable in accordance with this Section 4.6, which  reimbursement shall not be\n",
      "included in the calculation of Net Sales or Gross Profits.\n",
      "\n",
      "                           ARTICLE 5. CONFIDENTIALITY.\n",
      "\n",
      "         5.1      CONFIDENTIALITY.  During the term of this  Agreement and for a\n",
      "period of ten (10) years after its expiration or  termination,  each party shall\n",
      "maintain as confidential the Nostrum  Technology,  any know-how  relating to the\n",
      "Product,   the  Results  and  any  other  proprietary,   technical  or  business\n",
      "information   received  from  the  other  party   pursuant  to  this   Agreement\n",
      "(\"Confidential Information\") and shall only use such Confidential\n",
      "\n",
      "                                       8\n",
      "\n",
      "\n",
      "Information  in  furtherance  of this  Agreement.  Both  parties  agree that any\n",
      "employees provided or given access to the other partys Confidential Information\n",
      "shall be bound by confidentiality  obligations essentially the same as those set\n",
      "forth herein. The foregoing  obligations of confidentiality and use restrictions\n",
      "shall not apply, however, to the extent that such Confidential Information:\n",
      "\n",
      "         (i)      was known to the receiving  party, as evidenced by its written\n",
      "                  records, prior to receipt from the other party;\n",
      "\n",
      "         (ii)     is in the public  domain at time of  receipt  or  subsequently\n",
      "                  enters the public domain  through no breach of this  Agreement\n",
      "                  by the receiving party;\n",
      "\n",
      "         (iii)    after  the date of  receipt  from  the  disclosing  party,  is\n",
      "                  received without secrecy obligations from a third party with a\n",
      "                  bona fide right to disclose it without  violating any right of\n",
      "                  the disclosing party;\n",
      "\n",
      "         (iv)     is independently  developed by the receiving party without the\n",
      "                  aid,  application  or use of  any  of the  disclosing  partys\n",
      "                  Confidential Information (and such independent development can\n",
      "                  be properly documented by the receiving party);\n",
      "\n",
      "         (v)      is disclosed to governmental or other  regulatory  agencies in\n",
      "                  order  to  obtain  patents  or to  gain  approval  to  conduct\n",
      "                  clinical  trials or to market  the  Product  pursuant  to this\n",
      "                  Agreement,  but  such  disclosure  may be only  to the  extent\n",
      "                  reasonably necessary to obtain such patents or authorizations;\n",
      "\n",
      "         (vi)     is  necessary   to  be   disclosed  to  agents,   consultants,\n",
      "                  Affiliates  and/or  other third  parties  for the  developing,\n",
      "                  making,  using,  selling or  importing of Product (or for such\n",
      "                  third parties to determine  their interest in performing  such\n",
      "                  activities) in accordance with this Agreement on the condition\n",
      "                  that such third parties  agree to be bound by  confidentiality\n",
      "                  obligations  and use  restrictions  at least as restrictive as\n",
      "                  those contained in this Agreement; or\n",
      "\n",
      "         (vii)    is required to be disclosed  by law or court  order,  provided\n",
      "                  that notice is promptly  delivered to the disclosing  party in\n",
      "                  order to provide the disclosing party  sufficient  opportunity\n",
      "                  to seek a protective order or other similar order with respect\n",
      "                  to  such  Confidential  Information  and the  receiving  party\n",
      "                  thereafter  discloses only the minimum information required to\n",
      "                  be disclosed  in order to comply with the request,  whether or\n",
      "                  not a protective  order or other  similar order is obtained by\n",
      "                  the disclosing party.\n",
      "\n",
      "         5.2      NO PUBLICITY; DISCLOSURE OF AGREEMENT TERMS. Neither party may\n",
      "use  the  name  of the  other  party  or its  Affiliates  in  any  publicity  or\n",
      "advertising without the prior written permission of such party.  Notwithstanding\n",
      "the  provisions  of Section 5.1 and this Section 5.2,  either party may disclose\n",
      "the terms\n",
      "\n",
      "                                       9\n",
      "\n",
      "\n",
      "of this Agreement to the extent necessary to (a) actual or potential  lenders or\n",
      "investors;  (b) the partys agents,  consultants,  Affiliates and/or other third\n",
      "parties  necessary to facilitate  such a loan or investment;  or (c) the partys\n",
      "accountants,  consultants and attorneys,  for other corporate  transactions  and\n",
      "business, on a need to know basis.\n",
      "\n",
      "                               ARTICLE 6 - PATENTS\n",
      "\n",
      "         6.1      INFRINGEMENT AND THIRD PARTY LICENSES.\n",
      "\n",
      "                  (a)      In the event that Synovics  Labs, or its Affiliates\n",
      "making,  having made, using, offering for sale, selling or importing the Product\n",
      "infringes or misappropriates, will infringe or misappropriate or is alleged by a\n",
      "third party to  infringe  or  misappropriate  a third  partys  patents or other\n",
      "intellectual  property  rights,  the party hereto  becoming  aware of same shall\n",
      "promptly notify the other. The parties shall thereafter  attempt to agree upon a\n",
      "course of action with respect thereto.\n",
      "\n",
      "                  (b)      Synovics Labs shall be responsible, at Synovics Labs\n",
      "expense, for the defense of any claims, demands,  actions or proceedings arising\n",
      "from allegations that  development,  making,  having made,  using,  offering for\n",
      "sale,  selling or importing  the Product  infringes or  misappropriates  or will\n",
      "infringe  or  misappropriate  a third  partys  patents  or  other  intellectual\n",
      "property  rights.  Upon  Synovics  Labs  request  and  expense,  Nostrum  shall\n",
      "cooperate with Synovics Labs in such defense;  provided that Synovics Labs shall\n",
      "promptly  reimburse  Nostrum for  reasonable  out-of-pocket  costs and  expenses\n",
      "incurred by Nostrum in providing such cooperation.\n",
      "\n",
      "         6.2      INFRINGEMENT  OF NOSTRUMS  INTELLECTUAL  PROPERTY RIGHTS BY A\n",
      "THIRD PARTY.  Synovics Labs and Nostrum shall promptly  notify each other of any\n",
      "infringement of the patent rights included in the Nostrum  Technology as applied\n",
      "to the Product,  and/or any  misappropriation  or unauthorized use of any of the\n",
      "Nostrum Technology as applied to the Product, in the Territory which may come to\n",
      "their attention.  The parties shall thereafter attempt to agree upon a course of\n",
      "action  with  respect  thereto.  If  Nostrum  declines  to  participate  in  the\n",
      "prosecution of legal proceedings to prevent such infringement,  misappropriation\n",
      "or misuse of the Nostrum Technology,  Synovics Labs may do so at its own expense\n",
      "using counsel of its choice.\n",
      "\n",
      "                   ARTICLE 7 - REPRESENTATIONS AND WARRANTIES\n",
      "\n",
      "         7.1      REPRESENTATIONS  AND  WARRANTIES  BY  BOTH  PARTIES.  Each  of\n",
      "Synovics  Labs and Nostrum  hereby  represents  and  warrants to the other party\n",
      "that:\n",
      "\n",
      "         (i)      it is a corporation  duly organized and validly existing under\n",
      "                  the laws of the state or other  jurisdiction of  incorporation\n",
      "                  or formation;\n",
      "\n",
      "                                       10\n",
      "\n",
      "\n",
      "         (ii)     the execution,  delivery and  performance of this Agreement by\n",
      "                  such party has been duly authorized by all requisite corporate\n",
      "                  action;\n",
      "\n",
      "         (iii)    it has all  requisite  power  and  authority  to  execute  and\n",
      "                  deliver  this   Agreement  and  to  perform  its   obligations\n",
      "                  hereunder;\n",
      "\n",
      "         (iv)     the execution,  delivery and performance by such party of this\n",
      "                  Agreement  and its  compliance  with the terms and  provisions\n",
      "                  hereof  does not and will not  conflict  with or  result  in a\n",
      "                  breach of any of the terms and  provisions  of or constitute a\n",
      "                  default  under  (i)  a  loan  agreement,  guaranty,  financing\n",
      "                  agreement, agreement affecting a product or other agreement or\n",
      "                  instrument  binding or affecting it or its property;  (ii) the\n",
      "                  provisions  of its charter  documents or bylaws;  or (iii) any\n",
      "                  order, writ, injunction or decree of any court or governmental\n",
      "                  authority  entered  against it or by which any of its property\n",
      "                  is bound;\n",
      "\n",
      "         (v)      except for the governmental and regulatory  approvals required\n",
      "                  to  market  the  Product  in  the  Territory,  the  execution,\n",
      "                  delivery and  performance of this Agreement by such party does\n",
      "                  not require the  consent,  approval  or  authorization  of, or\n",
      "                  notice,   declaration,   filing  or  registration   with,  any\n",
      "                  governmental  or  regulatory   authority  and  the  execution,\n",
      "                  delivery or performance of this Agreement will not violate any\n",
      "                  law, rule or regulation applicable to such party;\n",
      "\n",
      "         (vi)     this  Agreement  constitutes  such  partys  legal,  valid and\n",
      "                  binding obligation  enforceable  against it in accordance with\n",
      "                  its  terms  subject,   as  to   enforcement,   to  bankruptcy,\n",
      "                  insolvency,   reorganization   and  other   laws  of   general\n",
      "                  applicability  relating to or affecting  creditors rights and\n",
      "                  to the  availability  of  particular  remedies  under  general\n",
      "                  equity principles; and\n",
      "\n",
      "         (vii)    it shall comply with all applicable  material laws,  rules and\n",
      "                  regulations  relating to the  performance  of its  obligations\n",
      "                  relating to the Product under this Agreement.\n",
      "\n",
      "         7.2      REPRESENTATIONS  AND  WARRANTIES  BY NOSTRUM.  Nostrum  hereby\n",
      "represents and warrants to Synovics Labs that:\n",
      "\n",
      "         (i)      it owns all right,  title and  interest  in and to the Nostrum\n",
      "                  Technology  as applied to the  Product,  free and clear of all\n",
      "                  liens,   charges,   encumbrances   and  to  Nostrums   actual\n",
      "                  knowledge, other adverse claims;\n",
      "\n",
      "         (ii)     to Nostrums  actual  knowledge as of the Effective  Date, (1)\n",
      "                  the  Nostrum  Technology  as applied to the Product and Future\n",
      "                  Product does not, and (2) the use of the Nostrum Technology as\n",
      "                  applied to the Product and Future Product,  will not, infringe\n",
      "                  on or  misappropriation  the  existing  intellectual  property\n",
      "                  rights of any other party;\n",
      "\n",
      "                                       11\n",
      "\n",
      "\n",
      "         (iii)    there are no adverse actions,  suits or claims pending against\n",
      "                  Nostrum  or any of its  Affiliates  in or before  any court or\n",
      "                  governmental  or  regulatory  authority  with  respect  to the\n",
      "                  Product  and/or  the  Nostrum  Technology  as  applied  to the\n",
      "                  Product,  and no such  actions,  suits  or  claims  have  been\n",
      "                  threatened against Nostrum or any of its Affiliates;\n",
      "\n",
      "         (iv)     to  the  best  of  Nostrums  knowledge,  all  data  summaries\n",
      "                  provided  in writing to Synovics  Labs by Nostrum  relating to\n",
      "                  the Pre-study  accurately  represent  the raw data  underlying\n",
      "                  such summaries;\n",
      "\n",
      "         (v)      as of the Effective Date, to the best of Nostrums  knowledge,\n",
      "                  there is no reason  (e.g.,  debarment  under the Federal Food,\n",
      "                  Drug, and Cosmetic Act) that would prevent  Synovics Labs from\n",
      "                  using data and  information  supplied by  Nostrum,  as part of\n",
      "                  Synovics Labs regulatory submissions for the Product.\n",
      "\n",
      "         7.3      CONTINUING REPRESENTATIONS. The representations and warranties\n",
      "of each party  contained in Sections 7.1 and 7.2 shall  survive the execution of\n",
      "this Agreement.\n",
      "\n",
      "         7.4      NO INCONSISTENT AGREEMENTS.  As of the Effective Date, neither\n",
      "Party has entered  into,  and during the term of this  Agreement,  neither party\n",
      "shall enter into,  any oral or written  agreement or  arrangement  that would be\n",
      "inconsistent with its obligations under this Agreement.\n",
      "\n",
      "         7.5      NO WARRANTY AS TO REGULATORY APPROVAL. Nothing herein shall be\n",
      "construed as a  representation  or warranty by either party that the  applicable\n",
      "health regulatory  authorities within the Territory will consider the Product to\n",
      "be safe and effective,  or will grant regulatory approval to market and sell the\n",
      "Product in the Territory even if any  additional  studies are conducted by or on\n",
      "behalf of Synovics Labs or its Affiliates.\n",
      "\n",
      "                           ARTICLE 8 - INDEMNIFICATION\n",
      "\n",
      "         8.1      INDEMNIFICATION  BY NOSTRUM.  Nostrum shall,  at its sole cost\n",
      "and  expense,  defend,  indemnify  and  hold  harmless  Synovics  Labs  and  its\n",
      "Affiliate(s),  and their respective  officers,  directors,  agents and employees\n",
      "from and against all claims, liens, demands, damages, liability, actions, causes\n",
      "of action,  losses,  judgments,  amounts paid in settlement,  costs and expenses\n",
      "(including,  without  limitation,   reasonable  attorneys  fees)  (collectively\n",
      "\"Claim(s)\") to the extent such Claims arise out of or in connection with, result\n",
      "from,  or are caused by:  (i) any  breach by Nostrum of its  representations  or\n",
      "warranties contained in Sections 7.1 or 7.2 of this Agreement; or (ii) the gross\n",
      "negligence  or  willful   misconduct  of  Nostrum  in  the  performance  of  its\n",
      "obligations under this Agreement;  PROVIDED, HOWEVER, that Nostrum shall have no\n",
      "liability or indemnification  obligations hereunder to the extent any such Claim\n",
      "is caused by the gross  negligence or\n",
      "\n",
      "                                       12\n",
      "\n",
      "\n",
      "willful  misconduct  of  Synovics  Labs,  its  Affiliates  or  their  respective\n",
      "officers, directors, agents and employees.\n",
      "\n",
      "         8.2      INDEMNIFICATION BY SYNOVICS LABS.  Synovics Labs shall, at its\n",
      "sole cost and  expense,  defend,  indemnify  and hold  harmless  Nostrum and its\n",
      "Affiliate(s),  and their respective  officers,  directors,  agents and employees\n",
      "from and  against  all  Claims  to the  extent  such  Claims  arise out of or in\n",
      "connection with,  result from, or are caused by: (i) any breach by Synovics Labs\n",
      "of its representations or warranties contained in Section 7.1 of this Agreement;\n",
      "(ii)  the  gross  negligence  or  willful  misconduct  of  Synovics  Labs or its\n",
      "Affiliates in the performance of its or their  obligations under this Agreement;\n",
      "(iii) the marketing, manufacture, use or sale of the Product in the Territory by\n",
      "or on behalf of Synovics Labs or its Affiliates;  or (iv)  allegations  that the\n",
      "manufacture,  use or sale of the  Product  in the  Territory  by or on behalf of\n",
      "Synovics Labs or its Affiliates infringes third party patents or misappropriates\n",
      "the other intellectual  property rights of any third party;  PROVIDED,  HOWEVER,\n",
      "that  Synovics  Labs  shall have no  liability  or  indemnification  obligations\n",
      "hereunder  to the  extent any such  Claim is caused by the gross  negligence  or\n",
      "willful  misconduct of Nostrum,  its  Affiliates or their  respective  officers,\n",
      "directors, agents and employees.\n",
      "\n",
      "         8.3      CONDITIONS  TO   INDEMNIFICATION.   The   obligations  of  the\n",
      "indemnifying  party under Articles 8.1 and 8.2 are conditioned upon the delivery\n",
      "of written  notice to the  indemnifying  party of any potential  Claim  promptly\n",
      "after the indemnified party becomes aware of such potential Claim. The foregoing\n",
      "notwithstanding,   the  parties  acknowledge  and  agree  that  failure  of  the\n",
      "indemnified party to promptly notify the indemnifying party of a potential Claim\n",
      "shall not  constitute a waiver of, or result in the loss of, such partys  right\n",
      "to  indemnification  under  Articles 8.1 or 8.2, as  appropriate,  except to the\n",
      "extent  that the  indemnifying  partys  rights,  and/or  its  ability to defend\n",
      "against such liability are materially  prejudiced by such failure to notify. The\n",
      "indemnifying  party is hereby  authorized to carry out the sole  management  and\n",
      "defense of such potential  Claim, and shall have the right to assume the defense\n",
      "of any suit or claim related to the Claim if it has assumed  responsibility  for\n",
      "the Claim in writing.  However, if in the reasonable judgment of the indemnified\n",
      "party,  such Claim  involves an issue or matter  which  could have a  materially\n",
      "adverse effect on the business  operations or assets of the  indemnified  party,\n",
      "the indemnified party may waive its rights to indemnity under this Agreement and\n",
      "control the defense or settlement thereof. If the indemnifying party defends the\n",
      "suit or claim,  the  indemnified  party may participate in (but not control) the\n",
      "defense thereof at its sole cost and expense.\n",
      "\n",
      "         8.4      SETTLEMENTS.  Neither  party  may  settle  a claim  or  action\n",
      "related to a Claim  without the consent of the other party,  if such  settlement\n",
      "would  impose any  monetary  obligation  on the other party or require the other\n",
      "party to submit to an  injunction or otherwise  limit the other  partys  rights\n",
      "under this  Agreement.  Any payment  made by a party to settle any such claim or\n",
      "action shall be at its own cost and expense.\n",
      "\n",
      "         8.5      LIMITATION  OF  LIABILITY.  With  respect  to any claim by one\n",
      "party against the other arising out of the performance or failure of performance\n",
      "of the other party under\n",
      "\n",
      "                                       13\n",
      "\n",
      "\n",
      "this Agreement,  the parties expressly agree that the liability of such party to\n",
      "the other  party for such  breach  shall be  limited  under  this  Agreement  or\n",
      "otherwise at law or equity to compensatory  damages only and in no event shall a\n",
      "party be liable for punitive or exemplary damages. The foregoing limitation will\n",
      "not prevent a party entitled to indemnification  pursuant to this Agreement from\n",
      "recovering  all  components  of any judgment or award against such a party by an\n",
      "unaffiliated party.\n",
      "\n",
      "         8.6      INSURANCE.  During the term of this  Agreement  Synovics  Labs\n",
      "shall maintain adequate insurance and/or a self-insurance  program for liability\n",
      "insurance, including products liability insurance,  adequately covering Synovics\n",
      "Labs obligations under this Agreement. Synovics Labs shall provide Nostrum with\n",
      "evidence of such insurance and/or self-insurance upon request.\n",
      "\n",
      "                        ARTICLE 9 - TERM AND TERMINATION\n",
      "\n",
      "         9.1      TERM AND  EXPIRATION.  This Agreement shall be effective as of\n",
      "the  Effective  Date and unless  terminated  earlier  pursuant to this Article 9\n",
      "shall  continue  in effect for the longer of a period of ten (10) years from the\n",
      "first  commercial  sale of the Product by or on behalf of  Synovics  Labs in the\n",
      "Territory,  or until such time as the  commercial  sale of the  Product by or on\n",
      "behalf of Synovics Labs in the Territory is discontinued.\n",
      "\n",
      "         9.2      RIGHTS OF SYNOVICS LABS TO TERMINATE.\n",
      "\n",
      "     a)  With respect to the Future Product, in the event that (i) Synovics Labs\n",
      "         determines  that the  results of the  Pivotal  Study do not  adequately\n",
      "         demonstrate  bioequivalence  of the Future  Strength with the Reference\n",
      "         Product,  or (ii)  Synovics Labs fails to obtain FDA approval to market\n",
      "         and sell the Product in the  Territory,  then  Synovics Labs shall have\n",
      "         the right to terminate this  Agreement by notifying  Nostrum in writing\n",
      "         to that effect.\n",
      "\n",
      "     b)  With  respect to the  Product,  Synovics  Labs shall have the option to\n",
      "         terminate  this  Agreement in the event that Synovics Labs  determines,\n",
      "         based on the actual results of manufacturing,  distribution and sale of\n",
      "         the Product,  that the profitability or market size of the Product does\n",
      "         not equal or exceed the profitability or market size, as applicable, of\n",
      "         other Synovics Labs products of similar market size and cost structure.\n",
      "\n",
      "         9.3      TERMINATION  FOR CAUSE.  Either  party shall have the right to\n",
      "terminate  this  Agreement  upon sixty (60) days written notice in the event the\n",
      "other party is in breach of one or more of its material  obligations  under this\n",
      "Agreement;  provided that the breaching party shall have the opportunity to cure\n",
      "any  alleged  breach  during  such sixty  (60) day  period.  To assist  with the\n",
      "interpretation  of this Agreement,  the parties agree that: a breach by Synovics\n",
      "Labs of the provisions of any of Sections 3.1(c),  3.2(a),  3.2(b), 3.2(c),\n",
      "\n",
      "                                       14\n",
      "\n",
      "\n",
      "3.3, 4.1, 4.2, 4.3 and 4.5 shall be a material  breach;  and a breach by Nostrum\n",
      "of the provisions of any of Sections 3.1(a),  3.1(b), 3.1(c) and 3.1(d) shall be\n",
      "a material breach. For avoidance of doubt, the provisions listed in this Section\n",
      "9.3 do not constitute an exhaustive list of those provisions the breach of which\n",
      "may be material.\n",
      "\n",
      "         9.4      BANKRUPTCY  OR  INSOLVENCY.  Either party shall be entitled to\n",
      "immediately   terminate  this  Agreement  upon  the  filing  or  institution  of\n",
      "bankruptcy,  reorganization (in connection with any insolvency),  liquidation or\n",
      "receivership proceedings,  or upon an assignment of a substantial portion of the\n",
      "assets  for the  benefit  of  creditors  by the other  party,  or in the event a\n",
      "receiver or custodian  is appointed  for such other  partys  business,  or if a\n",
      "substantial  portion of such other partys  business is subject to attachment or\n",
      "similar  process;  PROVIDED,  HOWEVER,  that  in the  case  of  any  involuntary\n",
      "bankruptcy  proceeding or the  attachment of a substantial  portion of a partys\n",
      "assets such right to terminate shall only become  effective if the proceeding or\n",
      "attachment is not dismissed within sixty (60) days after the filing thereof.\n",
      "\n",
      "         9.5      EFFECT OF  TERMINATION.  In the event that this  Agreement  is\n",
      "terminated,  the  license  granted  to  Synovics  Labs under  Section  2.1 shall\n",
      "terminate,  Synovics  Labs shall  transfer to Nostrum  all of the  formulations,\n",
      "processes and other technology,  approvals,  applications and records related to\n",
      "the  development  and  commercialization  of  the  Product,  and  Nostrum  shall\n",
      "thereafter have the right to develop,  manufacture  and otherwise  commercialize\n",
      "the  Product  in the  Territory,  together  with all other  countries  and their\n",
      "territories, possessions and commonwealths.\n",
      "\n",
      "         9.6      SURVIVING  TERMS.  The  provisions  of  Section  9.5,  and  of\n",
      "Articles 5, 8 and 11,  Nostrums  audit rights under Section 4.5, and such other\n",
      "provisions of this Agreement  which by their expressed terms are to be performed\n",
      "or complied with  subsequent to the termination or expiration of this Agreement,\n",
      "shall survive such  termination  or expiration  and shall continue in full force\n",
      "and effect in accordance with their respective terms.\n",
      "\n",
      "                            ARTICLE 10. FORCE MAJEURE\n",
      "\n",
      "                  (a)      No  failure  or   omission  by  the  parties  in  the\n",
      "performance  of any  obligation  according to this  Agreement  shall be deemed a\n",
      "breach of this  Agreement  or create any  liability if the same shall arise from\n",
      "any cause or causes beyond the control of the party, including,  but not limited\n",
      "to, strikes, riots, war, acts of God, invasion,  fire, explosion,  floods, delay\n",
      "of carrier,  energy shortages and acts of government or governmental agencies or\n",
      "instrumentalities.\n",
      "\n",
      "                  (b)      In the event that due to force  majeure  either party\n",
      "hereto shall be delayed or hindered in or prevented from the  performance of its\n",
      "duties or doing acts required under the terms of this Agreement, the performance\n",
      "of such act,  except for the obligation to pay amounts due under this Agreement,\n",
      "shall be excused for the period of delay.  Notwithstanding  the  aforementioned,\n",
      "the party subject to force majeure shall promptly take all  reasonable  steps to\n",
      "resolve the condition(s) forming the basis of force\n",
      "\n",
      "                                       15\n",
      "\n",
      "\n",
      "majeure;  provided,  however,  that nothing  contained  herein shall require any\n",
      "party to settle on terms  unsatisfactory  to such party any strike,  lock-out or\n",
      "other labor difficulty, any investigation or proceeding by any public authority,\n",
      "or any litigation by any third party. If a condition  constituting force majeure\n",
      "as defined herein exists for more than ninety (90) consecutive days, the parties\n",
      "shall meet to negotiate a mutually  satisfactory  resolution to the problem,  if\n",
      "practicable.\n",
      "\n",
      "                           ARTICLE 11 - MISCELLANEOUS\n",
      "\n",
      "         11.1     ASSIGNMENT.  (a) Neither this  Agreement nor any or all of the\n",
      "rights and obligations of a party hereunder shall be assigned,  delegated, sold,\n",
      "transferred,  sublicensed  (except as  otherwise  provided  herein) or otherwise\n",
      "disposed of, by operation of law or  otherwise,  to any third party  without the\n",
      "prior written consent of the other party. Any attempted assignment,  delegation,\n",
      "sale,  transfer,  sublicense  or  other  disposition,  by  operation  of  law or\n",
      "otherwise,  of this Agreement or of any rights or obligations hereunder contrary\n",
      "to this  Article  11.1  shall be a  material  breach  of this  Agreement  by the\n",
      "attempting party, and shall be void and without force or effect. Notwithstanding\n",
      "the foregoing,  either party may, without the consent of the other party, assign\n",
      "the Agreement and its rights and obligations hereunder (i) to an Affiliate; (ii)\n",
      "in  connection  with the  transfer  or sale of all or  substantially  all of its\n",
      "assets related to the subject division or the subject business;  or (iii) in the\n",
      "event of its merger or consolidation.\n",
      "\n",
      "                  (b)      Any  assignment,  sublicense  or  other  transfer  by\n",
      "either  party  permitted  by this Section 11.1 shall not operate to release such\n",
      "party from its responsibilities under this Agreement.\n",
      "\n",
      "         11.2     NO  WAIVER.  No  failure  by a party to  exercise  any  rights\n",
      "hereunder in the event of a breach or violation  hereof by the other party shall\n",
      "constitute a waiver of any such rights.  No waiver by any party of any breach or\n",
      "violation hereof by the other party,  shall constitute a waiver of any rights in\n",
      "respect of any other or subsequent breach or violation.\n",
      "\n",
      "         11.3     NOTICES. All notices required to be given under this Agreement\n",
      "shall be in writing  and given by  personal  delivery,  facsimile  transmission,\n",
      "nationally  recognized  overnight  courier  (prepaid) or registered or certified\n",
      "mail, postage prepaid with return receipt requested. Notices shall be addressed:\n",
      "\n",
      "                  if to Nostrum, at\n",
      "\n",
      "                           10 Erin Ct.\n",
      "                           Kendall Park, New Jersey   08824\n",
      "                           Attn: Nirmal Mulye, Ph.D.\n",
      "                           Fax: (732) 422-0416\n",
      "\n",
      "                                       16\n",
      "\n",
      "\n",
      "                  if to Synovics Labs, at\n",
      "\n",
      "                           Synovics Laboratories, Inc.\n",
      "                           505 Thornhall Street, Suite 304\n",
      "                           Edison, New Jersey 08837\n",
      "                           Attention:  Theodore Miro\n",
      "                           Fax:  (732) 635-0042\n",
      "\n",
      "A party may change its address by written notice in accordance with this Section\n",
      "11.3\n",
      "\n",
      "         11.4     GOVERNING  LAW/DISPUTES.  This Agreement  shall be governed by\n",
      "and  construed  in  accordance  with the laws of the  State of New York  without\n",
      "regard to the conflict of laws provisions  thereof.  In the event of any dispute\n",
      "hereunder or otherwise arising out of or relating to this Agreement, the parties\n",
      "hereto  agree  that  such  dispute  will  be  resolved  only by  arbitration  in\n",
      "accordance with the terms set forth in Article 12, attached hereto.\n",
      "\n",
      "         11.5     INDEPENDENT  CONTRACTOR.   The  parties  shall  be  considered\n",
      "independent  contractors,  and  neither  the  making of this  Agreement  nor the\n",
      "performance  of any of the  provisions  hereof shall be construed to make either\n",
      "party an agent,  employee or legal  representative  of the other, nor shall this\n",
      "Agreement be deemed to establish a joint venture or partnership.\n",
      "\n",
      "         11.6     SEVERABILITY.  Should any section, or portion thereof, of this\n",
      "Agreement be held invalid by reason of any law,  statute or regulation  existing\n",
      "now or in the future in any jurisdiction by any court of competent  authority or\n",
      "by a legally  enforceable  directive of any governmental body, then such section\n",
      "or portion thereof shall be validly  reformed so as to approximate the intent of\n",
      "the  parties  as  nearly  as  possible  and,  if  unreformable,  shall be deemed\n",
      "divisible and deleted with respect to such jurisdiction and this Agreement shall\n",
      "not otherwise be affected.\n",
      "\n",
      "         11.7     EFFECT OF ASSIGNMENT.  This  Agreement  shall be binding upon,\n",
      "and inure to the  benefit  of,  each  party  and its  permitted  successors  and\n",
      "permitted assigns.  Each party shall be responsible for the compliance by any of\n",
      "its permitted assignees with the terms and conditions of this Agreement.\n",
      "\n",
      "         11.8     RECORDING.  Each party shall have the right,  at any time,  to\n",
      "record, register, or otherwise notify this Agreement in appropriate governmental\n",
      "or regulatory  offices anywhere in the Territory,  and Nostrum or Synovics Labs,\n",
      "as the  case  may be,  shall  provide  reasonable  assistance  to the  other  in\n",
      "effecting such recording, registering or notifying.\n",
      "\n",
      "                                       17\n",
      "\n",
      "\n",
      "         11.9     FURTHER ACTIONS. Each party agrees to execute, acknowledge and\n",
      "deliver  such  further  instruments  and to do all such  other  acts,  as may be\n",
      "necessary or  appropriate  in order to carry out the purposes and intent of this\n",
      "Agreement.\n",
      "\n",
      "         11.10    COUNTERPARTS. This Agreement shall become binding when any one\n",
      "or more  counterparts  hereof,  individually or taken  together,  shall bear the\n",
      "signatures of each of the parties  hereto and is delivered to the other party in\n",
      "accordance  with Section 11.3.  This  Agreement may be executed in any number of\n",
      "counterparts,  each of which shall be an original as against  either party whose\n",
      "signature appears thereon,  but all of which taken together shall constitute but\n",
      "one and the same instrument.\n",
      "\n",
      "         11.11    ENTIRE AGREEMENT.  This Agreement,  together with the attached\n",
      "schedule,  represents the entire  agreement  between the parties with respect to\n",
      "the subject matter hereof and  supersedes and replaces all prior  agreements and\n",
      "understandings,  whether  written  or  oral.  No  terms  or  provisions  of this\n",
      "Agreement shall be varied or modified and no subsequent  alteration,  amendment,\n",
      "change or addition to this  Agreement  shall be binding upon the parties  unless\n",
      "reduced to writing and signed by an authorized officer of each party.\n",
      "\n",
      "                                   ARTICLE 12\n",
      "                          DISPUTE RESOLUTION PROCEDURES\n",
      "\n",
      "         12.1     Except as otherwise set forth in the  Agreement,  any dispute,\n",
      "controversy  or claim arising out of or relating to the validity,  construction,\n",
      "enforceability or performance of this Agreement,  including disputes relating to\n",
      "an alleged breach or termination of this Agreement,  shall be settled by binding\n",
      "arbitration in the manner set forth below in this Article 12; provided, however,\n",
      "that the neutral  referred to below shall give effect to the  provisions of this\n",
      "Agreement and shall not adjust,  modify or change the effects of  termination as\n",
      "set forth in Article 9 of this Agreement  Notwithstanding the foregoing,  in the\n",
      "event of a claim,  action,  suit or  proceeding  against or involving  any party\n",
      "entitled to indemnification  pursuant to this Agreement brought or asserted by a\n",
      "third party that is not affiliated with either party to this Agreement, then the\n",
      "entitled to the indemnification will have the option to include the indemnifying\n",
      "party to such claim, action suit or proceeding notwithstanding the provisions of\n",
      "this Article 12.\n",
      "\n",
      "         12.2     If a party  intends  to  begin an  arbitration  to  resolve  a\n",
      "dispute, such party shall provide written notice (the \"Request\") by certified or\n",
      "registered  mail or properly  documented  overnight  delivery to the other party\n",
      "informing such other party of such intention and the issues to be resolved.  The\n",
      "notice  shall  explain  the nature of the  complaint  and refer to any  relevant\n",
      "Articles of the  Agreement  upon which the complaint is based.  The  complaining\n",
      "party  shall also set forth a proposed  solution  to the  problem,  including  a\n",
      "suggested time frame within which the parties must act.\n",
      "\n",
      "         12.3     The  non-complaining  party must  respond  in  writing  within\n",
      "thirty (30) calendar  days of receiving  notice with an  explanation,  including\n",
      "references  to the relevant\n",
      "\n",
      "                                       18\n",
      "\n",
      "\n",
      "provisions  of the  Agreement  and a  response  to  the  proposed  solution  and\n",
      "suggested time frame for action.  The  non-complaining  party may add additional\n",
      "issues to be resolved.\n",
      "\n",
      "         12.4     Within ten (10)  business days of receipt of the response from\n",
      "the  non-complaining  party,  the  parties  shall meet and  discuss  options for\n",
      "resolving the dispute. Each party shall make available all appropriate personnel\n",
      "to meet and confer with the other party within the ten (10)  business day period\n",
      "following the complaining partys receipt of the response by the non-complaining\n",
      "party.\n",
      "\n",
      "         12.5     Any and all  disputes  that  cannot be  resolved  pursuant  to\n",
      "Paragraphs  (b), (c) and (d) above shall be submitted to an arbitrator  selected\n",
      "by mutual  agreement of the parties.  If the parties are unable to agree upon an\n",
      "arbitrator,  then  the  arbitrator  shall be  selected  in  accordance  with the\n",
      "procedures of the American Arbitration  Association.  The arbitrator shall be an\n",
      "individual who shall preside over and resolve any disputes  between the parties.\n",
      "The arbitrator  selected shall be a former judge of a state or federal court and\n",
      "shall not be an employee,  director or  shareholder  of, or  otherwise  have any\n",
      "current  or  previous   relationship   with,  either  party  or  its  respective\n",
      "Affiliates. The arbitration shall be conducted in accordance with the commercial\n",
      "arbitration  rules  of the  American  Arbitration  Association  then in  effect,\n",
      "subject  to the time  periods  and other  provisions  of this  Article  12 or as\n",
      "otherwise set forth in the Agreement.\n",
      "\n",
      "         12.6     Consistent  with the time  schedule  established  pursuant  to\n",
      "Paragraphs  (g) and (h) below,  the  arbitrator  shall hold a hearing to resolve\n",
      "each of the issues  identified  by the  parties  and shall  render a decision as\n",
      "expeditiously  as possible but in no event more than thirty (30)  calendar  days\n",
      "after the close of hearings. In rendering the decision the arbitrator shall rule\n",
      "on each disputed  issue and shall adopt in whole or in part the proposed  ruling\n",
      "of one of the parties on each disputed issue.\n",
      "\n",
      "         12.7     During the meeting  referred to in  Paragraph  (d) above,  the\n",
      "parties  shall  negotiate  in good faith the scope and  schedule  of  discovery,\n",
      "relating to depositions, document production and other discovery devices, taking\n",
      "into account the nature of the dispute submitted for resolution.  If the parties\n",
      "are unable to reach  agreement  as to the scope and schedule of  discovery,  the\n",
      "arbitrator may order such discovery as the arbitrator  deems  necessary.  To the\n",
      "extent  practicable  taking into account the nature of the dispute submitted for\n",
      "resolution,  such discovery  shall be completed  within sixty (60) calendar days\n",
      "from the date of the selection of the  arbitrator.  At the hearing,  which shall\n",
      "commence within twenty (20) business days after  completion of discovery  unless\n",
      "the arbitrator  otherwise orders, the parties may present testimony (either live\n",
      "witness or deposition), subject to cross-examination,  and documentary evidence.\n",
      "To the  extent  practicable  taking  into  account  the  nature  of the  dispute\n",
      "submitted for resolution and the  availability  of the  arbitrator,  the hearing\n",
      "shall be conducted over a period not to exceed thirty (30) consecutive  business\n",
      "days, with each party entitled to approximately half of the allotted time unless\n",
      "otherwise ordered by the arbitrator.  The hearing shall be held in New York, New\n",
      "York at such place as may be agreed upon by the parties.  The  arbitrator  shall\n",
      "have sole  discretion with regard to the  admissibility  of any evidence and all\n",
      "other matters relating to the conduct of the hearing.  The arbitrator  shall, in\n",
      "rendering  its\n",
      "\n",
      "                                       19\n",
      "\n",
      "\n",
      "decision, apply the substantive laws of the State of New York (regardless of its\n",
      "or any other  jurisdictions  choice of law  principles).  The  decision  of the\n",
      "arbitrator shall be final and not appealable, except in the case of fraud or bad\n",
      "faith on the part of the arbitrator or any party to the  arbitration  proceeding\n",
      "in connection with the conduct of such  proceedings;  manifest  disregard of the\n",
      "law by the  arbitrator  concerning a material issue in rendering the decision or\n",
      "upon any other  ground for vacating or  modifying  the decision  pursuant to the\n",
      "Federal Arbitration Act, as amended..\n",
      "\n",
      "         12.8     At least ten (10)  business days prior to the date set for the\n",
      "hearing,  each party shall submit to each other party and the  arbitrator a list\n",
      "of all  documents  on which  such  party  intends to rely in any oral or written\n",
      "presentation  to the arbitrator and a list of all witnesses,  if any, such party\n",
      "intends to call at such hearing and a brief summary of each witness  testimony.\n",
      "At least five (5) business days prior to the hearing,  each party must submit to\n",
      "the  arbitrator  and serve on each other  party a proposed  findings of fact and\n",
      "conclusions  of law on  each  issue  to be  resolved.  Following  the  close  of\n",
      "hearings,  the  parties  shall  each  submit  such  post-hearing  briefs  to the\n",
      "arbitrator  addressing the evidence and issues to be resolved as may be required\n",
      "or permitted by the arbitrator.\n",
      "\n",
      "         12.9     Except as otherwise set forth  herein,  the  arbitrator  shall\n",
      "determine  the  proportion  in which the parties shall pay the costs and fees of\n",
      "the  arbitration,  and each party  shall pay its own costs  (including,  without\n",
      "limitation,  reasonable  attorneys  fees) and expenses in connection  with such\n",
      "arbitration;  provided,  however,  that if the  arbitrator  determines  that the\n",
      "action of any party was arbitrary, frivolous or in bad faith, the arbitrator may\n",
      "award such costs and expenses to the prevailing party.\n",
      "\n",
      "         12.10    The arbitration  proceeding shall be confidential  and, except\n",
      "as required by law,  neither  party shall make (or  instruct the  arbitrator  to\n",
      "make) any public announcement with respect to the proceedings or decision of the\n",
      "arbitrator  without the prior written consent of the other party.  The existence\n",
      "of any dispute submitted for arbitration, and the award of the arbitrator, shall\n",
      "be kept in confidence by the parties and the  arbitrator,  except as required in\n",
      "connection  with the  enforcement  of such  award or as  otherwise  required  by\n",
      "applicable law.\n",
      "\n",
      "         12.11    Judgment  upon any award  rendered  by the  Arbitrator  may be\n",
      "entered in any court having jurisdiction thereof.\n",
      "\n",
      "         12.12    Nothing  contained  herein  shall be  construed  to permit the\n",
      "arbitrator or any court or any other forum to award  punitive,  exemplary or any\n",
      "similar  damages.  By entering  into this  Agreement to  arbitrate,  the parties\n",
      "expressly waive any claim for punitive,  exemplary or any similar  damages.  The\n",
      "only damages  recoverable  under this Agreement are  compensatory  damages.  The\n",
      "foregoing  limitation  will not  prevent  a party  entitled  to  indemnification\n",
      "pursuant to this  Agreement  from  recovering  all components or any judgment or\n",
      "award against such party by an unaffiliated third party.\n",
      "\n",
      "                                       20\n",
      "\n",
      "\n",
      "         12.13    The procedures  specified in this Article 12 shall be the sole\n",
      "and exclusive  procedures  for the  resolution  of disputes  between the parties\n",
      "which are expressly  identified for  resolution in accordance  with this Article\n",
      "12.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "         IN WITNESS WHEREOF,  the parties have executed this Agreement as of the\n",
      "date set forth above.\n",
      "\n",
      "NOSTRUM PHARMACEUTICALS, INC.                 SYNOVICS LABORATORIES, INC.\n",
      "\n",
      "\n",
      "By:                                           By:\n",
      "    ------------------------------                ------------------------------\n",
      "\n",
      "Name:  Nirmal Mulye, Ph.D.                    Name: Ronald Howard Lane. Ph.D.\n",
      "Title: President                              Title: President\n",
      "\n",
      "                                       21\n",
      "\n",
      "\n",
      "\n",
      "Bottom of Form\n",
      "© Copyright 2000 - 2016 RoyaltyStat.\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "file_path = '/home/kprasath/DS/NLPInternship/txt_data/ref_1_txt/8866.txt' \n",
    "text = read_txt(file_path)\n",
    "print(text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "a7ffb61c",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Top of Form\n",
      "\n",
      "\n",
      " ",
      " ",
      "Type: EX-10.2 Description: No Description ",
      " ",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "  \n",
      "    \n",
      "      Exhibit 10.4 Joint HIV Barrel Product Marketing Agreement\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "  \n",
      "    \n",
      "\n",
      "      \n",
      "\n",
      "        \n",
      "\n",
      "          \n",
      "\n",
      "\n",
      "        \n",
      "\n",
      "        \n",
      "\n",
      "          \n",
      "\n",
      "\n",
      "        \n",
      "\n",
      "        \n",
      " \n",
      "\n",
      "        \n",
      "\n",
      "          \n",
      "FINAL\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "Joint\n",
      "            HIV Barrel Product Commercialization Agreement\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "PREAMBLE\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "This\n",
      "            Joint HIV Barrel Product Commercialization Agreement (the “Agreement”)\n",
      "            is\n",
      "            made as of September 29, 2006 (“Effective\n",
      "            Date”),\n",
      "            by\n",
      "            and between Chembio\n",
      "            Diagnostic Systems, Inc.,\n",
      "            a\n",
      "            Delaware corporation having its principal place of business at 3661 Horseblock\n",
      "            Road, Medford, NY 11763 (“Chembio”),\n",
      "            and\n",
      "StatSure\n",
      "            Diagnostic Systems, Inc.,\n",
      "            (f/k/a\n",
      "            Saliva Diagnostic Systems) a Delaware corporation having its principal\n",
      "            place of\n",
      "            business at One Clarks Hill, Framingham, MA 01702 (“SDS”)\n",
      "            (Chembio and SDS are each referred to herein as a “Party” and jointly as the\n",
      "“Parties”).\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "RECITALS\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "Chembio,\n",
      "            among other things, is in the business of developing, marketing and selling\n",
      "            products used to diagnose various diseases, including HIV, and has designed,\n",
      "            developed or is in the process of developing products for the diagnosis\n",
      "            or\n",
      "            detection of HIV or HIV infection (“HIV\n",
      "            Products”) and has received approval of a pre-market application to the FDA for\n",
      "            the HIV Barrel Product for manufacture by Chembio at its facility in\n",
      "            Medford,\n",
      "            New York and for Chembio to market to clinical laboratories and hospitals\n",
      "            in the\n",
      "            United States\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "SDS,\n",
      "            among other activities, is in the business of developing, manufacturing\n",
      "            and\n",
      "            marketing medical diagnostic products and owns the SDS Patents.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "SDS,\n",
      "            Chembio and Inverness Medical Innovations, Inc., a Delaware corporation,\n",
      "            (“Inverness”) have entered into a License, Marketing and Distribution Agreement\n",
      "            of even date herewith (the “3-Way Agreement”), pursuant to which Inverness has\n",
      "            been granted the worldwide exclusive right to market and distribute the\n",
      "            HIV\n",
      "            Barrel Product. \n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "During\n",
      "            the Term, to the extent such license is necessary, SDS wishes to license\n",
      "            the SDS\n",
      "            Patents to Chembio on an exclusive basis with respect to the HIV Barrel\n",
      "            Product,\n",
      "            and Chembio wishes to accept such license without acknowledging or agreeing\n",
      "            to\n",
      "            its necessity with respect to the HIV Barrel Product, on an exclusive\n",
      "            basis,\n",
      "            with respect to manufacture of the HIV Barrel Products solely for resale\n",
      "            by\n",
      "            Inverness as long as the 3-Way Agreement is in effect or, in the event\n",
      "            of\n",
      "            termination of the 3-Way Agreement, as otherwise set forth herein.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "The\n",
      "            Parties may also enter into such other ancillary agreements, licenses\n",
      "            and\n",
      "            covenants as may be appropriate to permit the parties to fulfill the\n",
      "            business\n",
      "            objectives of this Agreement.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "Chembio\n",
      "            and SDS wish to collaborate exclusively with each other, and to agree\n",
      "            to work\n",
      "            only with each other and not alone, to develop and commercialize products\n",
      "            in the\n",
      "            Barrel Field for the diagnosis or detection of HIV or HIV infection in\n",
      "            order to\n",
      "            facilitate introduction, distribution and sale of such products in the\n",
      "            market.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "NOW,\n",
      "            THEREFORE, in consideration of the premises and the mutual promises,\n",
      "            covenants\n",
      "            and conditions hereinafter set forth, the receipt and adequacy of which\n",
      "            are\n",
      "            hereby acknowledged, Chembio and SDS hereby agree as follows:\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "1.\n",
      "            Definitions.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "1.1.\n",
      "            Certain\n",
      "            Definitions.\n",
      "            For\n",
      "            purposes of this Agreement, in addition to the terms that are defined\n",
      "            on first\n",
      "            use herein, the following terms shall have the following meanings:\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(a)\n",
      "            The\n",
      "“Act”\n",
      "shall\n",
      "            mean the Federal Food, Drug and Cosmetic Act, as amended, and all relevant\n",
      "            federal regulations pertaining thereto.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(b)\n",
      "            “Affiliate”\n",
      "shall\n",
      "            mean any Person that controls, is controlled by, or is under common control\n",
      "            with\n",
      "            a Party hereto. For purposes of this definition, “control” shall mean (i) in the\n",
      "            case of corporate entities, direct or indirect ownership of a majority\n",
      "            of the\n",
      "            stock or shares having the right to vote for the election of directors,\n",
      "            and (ii)\n",
      "            in the case of non-corporate entities, direct or indirect ownership of\n",
      "            a\n",
      "            majority of the equity interest with the power to direct the management\n",
      "            and\n",
      "            policies of such non-corporate entities.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(c)\n",
      "            “Audit”\n",
      "            shall\n",
      "            mean examination of each and every document relating to the licenses\n",
      "            and rights\n",
      "            granted herein, including but not limited to books, records, agreements,\n",
      "            communications, shipping records, purchase orders, invoices, credit memos\n",
      "            and\n",
      "            record of payments received or made by a nationally recognized public\n",
      "            accounting\n",
      "            firm.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(d)\n",
      "            “Barrel\n",
      "            Field”\n",
      "means\n",
      "            diagnostic testing for the presence of HIV antibodies utilizing an integrated\n",
      "            in-vitro diagnostic testing device that (i) is a single-use disposable\n",
      "            device,\n",
      "            (ii) collects a physiologic sample from a patient directly into the device\n",
      "            using\n",
      "            a tip at one end of the device and delivers that sample into a system\n",
      "            contained\n",
      "            in the device, where the reaction reagent medium (for example, a reagent\n",
      "            strip)\n",
      "            is enclosed in a barrel or other container with a transparent portion\n",
      "            which\n",
      "            allows the results of the reaction to be visible, designed to protect\n",
      "            the user\n",
      "            from contact with its contents, (iii) produces a visually readable result\n",
      "            in\n",
      "            less than twenty minutes, and (iv) is primarily designed to be used in\n",
      "            a Point\n",
      "            of Care environment or for self-testing by consumers.\n",
      "            \n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(e)\n",
      "            “Challenge”\n",
      "means,\n",
      "            with respect to Patent Rights, to challenge the validity or enforceability\n",
      "            of\n",
      "            any Patent Rights, including without limitation by (i) filing a declaratory\n",
      "            judgment action in which Patent Rights are alleged to be invalid or\n",
      "            unenforceable; (ii) citing prior art pursuant to 35 U.S.C. Sec. 301,\n",
      "            making a\n",
      "            request for re-examination of Patent Rights pursuant to 35 U.S.C. Sec.\n",
      "            302\n",
      "            and/or 311, or provoking or becoming party to an interference with an\n",
      "            application for Patent Rights pursuant to 35 U.S.C. Sec. 135; or (iii)\n",
      "            filing or\n",
      "            commencing any opposition, cancellation, nullity or similar proceedings\n",
      "            against\n",
      "            Patent Rights in any country.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(f)\n",
      "            “Chembio\n",
      "            IP”\n",
      "shall\n",
      "            mean all proprietary rights and Intellectual Property Rights, including\n",
      "            but not\n",
      "            limited to Patent Rights, owned or Controlled by Chembio, which are necessary\n",
      "            or\n",
      "            useful for, or would be infringed or that Chembio asserts would be infringed,\n",
      "            by\n",
      "            the manufacture, use, sale, distribution, import or export of the HIV\n",
      "            Barrel\n",
      "            Products or New HIV Barrel Products, whether in existence now or in the\n",
      "            future,\n",
      "            including but not limited to those listed on Schedule A.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(g)\n",
      "            “Confidential\n",
      "            Information”\n",
      "shall\n",
      "            mean all Technology and ideas and information of any kind, whether in\n",
      "            written,\n",
      "            oral, graphical, machine-readable or other form, whether or not marked\n",
      "            or\n",
      "            identified as confidential or proprietary, which are transferred, disclosed\n",
      "            or\n",
      "            made available by either Party hereto to the other.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(h)\n",
      "            “Control”\n",
      "            or\n",
      "“Controlled\n",
      "            by”\n",
      "            shall\n",
      "            mean, in the context of Patent Rights or other Intellectual Property\n",
      "            Rights,\n",
      "            possession of the ability on the part of a Party to grant access to or\n",
      "            a license\n",
      "            or sublicense as provided for herein without violating the terms of any\n",
      "            agreement or other arrangement with any Third Party existing at the time\n",
      "            such\n",
      "            Party would be required hereunder to grant another Party such access\n",
      "            or license\n",
      "            or sublicense.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(i)\n",
      "            “Distributor”\n",
      "shall\n",
      "            mean any Third Party to which a Party grants a right to resell or distribute\n",
      "            HIV\n",
      "            Barrel Products or New HIV Barrel Products.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(j)\n",
      "            “Exploit”\n",
      "or\n",
      "            “Exploitation”\n",
      "shall\n",
      "            mean to sell, offer for sale, import, export, transport, register, distribute,\n",
      "            promote and market, together with other activities typically associated\n",
      "            with\n",
      "            maximizing the market penetration, profit margins and commercialization\n",
      "            of a\n",
      "            diagnostic medical product that is marketed to hospitals and clinical\n",
      "            laboratories for professional use and to doctors’ offices, insurance companies,\n",
      "            military facilities, and other Point of Care clinics, as well as to the\n",
      "            public\n",
      "            for self-testing.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(k)\n",
      "            “FDA”\n",
      "means\n",
      "            the U.S. Food and Drug Administration.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(l)\n",
      "            “First\n",
      "            Commercial Sale”\n",
      "shall\n",
      "            mean, with respect to a product, the first sale to any Third Party.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(m)\n",
      "            “GAAP”\n",
      "means\n",
      "            United States Generally Accepted Accounting Principles, as applicable\n",
      "            to the\n",
      "            Party in question.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(n)\n",
      "            “GMP”\n",
      "means\n",
      "            current Good Manufacturing Practices as promulgated by the FDA.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(o)\n",
      "            “HIV\n",
      "            Barrel Product”\n",
      "means\n",
      "            the product for HIV testing known as SURE CHECK(R)\n",
      "            HIV 1/2\n",
      "            as described in Chembio’s PMA on file with the FDA and further described in the\n",
      "            SURE CHECK(R)\n",
      "            HIV 1/2\n",
      "            package insert, Catalog #HIV202, attached hereto as Schedule A, together\n",
      "            with\n",
      "            any improvements thereto.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(p)\n",
      "            “Intellectual\n",
      "            Property Rights”\n",
      "shall\n",
      "            mean (i)  Patent Rights; (ii) rights associated with works of\n",
      "            authorship including copyrights, copyright applications and copyright\n",
      "            registrations; and (iii) rights relating to the protection of trade\n",
      "            secrets, know-how and Confidential Information, but shall not include\n",
      "            any rights\n",
      "            to trade marks, trade names, or other distinctive brand names or logos.\n",
      "            \n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(q)\n",
      "            “New\n",
      "            HIV Barrel Product”\n",
      "means\n",
      "            (i) the patent pending product in the Barrel Field for the diagnosis\n",
      "            or\n",
      "            detection of HIV or HIV infection currently being\n",
      "            designed and developed by Chembio which Chembio describes as set forth\n",
      "            in\n",
      "            Schedule D, and/or (ii) any other new product in the Barrel Field for\n",
      "            the\n",
      "            diagnosis or detection of HIV or HIV infection Controlled by SDS or\n",
      "            Chembio.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(r)\n",
      "            “Patent\n",
      "            Rights”\n",
      "shall\n",
      "            mean all patents, patent applications and inventions on which patent\n",
      "            applications are filed and all patents issuing therefrom worldwide, all\n",
      "            disclosures of inventions, together with any extensions, registrations,\n",
      "            confirmations, reissues, divisionals, continuations, continuations-in-part,\n",
      "            reexamination certificates, substitutions or renewals, supplemental protection\n",
      "            certificates, term extensions (under applicable patent law or other law),\n",
      "            provisional rights and certificates of inventions.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(s)\n",
      "            “Person”\n",
      "shall\n",
      "            mean an individual, corporation, partnership, limited partnership, limited\n",
      "            liability company, unincorporated association, trust, joint venture or\n",
      "            other\n",
      "            organization or entity, including a governmental authority.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(t)\n",
      "            “POC”\n",
      "or\n",
      "            “Point\n",
      "            of Care”\n",
      "means\n",
      "            an environment where sampling and testing is performed in the presence\n",
      "            or\n",
      "            near-presence of the patient.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(u)\n",
      "            “Related\n",
      "            Documents”\n",
      "shall\n",
      "            mean the\n",
      "            3-Way\n",
      "            Agreement, the Settlement Agreement between SDS and Chembio, the License\n",
      "            and\n",
      "            Distribution Agreement between SDS and Inverness, the License and Distribution\n",
      "            Agreement between Chembio and Inverness, and the HIV Cassette Agreement\n",
      "            between\n",
      "            Chembio and Inverness.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(v)\n",
      "            “SDS\n",
      "            Patents”\n",
      "shall\n",
      "            mean all Patent Rights owned or Controlled by SDS that would be infringed,\n",
      "            or\n",
      "            that SDS asserts would be infringed, by the manufacture, use, sale,\n",
      "            distribution, import or export of the HIV Barrel Products or New HIV\n",
      "            Barrel\n",
      "            Products, whether in existence now or in the future, including but not\n",
      "            limited\n",
      "            to those listed in Schedule B.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(w)\n",
      "            “Sell”\n",
      "            shall\n",
      "            mean to sell, offer for sale, market, promote, transport, export and\n",
      "            use in\n",
      "            furtherance of sales activities.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(x)\n",
      "            “Settlement\n",
      "            Agreement”\n",
      "shall\n",
      "            mean the Settlement Agreement of even date herewith between the\n",
      "            Parties.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(y)\n",
      "            “Sublicensee”\n",
      "shall\n",
      "            mean any sublicensee of any of the rights granted to a Party under this\n",
      "            Agreement, other than an Affiliate or a Distributor.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(z)\n",
      "            “Technology”\n",
      "shall\n",
      "            mean all techniques, inventions, practices, procedures, knowledge, improvements,\n",
      "            designs, processes, protocols, compositions, products, methods, works\n",
      "            of\n",
      "            authorship, know-how, data, clinical data, preclinical data, research\n",
      "            and\n",
      "            creations (whether or not subject to protection by any Intellectual Property\n",
      "            Rights). \n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(aa)\n",
      "            “Third\n",
      "            Party”\n",
      "shall\n",
      "            mean any Person other than SDS or Chembio or an Affiliate of either of\n",
      "            them.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(bb)\n",
      "            “United\n",
      "            States”\n",
      "means\n",
      "            the United States of America and its territories and possessions, including\n",
      "            without limitation Puerto Rico and the U.S. Virgin Islands.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "1.2.\n",
      "            Additional\n",
      "            Definitions.\n",
      "            Certain\n",
      "            additional capitalized terms are defined in the Preamble or the Recitals\n",
      "            or\n",
      "            below in the body of this Agreement and, if not otherwise defined, shall\n",
      "            have\n",
      "            the meaning as set forth in the 3-Way Agreement.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "2.\n",
      "             Joint\n",
      "            Exploitation of HIV Products in the Barrel Field. \n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "2.1  In\n",
      "            General.\n",
      "            The\n",
      "            Parties shall act together in all matters relating to the Exploitation\n",
      "            of the\n",
      "            HIV Barrel Product and any New HIV Barrel Product, with a goal of maximizing\n",
      "            the\n",
      "            commercial value of the HIV Barrel Product and any New HIV Barrel Product,\n",
      "            both\n",
      "            in geographic markets and in customer market segments.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "2.2  Under\n",
      "            the 3-Way Agreement.\n",
      "            The\n",
      "            Parties shall act together in all matters under the 3-Way Agreement,\n",
      "            other than\n",
      "            Chembio’s right and obligation to manufacture and supply the HIV Barrel Product\n",
      "            thereunder. Without limiting the generality of the foregoing:\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(a)\n",
      "            Neither Party shall (i) give any notice to Inverness under the 3-Way\n",
      "            Agreement,\n",
      "            (ii) terminate or attempt to terminate the 3-Way Agreement, or (iii)\n",
      "            modify or\n",
      "            amend the 3-Way Agreement without the prior written consent of the other\n",
      "            Party.\n",
      "            For clarity, if the Parties do not both agree to take an action described\n",
      "            in the\n",
      "            preceding sentence, then such action shall not be taken. \n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(b)\n",
      "            In\n",
      "            order to keep SDS properly informed, Chembio shall forward all forecasts,\n",
      "            Purchase Orders or alterations thereof received from Inverness pursuant\n",
      "            to\n",
      "            Section 7.2 or 7.3 of the 3-Way Agreement to SDS within five (5) business\n",
      "            days\n",
      "            of receipt thereof by Chembio.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(c)\n",
      "            In\n",
      "            the event either Party makes sales of HIV Barrel Products to a Third\n",
      "            Party\n",
      "            (other than Inverness) as permitted by the 3-Way Agreement, the selling\n",
      "            Party\n",
      "            shall pay the other Party a royalty of five percent (5%) of the Net Sales\n",
      "            (as\n",
      "            defined in the 3-Way Agreement) thereof. Sections 5.6 (other than subsections\n",
      "            (a) and (d)) and Section 5.7 (other than subsections (b), (c), and (e))\n",
      "            shall\n",
      "            apply to such royalties with appropriate adjustments to reflect the differences\n",
      "            in Payer and Payee.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "2.3 Outside\n",
      "            the 3-Way Agreement.\n",
      "            In the\n",
      "            event of any termination or expiration of the 3-Way Agreement, SDS and\n",
      "            Chembio\n",
      "            agree that they will jointly seek a qualified Third Party to replace\n",
      "            Inverness\n",
      "            as the Distributor of the HIV Barrel Product and any New HIV Barrel Product\n",
      "            and\n",
      "            will enter into a written agreement with respect thereto. SDS and Chembio\n",
      "            further agree that neither Party will Exploit the HIV Barrel Product\n",
      "            or any New\n",
      "            HIV Barrel Product except pursuant to this Agreement or another written\n",
      "            agreement with the other Party, and neither Party will enter into a license\n",
      "            agreement, a distribution agreement, a joint venture, or any other agreement\n",
      "            with a Third Party involving the Exploitation of a product in the Barrel\n",
      "            Field\n",
      "            for the diagnosis or detection of HIV or HIV infection without the prior\n",
      "            written\n",
      "            agreement of the other Party. If any royalties are due to Inverness pursuant\n",
      "            to\n",
      "            Section 5.6 of the 3-Way Agreement as a result of any Exploitation pursuant\n",
      "            to\n",
      "            this Section 2.3, then the sharing of such royalties will be determined\n",
      "            in\n",
      "            accordance with the agreement for such Exploitation executed pursuant\n",
      "            to this\n",
      "            Section 2.3.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "2.4 Non-Competition.\n",
      "            Neither\n",
      "            Party shall manufacture, promote, market, distribute, sell, offer for\n",
      "            sale,\n",
      "            import, export, seek or obtain regulatory approval of the HIV Barrel\n",
      "            Product or\n",
      "            any New HIV Barrel Product except under this Agreement and neither Party\n",
      "            shall\n",
      "            grant any license to, or in any way assist, any Affiliate or Third Party\n",
      "            to do\n",
      "            so. Each Party acknowledges and agrees that the exclusivity resulting\n",
      "            from this\n",
      "            Section is of critical importance to the other Party, and that without\n",
      "            such\n",
      "            exclusivity, the other Party would not have entered into this\n",
      "            Agreement.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "2.5 Joint\n",
      "            Operating Committee. \n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(a)\n",
      "            The\n",
      "            JOC.\n",
      "            Promptly\n",
      "            after the execution of the 3-Way Agreement, the Parties shall establish\n",
      "            a Joint\n",
      "            Operating Committee (“Joint\n",
      "            Operating Committee”\n",
      "or\n",
      "            “JOC”),\n",
      "            which\n",
      "            shall be responsible for planning and coordinating activities under this\n",
      "            Joint\n",
      "            Exploitation Agreement. The JOC shall be composed of three (3) members, one\n",
      "            designated by each Party and one agreed upon by the two Parties, who\n",
      "            (in the\n",
      "            case of the third member) shall have no affiliation or relationship with\n",
      "            either\n",
      "            Party. Either Party may replace its representative at any time upon prior\n",
      "            written notice to the other Party. If a Party’s representative is unable to\n",
      "            attend a meeting, such Party may designate an alternate to attend such\n",
      "            meeting\n",
      "            and perform the functions of such representative. \n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(b)\n",
      "            Responsibilities\n",
      "            of JOC.\n",
      "            The\n",
      "            Joint Operating Committee shall have the authority to make all decisions\n",
      "            under\n",
      "            Article 2 and Article 5 of this Agreement, including without limitation\n",
      "            all\n",
      "            actions under the 3-Way Agreement or outside the 3-way Agreement in the\n",
      "            event of\n",
      "            termination or expiration of the 3-way Agreement, as set forth in Sections\n",
      "            2.2\n",
      "            and 2.3. Neither Party shall take any action under the 3-Way Agreement\n",
      "            or any\n",
      "            action to Exploit the HIV Barrel Product or any New HIV Barrel Product\n",
      "            except\n",
      "            pursuant to a specific decision of the JOC.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(c)\n",
      "            Decision\n",
      "            Making Authority.\n",
      "            With\n",
      "            respect to the responsibilities of the Joint Operating Committee, each\n",
      "            member\n",
      "            (or alternate designated by a Party if a member representing a Party\n",
      "            is unable\n",
      "            to attend) shall have one (1) vote in all decisions. All decisions\n",
      "            shall be\n",
      "            made\n",
      "            by majority vote and\n",
      "            be\n",
      "            memorialized.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(d)\n",
      "            Meetings;\n",
      "            Minutes.\n",
      "            The\n",
      "            Joint Operating Committee shall meet quarterly, or more often as otherwise\n",
      "            agreed by the Parties, at such locations as the Parties agree. The JOC\n",
      "            may meet\n",
      "            in person, by teleconference, videoconference or as otherwise agreed.\n",
      "            Minutes of\n",
      "            the JOC meetings shall be taken, and shall, at a minimum, record all\n",
      "            decisions\n",
      "            made. A draft of such minutes shall be promptly provided to and approved\n",
      "            by both\n",
      "            Parties in accordance with a formal approval process established by the\n",
      "            JOC. A\n",
      "            Party may, with the prior consent of the other Party, invite a reasonable\n",
      "            number\n",
      "            of non-voting employees, consultants or scientific advisors to attend\n",
      "            the\n",
      "            meetings of the JOC, provided that such invitees are bound by appropriate\n",
      "            confidentiality obligations. Decisions shall be effective upon execution\n",
      "            of a\n",
      "            consent or approval agreed by a majority of the Joint Operating\n",
      "            Committee.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(e)\n",
      "            Other\n",
      "            Communications. In\n",
      "            addition to formal meetings, the Joint Operating Committee representatives\n",
      "            shall\n",
      "            communicate as necessary to ensure the appropriate joint Exploitation\n",
      "            of the HIV\n",
      "            Barrel Product and any New HIV Barrel Product. Each Party shall have\n",
      "            reasonable\n",
      "            access to the other Party’s facilities and personnel to facilitate joint\n",
      "            Exploitation of the HIV Barrel Product and any New HIV Barrel Product,\n",
      "            upon\n",
      "            reasonable notice.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(f)\n",
      "            Initial\n",
      "            Members.\n",
      "            The\n",
      "            Initial Members of the Joint Operating Committee shall be Lawrence A.\n",
      "            Siebert,\n",
      "            Steve M. Peltzman and a third person to be agreed upon by SDS and\n",
      "            Chembio.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(g)\n",
      "            Public\n",
      "            Announcements. Except\n",
      "            as\n",
      "            authorized in this Agreement or otherwise required by applicable law,\n",
      "            regulation\n",
      "            or the rules of any securities exchange or other trading market on which\n",
      "            such\n",
      "            Party’s securities are listed, all public communications relating to the actions\n",
      "            of the Joint Operating Committee shall be subject to the approval of\n",
      "            the\n",
      "            Parties.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "3. Licenses\n",
      "            and Intellectual Property Matters. \n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "3.1 Exclusive\n",
      "            Right to Manufacture.\n",
      "            SDS, on\n",
      "            and subject to the terms and conditions contained herein and in the 3-Way\n",
      "            Agreement, hereby grants to Chembio, and Chembio hereby accepts from\n",
      "            SDS,\n",
      "            without acknowledging or agreeing to its necessity with respect to the\n",
      "            HIV\n",
      "            Barrel Product, a worldwide exclusive license to manufacture the HIV\n",
      "            Barrel\n",
      "            Products for\n",
      "            resale by Inverness under the 3-Way Agreement or, in the event of termination\n",
      "            of\n",
      "            the 3-Way Agreement, as otherwise set forth herein.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "3.2 Technology.\n",
      "            Subject\n",
      "            to Article 4, the Parties will give each other access to their respective\n",
      "            know-how and Technology relevant to the HIV Barrel Product and any New\n",
      "            HIV\n",
      "            Barrel Products in order to optimize manufacturing processes and quality\n",
      "            and\n",
      "            reduce manufacturing costs. Notwithstanding the foregoing, neither Party\n",
      "            has any\n",
      "            obligation to disclose its intellectual property, including the Chembio\n",
      "            IP,\n",
      "            except as may be required to purchase, supply and assemble hardware components\n",
      "            related to the HIV Barrel Product and any New HIV Barrel Product.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "3.3 Patent\n",
      "            Validity.\n",
      "            Chembio,\n",
      "            having investigated and analyzed the SDS Patents, hereby acknowledges\n",
      "            that each\n",
      "            of the SDS Patents is valid and enforceable.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "3.4 No\n",
      "            Validity Challenge.\n",
      "            In order\n",
      "            to assure the orderly Exploitation of the HIV Barrel Product and New\n",
      "            HIV Barrel\n",
      "            Products and to make such products available to the public to address\n",
      "            medical\n",
      "            needs: \n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(a)\n",
      "            Chembio agrees not to (and to cause its Affiliates not to) Challenge\n",
      "            Patent\n",
      "            Rights in the SDS Patents,\n",
      "            or\n",
      "to\n",
      "            assist\n",
      "            any Third Party in doing so. \n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(b)\n",
      "            SDS\n",
      "            agrees not to (and to cause its Affiliates not to) Challenge any Patent\n",
      "            Rights\n",
      "            included in the Chembio IP or\n",
      "            to\n",
      "            assist any party in doing so,\n",
      "            unless\n",
      "            such Patent Rights are enforced or threatened to be enforced against\n",
      "            SDS or an\n",
      "            SDS customer or partner for infringement resulting from an SDS product\n",
      "            or\n",
      "            service other than a product in the Barrel Field that diagnoses or detects\n",
      "            HIV\n",
      "            or HIV infection which SDS product or service is sold in violation of\n",
      "            this\n",
      "            Agreement or the 3-Way Agreement. SDS further agrees not to challenge\n",
      "            Chembio’s\n",
      "            right to continued use for manufacture of the HIV Barrel Product of the\n",
      "            Confidential Information or Technology utilized by Chembio in the manufacture\n",
      "            of\n",
      "            the HIV Barrel Product.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(c)\n",
      "            Neither Party has investigated the Confidential Information or Technology\n",
      "            utilized by the other party in connection with the manufacture of the\n",
      "            HIV Barrel\n",
      "            Product, and nothing contained herein shall be construed as an admission\n",
      "            by\n",
      "            either Party that such Confidential Information or Technology is or is\n",
      "            not\n",
      "            covered by the SDS Patents or the Chembio IP.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "3.5 Consequences\n",
      "            of Violation.\n",
      "            If\n",
      "            either Party Challenges the Patent Rights of the other Party in violation\n",
      "            of\n",
      "            Section 3.4, then the Party whose rights were the subject of the Challenge\n",
      "            (the\n",
      "“Challenged Party”), may, by written notice to the Party violating Section 3.4\n",
      "            (the “Challenging Party”): \n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(i)\n",
      "            terminate this Agreement or terminate any or all rights and licenses\n",
      "            granted to\n",
      "            the Challenging Party hereunder, and \n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(ii)\n",
      "            if\n",
      "            the 3-Way Agreement is in effect at the time of the violation of Section\n",
      "            3.4,\n",
      "            then if the Challenging Party is Chembio, reduce Chembio’s share of the\n",
      "            SDS/Chembio share of Net Sales for the HIV Barrel Product or any New\n",
      "            HIV Barrel\n",
      "            Product under the 3-Way Agreement to 20% from 50% permanently; and if\n",
      "            the\n",
      "            Challenging Party is SDS, reduce SDS’s share of the SDS/Chembio share of Net\n",
      "            Sales for the HIV Barrel Product or any New HIV Barrel Product under\n",
      "            the 3-Way\n",
      "            Agreement to 20% from 50% permanently. The Challenged Party shall have\n",
      "            the right\n",
      "            to notify Inverness of any action taken under this Section, and the Parties\n",
      "            agree that Inverness shall have no liability for any action taken to\n",
      "            distribute\n",
      "            the SDS/Chembio share of Net Sales in accordance with such notice. In\n",
      "            the event\n",
      "            the alleged Challenging Party disputes in good faith that it has Challenged\n",
      "            the\n",
      "            Patent Rights of the other Party, then the matter will be resolved in\n",
      "            accordance\n",
      "            with Section 10.8 and the amounts of the foregoing reductions will be\n",
      "            placed in\n",
      "            escrow until the matter is resolved. \n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "4.\n",
      "            Confidentiality.\n",
      "            \n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "4.1 Limited\n",
      "            Disclosure and Use.\n",
      "            Each of\n",
      "            Chembio and SDS shall hold in confidence any Confidential Information\n",
      "            disclosed\n",
      "            by the other Party or otherwise obtained by such Party from the other\n",
      "            Party as a\n",
      "            result of this Agreement or the Settlement Agreement, and each of SDS\n",
      "            and\n",
      "            Chembio shall protect the confidentiality thereof with the same degree\n",
      "            of care\n",
      "            that it exercises with respect to its own information of a like nature,\n",
      "            but in\n",
      "            no event less than reasonable care. Without the prior written consent\n",
      "            of the\n",
      "            disclosing Party, a receiving Party shall not use, disclose, or distribute\n",
      "            any\n",
      "            Confidential Information, in whole or in part, except as required to\n",
      "            perform\n",
      "            such Party’s obligations or exercise such Party’s rights hereunder or under the\n",
      "            Settlement Agreement. Access to the disclosing Party’s Confidential Information\n",
      "            shall be restricted to the receiving Party’s employees and agents, who, in each\n",
      "            case, need to have access to carry out a permitted use and are bound\n",
      "            in writing\n",
      "            to maintain the confidentiality of such Confidential Information.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "4.2 Exceptions.\n",
      "            The\n",
      "            obligations set forth in Section 4.1 shall not apply to any portion of\n",
      "            the\n",
      "            Confidential Information that the receiving Party can demonstrate by\n",
      "            legally\n",
      "            sufficient evidence: (i) now or hereafter, through no act or failure to act\n",
      "            on the part of the receiving Party, is or becomes generally available;\n",
      "            (ii) is known to the receiving Party at the time of receiving such\n",
      "            Confidential Information and not subject to an obligation of confidentiality\n",
      "            to\n",
      "            a Third Party; (iii) is hereafter furnished to the receiving Party by a\n",
      "            Third Party as a matter of right (and without violating any agreement\n",
      "            with the\n",
      "            disclosing Party) without restriction on use or disclosure; or (iv) is\n",
      "            independently developed by the receiving Party without use of any Confidential\n",
      "            Information received from the other\n",
      "            Party.\n",
      "            In addition, each receiving Party may disclose Confidential Information\n",
      "            to the\n",
      "            extent such disclosure is reasonably necessary to prosecute or defend\n",
      "            litigation, to comply with applicable law or regulation or the rules\n",
      "            of any\n",
      "            securities exchange or other trading market on which such party’s securities are\n",
      "            listed, to protect Intellectual Property Rights, to obtain necessary\n",
      "            or\n",
      "            desirable regulatory approvals, to respond to a valid order of a court\n",
      "            or other\n",
      "            governmental body or any political subdivision thereof, or to conduct\n",
      "            preclinical or clinical trials, provided that, other than with respect\n",
      "            to\n",
      "            disclosure for protecting Intellectual Property Rights, the receiving\n",
      "            Party\n",
      "            shall use reasonable efforts to secure confidential treatment of such\n",
      "            Confidential Information required to be disclosed.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "4.3 Use\n",
      "            of Name; Disclosure of Terms of the Agreement.\n",
      "            Except\n",
      "            as\n",
      "            authorized in this Agreement or otherwise required by applicable law,\n",
      "            regulation\n",
      "            or the rules of any securities exchange or other trading market on which\n",
      "            such\n",
      "            Party’s securities are listed, neither Party shall use the name of the other\n",
      "            Party in any publicity or advertising without the prior written approval\n",
      "            of the\n",
      "            other Party, except that either Party may disclose that it has entered\n",
      "            into this\n",
      "            Agreement and the Settlement Agreement. Except as may be required by\n",
      "            applicable\n",
      "            law, regulation or the rules of any securities exchange or other trading\n",
      "            market\n",
      "            on which such Party’s securities are listed, neither Party shall disclose any\n",
      "            terms or conditions of this Agreement or the Settlement Agreement without\n",
      "            the\n",
      "            prior written consent of the other Party, provided that a Party may disclose\n",
      "            such terms and conditions to any Third Party with whom such Party has\n",
      "            entered\n",
      "            into or proposes to enter into a business relationship (including any\n",
      "            transaction that would result in a permitted assignment in accordance\n",
      "            with the\n",
      "            terms and conditions of Section 9.11 hereof), provided any such Third Party\n",
      "            is informed of the confidentiality restrictions herein with respect to\n",
      "            such\n",
      "            terms and conditions and agrees to abide by such restrictions.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "4.4 Survival.\n",
      "            The\n",
      "            obligations set forth in this Article 4 shall survive any termination\n",
      "            or\n",
      "            expiration of this Agreement in perpetuity (with respect to trade secrets)\n",
      "            and\n",
      "            for a period of five (5) years (with respect to all other data and\n",
      "            information).\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "5. Manufacturing\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "5.1 SDS\n",
      "            Manufacturing Equipment.\n",
      "            SDS\n",
      "            will lease a one-head assembler to Chembio. Chembio will make lease payments\n",
      "            to\n",
      "            SDS in accordance with Schedule C. \n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "5.2 Reduction\n",
      "            of Manufacturing Costs.\n",
      "            Chembio\n",
      "            will use commercially reasonable efforts to reduce Cost (as defined in\n",
      "            the 3-Way\n",
      "            Agreement) of the HIV Barrel Product for supply to Inverness under the\n",
      "            3-Way\n",
      "            Agreement, taking into consideration regulatory and quality obligations.\n",
      "            The\n",
      "            Parties will review all operations involved in such manufacturing and\n",
      "            consult on\n",
      "            appropriate changes in the process. Without limiting the generality of\n",
      "            the\n",
      "            foregoing, the Parties will consider (through the JOC) use of a Third\n",
      "            Party\n",
      "            manufacturer if significant cost savings can be achieved, as long as\n",
      "            such Third\n",
      "            Party manufacture is in compliance with applicable regulations, will\n",
      "            not impair\n",
      "            quality obligations or cause a material change in registrations or product\n",
      "            approvals.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "5.3 Manufacturing\n",
      "            Failures Under the 3-Way Agreement.\n",
      "            In the\n",
      "            event Chembio does not supply the quantity and/or quality of HIV Barrel\n",
      "            Products\n",
      "            required under the 3-Way Agreement, then the Joint Operating Committee,\n",
      "            with the\n",
      "            assistance of the Parties, will develop appropriate reasonable business\n",
      "            strategies to fulfill such requirements.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "6. Joint\n",
      "            Patent Rights. \n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "The\n",
      "            Parties do not intend to engage in joint research activities and acknowledge\n",
      "            that they have no obligation to do so. Nonetheless, in the course of\n",
      "            activities\n",
      "            hereunder, patentable inventions may be made. As between the Parties,\n",
      "            ownership\n",
      "            of Patent Rights shall be determined in accordance with inventorship.\n",
      "            The\n",
      "            determination of inventorship for Patent Rights shall be made in accordance\n",
      "            with\n",
      "            applicable laws relating to inventorship set forth in the patent laws\n",
      "            of the\n",
      "            United States. As between the Parties, SDS shall own any invention that\n",
      "            is\n",
      "            conceived or reduced to practice by an employee of SDS solely (or jointly\n",
      "            with a\n",
      "            Third Party subcontractor of SDS), and Chembio shall own any Invention\n",
      "            that is\n",
      "            made solely by an employee of Chembio (or jointly with a Third Party\n",
      "            subcontractor of Chembio). Any invention that is made jointly by both\n",
      "            an\n",
      "            employee of SDS (or a Third Party subcontractor of SDS) and an employee\n",
      "            of\n",
      "            Chembio (or a Third Party of Chembio) shall be jointly owned by the Parties\n",
      "            (“Joint\n",
      "            Patent Rights”).\n",
      "            Each\n",
      "            Party retains an undivided one-half interest in and to the Joint Patent\n",
      "            Rights.\n",
      "            Joint Patent Rights shall only be utilized in the Barrel Field under\n",
      "            this\n",
      "            Agreement. The Parties shall jointly control the filing and prosecution\n",
      "            of\n",
      "            patent applications for Joint Patent Rights, using mutually agreed counsel.\n",
      "            Each\n",
      "            Party may independently exercise its ownership rights in and to such\n",
      "            Joint\n",
      "            Patent Rights, for any other field, and including the right to license\n",
      "            and\n",
      "            sublicense or otherwise to exploit, transfer or encumber its ownership\n",
      "            interest,\n",
      "            without an accounting or obligation to, or consent required from, the\n",
      "            other\n",
      "            Party. \n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "7. Representations\n",
      "            and Warranties.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "7.1 Corporate\n",
      "            Power.\n",
      "            Each\n",
      "            Party represents to the other Party that it has full corporate power\n",
      "            and\n",
      "            authority to enter into this Agreement and to carry out the provisions\n",
      "            hereof.\n",
      "            Each Party represents to the other that this Agreement constitutes a\n",
      "            valid and\n",
      "            binding agreement, enforceable against it in accordance with its\n",
      "            terms.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "7.2 No\n",
      "            Default or Violation.\n",
      "            Each\n",
      "            Party represents and warrants to the other Party that the execution,\n",
      "            delivery\n",
      "            and performance of this Agreement does not (i) violate or require any\n",
      "            registration, qualification, consent, approval, or filing under, (1)\n",
      "            any law,\n",
      "            statute, ordinance, rule or regulation applicable to it, or (2) any judgment,\n",
      "            injunction, order, writ or decree of any court, arbitrator, or governmental\n",
      "            entity by which such Party or any of its assets or properties may be\n",
      "            bound or\n",
      "            (ii) conflict with, require any consent, approval, or filing under, result\n",
      "            in\n",
      "            the breach or termination of any provision of, constitute a default under,\n",
      "            result in the acceleration of the performance of any obligations under,\n",
      "            result\n",
      "            in the vesting or enhancement of any other Person’s rights under, or result in\n",
      "            the creation of any lien upon any of such Party’s properties, assets, or\n",
      "            businesses pursuant to (x) its organizing documents or By-Laws or (y)\n",
      "            any\n",
      "            material indenture, mortgage, deed of trust, license, permit, approval,\n",
      "            consent,\n",
      "            franchise, lease, contract, or other instrument or agreement to which\n",
      "            such Party\n",
      "            is a party or by which such Party or any of such Party’s properties or assets is\n",
      "            bound.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "7.3 Exclusion\n",
      "            of Other Representations and Warranties.\n",
      "            EXCEPT\n",
      "            AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY\n",
      "            REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT\n",
      "            LIMITATION\n",
      "            ANY REPRESENTATIONS OR WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR\n",
      "            PURPOSE OR NON-INFRINGEMENT. NEITHER PARTY WARRANTS THAT THE OTHER PARTY\n",
      "            WILL\n",
      "            RECEIVE ANY PARTICULAR AMOUNT, OR ANY, REVENUES OR PROFITS AS A RESULT\n",
      "            OF\n",
      "            ENTERING INTO THE BUSINESS ARRANGEMENTS DESCRIBED IN THIS\n",
      "            AGREEMENT.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "8. Term\n",
      "            and Termination.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "8.1 Term\n",
      "            of Agreement.\n",
      "            Unless\n",
      "            otherwise terminated by agreement of the Parties, this Agreement shall\n",
      "            continue\n",
      "            in effect perpetually with respect to all products in the Barrel Field\n",
      "            for the\n",
      "            diagnosis or detection of HIV or HIV infection.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "8.2 Material\n",
      "            Breach. If\n",
      "            there\n",
      "            is a:\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(i)\n",
      "            material breach by a Party of this Agreement which cannot be cured;\n",
      "            or\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(ii)\n",
      "            material breach by a Party of this Agreement that can be cured and such\n",
      "            Party\n",
      "            has failed to take steps to begin to cure the breach within sixty (60)\n",
      "            days\n",
      "            following written notice specifying the material breach by the Party\n",
      "            affected by\n",
      "            the breach or is not diligently pursuing a cure thereafter, or \n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(iii)\n",
      "            is\n",
      "            subject to a petition for relief under any bankruptcy legislation, or\n",
      "            makes an\n",
      "            assignment for the benefit of creditors, or is subject to the appointment\n",
      "            of a\n",
      "            receiver for all or substantially part of the Party’s assets, and such petition,\n",
      "            assignment or appointment, if involuntary, is not dismissed or vacated\n",
      "            within\n",
      "            ninety (90) days.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "then,\n",
      "            an\n",
      "            Event of Default shall be deemed to have occurred. Upon an Event of Default,\n",
      "            the\n",
      "            non-breaching Party shall have the right to exercise one or more of the\n",
      "            following remedies upon written notice by the non-breaching Party to\n",
      "            the\n",
      "            breaching Party within thirty (30) days of an Event of Default (if any)\n",
      "            (assuming that the non-breaching Party has not already given such a notice\n",
      "            upon\n",
      "            the occurrence of a prior material, uncured breach by the breaching Party):\n",
      "            (i)\n",
      "            to seek monetary damages for such material breach within the limitations\n",
      "            set\n",
      "            forth in Section 9 hereof; (ii) to seek equitable relief to prevent such\n",
      "            material breach from continuing or occurring again in the future; (iii)\n",
      "            if the\n",
      "            Event of Default can be cured, to effect a cure and be reimbursed for\n",
      "            the costs\n",
      "            incurred or (iv) at its option, to terminate this Agreement upon written\n",
      "            notice\n",
      "            to the breaching Party; provided, however, that in the event the alleged\n",
      "            breaching Party in good faith challenges the allegation of breach, then\n",
      "            the\n",
      "            matter shall be resolved in accordance with Section 10.8, and the cure\n",
      "            period\n",
      "            set forth in Section 8.2(ii), which shall be reduced to thirty (30) days,\n",
      "            shall\n",
      "            only commence upon a decision pursuant to Section 10.8 that such breach\n",
      "            has\n",
      "            occurred. \n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "8.3 Survival.\n",
      "            No\n",
      "            expiration or termination of this Agreement shall affect any rights or\n",
      "            liabilities of the Parties which may have accrued prior to the date of\n",
      "            expiration or termination. Notwithstanding anything herein to the contrary,\n",
      "            upon\n",
      "            any expiration or termination of this Agreement, in addition to any provisions\n",
      "            that by their terms survive, the provisions of Sections [to\n",
      "            be updated]\n",
      "            shall\n",
      "            survive and shall continue in full force and effect in accordance with\n",
      "            their\n",
      "            respective terms.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "9. Limitation\n",
      "            of Liability.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "9.1 EXCEPT\n",
      "            FOR BREACHES OF ITS CONFIDENTIALITY OBLIGATIONS HEREUNDER AND FOR VIOLATIONS\n",
      "            OF\n",
      "            THE OTHER PARTY’S INTELLECTUAL PROPERTY RIGHTS AND FOR DAMAGES CAUSED BY A\n",
      "            PARTY’S GROSS NEGLIGENCE OR INTENTIONAL MISCONDUCT, IN NO EVENT SHALL A PARTY\n",
      "            BE\n",
      "            LIABLE TO ANY OTHER PARTY FOR SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES,\n",
      "            INCLUDING, WITHOUT LIMITATION, DAMAGES RESULTING FROM LOSS OF USE, PROFITS,\n",
      "            BUSINESS OR GOODWILL, WHETHER OR NOT THE PARTY ALLEGEDLY CAUSING THE\n",
      "            DAMAGE HAS\n",
      "            BEEN ADVISED OF THE POSSIBILITY THEREOF. \n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "10. General.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "10.1 Waivers\n",
      "            and Amendments.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(a)\n",
      "            This\n",
      "            Agreement may be amended, modified or supplemented only by a written\n",
      "            instrument\n",
      "            executed by the Parties hereto. For clarity, the Joint Operating Committee\n",
      "            shall\n",
      "            have no power to amend or modify this Agreement.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "(b)\n",
      "            No\n",
      "            waiver of any provision of this Agreement, or consent to any departure\n",
      "            from the\n",
      "            terms hereof, shall be effective unless the same shall be in writing\n",
      "            and signed\n",
      "            by the Party waiving or consenting thereto. No failure on the part of\n",
      "            either\n",
      "            Party to exercise, and no delay in exercising, any right or remedy hereunder\n",
      "            shall operate as a waiver thereof, nor shall any single or partial exercise\n",
      "            of\n",
      "            any such right or remedy by such Party preclude any other or further\n",
      "            exercise\n",
      "            thereof or the exercise of any other right or remedy. The waiver by either\n",
      "            Party\n",
      "            hereto of a breach of any provision of this Agreement shall not operate\n",
      "            as a\n",
      "            waiver of any subsequent breach. All rights and remedies hereunder are\n",
      "            cumulative and are in addition to and not exclusive of any other rights\n",
      "            and\n",
      "            remedies provided by law.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "10.2 Entire\n",
      "            Agreement.\n",
      "            This\n",
      "            Agreement, the Schedules hereto and the Related Documents constitute\n",
      "            the entire\n",
      "            agreement between the Parties hereto with respect to the subject matter\n",
      "            hereof\n",
      "            and supersede all prior agreements and understandings, whether written\n",
      "            or oral,\n",
      "            between the Parties in connection with such subject matter.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "10.3 Severability.\n",
      "            If any\n",
      "            provision of this Agreement is found invalid or unenforceable by a court\n",
      "            of\n",
      "            competent jurisdiction, such provision shall be enforced to the maximum\n",
      "            extent\n",
      "            permissible by law and the other provisions of this Agreement shall remain\n",
      "            in\n",
      "            full force and effect.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "10.4 Relationship\n",
      "            of the Parties.\n",
      "            This\n",
      "            Agreement shall not constitute either Party the agent or legal representative\n",
      "            of\n",
      "            the other Party for any purpose whatsoever, and neither Party shall hold\n",
      "            itself\n",
      "            out as an agent of the other Party. This Agreement creates no relationship\n",
      "            of\n",
      "            joint venturers, partners, associates, employment or principal and agent\n",
      "            between\n",
      "            the Parties and each of the Parties is acting as an independent contractor.\n",
      "            Neither Party is granted herein any right or authority to, and shall\n",
      "            not attempt\n",
      "            to, assume or create any obligation or responsibility for or on behalf\n",
      "            of the\n",
      "            other Party. Neither Party shall have any authority to bind the other\n",
      "            Party to\n",
      "            any contract, whether of employment or otherwise, and each Party shall\n",
      "            bear all\n",
      "            of its respective expenses for its operations, including, without limitation,\n",
      "            the compensation of its employees and salespersons and the maintenance\n",
      "            of its\n",
      "            offices, service and warehouse facilities. Each Party shall each be solely\n",
      "            responsible for its own employees and salespersons and for their acts\n",
      "            and the\n",
      "            things done by them. \n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "10.5 No\n",
      "            Election of Remedies.\n",
      "            The\n",
      "            rights and remedies accorded herein are cumulative and in addition to\n",
      "            those\n",
      "            provided by law, and may be exercised separately, concurrently, or\n",
      "            successively.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "10.6 Notices.\n",
      "            All\n",
      "            notices and other communications hereunder shall be in writing and shall\n",
      "            be\n",
      "            deemed given if delivered personally, telecopied (with confirmation)\n",
      "            or mailed\n",
      "            by registered or certified mail (return receipt requested) or delivered\n",
      "            by\n",
      "            recognized courier service providing evidence of delivery to the Parties\n",
      "            at the\n",
      "            following addresses:\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "If\n",
      "            to\n",
      "            Chembio, to:\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "Chembio\n",
      "            Diagnostic Systems, Inc.\n",
      "\n",
      "          \n",
      "3661\n",
      "            Horseblock Road\n",
      "\n",
      "          \n",
      "Medford,\n",
      "            New York 11763\n",
      "\n",
      "          \n",
      "Attention:\n",
      "            Lawrence A. Siebert, President\n",
      "\n",
      "          \n",
      "Telecopier\n",
      "            No.: (631) 924-6033\n",
      "\n",
      "          \n",
      "\n",
      "\n",
      "          \n",
      "with\n",
      "            a\n",
      "            copy to:\n",
      "\n",
      "          \n",
      "\n",
      "\n",
      "          \n",
      "Ruskin\n",
      "            Moscou Faltischek, P.C.\n",
      "\n",
      "          \n",
      "1425\n",
      "            Reckson Plaza\n",
      "\n",
      "          \n",
      "15th\n",
      "            Floor,\n",
      "            East Tower\n",
      "\n",
      "          \n",
      "Uniondale,\n",
      "            New York 11556\n",
      "\n",
      "          \n",
      "Attention:\n",
      "            Michael L. Faltischek, Esq,\n",
      "\n",
      "          \n",
      "Telecopier\n",
      "            No.: (516) 663-6640\n",
      "\n",
      "          \n",
      "\n",
      "\n",
      "          \n",
      "If\n",
      "            to\n",
      "            SDS, to:\n",
      "\n",
      "          \n",
      "\n",
      "\n",
      "          \n",
      "StatSure\n",
      "            Diagnostic Systems, Inc.\n",
      "\n",
      "          \n",
      "One\n",
      "            Clark’s Hill\n",
      "\n",
      "          \n",
      "Framingham,\n",
      "            MA 01702\n",
      "\n",
      "          \n",
      "Attention:\n",
      "            Chief Executive Officer\n",
      "\n",
      "          \n",
      "Telecopier\n",
      "            No.: \n",
      "\n",
      "          \n",
      "\n",
      "\n",
      "          \n",
      "with\n",
      "            a\n",
      "            copy to:\n",
      "\n",
      "          \n",
      "\n",
      "\n",
      "          \n",
      "Mintz,\n",
      "            Levin, Cohn, Ferris,\n",
      "\n",
      "          \n",
      "Glovsky\n",
      "            and Popeo, P.C.\n",
      "\n",
      "          \n",
      "One\n",
      "            Financial Center\n",
      "\n",
      "          \n",
      "Boston,\n",
      "            MA 02111\n",
      "\n",
      "          \n",
      "Attention:\n",
      "            Jeffrey M. Wiesen, Esq.\n",
      "\n",
      "          \n",
      "Telecopier\n",
      "            No.: 617-542-2241\n",
      "\n",
      "          \n",
      "\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "or\n",
      "            at\n",
      "            such other address for a Party as shall be specified by like\n",
      "            notice.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "10.7 Governing\n",
      "            Law.\n",
      "            This\n",
      "            Agreement shall be governed by, and construed and enforced in accordance\n",
      "            with,\n",
      "            the substantive laws of the State of New York , without giving effect\n",
      "            to its\n",
      "            conflicts of laws rules. \n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "10.8 Dispute\n",
      "            Resolution.\n",
      "            In\n",
      "            the\n",
      "            event of any dispute or disagreement between the Parties as to the\n",
      "            interpretation of any provision of this Agreement or the performance\n",
      "            of any\n",
      "            obligations hereunder, the matter, upon written request of either Party,\n",
      "            shall\n",
      "            be referred to [mediation\n",
      "            and]\n",
      "            arbitration in accordance with the procedures set forth in Schedule F\n",
      "            to this\n",
      "            Agreement. \n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "10.9 Waiver\n",
      "            of Jury Trial.\n",
      "            The\n",
      "            Parties each hereby irrevocably and unconditionally waives all rights\n",
      "            to trial\n",
      "            by jury in any legal action, proceeding or counterclaim with respect\n",
      "            to any\n",
      "            matter whatsoever arising out of or in connection with or related to\n",
      "            this\n",
      "            Agreement or the enforcement thereof. \n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "10.10 Counterparts.\n",
      "            This\n",
      "            Agreement may be executed in two or more counterparts, all of which shall\n",
      "            be\n",
      "            considered one and the same agreement and shall become effective when\n",
      "            two or\n",
      "            more counterparts have been signed by both of the Parties and delivered\n",
      "            to the\n",
      "            other Party, it being understood that both Parties need not sign the\n",
      "            same\n",
      "            counterpart. Facsimile execution and delivery of this Agreement by either\n",
      "            Party\n",
      "            shall be legal, valid and binding execution and delivery of such document\n",
      "            for\n",
      "            all purposes.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "10.11 Assignment.\n",
      "            This\n",
      "            Agreement is personal to each of the Parties, and neither Party shall\n",
      "            assign any\n",
      "            of its rights or delegate any of its obligations hereunder without the\n",
      "            prior\n",
      "            written consent of the other Party, which consent may be withheld for\n",
      "            any\n",
      "            reason, provided,\n",
      "            however, that without\n",
      "            the consent of the other Party, each Party may (i) assign its rights\n",
      "            under this\n",
      "            Agreement and delegate its obligations hereunder, in whole or in part,\n",
      "            to any\n",
      "            Person that shall acquire the business of such Party to which this Agreement\n",
      "            relates, or to any Affiliate of such Party, if the assignee shall assume\n",
      "            such\n",
      "            Party’s obligations hereunder in writing, and (ii) assign this Agreement in\n",
      "            connection with a sale or transfer of substantially all of the assets\n",
      "            of, or a\n",
      "            majority interest in the voting shares of, such Party or its corporate\n",
      "            parent\n",
      "            to, or the merger or consolidation of such Party or its corporate parent\n",
      "            with or\n",
      "            into, any other Person.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "10.12 Force\n",
      "            Majeure.\n",
      "            Neither\n",
      "            Party shall be liable for failure to perform any of its obligations under\n",
      "            this\n",
      "            Agreement when such failure is due to fire, flood, strikes, labor troubles\n",
      "            or\n",
      "            other industrial disturbances, legal restriction, riot, insurrection,\n",
      "            or any\n",
      "            other cause beyond the reasonable control of the Party affected\n",
      "            thereby.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "[remainder\n",
      "            of this page intentionally left blank]\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "\n",
      "\n",
      "          \n",
      " \n",
      " ",
      "\n",
      "          \n",
      "\n",
      "            \n",
      "\n",
      "              \n",
      "\n",
      "                \n",
      " \n",
      "\n",
      "                \n",
      " \n",
      "\n",
      "              \n",
      "\n",
      "              \n",
      "\n",
      "              \n",
      "\n",
      "            \n",
      "\n",
      "            \n",
      "\n",
      "              \n",
      "\n",
      "              \n",
      "\n",
      "              \n",
      "\n",
      "                \n",
      "\n",
      "\n",
      "              \n",
      "\n",
      "            \n",
      "\n",
      "            \n",
      "\n",
      "              \n",
      "\n",
      "              \n",
      "\n",
      "              \n",
      "\n",
      "              \n",
      "\n",
      "            \n",
      "\n",
      "          \n",
      " ",
      " ",
      "\n",
      "          \n",
      "*\n",
      "            *\n",
      "            *\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "IN\n",
      "            WITNESS WHEREOF, the Parties have executed, or caused their duly authorized\n",
      "            representatives to execute, this Agreement under seal as of the date\n",
      "            first\n",
      "            written above.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "Chembio\n",
      "            Diagnostic Systems, Inc.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "By: \n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "Title: \n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "StatSure\n",
      "            Diagnostic Systems, Inc.\n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "By: \n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      "Title: \n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      " \n",
      "\n",
      "          \n",
      " \n",
      " \n",
      "\n",
      "          \n",
      "\n",
      "            \n",
      "\n",
      "\n",
      "          \n",
      "\n",
      "        \n",
      "\n",
      "        \n",
      "\n",
      "          \n",
      "\n",
      "\n",
      "        \n",
      "\n",
      "      \n",
      "\n",
      "    \n",
      "\n",
      "  \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Bottom of Form\n",
      "© Copyright 2000 - 2016 RoyaltyStat.\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "file_path = '/home/kprasath/DS/NLPInternship/txt_data/ref_1_txt/9740.txt' # Replace with the actual path to your TXT file\n",
    "text = read_txt(file_path)\n",
    "print(text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "6ae9506f",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Top of Form\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "                            ASSET PURCHASE AGREEMENT\n",
      "\n",
      "         This Asset Purchase Agreement  (\"Agreement\"),  is entered into as of 19\n",
      "June  2006  (the  \"Effective   Date\")  by  and  between  the  following  parties\n",
      "(collectively, the \"Parties\"):\n",
      "\n",
      "     Implantable  Vision,  Inc. a Utah  Corporation  with a principal  office at\n",
      "25730 Lorain Rd., North Olmsted, OH 44070 (\"IMPLANTABLE VISION\"), and,\n",
      "\n",
      "     CIBA  Vision AG, a Swiss  corporation  with  offices at  Hardhoftrasse  15,\n",
      "CH-8424, Embrach, Switzerland (\"CIBA\")\n",
      "\n",
      "         Whereas,  CIBA desires to convey to IMPLANTABLE  VISION and IMPLANTABLE\n",
      "VISION desires to acquire from CIBA certain intangible assets relating to CIBAs\n",
      "ophthalmic surgical products business;\n",
      "\n",
      "         Now, therefore,  in consideration of the obligations undertaken by each\n",
      "party and other good and  valuable  consideration,  and  intending to be legally\n",
      "bound, the Parties hereby agree as follows:\n",
      "\n",
      "1.       Definitions\n",
      "\n",
      "         As used in this Agreement,  the following terms shall have the meanings\n",
      "set forth below:\n",
      "\n",
      "     1.1.  \"Affiliate\" means any person or legal entity controlling,  controlled\n",
      "by, or under common control with a party to this Agreement.\n",
      "\n",
      "     1.2 \"Assets\" means CIBAs U.S. and Japanese  rights,  title and interest to\n",
      "the following:\n",
      "\n",
      "          1.1.1 \"Patent Rights\"\n",
      "\n",
      "          1.1.1.1 US Patent  No.  6,706,066:  Floating  phakic  refractive  lens\n",
      "     design for preserving eye dynamics;\n",
      "\n",
      "          1.1.1.2 US Patent No.  6,015,435:  Self-centering  phakic  intraocular\n",
      "     lens;\n",
      "\n",
      "          1.1.1.3 US Patent No.  6,428,574:  Self-centering  phakic  intraocular\n",
      "     lens;\n",
      "\n",
      "          1.1.1.4 US Patent No.  6,506,212:  Anatomically  compatible  posterior\n",
      "     chamber phakic refractive lenses;\n",
      "\n",
      "          1.1.1.5 US Patent No.  6,638,307:  Methods  of surface  treatment  for\n",
      "     enhancing the performance of a floating phakic refractive lens design.\n",
      "\n",
      "          1.1.1.6 Japanese Application No. 2001-51980\n",
      "\n",
      "          1.1.1.7 Japanese Application No. 10-519657\n",
      "\n",
      "          1.1.1.8 Japanese Application No. 2002-508351\n",
      "\n",
      "          1.1.1.9 Japanese Application No. 2001-548033\n",
      "\n",
      "              These patent rights are and shall remain subject to a nonexclusive\n",
      "              license to Medennium  Corporation to manufacture  the Products.  A\n",
      "              copy of the license  agreement  has been  provided to  IMPLANTABLE\n",
      "              VISION.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "         1.1.2 Sponsorship of the US FDA trial Investigational  Device Exemption\n",
      "               IDE  G980278  for  ongoing  PRL  clinical  trial and  related FDA\n",
      "               documentation.\n",
      "\n",
      "         1.1.3 PRL  Trademark  in US (US Reg. No.  2532974) and Japan  (Japanese\n",
      "               Registration No 4614342 )\n",
      "\n",
      "\n",
      "\n",
      "     1.2. \"Closing\"  means  the  consummation  of the  purchase  and sale of the\n",
      "          Assets and related transactions contemplated under this Agreement.\n",
      "\n",
      "     1.3. \"Closing  Date\" means the time and date on which the  Closing  becomes\n",
      "          effective.\n",
      "\n",
      "     1.4. Net Sales means shall mean the amount  billed by  IMPLANTABLE  VISION,\n",
      "          its  Affiliates  and any  licensee  to third  parties  for the sale of\n",
      "          Products,  less cash  discounts  and/or  quantity  discounts  allowed;\n",
      "          credits for customers;  returns and  allowances;  charges for freight,\n",
      "          handing and transportation  separately billed; and sales and use taxes\n",
      "          and other similar taxes incurred; all as determined in accordance with\n",
      "          generally  accepted  GAAP  accounting  principles in the US. Net Sales\n",
      "          shall be converted to US Dollars based on the applicable exchange rate\n",
      "          published  in  the  Wall  Street  Journal  as of the  last  day of the\n",
      "          applicable calendar quarter.\n",
      "\n",
      "     1.5. \"Products\" means any Phakic Refractive Lens (PRL) for the treatment of\n",
      "          myopia and  hyperopia,  for  commercial  sale in the US and Japan that\n",
      "          includes  or is based  upon the  ASSETS  and any other PRL that  would\n",
      "          otherwise infringe the Patent Rights.\n",
      "\n",
      "     1.6. \"Total Royalty Period\" means the period  commencing upon the Effective\n",
      "          Date of the  Definitive  Agreement  and  extending  seven (7) years or\n",
      "          until the  expiry  or  invalidation  of each and  every of the  Patent\n",
      "          Rights on a country by country basis, whichever comes first.\n",
      "\n",
      "2.       CONVEYANCE OF ASSETS\n",
      "\n",
      "     2.1. Purchase  and Sale.  Upon the terms and subject to the  conditions  of\n",
      "          this Agreement,  CIBA shall sell, assign, transfer, convey and deliver\n",
      "          to IMPLANTABLE VISION, and IMPLANTABLE VISION shall purchase,  acquire\n",
      "          and accept, all right, title and interest of CIBA in and to the Assets\n",
      "          as of the Closing Date.\n",
      "\n",
      "No other Conveyance. CIBA and IMPLANTABLE VISION expressly acknowledge and agree\n",
      "that, except for the Assets, no other tangible or intangible  property,  rights,\n",
      "or  licenses  are  intended  or  shall  be  conveyed  to CIBA  pursuant  to this\n",
      "Agreement.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "CONSIDERATION.\n",
      "\n",
      "            In  consideration  for the  conveyance  of the  Assets  pursuant  to\n",
      "Article 2, IMPLANTABLE VISION shall:\n",
      "\n",
      "     2.1. Pay CIBA ONE MILLION US Dollars  ($1,000,000) by wire transfer from an\n",
      "          Escrow account on the Closing Date; and\n",
      "\n",
      "     2.2. For a period of two (2) years  following  the  Effective  Date (\"First\n",
      "          Royalty Period\"), Implantable Vision shall pay CIBA a royalty of eight\n",
      "          and one-half  percent  (8.5%) of Net Sales of Products.  For the three\n",
      "          (3) years following the First Royalty Period (\"Second Royalty Period\")\n",
      "          Implantable  Vision  shall pay a royalty of seven  percent (7%) of Net\n",
      "          Sales.  After the Second Royalty Period,  Implantable Vision shall pay\n",
      "          CIBA a royalty of five  percent (5%) of Net Sales until the end of the\n",
      "          Total Royalty  Period.  Royalties will be due  quarterly,  thirty (30)\n",
      "          days after quarter end until the expiry of the Total  Royalty  Period.\n",
      "          Royalties  will be paid only  where the  Products  are sold and one or\n",
      "          more of the patents are not  declared  invalid by a court of competent\n",
      "          jurisdiction and all rights of appeal are exhausted.\n",
      "\n",
      "3.       ASSIGNMENT OF ASSETS\n",
      "\n",
      "     3.1. Assigned  Assets.  As of  the  Closing  Date,  CIBA  shall  assign  to\n",
      "          IMPLANTABLE  VISION all of the rights and interests  CIBA possesses in\n",
      "          and under the Assets subject to the existing  license and  IMPLANTABLE\n",
      "          VISION shall assume all of the  liabilities  and  obligations  of CIBA\n",
      "          arising out or relating to the Assets as of or  following  the Closing\n",
      "          Date.\n",
      "\n",
      "     3.2. No Continuing Obligations.  Following the closing,  Implantable Vision\n",
      "          shall be solely  responsible for prosecution,  maintenance and defense\n",
      "          of the patents,  patent applications and trademarks that are described\n",
      "          as Assets.  Implantable Vision shall be solely responsible for pursuit\n",
      "          of any further actions with respect to IDE G980278 and any liabilities\n",
      "          related to the clinical trial.\n",
      "\n",
      "     3.3. Patent Maintenance. In the event IMPLANTABLE VISION chooses to abandon\n",
      "          Patent Rights, IMPLANTABLE VISION shall give written notice to CIBA at\n",
      "          least  ninety  (90)  days  prior to  abandonment.  In the case of such\n",
      "          notice of intent to abandon by Implantable  Vision, CIBA may take back\n",
      "          title to Patent Rights by notifying  IMPLANTABLE  VISION within ninety\n",
      "          (90) days after  IMPLANTABLE  VISIONs notice of intent to abandon and\n",
      "          paying the required maintenance fees\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "4.       REPRESENTATIONS AND WARRANTIES OF CIBA\n",
      "\n",
      "         CIBA hereby represents and warrants to IMPLANTABLE VISION as follows:\n",
      "\n",
      "     4.1. Corporate Status.  Each of the entities included within the definition\n",
      "          of CIBA is a corporation duly organized,  validly existing and in good\n",
      "          standing under the laws of the  jurisdiction  in which it is organized\n",
      "          and has all  requisite  corporate  power and authority to carry on its\n",
      "          business as it is now being  conducted,  and to  execute,  deliver and\n",
      "          perform this Agreement and to consummate the transactions contemplated\n",
      "          hereby.\n",
      "\n",
      "     4.2. Title to Assets. CIBA and/or its patent,  Novartis AG believes in good\n",
      "          faith  that it has good  and  marketable  title  to all of the  Assets\n",
      "          subject to the aforementioned  licenses. To CIBAs knowledge there are\n",
      "          no  outstanding  agreements,  liens or  encumbrances,  except  for the\n",
      "          aforementioned  license,  which is inconsistent with the provisions of\n",
      "          this Agreement to which CIBA is a party.\n",
      "\n",
      "     4.3. Compliance  with Law. CIBA has not received any notice of any material\n",
      "          violation of any applicable  law,  regulation or other  requirement of\n",
      "          any  governmental  body,  agency or authority or court relating to the\n",
      "          Assets which remains unresolved as of the Closing Date.\n",
      "\n",
      "     4.4. Disclaimer  and  Limitation of Liability.  EXCEPT AS SET FORTH IN THIS\n",
      "          ARTICLE 5, (i) CIBA MAKES NO  REPRESENTATION  OR WARRANTY,  EXPRESS OR\n",
      "          IMPLIED,  RELATING TO THE ASSETS,  INCLUDING WITHOUT  LIMITATION,  ANY\n",
      "          REPRESENTATION OR WARRANTY AS TO VALUE, MERCHANTABILITY, FITNESS FOR A\n",
      "          PARTICULAR  PURPOSE  OR FOR  ORDINARY  PURPOSES,  VALIDITY,  TITLE  OR\n",
      "          NON-INFRINGEMENT.  OR ANY  OTHER  MATTER;  AND  (ii)  THE  ASSETS  ARE\n",
      "          CONVEYED  TO  IMPLANTABLE  VISION ON AN \"AS IS,  WHERE IS\" BASIS AND T\n",
      "          IMPLANTABLE  VISION SHALL RELY ON ITS OWN EXAMINATION  THEREOF.  IN NO\n",
      "          EVENT SHALL CIBA BE LIABLE FOR ANY MATTER  WHATSOEVER  RELATING TO THE\n",
      "          USE OF THE ASSETS FOLLOWING THE EFFECTIVE DATE BY IMPLANTABLE  VISION,\n",
      "          ITS  AFFILIATES  OR ANY THIRD PARTY.  IN NO EVENT SHALL CIBA BE LIABLE\n",
      "          FOR INDIRECT, SPECIAL,  INCIDENTAL,  CONSEQUENTIAL OR PUNITIVE DAMAGES\n",
      "          OR LOST PROFITS.\n",
      "\n",
      "5.       REPRESENTATIONS AND WARRANTIES OF IMPLANTABLE VISION\n",
      "\n",
      "         IMPLANTABLE VISION hereby represents and warrants to CIBA as follows:\n",
      "\n",
      "     5.1  Corporate Status.  IMPLANTABLE VISION is a corporation duly organized,\n",
      "          validly   existing  and  in  good  standing  under  the  laws  of  the\n",
      "          jurisdiction in which it is organized and has all requisite  corporate\n",
      "          power  and  authority  to carry  on its  business  as it is now  being\n",
      "          conducted,  and to execute,  deliver and perform this Agreement and to\n",
      "          consummate   the   transactions   contemplated   hereby.\n",
      "\n",
      "\n",
      "     5.2  Consents and  Approvals.  The execution,  delivery and  performance of\n",
      "          this Agreement and the consummation of the  transactions  contemplated\n",
      "          hereby  have  been  duly  and  validly  authorized  by  all  necessary\n",
      "          corporate  action  on the  part of  IMPLANTABLE  VISION.  Neither  the\n",
      "          execution and delivery by IMPLANTABLE  VISION of this Agreement or the\n",
      "          Transaction  Documents,  nor the performance  thereof will require any\n",
      "          filing, consent or approval or constitute a material default or breach\n",
      "          under  (a)  any law or  regulation  to  which  IMPLANTABLE  VISION  is\n",
      "          subject,  (b) the charter  documents of  IMPLANTABLE  VISION,  (c) any\n",
      "          other agreement to which the IMPLANTABLE  VISION may be a party.  This\n",
      "          Agreement  shall be the  sole  constitutor  of the  legal,  valid  and\n",
      "          binding  obligation of IMPLANTABLE  VISION and shall be enforceable in\n",
      "          accordance with its terms.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "6.       CLOSING; CONDITIONS PRECEDENT\n",
      "\n",
      "     6.1. Closing.  The  closing  of  the  transactions   contemplated  by  this\n",
      "          Agreement  shall take place by signing of the  Agreement  by executive\n",
      "          representatives of both parties,  and shall become effective as of the\n",
      "          Closing Date.\n",
      "\n",
      "     6.2. Conditions to the Obligations of IMPLANTABLE  VISION.  The obligations\n",
      "          of  IMPLANTABLE  VISION to purchase  the Assets and assume the Assumed\n",
      "          Liabilities,  and to consummate the other transactions contemplated by\n",
      "          this  Agreement,  are  subject  to the  satisfaction  on and as of the\n",
      "          Closing Date of each of the following conditions:\n",
      "\n",
      "          6.2.1.  Representations   and  Warranties.   The  representations  and\n",
      "               warranties of CIBA set forth in this Agreement  shall be true and\n",
      "               correct  as  of  the  Closing   Date,   except  for  breaches  of\n",
      "               representations  and warranties as to matters that,  individually\n",
      "               or in the aggregate,  would not have a material adverse effect on\n",
      "               the Business.\n",
      "\n",
      "          6.2.2. Performance  of Obligations of CIBA.  CIBA shall have performed\n",
      "               or  complied  in all  material  respects  with  all  obligations,\n",
      "               conditions  and  covenants  required to be  performed by it under\n",
      "               this Agreement at or prior to the Closing Date.\n",
      "\n",
      "          6.2.3.   Deliveries.   CIBA  shall  have  executed  and  delivered  to\n",
      "               IMPLANTABLE  VISION,  the FDA  Study  in the  form of  Exhibit  A\n",
      "               hereto,  each Patent Assignment attached hereto as Exhibit B, and\n",
      "               each Trademark Assignment attached hereto as Exhibit C.\n",
      "\n",
      "     6.3. Conditions to the  Obligations  of CIBA.  The  obligations  of CIBA to\n",
      "          sell, assign, convey the Assets are subject to the satisfaction on and\n",
      "          as of the Closing Date of each of the following conditions:\n",
      "\n",
      "          6.3.1.  Representations   and  Warranties.   The  representations  and\n",
      "               warranties  of  IMPLANTABLE  VISION  set forth in this  Agreement\n",
      "               shall be true and  correct  in all  material  respects  as of the\n",
      "               Closing  Date,  except  for  breaches  of   representations   and\n",
      "               warranties  as to matters that  individually  or in the aggregate\n",
      "               would  not  materially   interfere  with   IMPLANTABLE   VISIONs\n",
      "               performance of its obligations hereunder.\n",
      "\n",
      "          6.3.2. Performance of Obligations of IMPLANTABLE  VISION.  IMPLANTABLE\n",
      "               VISION  shall  have  performed  in  all  material   respects  all\n",
      "               obligations  required to be performed by it under this  Agreement\n",
      "               at or prior to the Closing Date.\n",
      "\n",
      "7.       INDEMNIFICATION\n",
      "\n",
      "     7.1. By CIBA.  From and after the Closing Date,  to the extent  provided in\n",
      "          this Article 8, CIBA shall  indemnify  and hold  harmless  IMPLANTABLE\n",
      "          VISION and each Affiliate and agent of  IMPLANTABLE  VISION (the \"CIBA\n",
      "          Indemnified  Parties\")  from  and  against  any (i)  losses,  damages,\n",
      "          judgments,  awards,  penalties and settlements;  (ii) demands, claims,\n",
      "          suits,  actions,  causes of action,  proceedings and assessments;  and\n",
      "          (iii) costs and expenses,  penalties,  court costs and reasonable fees\n",
      "          and  expenses of  attorneys  and expert  witnesses  incurred by a CIBA\n",
      "          Indemnified  Party resulting  from,  arising out of or relating to any\n",
      "          events prior to the Effective Date of this Agreement.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "     7.2. Limitation of CIBAs Liability.  Notwithstanding any provision of this\n",
      "          Agreement to the contrary,  CIBAs obligations under Section 8.1 shall\n",
      "          be limited as follows:\n",
      "\n",
      "          7.2.1. All claims for indemnification by a CIBA Indemnified Party must\n",
      "               be asserted no later than two (2) years after the Closing Date;\n",
      "\n",
      "          7.2.2. No claim  shall be made  against  CIBA  unless  and  until  the\n",
      "               aggregate  amount of such claims exceeds fifty  thousand  dollars\n",
      "               ($50,000),  in which  event a CIBA  Indemnified  Party  may claim\n",
      "               indemnification  for the  amount  in  excess  of  fifty  thousand\n",
      "               dollars  ($50,000),  and may  offset  indemnity  amounts  against\n",
      "               royalties due in the future;\n",
      "\n",
      "          7.2.3. Any  amounts  payable by CIBA shall be reduced by the amount of\n",
      "               any  insurance  proceeds,  third  party  reimbursement  or  other\n",
      "               compensation received by a CIBA Indemnified Party with respect to\n",
      "               the matter  for which  indemnification  is  claimed  but not from\n",
      "               insurance policies of which Implantable is the primary insured;\n",
      "\n",
      "          7.2.4. The maximum aggregate  liability of CIBA to IMPLANTABLE  VISION\n",
      "               shall  be  limited  to  the  aggregate  cash   consideration  and\n",
      "               royalties paid by IMPLANTABLE VISION to CIBA under Article 3.\n",
      "\n",
      "     7.3. By IMPLANTABLE  VISION. From and after the Closing Date, to the extent\n",
      "          provided in this Article 8,  IMPLANTABLE  VISION shall  indemnify  and\n",
      "          hold  harmless  CIBA  and  each  Affiliate  and  agent  of  CIBA  (the\n",
      "          \"IMPLANTABLE  VISION  Indemnified  Parties\")  from and against any (i)\n",
      "          losses, damages,  judgments,  awards, penalties and settlements;  (ii)\n",
      "          demands,  claims,  suits, actions,  causes of action,  proceedings and\n",
      "          assessments; and (iii) costs and expenses,  penalties, court costs and\n",
      "          reasonable  fees  and  expenses  of  attorneys  and  expert  witnesses\n",
      "          incurred by  IMPLANTABLE  VISION  resulting  from events arising on or\n",
      "          after the Effective Date of this Agreement,  but not for any liability\n",
      "          related to  implantations,  or testing  arising prior to the effective\n",
      "          date hereof.\n",
      "\n",
      "     7.4. Procedure  for Claims.  In the event that any party (the  \"Indemnified\n",
      "          Party\") receives notice of, or becomes aware of, a claim for which the\n",
      "          Indemnified Party intends to seek indemnity hereunder, the Indemnified\n",
      "          Party  shall  promptly  provide  the other  party  (the  \"Indemnifying\n",
      "          Party\") with notice of such claim. The  Indemnifying  Party shall have\n",
      "          the right,  at its option and its own expense,  to be  represented  by\n",
      "          counsel of its own choice and to defend against,  negotiate, settle or\n",
      "          otherwise deal with any such claim,  provided the  Indemnifying  Party\n",
      "          shall not enter into any  settlement  or  compromise of any such claim\n",
      "          which  could  lead to  liability  or  create  any  financial  or other\n",
      "          obligation  on  the  part  of  the   Indemnified   Party  without  the\n",
      "          Indemnified  Partys prior written consent.  The Indemnified Party may\n",
      "          participate in the defense of any claim with counsel of its own choice\n",
      "          and at its own expense. The parties agree to cooperate fully with each\n",
      "          other in connection with the defense, negotiation or settlement of any\n",
      "          such  claim.  In the  event  that  the  Indemnifying  Party  does  not\n",
      "          undertake  the  defense,  compromise  or  settlement  of a claim,  the\n",
      "          Indemnified  Party  shall  have the right to  control  the  defense or\n",
      "          settlement  of such  Claim  with  counsel  of its  choosing  provided,\n",
      "          however, that the Indemnified Party shall not settle or compromise any\n",
      "          such claim without the  Indemnifying  Partys  prior written  consent,\n",
      "          which consent shall not be unreasonably withheld.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "8.       MISCELLANEOUS\n",
      "\n",
      "     8.1. Counterparts.   This   Agreement  may  be  executed  in  one  or  more\n",
      "          counterparts,  all of  which  shall  be  considered  one and the  same\n",
      "          agreement,  and shall become  effective when one or more  counterparts\n",
      "          have been  signed by each of the Parties  and  delivered  to the other\n",
      "          Party.\n",
      "\n",
      "     8.2. Entire  Agreement.  This Agreement and the exhibits hereto contain the\n",
      "          entire  agreement  between  the  parties  with  respect to the subject\n",
      "          matter  hereof and supersede  all previous  agreements,  negotiations,\n",
      "          discussions, writings,  understandings,  commitments and conversations\n",
      "          with respect to such subject matter.\n",
      "\n",
      "     8.3. Amendments  and Waivers.  No  provisions  of this  Agreement  shall be\n",
      "          deemed waived, amended,  supplemented or modified by any party, unless\n",
      "          such waiver,  amendment,  supplement or modification is in writing and\n",
      "          signed by the authorized  representative  of the party against whom it\n",
      "          is sought to be enforced.\n",
      "\n",
      "     8.4. Governing Law. This  Agreement  shall be governed by and construed and\n",
      "          interpreted  in  accordance  with  the laws of the  State of  Georgia,\n",
      "          irrespective  of its  choice of laws  principles,  as to all  matters,\n",
      "          including matters of validity,  construction,  effect, enforceability,\n",
      "          performance and remedies.\n",
      "\n",
      "     8.5. Assignability.  This Agreement  shall be binding upon and inure to the\n",
      "          benefit of the Parties  hereto and  thereto,  respectively,  and their\n",
      "          respective   successors  and  assigns.   Without   limitation  of  the\n",
      "          foregoing,  the  obligations to pay royalties under Article 3 shall be\n",
      "          binding on any successor in interest,  whether by acquisition,  merger\n",
      "          or  otherwise,  to the  IMPLANTABLE  VISION.  No party may  assign its\n",
      "          respective  rights or delegate its respective  obligations  under this\n",
      "          Agreement  without  the  express  prior  written  consent of the other\n",
      "          party,  provided  that  CIBA may  assign  all or part of the  right to\n",
      "          receive  ongoing  payments  under  this  Agreement  subsequent  to the\n",
      "          Closing without the consent of IMPLANTABLE VISION.\n",
      "\n",
      "     8.6. Confidentiality  : The  terms of the  Secrecy  Agreement  between  the\n",
      "          parties  dated  October  31,  2005  shall  apply  to  all  information\n",
      "          exchanged  between  the  parties  in the  course of  negotiating  this\n",
      "          Agreement.\n",
      "\n",
      "     8.7. Third Party  Beneficiaries.  There are no third party beneficiaries of\n",
      "          this  Agreement.  The  provisions of this Agreement are solely for the\n",
      "          benefit of the  parties  and are not  intended to confer any rights or\n",
      "          remedies to any person which is not a party to this Agreement.\n",
      "\n",
      "     8.8. Notices.  All notices and other  communications  hereunder shall be in\n",
      "          writing  and shall be deemed duly given (a) on the date of delivery if\n",
      "          delivered personally, (b) on the third business day following the date\n",
      "          of dispatch if  delivered  by an  internationally  recognized  express\n",
      "          courier service. All notices hereunder shall be addressed as follows:\n",
      "\n",
      "\n",
      "              If to IMPLANTABLE VISION, to:\n",
      "\n",
      "\n",
      "              If to CIBA, to:\n",
      "\n",
      "                                    CIBA Vision Corporation\n",
      "                                    Attn: General Counsel\n",
      "                                    11460 Johns Creek Parkway\n",
      "                                    Duluth, Georgia, 30097\n",
      "                                    Attention:  General Counsel\n",
      "\n",
      "\n",
      "              Any party  may,  by notice  to the other  party  given in the form\n",
      "              specified in this  Section  9.8,  change the address to which such\n",
      "              notices are to be given.\n",
      "\n",
      "     8.9. Severability.  If any  provision of this  Agreement is determined by a\n",
      "          court of competent  jurisdiction to be invalid, void or unenforceable,\n",
      "          the remaining  provisions hereof shall remain in full force and effect\n",
      "          and shall in no way be affected,  impaired or invalidated  thereby, so\n",
      "          long  as  the  economic  or  legal   substance  of  the   transactions\n",
      "          contemplated hereby is not affected in any manner adverse to any party\n",
      "          and the parties  shall  negotiate  in good faith in an effort to agree\n",
      "          upon a suitable and equitable  means to effect the original  intent of\n",
      "          the parties.\n",
      "\n",
      "     8.10.Force  Majeure.  No Party shall be deemed in default of this Agreement\n",
      "          to the  extent  that any delay or failure  in the  performance  of its\n",
      "          obligations  under this  Agreement  results  from any cause beyond its\n",
      "          reasonable  control and without its fault or negligence,  such as acts\n",
      "          of God,  acts of  civil  or  military  authority,  acts of  terrorism,\n",
      "          embargoes,  epidemics, war, riots,  insurrections,  fires, explosions,\n",
      "          earthquakes,   floods,  unusually  severe  weather  conditions,  labor\n",
      "          problems  or  unavailability  of parts,  or,  in the case of  computer\n",
      "          systems, any failure in electrical or air conditioning  equipment.  In\n",
      "          the event of any such excused delay, the time for performance shall be\n",
      "          extended for a period equal to the time lost by reason of the delay.\n",
      "\n",
      "     8.11.Headings.  The article,  section and paragraph  headings  contained in\n",
      "          this Agreement are for reference purposes only and shall not affect in\n",
      "          any way the meaning or interpretation of this Agreement.\n",
      "\n",
      "     8.12.Schedules and Exhibits.  All Schedules and Exhibits referenced in this\n",
      "          Agreement and attached hereto are incorporated herein by reference and\n",
      "          shall be considered for all purposes as part of this Agreement.\n",
      "\n",
      "     8.13.Waivers  of  Default.  Waiver by either  Party of any  default  by the\n",
      "          other Party of any provision of this  Agreement  shall not be deemed a\n",
      "          waiver by the waiving Party of any  subsequent or other  default,  nor\n",
      "          shall it prejudice the rights of the other Party.\n",
      "\n",
      "     8.14.Public  Announcements.  Neither party shall issue any press release or\n",
      "          other public announcement concerning the transactions  contemplated by\n",
      "          this agreement  without the prior written consent of both the CIBA and\n",
      "          IMPLANTABLE VISION, which consent shall not be unreasonably  withheld.\n",
      "          CIBA  consents  to allow SEC  filings as required by law to be made on\n",
      "          Form 8-K and as necessary in other SEC filings.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "       IN WITNESS  WHEREOF,  the  Parties,  intending to be bound  hereby,  have\n",
      "executed this Agreement as of the Closing Date.\n",
      "\n",
      "\n",
      "\n",
      "         SELLER:                                     BUYER:\n",
      "\n",
      "         CIBA   VISION                               IMPLANTABLE VISION\n",
      "\n",
      "                                                /s/George Rozakis\n",
      "By:_______________________                By: ______________________________\n",
      "\n",
      "                                                George Rozakis\n",
      "Name:_____________________                Name:_____________________________\n",
      "\n",
      "                                                President\n",
      "Title: ___________________               Title: ______________________________\n",
      "\n",
      "\n",
      "Date:_____________________                Date: ______________________________\n",
      "\n",
      "\n",
      "\n",
      "         CIBA VISION\n",
      "\n",
      "\n",
      "\n",
      "By:_______________________\n",
      "\n",
      "\n",
      "Name:_____________________\n",
      "\n",
      "\n",
      "Title:____________________\n",
      "\n",
      "Date:_____________________\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Bottom of Form\n",
      "© Copyright 2000 - 2016 RoyaltyStat.\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "file_path = '/home/kprasath/DS/NLPInternship/txt_data/ref_1_txt/10899.txt' # Replace with the actual path to your TXT file\n",
    "text = read_txt(file_path)\n",
    "print(text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "362679eb",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Top of Form\n",
      "\n",
      "\n",
      " ",
      " ",
      "Type: EX-10.15 Description: SETTLEMENT, LICENSE AND DEVELOPMENT AGREEMENT ",
      " ",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      " \n",
      "[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED\n",
      "IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED\n",
      "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2\n",
      "OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. \n",
      " \n",
      "Exhibit 10.15 \n",
      " \n",
      "SETTLEMENT, LICENSE AND DEVELOPMENT AGREEMENT \n",
      " \n",
      "THIS SETTLEMENT, LICENSE AND DEVELOPMENT AGREEMENT (the\n",
      "“Agreement”), is entered into as of March 5, 2007 (the “Execution Date”) by and between Tercica, Inc., a company incorporated under the laws of Delaware with offices at 2000 Sierra Point Parkway, Suite 400,\n",
      "Brisbane, CA 94005, United States of America (“Tercica”), Insmed Incorporated, a company incorporated under the laws of Virginia with offices at 8720 Stony Point Parkway, Suite 200, Richmond, VA 23235, Insmed Therapeutic Proteins,\n",
      "Inc., a company incorporated under the laws of Colorado with offices at 2590 Central Avenue, Boulder, CO 80301, and Celtrix Pharmaceuticals, Inc., a company incorporated under the laws of Delaware with offices at 8720 Stony Point Parkway, Suite 200,\n",
      "Richmond, VA 23235 (collectively, “Insmed”) and Genentech, Inc., a company incorporated under the laws of Delaware with offices at 1 DNA Way, South San Francisco, California 94080 (“GNE”). Tercica, GNE and Insmed\n",
      "are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” \n",
      " \n",
      "RECITALS\n",
      " \n",
      "Whereas, Tercica and GNE have entered into that certain License and Collaboration Agreement dated April 15, 2002, as\n",
      "amended on July 25, 2003 and November 25, 2003 (the “GNE US License”); and Tercica and GNE have also entered into that certain International License and Collaboration Agreement dated July 25, 2003 (the “GNE\n",
      "Ex-US License”); whereby, inter alia, GNE has granted to Tercica a license under the GNE Patents (as defined below), including U.S. Patent No. 5,258,287; U.S. Patent No. 5,187,151; and U.S. Patent No. 6,331,414; \n",
      " \n",
      "Whereas, certain disputes and controversies have arisen between the Parties relating to the claims, counter-claims, cross-claims, and demands set\n",
      "forth in the following civil action filed on December 23, 2004: Genentech Inc., et al. v. Insmed Incorporated, et al., United States District Court for the Northern District of California (the “Court”), Case\n",
      "No. 04-CV-05429-CW (EMC) (the “Lawsuit”). Tercica and GNE alleged that Insmed’s making, using, selling, offering to sell, importing or exporting of the product known as IPLEX™, infringed or will infringe under 35\n",
      "U.S.C. § 271(a) – (c) and (g), certain asserted claims of United States Patent Nos. 5,187,151 (the “’151 Patent”), 5,258,287 (the “’287 Patent”) and 6,331,414 (the “’414\n",
      "Patent”) (collectively, the “Asserted Patents”); \n",
      " \n",
      "Whereas, Insmed denied such allegations and further\n",
      "alleged, among other defenses, that the asserted claims of the Asserted Patents were invalid under various theories, including those arising under 35 U.S.C. § 102, 103, 112 and 135. Insmed further asserted that the ’151 Patent was\n",
      "unenforceable for alleged inequitable conduct; \n",
      " \n",
      "Whereas, the Parties had a full and fair opportunity to litigate the case fully,\n",
      "including asserting motions for summary judgment and jury trial; \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "Whereas, the Court adjudicated as a matter of law on June 30, 2006 that Insmed’s method\n",
      "of making the rhIGF-I component of IPLEX™ literally infringed Claims 1 and 9 of the ’414 Patent (Docket No. 510), and Insmed subsequently stipulated that its methodology literally infringed Claims 2, 3, 4 and 10 of the ’414\n",
      "Patent; \n",
      " \n",
      "Whereas, a jury trial that commenced on November 6, 2006, resulted in the Verdict Form (Docket # 1006) filed\n",
      "December 6, 2006. The Jury further awarded damages to Tercica and GNE of $7.5 million and a royalty of 15% of IPLEX™ sales through December 6, 2006 (the “Damages”); \n",
      " \n",
      "Whereas, legal proceedings among the Parties (and also Avecia Limited, a company incorporated under the laws of England and Wales, whose\n",
      "registered office is at PO Box 42, Hexagon Tower, Blackley, Manchester M9 8ZS, United Kingdom (“Avecia”)) and relating to European Patent (UK) No. 0 571 417 have been commenced in the United Kingdom in the High Court of Justice\n",
      "under action numbers HC 04 C 03940 and HC 05 C 00415 (the “UK Proceedings”); \n",
      " \n",
      "Whereas, the Parties have determined\n",
      "that it is in their mutual interest to avoid the expense, distraction, and uncertainty of further litigation and have therefore agreed to conclude and resolve all of their disputes under the Lawsuit and UK Proceedings and settle and consent to\n",
      "judgment of such Lawsuit and UK Proceedings pursuant to the terms and conditions of this Agreement, the Consent Judgment and Permanent Injunction, and the UK Proceedings Settlement Agreement; and \n",
      " \n",
      "Whereas, the Parties and Avecia have agreed, as of the date hereof, to enter into that certain Settlement Agreement (the “UK Proceedings\n",
      "Settlement Agreement”) which sets forth the terms and conditions by which the Parties and Avecia have agreed to settle the UK Proceedings. \n",
      " \n",
      "Now, therefore, in consideration of the releases and mutual promises, covenants and conditions contained herein, and other good and valuable consideration, including this Agreement, the Consent Judgment and\n",
      "Permanent Injunction, and the UK Proceedings Settlement Agreement, the Parties agree as follows: \n",
      " \n",
      "ARTICLE 1 \n",
      " \n",
      "DEFINITIONS \n",
      " \n",
      "1.1 “Adult\n",
      "Primary IGF-1 Deficiency” means abnormally low concentrations of IGF-1 in adults that are: (a) not secondary to growth hormone deficiency; and (b) not secondary to specific pathophysiological states outside the GH/IGF-1 system.\n",
      " \n",
      "1.2 “Affiliate” means any corporation, company, partnership, joint venture and/or firm which controls, is controlled by,\n",
      "or is under common control with a Party; provided that F. Hoffman-la Roche AG (including its subsidiaries) shall be considered a Third Party for purposes of this Agreement, rather than as an Affiliate of GNE. For purposes of the foregoing sentence,\n",
      "“control” and, with correlative meanings, the terms “controlled by” and “under common control \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "2 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "with”, mean (a) in the case of corporate entities, direct or indirect ownership of at least fifty percent (50%) of the stock or shares having\n",
      "the right to vote for the election of directors and (b) in the case of non-corporate entities, direct or indirect ownership of at least fifty percent (50%) of the equity interest with the power to direct the management and policies of such\n",
      "non-corporate entities. \n",
      " \n",
      "1.3 “Agreement” has the meaning assigned to it in the preamble above. \n",
      " \n",
      "1.4 “Aggregated Named Patient and Off-Label Sales” has the meaning assigned to it in Section 7.1(a)(iv)(3). \n",
      " \n",
      "1.5 “ALS” means Lou Gehrig’s disease. \n",
      " \n",
      "1.6 “ALS Portion” has the meaning assigned to it in Section 7.1(a)(iii). \n",
      " \n",
      "1.7\n",
      "“ALS Royalty” has the meaning assigned to it in Section 7.1(a)(iii). \n",
      " \n",
      "1.8 “Avecia” has the meaning\n",
      "assigned to it in the Recitals of this Agreement. \n",
      " \n",
      "1.9 “Booking Party” means the Party responsible for booking sales of a\n",
      "Product for an Opt-In Indication after Tercica or GNE has exercised its Opt-In right. \n",
      " \n",
      "1.10 “Claims” has the meaning\n",
      "assigned to it in Section 11.1. \n",
      " \n",
      "1.11 “Commercialization Plan” means, in the event Tercica or GNE exercises its\n",
      "Co-Promotion Option for a particular Permitted Indication, the plan prepared by the JCC that would govern the Parties’ co-promotion and related commercialization activities for a Product with respect to such Permitted Indication in accordance\n",
      "with Section 5.3(c). \n",
      " \n",
      "1.12 “Committee” means the Joint Development Committee or Joint Commercialization Committee, as\n",
      "applicable. \n",
      " \n",
      "1.13 “Completion” means, with respect to a given clinical trial, the completion of all data analysis to be\n",
      "conducted in connection with such clinical trial. \n",
      " \n",
      "1.14 “Confidential Information” has the meaning assigned to it in\n",
      "Section 9.1. \n",
      " \n",
      "1.15 “Control” with the correlative meaning “Controlled by” means, with respect to\n",
      "intellectual property, possession of the right to grant a license or sublicense as provided for herein without violating (a) any law or governmental regulation applicable to such license or sublicense; or (b) the terms of any agreement or\n",
      "other arrangement with any Third Party that exists as of the Effective Date, or, if the applicable intellectual property is acquired or the right to such intellectual property is to be granted after the Effective Date, the date of such acquisition\n",
      "or proposed grant, whichever is later. \n",
      " \n",
      "1.16 “Co-Promotion Agreement” has the meaning assigned to it in\n",
      "Section 5.3(b). \n",
      " \n",
      "1.17 “Co-Promotion Option” has the meaning assigned to it in Section 5.2. \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "3 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "1.18 “Co-Promotion Term” has the meaning assigned to it in Section 5.3(b).\n",
      " \n",
      "1.19 “Court” has the meaning assigned to it in the Recitals of this Agreement. \n",
      " \n",
      "1.20 “Damages” has the meaning assigned to it in the Recitals of this Agreement. \n",
      " \n",
      "1.21 “Data Services” has the meaning assigned to it in Section 5.5(a)(i). \n",
      " \n",
      "1.22 “Development Costs” has the meaning assigned to it in Exhibit A. \n",
      " \n",
      "1.23 “Diabetes” means a progressive disease of carbohydrate metabolism involving inadequate production or utilization of insulin that is\n",
      "characterized by hyperglycemia and glycosuria. The term shall apply to any form of diabetes, including without limitation, Type 1 and Type 2 diabetes, as well as other hyperglycemic disorders, such as hyperinsulinemia, hyperlipidemia,\n",
      "insulin-resistant diabetes such as Mendenhall’s Syndrome, Werner Syndrome, leprechaunism, lipoatrophic diabetes. \n",
      " \n",
      "1.24\n",
      "“Diabetes Orphan Indication” means any Diabetes indication that is also an Orphan Indication. \n",
      " \n",
      "1.25 “Disclosing\n",
      "Party” has the meaning assigned to it in Section 9.1. \n",
      " \n",
      "1.26 “Dispute” has the meaning assigned to it in\n",
      "Section 13.1. \n",
      " \n",
      "1.27 “Effective Date” has the meaning assigned to it in Section 2.1. \n",
      " \n",
      "1.28 “EMEA” means the European Medicines Agency, a decentralized body of the European Union. \n",
      " \n",
      "1.29 “European Union” or “EU” means all of the European Union member states as of the applicable time during the Term.\n",
      " \n",
      "1.30 “Excluded Indications” means (a) Excluded Indications as such term is defined in Section 1.21 of the GNE\n",
      "US License, and (b) Excluded Indications as such term is defined in Section 1.19 of the GNE Ex-US License. \n",
      " \n",
      "1.31\n",
      "“Execution Date” has the meaning assigned to it in the preamble of this Agreement. \n",
      " \n",
      "1.32 “Existing Insmed\n",
      "Indications” means myotonic muscular dystrophy, HIV related Adipose Redistribution Syndrome (HARS), retinopathy of prematurity, recovery from burns and trauma, and recovery from hip fracture. \n",
      " \n",
      "1.33 “Existing Patient” has the meaning assigned to it in Section 3.1(a). \n",
      " \n",
      "1.34 “FDA” means the United States Food and Drug Administration or its successor. \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "4 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "1.35 “Fully Burdened Manufacturing Costs” has the meaning assigned to it in Exhibit\n",
      "A. \n",
      " \n",
      "1.36 “GNE Licenses” means both the GNE US License and the GNE Ex-US License, as each is defined in the Recitals of\n",
      "this Agreement. \n",
      " \n",
      "1.37 “GNE Patents” means (a) GNE Patents as such term is defined in Section 1.35 of the GNE US\n",
      "License, and (b) GNE Patents as such term is defined in Section 1.33 of the GNE Ex-US License. \n",
      " \n",
      "1.38 “IGF-1”\n",
      "means native-sequence insulin-like growth factor-1 from any species with or without an N-terminal methionine, allelic variants thereof, and sequence variants thereof wherein substitutions and/deletions are made in the region from 1 to 5 amino acids\n",
      "from the N-terminus of the mature native-sequence IGF-1 of any species, including des-IGF-1 and variants wherein at least the glutamic acid residue is absent at position 3 from the N-terminus of native-sequence human IGF-1. \n",
      " \n",
      "1.39 “IGFBP-3” means native-sequence, insulin-like growth factor binding protein-3 as described in WO 89/09268 published October 5,\n",
      "1989, that binds IGF-1, including allelic variants of, and animal equivalents to, human BP3 as well as human BP3, for example, the bovine, ovine, porcine and equine species, and may be from any source, whether natural, synthetic, or recombinant,\n",
      "provided that it will bind to the appropriate binding domain of IGF-1. \n",
      " \n",
      "1.40 “IND” means an investigational new drug\n",
      "application as defined under United States law and foreign equivalents. \n",
      " \n",
      "1.41 “Indemnified Party” has the meaning assigned\n",
      "to it in Section 11.4. \n",
      " \n",
      "1.42 “Indemnifying Party” has the meaning assigned to it in Section 11.4. \n",
      " \n",
      "1.43 “Infringing Activity” means any manufacture, use, sale, offer for sale, or importation of a Product, either by Insmed or through an\n",
      "Affiliate or Sublicensee or subcontractor, that would infringe any unexpired GNE Patents in the Other Territory. \n",
      " \n",
      "1.44 “Insmed\n",
      "Patents” means all patents and patent applications Controlled by Insmed as of the Effective Date (if any) or during the Term, in any country of the Territory, that claim the manufacture, use, sale, offer for sale, or importation of Product\n",
      "or IGF-1. \n",
      " \n",
      "1.45 “Ipsen” means Tercica’s sublicensee of certain of the Licensed Patents, Beaufour Ipsen Pharma or its\n",
      "Affiliates, in the Other Territory, pursuant to that certain Increlex™ License and Collaboration Agreement between Tercica and Ipsen dated October 13, 2006. \n",
      " \n",
      "1.46 “Joint Commercialization Committee” or “JCC” means the committee formed by the Parties as described in Section 6.3(a). \n",
      " \n",
      "1.47 “Joint Development Committee” or “JDC” means the committee formed by the Parties as described in\n",
      "Section 6.2(a). \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "5 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "1.48 “Launch Date” has the meaning assigned to it in Section 5.3(b). \n",
      " \n",
      "1.49 “Lawsuit” has the meaning assigned to it in the Recitals of this Agreement. \n",
      " \n",
      "1.50 “Licensed Patents” means (a) the GNE Patents and (b) all patents and patent applications Controlled by Tercica as of the\n",
      "Effective Date or during the Term that claim the manufacture, use, sale or importation of Product and/or that claim the manufacture, use, sale, or importation of any product or process used in Insmed’s production of Product, including, but not\n",
      "limited to recombinant production of IGF-1 or any IGF-1 binding protein, and purification of IGF-1 or any IGF-1 binding protein. \n",
      " \n",
      "1.51\n",
      "“Marketing Authorization” means an approval necessary for the manufacture, marketing, importation and sale of a Product for one or more indications in a country or regulatory jurisdiction, which may include, without limitation, the\n",
      "approval of an NDA or MAA, satisfaction of all applicable regulatory and notification requirements, and Pricing Approval (if required). For purposes of this definition, “Pricing Approval” means such approval, agreement, determination or\n",
      "governmental decision establishing prices for a Product that can be charged to consumers and will be reimbursed by governmental authorities in countries, territories or possessions where governmental authorities or Regulatory Authorities of such\n",
      "country, territory or possession approve or determine pricing of pharmaceutical products for reimbursement or otherwise. \n",
      " \n",
      "1.52\n",
      "“Material Breach” has the meaning assigned to it in Section 12.2. \n",
      " \n",
      "1.53 “Named Patient Basis” means the\n",
      "supply of a Product for a particular individual for the treatment of an indication for which such Product does not yet have Marketing Authorization in the country in which it is prescribed, in response to a specific request of a prescribing\n",
      "physician for such individual patient, where permitted by and in accordance with the laws of the EU member state(s) concerned and in accordance with Directive 2001/83/EC (and in particular Article 5 thereof), as amended by Directive 2004/27/EC, and\n",
      "Regulation (EC) No. 726/2004. \n",
      " \n",
      "1.54 “Named Patient Indications” means myotonic muscular dystrophy, HIV related\n",
      "Adipose Redistribution Syndrome (HARS), retinopathy of prematurity, recovery from burns and trauma, and recovery from hip fracture. \n",
      " \n",
      "1.55 “Net Sales” has the meaning assigned to it in Exhibit A. \n",
      " \n",
      "1.56 “New Sales Tracking\n",
      "Data” has the meaning assigned to it in Section 5.5(a)(ii). \n",
      " \n",
      "1.57 “Non-ALS Portion” has the meaning assigned\n",
      "to it in Section 7.1(a)(iv)(3) \n",
      " \n",
      "1.58 “Non-Booking Party” means the Party that is not responsible for booking sales of\n",
      "a Product for an Opt-In Indication after Tercica or GNE has exercised its Opt-In right. \n",
      " \n",
      "1.59 “Non-Orphan Indication”\n",
      "means any Permitted Indication which is not an Orphan Indication. \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "6 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "1.60 “Non-Permitted Indications” means (a) primary IGFD, (b) severe primary\n",
      "IGFD, (c) Noonan’s syndrome, (d) growth hormone deficiency, (e) adult growth hormone deficiency (as approved by the FDA and consisting of two subgroups: adult and child onset), (f) Adult Primary IGF-1 Deficiency,\n",
      "(g) idiopathic short stature, (h) any other short stature indications, (i) Laron’s Syndrome, (j) growth hormone insensitivity (GHIS), (k) any diseases or conditions which are approved for sale by Tercica or GNE, as of\n",
      "the Effective Date, for the treatment by growth hormone, and (l) all Excluded Indications, which, for the purpose of this Agreement and with respect to Insmed, includes ALS, but which inclusion for purposes of this definition of Non-Permitted\n",
      "Indications shall in no event be interpreted as a concession on the part of either Tercica or GNE as to whether ALS is or is not included within the Excluded Indications with respect to Tercica’s license from GNE under the GNE Licenses.\n",
      " \n",
      "1.61 “Non-Permitted Product” means (a) any product containing IGF-1 without any other bioactive agent, in any dosage\n",
      "or formulation, including without limitation the product known as INCRELEX (mecasermin) that is sold by Tercica as of the Effective Date, or (b) any product containing a combination of IGF-1 and any other active ingredient(s) (excluding IGFBP-3\n",
      "unless and only as permitted in Section 3.2(b) below). \n",
      " \n",
      "1.62 “North American Territory” means the United States and\n",
      "Canada. \n",
      " \n",
      "1.63 “Off-Label Sales” has the meaning assigned to it in Section 7.1(a)(iv)(2). \n",
      " \n",
      "1.64 “Operating Profit (Loss)” has the meaning assigned to it in Exhibit A. \n",
      " \n",
      "1.65 “Opt-In” has the meaning assigned to it in Section 4.2(a). \n",
      " \n",
      "1.66 “Opt-In Diabetes Orphan Indication” has the meaning assigned to it in Section 4.3(d). \n",
      " \n",
      "1.67 “Opt-In Effective Date” has the meaning assigned to it in Section 4.2(b). \n",
      " \n",
      "1.68 “Opt-In Exercise Notice” has the meaning assigned to it in Section 4.2(b). \n",
      " \n",
      "1.69 “Opt-In Indication” has the meaning assigned to it in Section 4.2(b). \n",
      " \n",
      "1.70 “Opt-In Information” means any and all information that is reasonably available to Insmed and which would be reasonably material\n",
      "for Tercica and/or GNE to make a decision regarding the exercise of its Opt-In right at such stage of development and may include, without limitation, any of the following information to the extent generated: a copy of formulation, stability,\n",
      "toxicology, pharmacokinetic, preclinical and clinical development plans and data; complete analysis, results, reports, and interpretations of the foregoing; an accounting of all Development Costs; any pertinent manufacturing information; and any\n",
      "related FDA documentation (including the IND, clinical protocol, investigator’s brochure, FDA minutes and correspondence). \n",
      " \n",
      "1.71\n",
      "“Opt-In Party” has the meaning assigned to it in Section 4.2(b). \n",
      " \n",
      "1.72 “Opt-In Payment” has the meaning\n",
      "assigned to it in Section 4.2(e). \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "7 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "1.73 “Opt-In Period” has the meaning assigned to it in Section 4.2(b). \n",
      "\n",
      "1.74 “Opt-Out” has the meaning assigned to it in Section 4.4. \n",
      " \n",
      "1.75 “Orphan Indication” means an indication for which the FDA has granted orphan status as defined in 21 C.F.R. Pt. 316, as may be\n",
      "amended from time to time. As of the Execution Date, such term is defined in 21 C.F.R. Pt. 316 as a rare disease or condition within the Permitted Indications which: (a) affects less than 200,000 persons in the U.S. or (b) affects more\n",
      "than 200,000 persons in the U.S. but for which there is no reasonable expectation that the cost of developing and making available in the U.S. a drug for such disease or condition will be recovered from sales in the United States of such drug, as\n",
      "further defined in and for which Orphan Drug designation may be sought under the Orphan Drug Act of 1983. \n",
      " \n",
      "1.76 “Other\n",
      "Territory” means all countries of the Territory other than the United States. \n",
      " \n",
      "1.77 “Percentage Interest” has the\n",
      "meaning assigned to it in Section 4.2(a). \n",
      " \n",
      "1.78 “Permanent Injunction” has the meaning assigned to in\n",
      "Section 2.1. \n",
      " \n",
      "1.79 “Permitted Indications” means all indications except the Non-Permitted Indications. For the\n",
      "avoidance of doubt, Permitted Indications includes (a) the treatment by growth hormone of HIV patients with wasting or cachexia; and (b) all Existing Insmed Indications. \n",
      " \n",
      "1.80 “Phase III Enabling Trial” means, with respect to any given Permitted Indication, a human clinical trial on a sufficient number of\n",
      "subjects (who are patients with the condition being addressed), with clinically meaningful, regulatorily recognized efficacy endpoints which generates statistically significant efficacy and establishes a safe and effective dose and is designed such\n",
      "that, if successful, Insmed would be allowed by the FDA and/or EMEA to proceed with a pivotal clinical trial that would support the filing of an application for marketing approval for such Permitted Indication. As further discussed in\n",
      "Section 6.2, the Joint Development Committee is responsible for determining whether a given proposed trial by Insmed meets the foregoing definition for a Phase III Enabling Trial prior to the conduct of such trial. \n",
      " \n",
      "1.81 “Product” means any product containing IGF-1 and IGFBP-3, in any dosage, formulation or method of administration, or any\n",
      "co-administration of IGF-1 and IGFBP-3, including without limitation the product known as IPLEX (mecasermin rinfabate) that is sold by Insmed as of the Execution Date. Product does not include any combination product containing IGF-1 and IGFBP-3 and\n",
      "any other active ingredient(s). For purposes of this definition, the term “active ingredient(s)” does not include drug delivery vehicles, adjuvants, and excipients except for those that are recognized by the FDA as active ingredients.\n",
      " \n",
      "1.82 “Product Labeling” means (a) the full prescribing information for a Product approved by the applicable\n",
      "Regulatory Authority, and (b) all labels and other written, printed or \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "8 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "graphic information (including without limitation any Product trademarks) included in or placed upon any container, wrapper or package insert used with or\n",
      "for a Product. \n",
      " \n",
      "1.83 “Promotional Materials” means all sales representative training materials and all written, printed,\n",
      "graphic, electronic, audio or video matter, including, without limitation, journal advertisements, sales visual aids, leave items, formulary binders, reprints, direct mail, direct-to-consumer advertising, internet postings, broadcast advertisements\n",
      "and sales reminder aides (for example, note pads, pens and other such items) intended for use or used by a Party or its Affiliates, sublicensees or licensees in connection with any promotion of a Product for such Permitted Indication, but excluding\n",
      "Product Labeling. \n",
      " \n",
      "1.84 “Receiving Party” has the meaning assigned to it in Section 9.1. \n",
      " \n",
      "1.85 “Regulatory Authority” means any government agency having the responsibility for granting Marketing Authorizations and any other\n",
      "government entities with authority over the manufacturing and the marketing of a Product. \n",
      " \n",
      "1.86 “ROW Territory” means all\n",
      "countries and territories in the Territory other than the countries in the North American Territory. \n",
      " \n",
      "1.87 “Sale Country”\n",
      "means a country in which a Product is used, sold, offered for sale, or imported. \n",
      " \n",
      "1.88 “Sales Tracking Dispute” has the\n",
      "meaning assigned to it in Section 7.1(f). \n",
      " \n",
      "1.89 “Sales Tracking Methodology” has the meaning assigned to it in\n",
      "Section 5.5(a)(i). \n",
      " \n",
      "1.90 “Sales Tracking Panel” has the meaning assigned to it in Section 5.5(d). \n",
      " \n",
      "1.91 “Sole Promotion Option” has the meaning assigned to it in Section 5.2. \n",
      " \n",
      "1.92 “Sublicensee” means a Third Party to whom Insmed or its Affiliates sublicenses its rights and obligations under Section 3.1 of\n",
      "this Agreement. Sublicensee shall also include any Third Party who purchases its supply of Product, in finished form from Insmed, its Affiliates or Sublicensee for resale into the market, where, as a partial or full consideration for such purchase,\n",
      "such Third Party has a payment obligation to Insmed, its Affiliates or Sublicensee that is a percentage of its net sales, including without limitation a royalty obligation. \n",
      " \n",
      "1.93 “Supply Agreement” has the meaning assigned to it in Section 5.4(b). \n",
      " \n",
      "1.94 “Term” has the meaning assigned to it in Section 12.1(a). \n",
      " \n",
      "1.95 “Territory” means all countries of the world. \n",
      " \n",
      "1.96 “Third Party” means a person or entity other than Tercica, GNE, Insmed, or any of their Affiliates. \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "9 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "1.97 “Trademark” means IPLEX™ and all other trademarks used or intended for use by\n",
      "Insmed or its Affiliates on the Effective Date or during the Term in connection with the marketing or sale of a Product, other than the corporate names of Insmed and its Affiliates, their trade names, service marks, domain names, and associated\n",
      "logos and designs. \n",
      " \n",
      "1.98 “Triggering Delivery” has the meaning assigned to it in Section 4.2(c). \n",
      " \n",
      "1.99 “UK Proceedings” has the meaning assigned to it in the Recitals of this Agreement. \n",
      " \n",
      "1.100 “UK Proceedings Settlement Agreement” has the meaning assigned to it in the Recitals of this Agreement. \n",
      " \n",
      "ARTICLE 2 \n",
      " \n",
      "CONSENT JUDGMENT AND\n",
      "PERMANENT INJUNCTION; \n",
      " \n",
      "RELEASES AND WAIVER \n",
      " \n",
      "2.1 Entry of Consent Judgment and Permanent Injunction. A Consent Judgment and Permanent Injunction in the form of Exhibit B will be executed herewith (the “Permanent Injunction”), and the\n",
      "Parties agree to take all steps necessary to have the Permanent Injunction executed by the Court and filed with the Court and hereby authorize and instruct their respective counsel to take those steps. This Agreement shall only become effective upon\n",
      "the execution of the Permanent Injunction by or on behalf of the Parties to the action and the Court, the entry and filing of the Permanent Injunction, and the execution of the UK Proceedings Settlement Agreement in the form of Exhibit C (the\n",
      "date by which the last of such events has occurred, the “Effective Date”). \n",
      " \n",
      "2.2 Waiver of Damages. Tercica waives all\n",
      "rights to any Damages awarded in the Lawsuit upon execution and entry by the Court of the Permanent Injunction and the execution of the UK Proceedings Settlement Agreement. \n",
      " \n",
      "2.3 Release by Tercica. Tercica, by and for itself and on behalf of its employees, agents, other representatives, sublicensees, officers,\n",
      "directors, stockholders, partners, members, subsidiaries, predecessors, successors, and assigns, irrevocably, perpetually and fully releases and discharges Insmed as well as Insmed’s employees, agents, fill-finishers, customers, downstream\n",
      "sellers and users of a Product, and Insmed’s other representatives, officers, directors, stockholders, partners, members, subsidiaries, predecessors, successors, licensees, distributors, and assigns, from any and all claims, rights, demands,\n",
      "liabilities, obligations, damages, actions, and causes of action, of every kind and nature, in law, equity, or otherwise, known and unknown, suspected and unsuspected, disclosed and undisclosed, arising out of any act, omission, event, transaction\n",
      "or occurrence on or before the Effective Date solely to the extent relating to both (a) a Product and (b) the Licensed Patents; provided that this release shall not extend to and affect the rights and obligations under the Permanent\n",
      "Injunction. \n",
      " \n",
      "2.4 Release by GNE. GNE, by and for itself and on behalf of its employees, agents, other representatives, sublicensees,\n",
      "officers, directors, stockholders, partners, members, \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "10 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "subsidiaries, predecessors, successors, and assigns, irrevocably, perpetually and fully releases and discharges Insmed as well as Insmed’s employees,\n",
      "agents, fill-finishers, customers, downstream sellers and users of a Product, and Insmed’s other representatives, officers, directors, stockholders, partners, members, subsidiaries, predecessors, successors, licensees, distributors, and\n",
      "assigns, from any and all claims, rights, demands, liabilities, obligations, damages, actions, and causes of action, of every kind and nature, in law, equity, or otherwise, known and unknown, suspected and unsuspected, disclosed and undisclosed,\n",
      "arising out of any act, omission, event, transaction or occurrence on or before the Effective Date solely to the extent relating to both (a) a Product and (b) the GNE Patents; provided that this release shall not extend to and affect the\n",
      "rights and obligations under the Permanent Injunction. \n",
      " \n",
      "2.5 Release by Insmed. Insmed, by and for itself and on behalf of its\n",
      "employees, agents, other representatives, sublicensees, officers, directors, stockholders, partners, members, subsidiaries, predecessors, successors, and assigns, irrevocably, perpetually and fully releases and discharges Tercica and GNE as well as\n",
      "each of Tercica’s and GNE’s respective employees, agents, fill-finishers, customers, downstream sellers and users of Increlex, and Tercica’s and GNE’s other representatives, officers, directors, stockholders, partners, members,\n",
      "subsidiaries, predecessors, successors, licensees, distributors, and assigns, from any and all claims, rights, demands, liabilities, obligations, damages, actions, and causes of action, of every kind and nature, in law, equity, or otherwise, known\n",
      "and unknown, suspected and unsuspected, disclosed and undisclosed, arising out of any act, omission, event, transaction or occurrence on or before the Effective Date solely to the extent relating to both (a) the Insmed Patents and (b) any\n",
      "Non-Permitted Products; provided that this release shall not affect the rights and obligations under the Permanent Injunction. \n",
      " \n",
      "2.6\n",
      "Waiver of Section 1542 of California Civil Code. Each of Tercica, GNE and Insmed hereby declares and acknowledges the contents of Section 1542 of the California Civil Code, and that section and the benefits thereof are hereby expressly\n",
      "waived. Section 1542 provides as follows: “A general release does not extend to claims which the creditor does not know or suspect to exist in his favor at the time of executing the release, which if known by him must have materially\n",
      "affected his settlement with the debtor.” \n",
      " \n",
      "2.7 Other Waivers and Stipulations. The Parties hereby incorporate by reference the\n",
      "conclusions of law, the findings of fact, waivers and stipulations set forth in the Permanent Injunction. \n",
      " \n",
      "2.8 Discontinuance of UK\n",
      "Proceedings. The Parties shall promptly and permanently discontinue the claims and counterclaims in the UK Proceedings, on the basis that each Party shall be responsible for the costs incurred by it in connection with those proceedings (other\n",
      "than costs which have already been paid by one Party to another pursuant to an order of the United Kingdom Court made prior to the Effective Date). The Parties shall accordingly enter into and perform the UK Proceedings Settlement Agreement\n",
      "relating to the UK Proceedings in the form of Exhibit C forthwith following the execution of this Agreement. Insmed shall ensure that Avecia shall, and shall cause Avecia to, execute such settlement agreement and do all such acts and\n",
      "execute all such documents as may be necessary or desirable to give effect to the provisions of such settlement agreement, including the discontinuance of the claims brought by Avecia against Tercica and GNE in the course of the UK Proceedings.\n",
      "Notwithstanding \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "11 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "anything to the contrary in this Section 2.8, as between Tercica and GNE, Tercica shall absorb and bear sole responsibility for payment of any fees,\n",
      "costs, and expenses incurred by GNE relating to the prosecution and/or defense of the Lawsuit and/or the UK Proceedings (with the exception of the time and expenses of any GNE employee(s) allocated or attributed to such prosecution and/or defense,\n",
      "which costs shall be borne by GNE). \n",
      " \n",
      "2.9 Survival of this Article 2. The Parties hereby agree and acknowledge that the releases,\n",
      "waivers, and covenants made in this Article 2 shall survive the expiration or any termination of this Agreement, including any termination based on a claim by a Party that another Party has breached this Agreement, the Permanent Injunction or the UK\n",
      "Proceedings Settlement Agreement and any such breach shall not be construed as evidence of a failure of consideration for the granting of the releases, waivers and covenants set forth in this Article 2. \n",
      " \n",
      "ARTICLE 3 \n",
      " \n",
      "LICENSE GRANTS\n",
      " \n",
      "3.1 Licenses to Insmed. \n",
      " \n",
      "(a) Limited License for Non-Permitted Indications in the United States. Subject to the terms and conditions of this Agreement, including without limitation Insmed’s fulfillment of its royalty obligations under Section 7.1\n",
      "below and Insmed’s continued compliance with its covenants in Section 3.5 and the Permanent Injunction and the UK Proceedings Settlement Agreement, Tercica hereby grants Insmed a non-exclusive, non-sublicenseable license or sublicense, as\n",
      "applicable, under Tercica’s entire right, title and interest in and to the Licensed Patents to make, have made, use, sell, offer for sale, and import Product for sale in the United States for any Non-Permitted Indication solely for the\n",
      "continuing treatment of any Existing Patient, for a period of twelve (12) months from the Effective Date. “Existing Patient” means no more than one hundred ten (110) patients for whom a Product is prescribed for a\n",
      "Non-Permitted Indication as of the Effective Date. The Parties agree to send to prescribing physicians a joint letter in the form attached hereto as Exhibit D. The license granted under this Section 3.1(a) shall be royalty-free with\n",
      "respect to Net Sales arising from sales to the Existing Patients during the first three (3) months after the Effective Date. If any such sales to Existing Patients occur after such three (3)-month period, such sales shall be royalty-bearing\n",
      "pursuant to Section 7.1(a)(i), but only until the date which is twelve (12) months after the Effective Date. Any sales of a Product by Insmed to such Existing Patients after such twelve (12)-month period, or any sales of a Product by\n",
      "Insmed to any patient who is not an Existing Patient for the treatment of any Non-Permitted Indication at any time after the Effective Date, shall be evidence of Material Breach by Insmed of this Section 3.1(a) and/or a violation of the\n",
      "Permanent Injunction, and Tercica may take any action and/or seek any remedy in law or equity for such breach or violation. \n",
      " \n",
      "(b) License\n",
      "for Named Patient Indications in the European Union on Named Patient Basis. Subject to the terms and conditions of this Agreement, including without limitation Insmed’s fulfillment of its royalty obligations under Section 7.1 below,\n",
      "and Insmed’s continued compliance with its covenants in Section 3.5 and the Permanent Injunction and UK Proceedings Settlement Agreement, Tercica hereby grants Insmed a limited, non-exclusive, non- \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "12 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "sublicenseable, royalty-bearing license, or sublicense, as applicable, under Tercica’s entire right, title and interest in and to the Licensed Patents\n",
      "to make, have made, use, sell, offer for sale, and import Product for sale in any country in the European Union solely for the treatment of one or more of the Named Patient Indications, on a Named Patient Basis only; provided that Tercica and GNE\n",
      "each shall have the right to perform audits, either by itself or through its designee, on Insmed’s compliance with any laws, regulations and guidelines applicable to conducting such activities on a Named Patient Basis in addition to, and\n",
      "pursuant to the procedures described in, Section 7.8. \n",
      " \n",
      "(c) License for Permitted Indications in the Territory. Subject to the\n",
      "terms and conditions of this Agreement, including without limitation the exclusion of rights and restrictive covenants set forth in Section 3.1(e), Tercica’s and GNE’s Opt-In rights described in Section 4.2, Insmed’s royalty\n",
      "obligations under Section 7.1 below, and Insmed’s continued compliance with its covenants in Section 3.5 and the Permanent Injunction and UK Proceedings Settlement Agreement, Tercica hereby grants Insmed a non-exclusive,\n",
      "royalty-bearing license, or sublicense, as applicable, with the right to sublicense solely as permitted under this Section 3.1(c), under Tercica’s entire right, title and interest in and to the Licensed Patents to make, have made, use,\n",
      "sell, offer for sale, and import Product for sale in all countries in the Territory, solely for use in the treatment of any of the Permitted Indications. Subject to Tercica’s and GNE’s Opt-In rights under Section 4.2, the license\n",
      "granted in this Section 3.1(c) may be sublicensed by Insmed to Third Parties with the prior written consent of Tercica and GNE, such consent not to be unreasonably withheld or delayed. \n",
      " \n",
      "(d) Limited Covenant-Not-To-Sue for ALS Indication on Named Patient Basis in Italy. Subject to the terms and conditions of this Agreement,\n",
      "including without limitation Insmed’s fulfillment of its royalty obligations to GNE under Section 7.1 below, and Insmed’s continued compliance with its covenants in Section 3.5 and the Permanent Injunction and UK Proceedings\n",
      "Settlement Agreement, each of GNE and Tercica hereby covenants that it shall not, to the extent it has the right to do so, enforce, or permit or encourage the enforcement of, against Insmed or its Affiliates any Licensed Patents in connection with\n",
      "the making, having made and using of a Product for the limited purpose of: (i) using, selling, offering for sale, and importing Product for sale in Italy solely for the treatment of ALS on a Named Patient Basis only; provided that each of\n",
      "Tercica and GNE shall have the right to perform audits, either by itself or through its designee, on Insmed’s compliance with any laws, regulations and guidelines applicable to conducting such activities on a Named Patient Basis in addition to,\n",
      "and pursuant to the procedures described in, Section 7.8, and (ii) conducting a single non-pivotal clinical trial (i.e., such clinical trial cannot and shall not be used to support regulatory filing or application for Marketing\n",
      "Authorizations anywhere in the Territory), for the ALS indication in Italy, in connection with Insmed’s treating patients in Italy for the ALS indication on a Named Patient Basis. For the avoidance of doubt, and notwithstanding the payment of\n",
      "royalties solely to GNE pursuant to Section 7.1(a)(iii) based upon Insmed’s sales under this Section 3.1(d) and Tercica’s audit rights set forth in this Section 7.1(d), each of Tercica and GNE reserves the right to its\n",
      "respective interpretation of the GNE Licenses as to whether the scope of the GNE Licenses includes a grant of rights to the ALS indication by GNE to Tercica. \n",
      " \n",
      "(e) Diabetes Restriction in the Other Territory. Insmed hereby covenants that, notwithstanding the license grant in Section 3.1(c), it will not market, sell, offer for sale or \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "13 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "have sold a Product for Diabetes in the Other Territory to the extent the manufacture, use or sale of such Product would infringe, in the Other Territory and\n",
      "if not for the licenses granted under this Agreement, the patent rights licensed to Tercica and sublicensed to Insmed under the GNE Licenses. \n",
      " \n",
      "(f) Included Subsidiary Rights. For avoidance of doubt, the above licenses and limited covenant-not-to-sue granted in Sections 3.1(a) through (d) relating to a Product include the right to make (and have made) IGF-1 and IGFBP-3,\n",
      "solely for use in the manufacture of Product, but such licenses do not include the right to use, sell, offer for sale or import either IGF-1 or IGFBP-3 separately. \n",
      " \n",
      "3.2 Rights Granted to Tercica and GNE. \n",
      " \n",
      "(a) Covenant not to Sue. Insmed hereby covenants that\n",
      "it shall not enforce, or permit or encourage the enforcement of, against Tercica, GNE or Ipsen, or any of their respective Affiliates, sublicensees, successors or assigns any Insmed Patents in connection with the development or commercialization of\n",
      "any Non-Permitted Product in the Territory, and in the event Insmed transfers any right under such Insmed Patents to a Third Party, Insmed shall ensure that such covenant not to sue is binding upon such Third Party in writing. \n",
      " \n",
      "(b) License in the Event of an Opt-In. In the event Tercica and/or GNE exercises its Opt-In right with respect to a given Permitted Indication\n",
      "pursuant to Section 4.2 below, Insmed hereby grants such Opt-In Party a non-exclusive, worldwide license, with the right to grant sublicenses as provided in this Section 3.2(b), under the Insmed Patents to make, have made, use, sell, offer\n",
      "for sale and import Product for the Opt-In Indication as and to the extent permitted under this Agreement. Any sublicense by Tercica or GNE (or their assignees as permitted under Section 4.2(a)) under the rights granted in this\n",
      "Section 3.2(b) to a sublicensee other than a distributor, subcontractor or consultant in the normal course of business shall be made by Tercica or GNE only with the consent of Insmed, such consent not to be unreasonably withheld, provided\n",
      "however that sublicenses to Ipsen shall not require the consent of Insmed. In addition, Insmed agrees to execute all documents as may be reasonably required by Tercica or GNE or Ipsen or their authorized sublicensees for the purpose of recording any\n",
      "such sublicense(s) with any relevant regulatory or administrative authorities and in the event Insmed transfers any right in the affected Insmed Patents to a Third Party, Insmed shall ensure that such Third Party is bound, in writing, by the\n",
      "obligation set forth in this sentence. \n",
      " \n",
      "3.3 GNE Licenses. The Parties acknowledge that the license granted to Insmed under\n",
      "Section 3.1 above constitutes a sublicense with respect to the GNE Patents under the licenses granted to Tercica by GNE under the GNE Licenses. As a result, the licenses granted under Section 3.1 above, and the terms and conditions of this\n",
      "Agreement, shall be subject to the terms and conditions of the GNE Licenses. GNE hereby agrees to the granting of such sublicense to Insmed by Tercica as set forth in Section 3.1. Nothing in this Agreement shall be construed as: (a) the\n",
      "expansion or reduction of the scope of licenses Tercica received from GNE under the GNE Licenses; or (b) implying whether or not the license granted to Tercica under the GNE Agreements includes the ALS indication. \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "14 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "3.4 No Implied Licenses. Except as explicitly set forth in this Agreement, no Party grants any\n",
      "license, express or implied, under its intellectual property rights to any other Party. Each Party covenants that it will not use or practice any other Party’s intellectual property rights licensed to it under this Agreement except for the\n",
      "purposes expressly permitted in the applicable license grant. \n",
      " \n",
      "3.5 Insmed Covenants. In light of the Lawsuit and the Damages awarded\n",
      "therein, and in consideration of the licenses granted by Tercica and GNE to Insmed in Section 3.1, Insmed hereby covenants the following (which covenants shall be in addition to those set forth in the Permanent Injunction): \n",
      " \n",
      "(a) Insmed shall not, and shall cause its Affiliates and Sublicensees to not, directly or indirectly: (i) conduct clinical trials for or\n",
      "otherwise seek any Marketing Authorization for, promote, market, or knowingly sell or offer for sale a Product for the treatment of any Non-Permitted Indication in any country in the Other Territory except as expressly permitted under\n",
      "Section 3.1(b) above with respect to the Named Patient Indications on a Named Patient Basis and Section 3.1(d) above with respect to the ALS indication on a Named Patient Basis, for so long as (A) any such clinical trial or Marketing\n",
      "Authorization uses or depends on the supply of such Product manufactured in a country in which such manufacture is covered by any unexpired Licensed Patents in such country, (B) any such promotion, marketing, sale or offer for sale of such\n",
      "Product depends on the supply of such Product manufactured in a country in which such manufacture is covered by any unexpired Licensed Patents in such country, or (C) any such promotion, marketing, sale or offer for sale of such Product arises\n",
      "from or depends on the use, sale, offer for sale, or importation of such Product in a country in which such use, sale, offer for sale, or importation is covered by any unexpired Licensed Patents in such country. For purposes of determining the\n",
      "duration of such covenant in countries in the Other Territory where a Product is sold which is manufactured in the United States, the last to expire Licensed Patents with respect to such countries shall include U.S. Patent No. 6,331,414 to the\n",
      "extent such patent covers the manufacture of the Product sold (or any components thereof). \n",
      " \n",
      "(b) Within fifteen (15) business\n",
      "days after the Effective Date, Insmed shall withdraw, or cause to be withdrawn, all currently pending applications for Marketing Authorization in the Other Territory, including specifically its currently pending application for Marketing\n",
      "Authorization with the EMEA for a Product for the treatment of primary IGF-1 deficiency and patients with growth hormone gene deletion. \n",
      " \n",
      "(c) Insmed shall not apply for or submit an application with the EMEA or any other governmental authority within the European Union or anywhere else in the Other Territory for Marketing Authorization of a Product for any of the\n",
      "Non-Permitted Indications; provided, however, that for any such Marketing Authorization the foregoing covenant shall terminate upon the expiration of the last to expire Licensed Patents (i) that exists in a country in the European Union or the\n",
      "Other Territory and that covers the manufacture, use, sale, offer for sale, or importation of such Product to be performed under the license of the Marketing Authorization, or (ii) that exists in a country in the Territory and that covers the\n",
      "process by which such Product is manufactured in such country for subsequent use, sale, offer for sale, or importation in the European Union or other country in the Other Territory under the license of the Marketing Authorization. \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "15 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "(d) If Insmed or its Affiliates or Sublicensees challenge(s) the validity or enforceability of the\n",
      "Licensed Patents anywhere in the Territory, then either Tercica or GNE shall have the right to terminate the licenses granted to Insmed under Section 3.1 of this Agreement pursuant to Section 12.3(a)(i) below. \n",
      " \n",
      "3.6 Non-Disparagement. Insmed, Tercica and GNE each shall not defame, libel, slander or otherwise disparage in any manner, or tortiously interfere\n",
      "with the business, contracts, relationships or prospective economic advantage appurtenant to: (a) the market opportunity for any product (e.g., the size of the market for severe Primary IGFD); or (b) any product of the other Parties.\n",
      " \n",
      "ARTICLE 4 \n",
      " \n",
      "DEVELOPMENT AND OPT-IN RIGHTS \n",
      " \n",
      "4.1 Development of Product Prior to Opt-In. Unless and until Tercica or GNE exercises\n",
      "its Opt-In right under Section 4.2 below, Insmed shall have the sole responsibility for the development of a Product for use in a given Permitted Indication. As between the Parties to this Agreement, Insmed shall bear all Development Costs\n",
      "incurred with respect to a Product for all Permitted Indications prior to the Opt-in Effective Date, subject to the Opt-In Party’s reimbursement of a portion of such Development Costs pursuant to Section 4.2(e) below. \n",
      " \n",
      "4.2 GNE and Tercica’s Opt-In Right for Permitted Indications. \n",
      " \n",
      "(a) General. Tercica and GNE shall each have the option to co-develop a Product for any particular Permitted Indication at any time during the period when such Product is being developed clinically for such\n",
      "Permitted Indication, until the end of the Opt-In Period for such Permitted Indication. Such co-development right, once exercised, allows Tercica or GNE as the Opt-In Party to fund 50% (such percentage, the “Percentage Interest”) of\n",
      "the Development Costs for a Product for such Permitted Indication and participate in a corresponding 50% portion of the Operating Profit (Loss) resulting from the commercialization of such Product for such Permitted Indication, participate in\n",
      "development decision-making, and participate in commercialization, all as and to the extent set forth below and in Article 5 (the “Opt-In”). It is understood and agreed that Insmed shall not enter into any agreement with a Third\n",
      "Party to develop or commercialize a Product for any Permitted Indication prior to the expiration of the Opt-In Period for such Permitted Indication. It is further understood and agreed that Tercica shall have the right to assign to Ipsen its Opt-In\n",
      "rights and obligations with respect to the ROW Territory or certain country(ies) within such ROW Territory, as well as its Co-Promotion Option and Sole Promotion Option, on a Permitted Indication-by-Permitted Indication basis, in which case\n",
      "reference to “Tercica” as used in this Section 4.2 and in Sections 4.3 and 4.4, and in Article 5, shall also include Ipsen. It is also further understood and agreed that GNE shall have the right to assign to a Third Party designee its\n",
      "Opt-In rights and obligations with respect to the ROW Territory or certain country(ies) within such ROW Territory, as well as its Co-Promotion Option and Sole Promotion Option, on a Permitted Indication-by-Permitted Indication basis, subject to\n",
      "Insmed’s consent, not to be unreasonably withheld, in which case reference to “GNE” as used in this Section 4.2 and in Sections 4.3 and 4.4, and in Article 5, shall also include such Third Party designee. \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "16 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "(b) Opt-In Period; Effectiveness. Tercica’s and GNE’s Opt-In rights shall commence, on a\n",
      "Permitted Indication by Permitted Indication basis, at the commencement of the first human clinical trials of a Product for such Permitted Indication, and shall terminate on the earlier of: (i) exercise by Tercica or GNE of such Opt-In, or\n",
      "(ii) 91 days after the Triggering Delivery for such Permitted Indication without exercise by either GNE or Tercica of its Opt-In rights (the “Opt-In Period” for such Permitted Indication), as described in more detail in this\n",
      "Section 4.2. For the avoidance of doubt, Tercica and GNE may exercise their respective Opt-In rights at any time during the Opt-In Period in accordance with this Section 4.2 by providing written notice to Insmed of the same (such notice,\n",
      "the “Opt-In Exercise Notice”). Insmed shall promptly submit a written confirmation to the Party whose Opt-In Exercise Notice has been received (unless otherwise properly rejected as not being properly submitted by the potential\n",
      "Opt-In Party pursuant to this Section 4.2), along with an invoice detailing the amount of the Opt-In Payment due Insmed. Such Opt-In shall become effective upon receipt by Insmed of such Opt-In Payment (the “Opt-In Effective\n",
      "Date”). At the Opt-In Effective Date, the Party having submitted such Opt-In Exercise Notice shall thereupon become an “Opt-In Party” and such Permitted Indication shall become an “Opt-In Indication.”\n",
      " \n",
      "(c) Opt-In Information; Triggering Delivery. On a regular basis but no less frequently than once per calendar quarter, Insmed shall\n",
      "provide to Tercica and GNE a written progress report setting forth, for each Permitted Indication then undergoing development and as to which the Opt-In rights have not been exercised or lapsed: (i) a summary of all clinical trials planned and\n",
      "actually conducted, as well as all results thereof, for a Product for treatment of each such Permitted Indication; (ii) all Opt-In Information that has not been previously disclosed to either Tercica or GNE as of such time; and (iii) a\n",
      "summary of all Development Costs incurred as of such time with respect to such Permitted Indication. In particular, and notwithstanding such quarterly reporting obligation, Insmed shall, within sixty (60) days after the Completion of the first\n",
      "Phase III Enabling Trial for a Product for such Permitted Indication, deliver to Tercica and GNE all Opt-In Information relating to such trial and any other Opt-In Information that has not been previously disclosed to either Tercica or GNE, as well\n",
      "as a summary of all Development Costs incurred as of such time with respect to such Permitted Indication (this delivery of such Opt-in Information and Development Cost information is the “Triggering Delivery”). Tercica and GNE shall\n",
      "use the Opt-In Information solely for the purpose of evaluating the Opt-In opportunity and such Opt-In Information and shall not disclose any non-public portion of such Opt-In Information to any Third Party without the prior written consent of\n",
      "Insmed. Following delivery of any such Opt-in Information and Development Cost information, Insmed shall promptly supply any additional information or respond to any questions as requested by GNE or Tercica based upon its review of such information.\n",
      "Upon the expiration of the Opt-In Period, each of GNE and Tercica shall return such Opt-In Information to Insmed if such Party has not exercised its Opt-In right under this Section 4.2. \n",
      " \n",
      "(d) Opt-In Rights and Procedures. \n",
      " \n",
      "(i) During the Opt-In Period, Tercica shall have the first right to exercise the Opt-In right throughout the Territory with respect to any Orphan Indication that is not a Diabetes Orphan Indication. In the event Tercica does not so\n",
      "exercise such right within sixty (60) days of the Triggering Delivery, it shall notify Insmed and GNE in writing. Upon receipt of such written notice, GNE shall have an additional period of thirty (30) days following \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "17 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "the date of such notice by Tercica to elect to exercise the Opt-In right with respect to such Orphan Indication. For avoidance of doubt, this Opt-In right\n",
      "shall expire upon the first to occur of the exercise of the Opt-In Right, or ninety one (91) days after the Triggering Delivery. \n",
      " \n",
      "(ii) During the Opt-In Period, GNE shall have the first right to exercise the Opt-In right with respect to (1) any Non-Orphan Indications throughout the Territory and (2) any Diabetes Orphan Indication in the United States.\n",
      "In the event GNE does not so exercise such right within sixty (60) days of the Triggering Delivery, it shall notify Insmed and Tercica in writing. Whereupon Tercica shall have an additional period of thirty (30) days following the date of\n",
      "such notice by GNE to elect to exercise the Opt-In right with respect to such Non-Orphan Indication or such Diabetes Orphan Indication. For avoidance of doubt, this Opt-In right shall expire upon the first to occur of the exercise of the Opt-In\n",
      "Right, or ninety one (91) days after the Triggering Delivery. \n",
      " \n",
      "(iii) If either Tercica or GNE provides Insmed with the Opt-In\n",
      "Exercise Notice within the Opt-In Period, then Insmed shall enter into a co-development and, where such Opt-in Party so elects under Section 5.2, co-commercialization relationship with the Party providing Insmed with such notice, on the terms\n",
      "set forth in this Article 4 and in Article 5. \n",
      " \n",
      "(e) Opt-In Payment; Accounting of Development Costs. The “Opt-In\n",
      "Payment” for a Product for a particular Permitted Indication shall be an amount equal to fifty percent (50%) of the total Development Costs allocable to the development of such Product for such Permitted Indication, and incurred as of\n",
      "the date of receipt of the Opt-In Exercise Notice for such Permitted Indication. Such Opt-In Payment shall be paid to Insmed in accordance with Section 4.2(b). All Development Costs incurred and allocable to any Permitted Indication as of the\n",
      "Effective Date will be provided, in writing, on a Permitted Indication-by-Permitted Indication basis, by Insmed to Tercica and GNE within thirty (30) days following the Effective Date. During the Term and prior to the expiration of the Opt-In\n",
      "Period, Insmed shall be responsible for maintaining a detailed account of all Development Costs expended for each Permitted Indication. \n",
      " \n",
      "4.3 Consequences of Tercica or GNE’s Exercise of Opt-In. If Tercica or GNE exercises the Opt-In in accordance with Section 4.2, the following shall apply: \n",
      " \n",
      "(a) Collaborative Development. Insmed and the Opt-In Party shall discuss, via the JDC, what if any operational matters in the development of a\n",
      "Product for such Opt-In Indication shall be the responsibility of the Opt-In Party. \n",
      " \n",
      "(b) Ongoing Co-Funding of Development Costs.\n",
      "The Opt-In Party shall bear fifty percent (50%) of the total Development Costs incurred from the day after the date of receipt of the Opt-In Exercise Notice for such Permitted Indication and allocable to the development of a Product for such\n",
      "Opt-In Indication. The process for reconciling payment of such Development Costs in order to give effect to each Opt-In Party’s Percentage Interest shall be in accordance with Article 7 and Exhibit A. \n",
      " \n",
      "(c) Decision-Making Control. The Opt-In Party may have the deciding vote with respect to decisions in the JDC regarding such Opt-In Indication, as\n",
      "provided in Section 6.2(d)(ii). \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "18 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "(d) Right for GNE to Develop and Commercialize Diabetes. In the event that GNE is the Opt-In Party\n",
      "and the Opt-In Indication is a Diabetes Orphan Indication (an “Opt-In Diabetes Orphan Indication”), at such time, if any, as GNE and Insmed using their respective scientific and business judgment disagree over whether the continued\n",
      "development of a Product for the Opt-In Diabetes Orphan Indication is desirable (such that Insmed does not wish to continue development of such Product for the Opt-In Diabetes Orphan Indication), GNE may elect to take over the development of such\n",
      "Product for the Opt-In Diabetes Orphan Indication at the sole expense of GNE and, upon notice to Insmed of such election, the Permitted Indications shall be amended to exclude such Opt-In Diabetes Orphan Indication solely for the purposes of the\n",
      "rights granted to Insmed under Section 3.1(c), provided that: \n",
      " \n",
      "(i) for all other purposes of this Agreement, including without\n",
      "limitation the licenses granted by Insmed to GNE as the Opt-In Party under Section 3.2(b), the Permitted Indications shall be deemed to include such Opt-In Diabetes Orphan Indication; \n",
      " \n",
      "(ii) GNE shall become, if not already, the Booking Party for such Opt-In Diabetes Orphan Indication and shall have final decision making\n",
      "authority in the commercialization of such Product for such Opt-In Diabetes Orphan Indication in the United States; and \n",
      " \n",
      "(iii) the\n",
      "profit-sharing arrangement applicable to such Opt-In Diabetes Orphan Indication shall continue only until the payments so received by Insmed from GNE equals the Development Costs incurred by Insmed for such Product for such Opt-In Diabetes Orphan\n",
      "Indication, and thereafter the profit share arrangement for such Opt-In Diabetes Orphan Indication shall terminate and GNE shall pay to Insmed royalties on the Net Sales for such Opt-In Diabetes Orphan Indication in the United States at a rate of [\n",
      "* ]; provided that, such royalty payment obligation shall apply only in the event that the use, sale, offer for sale, or importation of such Product for use in the Opt-In Diabetes Orphan Indication would infringe the Insmed Patents, and such royalty\n",
      "payment obligation shall thereafter expire upon the later of (y) the expiration of the last to expire Insmed Patents existing in the United States that would be infringed by the use, sale, offer for sale, or importation of such Product for use\n",
      "in such Opt-In Diabetes Orphan Indication in the United States but for the license grant in Section 3.2(b), and (z) the expiration of the last to expire Insmed Patents existing in a country and that covers the actual method of manufacture\n",
      "or use of such Product (or component thereof) as practiced by Insmed in the manufacture of such Product in such country that is subsequently sold for use in such Opt-In Diabetes Orphan Indication in the United States. \n",
      " \n",
      "(e) Ongoing Sharing of Profits and Losses. As further described in Section 7.2, Insmed and the Opt-In Party shall share Operating Profit\n",
      "(Loss) with respect to a given Opt-In Indication, based on the applicable Percentage Interest for such Opt-In Indication. \n",
      " \n",
      "(f) Opt-In\n",
      "Party’s Product Commercialization Rights for Opt-In Indication. If either Tercica or GNE exercises the Opt-In right under this Section 4.2, such Party shall have the right, at its discretion, to exercise the Sole Promotion Option or\n",
      "the Co-Promotion Option for the respective Opt-In Indication pursuant to Section 5.2. In addition, following such exercise of the Opt-In right, Insmed shall have no right to seek, negotiate or enter \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "19 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "into an agreement with, a Third Party partner for the co-development and/or co-commercialization of a Product. \n",
      " \n",
      "4.4 Opt-Out Rights. An Opt-In Party for a particular Opt-In Indication shall have the right to discontinue its ongoing funding obligations for\n",
      "such Opt-In Indication either in total or on a region-by-region or country-by-country basis in the Territory (the term “region” means and includes each of the following: the North American Territory, the EU, and Japan) for such Opt-In\n",
      "Indication, for any or no reason, for a period of ten (10) business days after the completion of an ongoing clinical trial and the reporting of results from such clinical trial for a Product for the treatment of such Opt-In Indication (the\n",
      "“Opt-Out”). An Opt-In Party may exercise such Opt-Out right by providing written notice to Insmed stating the same. Effective thirty (30) days following notice of such Opt-Out: (a) such Party shall cease to be an Opt-In\n",
      "Party and the license granted under Section 3.2(b) for such Permitted Indication shall terminate, (b) such Party shall have no further obligation to co-fund the ongoing Development Costs of such Product for such Permitted Indication other\n",
      "than for non-cancelable out-of-pocket costs incurred or committed to as of the effective date of the Opt-Out for activities previously approved in accordance herewith, (c) such Party shall have no right to share in a portion of the Operating\n",
      "Profits (Loss) for such Product for such Permitted Indication, (d) such Permitted Indication shall cease to be an Opt-In Indication, (e) such Party shall no longer have the Sole Promotion Option or Co-Promotion Option with respect to such\n",
      "Permitted Indication, and (f) such Party shall nor longer have any decision making control or input with respect to the development or commercialization of such Product for such Permitted Indication. If Insmed continues the development and/or\n",
      "commercialization of such Product for such Permitted Indication thereafter, then such Opt-In Party, after exercising its Opt-Out right, shall receive a royalty on the Net Sales of a Product for treatment of such Permitted Indication as further\n",
      "described in Section 7.1(a)(ii). For clarity, if an Opt-In Party exercises the Opt-Out right, it shall not have any right to a refund or reimbursement of any payments it had made to co-fund the Development Costs for a Product for such Permitted\n",
      "Indication. \n",
      " \n",
      "ARTICLE 5 \n",
      " \n",
      "COMMERCIALIZATION \n",
      " \n",
      "5.1 Commercialization by Insmed. Insmed shall have the primary right and responsibility for\n",
      "commercializing a Product for a given Permitted Indication; provided, however, that if the Opt-In Party for a particular Opt-In Indication elects to exercise its Co-Promotion Option or Sole Promotion Option for such Opt-In Indication, then the\n",
      "Parties shall proceed as set forth in this Article 5 and the terms of the Co-Promotion Agreement (as defined in Section 5.3) or the terms of the Supply Agreement (as defined in Section 5.4) shall apply to the commercialization of such\n",
      "Product for the treatment of such Opt-In Indication. \n",
      " \n",
      "5.2 Commercialization by an Opt-In Party. Subject to the proper exercise of\n",
      "the Opt-In right described in Section 4.2, Insmed hereby grants the Opt-In Party, for the corresponding Opt-In Indication: (a) an option to co-promote, worldwide, a Product with Insmed for the treatment of such Opt-In Indication (the\n",
      "“Co-Promotion Option”); and (b) an option to assume sole responsibility for the commercialization of a Product for the treatment of such Opt-In Indication (the “Sole Promotion Option”). It is further understood\n",
      "and agreed that Tercica \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "20 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "shall have the right to assign to Ipsen such Co-Promotion Option or Sole Promotion Option with respect to the ROW Territory or certain country(ies) within\n",
      "such ROW Territory, in which case the “Opt-In Party” as used in this Article 5 shall also include Ipsen. It is also further understood and agreed that GNE shall have the right to assign to a Third Party designee such Co-Promotion Option or\n",
      "Sole Promotion Option with respect to the ROW Territory or certain country(ies) within such ROW Territory, in which case the “Opt-In Party” as used in this Article 5 shall also include such Third Party designee. \n",
      " \n",
      "5.3 Opt-In Party’s Co-Promotion Option for Product for an Opt-In Indication. \n",
      " \n",
      "(a) Exercise of Co-Promotion Option. The Opt-In Party may exercise the Co-Promotion Option as to an Opt-In Indication by providing written notice\n",
      "to Insmed within sixty (60) days following the JDC’s decision (as set forth in approved minutes of the JDC) to file the first application for Marketing Authorization for a Product for such Opt-In Indication in a given country. It is\n",
      "understood that such Co-Promotion Option shall be triggered with respect to the North American Territory and the ROW Territory independently, such that if, by way of example, the Opt-In Party does not exercise its Co-Promotion Option for the North\n",
      "American Territory (or part thereof), it may nonetheless exercise its Co-Promotion Option for the ROW Territory (or part thereof), provided such Opt-In Party has not exercised its right to Opt-Out of co-development for any such North American\n",
      "Territory or ROW Territory. If the Opt-In Party exercises the Co-Promotion Option, the Opt-In Party shall co-promote such Product for the treatment of such Opt-In Indication with Insmed, during the Co-Promotion Term pursuant to the terms of a\n",
      "Co-Promotion Agreement, as further described in Section 5.3(b) below. Co-promotion of Product for the treatment of such Opt-In Indication shall be overseen and coordinated by the JCC. \n",
      " \n",
      "(b) Co-Promotion Agreement. Promptly following the Opt-In Party’s exercise of the Co-Promotion Option with respect to a particular Opt-In\n",
      "Indication in a region or country, the Opt-In Party and Insmed shall engage in good faith negotiations to prepare and execute a definitive co-promotion agreement describing the co-promotion activities of the Parties for promoting a Product for the\n",
      "treatment of such Opt-In Indication in such region or country (the “Co-Promotion Agreement”). The Co-Promotion Agreement will have the terms and conditions set forth in this Article 5 and in the term sheet attached to this Agreement\n",
      "as Exhibit E, as well as such other terms as the Opt-In Party and Insmed may agree. The Opt-In Party and Insmed will use reasonably diligent efforts to execute the Co-Promotion Agreement at least twelve (12) months prior to the\n",
      "anticipated receipt of Marketing Authorization for such Product for such Opt-In Indication as determined by the JCC (such date, the “Launch Date”) for the treatment of such Permitted Indication in the relevant jurisdiction. The\n",
      "“Co-Promotion Term” will commence upon execution of the Co-Promotion Agreement and will extend for so long as Insmed is selling a Product or the termination of this Agreement, whichever occurs first. \n",
      " \n",
      "(c) Commercialization Plan. If the Opt-In Party exercises its Co-Promotion Option with respect to a particular Opt-In Indication, the strategy and\n",
      "tactics for the commercial launch of a Product for the Opt-In Indication shall be described in a comprehensive plan that describes the launch and subsequent co-promotion and related commercialization activities for such Product by the Opt-In Party\n",
      "and Insmed (including advertising, education, planning, marketing, sales force training and detail allocation) (the “Commercialization Plan”). The \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "21 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "JCC shall prepare an initial draft of the Commercialization Plan within one (1) month after the filing of the first application for Marketing\n",
      "Authorization and shall approve a final Commercialization Plan at least six (6) months prior to the anticipated Launch Date for such Product for the treatment of such Opt-In Indication. The JCC shall update such Commercialization Plan as needed\n",
      "thereafter, but in any event annually. \n",
      " \n",
      "5.4 The Opt-In Party’s Sole Promotion Option for Product for an Opt-In Indication.\n",
      " \n",
      "(a) Exercise of Sole Promotion Option. The Opt-In Party may exercise the Sole Promotion Option for each of its Opt-In\n",
      "Indications by providing written notice to Insmed within sixty (60) days following the JDC’s decision (as set forth in approved minutes of the JDC) to file an application for Marketing Authorization for a Product for such Opt-In Indication\n",
      "in a given country. It is understood that such Sole Promotion Option shall be triggered with respect to the North American Territory and the ROW Territory independently, such that if, by way of example, the Opt-In Party does not exercise its Sole\n",
      "Promotion Option for the North American Territory (or part thereof), it may nonetheless exercise its Sole Promotion Option for the ROW Territory (or part thereof), provided such Opt-In Party has not exercised its right to Opt-Out of co-development\n",
      "for any such North American Territory or ROW Territory or part thereof. If the Opt-In Party exercises the Sole Promotion Option, the Opt-In Party shall thereafter have the sole right to market, promote, sell, and offer for sale such Product for the\n",
      "treatment of such Opt-In Indication, in the region or country(ies) as to which such option is exercised, including without limitation, the sole right to book all sales of such Product for such Opt-In Indication. \n",
      " \n",
      "(b) Supply of Product by Insmed. Promptly following the Opt-In Party’s exercise of the Sole Promotion Option, the Opt-In Party and Insmed\n",
      "shall engage in good faith negotiations to prepare and execute a definitive supply agreement describing terms and conditions by which Insmed shall supply or cause to be supplied (by manufacturing itself or by procuring from a Third Party) commercial\n",
      "quantities of finished, filled, and packaged Product to the Opt-In Party for such Opt-In Indication, at a price equal to Insmed’s Fully Burdened Manufacturing Cost not to exceed $2,500/gram (such agreement, the “Supply\n",
      "Agreement”). The Supply Agreement will set forth the terms and conditions as the Opt-In Party and Insmed may agree and as are customary in an agreement of that type, including without limitation, any supply capacity constraints for a\n",
      "Product, forecasting and ordering, inspection and rejection provisions, and remedies in the event of supply default, including the ability of the Opt-In Party to make or have made a Product itself in such event. The Opt-In Party and Insmed will\n",
      "negotiate and execute the Supply Agreement at least twelve (12) months prior to the anticipated Launch Date of a Product for the treatment of such Opt-In Indication. \n",
      " \n",
      "(c) Trademark License. In the event Tercica and/or GNE exercises its Sole Promotion Option with respect to a given Opt-In Indication, Insmed hereby grants such Opt-In Party a non-exclusive, worldwide license,\n",
      "with the right to grant sublicenses as provided in this Section 5.4(c), to use the Trademark in connection with the marketing, promotion and sale of a Product for use in the Opt-In Indication. Any sublicense by Tercica or GNE under the rights\n",
      "granted in this Section 5.4(c) to a sublicensee other than Ipsen, or other than a distributor, subcontractor or consultant in the normal course of business, shall be made by Tercica or GNE only with the consent of Insmed, such consent not to be\n",
      "unreasonably withheld. It is expressly \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "22 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "understood that the Opt-In Party exercising such Sole Promotion Option shall not be required to use the Trademark in connection with the marketing or sale of\n",
      "a Product for such Opt-In Indication, but shall have the right to re-brand such Product for such Opt-In Indication under a new trademark, in which event the Opt-In Party shall own all rights in and to such new trademark and all associated goodwill.\n",
      " \n",
      "5.5 Sales Tracking. The Parties recognize that, subject to the licenses granted in Section 3.1, and in light of the\n",
      "Parties’ Opt-In rights with respect to given Permitted Indications, and Sole Promotion Option, a Product may be sold by Insmed for use in the treatment of one or more Permitted Indications as to which the Opt-In Party has exercised its rights,\n",
      "as well as Permitted Indications as to which no Opt-In rights have been exercised, as well as to patients on a Named Patient Basis as provided in Section 3.1(b), and to Existing Patients under Section 3.1(a), and may also be sold by either\n",
      "GNE or Tercica in the event of exercise of its Sole Promotion Option, for a given Opt-In Indication. In addition, Products marketed by Insmed (or its Sublicensee) or by GNE or Tercica (or their designee) in the future for an approved Permitted\n",
      "Indication may nonetheless be prescribed for use in the treatment of one or more indications which are other than such approved Permitted Indication (i.e., “Off Label Sales”). Given that different financial consideration is due and owing\n",
      "depending upon which of the foregoing situations is applicable (i.e., royalties vs. profit sharing), and in order to detect and account for such sales of Product in a manner most reflective of the Parties’ intent, the Parties agree as follows:\n",
      " \n",
      "(a) Sales Tracking Methodology. \n",
      " \n",
      "(i) Initial Methodology. Within one hundred eighty (180) days after the Effective Date, Tercica and Insmed shall meet and agree upon a method of tracking sales of Product for use in the treatment of each\n",
      "indication, in the country sold (a “Sales Tracking Methodology”) including (1) the use of data from Statements of Medical Necessity, or the acquisition of one or more forms of prescription data (including by way of example, IMS\n",
      "Xponent, NDCHealth Information Network, or Drug Distribution Data) or other relevant pharmaceutical sales tracking research services (including by way of example, audits of the corresponding statements of medical necessity, use of random sampling,\n",
      "use of data regarding distribution channels as a proxy for indication-specific sales or development of mathematical models for approximating indication-specific sales) generally recognized in the pharmaceutical industry as having a reasonable degree\n",
      "of accuracy and reliability in the tracking of sales of pharmaceutical products that have a similar nature as, and are prescribed by similar physicians as, a Product for the Named Patient Indications and Permitted Indications (the “Data\n",
      "Services”), and (2) the methodology for applying any such resulting data and information provided by such Data Services to determine the extent of sales in each country which are attributable to each such indication. It is expressly\n",
      "understood that sales of a Product for any Non-Permitted Indications are not anticipated except to the Existing Patients, and only for a period not to exceed twelve (12) months from the Effective Date, and any sales that are knowingly made to\n",
      "patients for use within a Non-Permitted Indication by Insmed or its Affiliates or Sublicensees and that are tracked to any Non-Permitted Indications after such twelve (12) month period (or to any patients who are other than Existing Patients\n",
      "within such twelve (12) month period) will be evidence of Insmed’s breach of its covenant in Section 3.5 and its license under Section 3.1(a). \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "23 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "(ii) Modifications to Methodology. The JCC may elect at any point to adopt a different or\n",
      "modified Sales Tracking Methodology, upon request of either Party. If the JCC fails to agree on a different Sales Tracking Methodology proposed by either Tercica or Insmed, the Sales Tracking Methodology then in effect shall continue to be used.\n",
      "Notwithstanding the foregoing, it is understood and agreed by Tercica and Insmed that each shall have the right, at its own expense, to undertake such market research and analysis, including “probes” or sampling of patient data, physician\n",
      "prescribing habits and the like (the “New Sales Tracking Data”) or otherwise propose modifications to the Sales Tracking Methodology at any time during the Term, and to present such data or otherwise propose modifications to the\n",
      "Sales Tracking Methodology to the JCC to enhance the validity or reliability of the Sales Tracking Methodology. It shall be the JCC’s continuing obligation to review any such New Sales Tracking Data in good faith, with the overriding obligation\n",
      "to ensure fair and accurate compensation to the Parties (as applicable) under this Agreement by tracking as accurately as reasonably possible, purchases of a Product for use in specific indications. In the event that the JCC adopts a new Sales\n",
      "Tracking Methodology that incorporates New Sales Tracking Data proposed by a Party, the costs of such new Sales Tracking Methodology shall be allocated between Tercica and Insmed as provided in Section 5.5(c). \n",
      " \n",
      "(b) Implementation by Insmed. Promptly following the selection and adoption by the JCC of the Sales Tracking Methodology (and any new Sales\n",
      "Tracking Methodology as applicable), Insmed hereby agrees to implement such Sales Tracking Methodology with respect to Insmed’s annual worldwide sales of Product. \n",
      " \n",
      "(c) Costs. Insmed and Tercica shall share equally all costs incurred in implementing the Sales Tracking Methodology until such time as GNE exercises its first Opt-In right, in which event all such costs shall\n",
      "be shared equally between Insmed, Tercica and GNE. \n",
      " \n",
      "(d) Dispute Resolution with Respect to Sales Tracking. Notwithstanding the\n",
      "dispute resolution mechanism set forth in Article 13 below, the Parties agree that all disputes relating to matters pertaining to sales tracking, including without limitation the methodology(ies) to be used or implementation thereof, shall be\n",
      "resolved as soon as practicable as follows: Any Party shall bring such dispute to the attention of the other Parties by providing the other Parties with a written notice stating such dispute, and the Parties shall use good faith efforts to resolve\n",
      "such dispute through the JCC within thirty (30) days after the receipt of such notice. If the JCC cannot reach resolution on such matter during such thirty (30)-day period, then the matter shall be referred to the Chief Commercial Officer or\n",
      "equivalent (or his/her designee who has decision-making authority) of the Parties for resolution. If such executives cannot reach resolution on such matter within ten (10) business days, then the Parties shall refer the matter to the Sales\n",
      "Tracking Panel (as defined below) for resolution, and the Sales Tracking Panel’s decision (which shall require the consent and agreement of 2 of the 3 panelists) on such matter shall be final and binding upon all Parties. Notwithstanding the\n",
      "foregoing, GNE may, at its option, recuse itself from such disputes with respect to sales tracking at any time by providing the other Parties with written notice stating such election. “Sales Tracking Panel” shall mean a panel of\n",
      "three experts, each of whom have experience in market research and intelligence gathering with respect to pharmaceutical products (e.g., former employees of IMS), and at least one of whom has experience in market research and drug distribution and\n",
      "prescribing information collection involving specialty pharmaceuticals. The Parties shall appoint such experts serving on the Sales \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "24 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "Tracking Panel within thirty (30) days after the Effective Date through mutual agreement, and shall maintain the number of experts on such Sales\n",
      "Tracking Panel during the Term. \n",
      " \n",
      "ARTICLE 6 \n",
      " \n",
      "GOVERNANCE \n",
      " \n",
      "6.1 Overview. The Parties desire to establish certain committees to facilitate\n",
      "the sharing of information between the Parties and to coordinate the development and commercialization of a Product for the treatment of Permitted Indications (as applicable) and the implementation of the Sales Tracking Methodology. It is understood\n",
      "and acknowledged by each Party that, subject to Tercica’s and GNE’s opt-in rights in Section 4.2, Insmed will be primarily responsible for the development and commercialization of a Product strictly in accordance with the licenses\n",
      "granted by Tercica under Section 3.1. \n",
      " \n",
      "6.2 Joint Development Committee. \n",
      " \n",
      "(a) Formation; Composition. Within thirty (30) days after the Effective Date, the Parties shall establish a committee to oversee development\n",
      "of a Product and to serve as a forum for sharing information regarding such development between the Parties (the “JDC”). Tercica and Insmed each shall initially appoint three (3) representatives to the JDC, and GNE may\n",
      "initially appoint up to three (3) representatives to the JDC. Following any exercise of its Opt-In rights, GNE shall appoint or retain at least one (1) representative, but no more than three (3) representatives, to the JDC. The JDC\n",
      "may change its size from time to time by mutual consent of its members, provided that the JDC shall include at all times an equal number of representatives of each of Tercica, Insmed, and where GNE so elects, of GNE. Each Party may replace its JDC\n",
      "representatives at any time upon written notice to the other Party(ies). The JDC may invite non-members to participate in the discussions and meetings of the JDC, provided that such participants shall have no voting authority at the JDC. The JDC\n",
      "will be chaired by Insmed. The chairperson shall be responsible for administering JDC meetings, but shall have no additional powers or rights beyond those held by the other representatives of the JDC. \n",
      " \n",
      "(b) Specific Responsibilities of the JDC. In addition to its general responsibilities, the JDC shall in particular: \n",
      " \n",
      "(i) prior to an Opt-In Party’s exercise of the Opt-In in accordance with Section 4.2 and throughout the Opt-In Period, facilitate the\n",
      "flow of information from Insmed to Tercica and GNE with respect to the development of, and obtaining Marketing Authorization for, a Product for the treatment of any Permitted Indications; \n",
      " \n",
      "(ii) prior to an Opt-In Party’s exercise of the Opt-In in accordance with Section 4.2 and throughout the Opt-In Period, determine,\n",
      "prior to the conduct of such trial, whether a proposed clinical trial for a Product satisfies the criteria of a Phase III Enabling Trial for the applicable Opt-In Indication; and \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "25 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "(iii) following an Opt-In Party’s exercise of the Opt-In in accordance with Section 4.2\n",
      "for a particular Permitted Indication, coordinate and oversee the Parties’ development of a Product for the treatment of the applicable Opt-In Indication. \n",
      " \n",
      "(c) Meetings. The JDC shall meet at least once per calendar quarter after the Effective Date unless the Parties mutually agree in writing to a different frequency. The JDC may meet in person, by\n",
      "videoconference, or by teleconference. The location of in-person JDC meetings will be held at locations alternately selected by Tercica, Insmed, and GNE. Each Party shall report to the JDC on all material issues relating to the development of a\n",
      "Product promptly after such issues arise. Each Party will bear the expense of its respective JDC members’ participation in JDC meetings. Meetings of the JDC shall be effective only if at least one representative of each Party having incumbent\n",
      "member(s) of the JDC is present or participating in such meeting. The chairperson of the JDC shall be responsible for keeping reasonably detailed written minutes of all JDC meetings that reflect, without limitation, material decisions made at such\n",
      "meetings. Meeting minutes will be sent to each member of the JDC for review and approval within ten (10) business days after a meeting. \n",
      " \n",
      "(d) Decision-Making. The JDC shall act by consensus. The representatives from each Party will have, collectively, one (1) vote on behalf of that Party. If the JDC cannot reach consensus on any issue that comes before the JDC,\n",
      "then: \n",
      " \n",
      "(i) prior to Tercica’s or GNE’s exercise of the Opt-In in accordance with Section 4.2, Insmed shall have the\n",
      "deciding vote for all issues to be determined by the JDC; and \n",
      " \n",
      "(ii) following the date when an Opt-In Party exercises its Opt-In\n",
      "rights, such Opt-In Party would have the deciding vote on all matters related to the Opt-In Indication before the JDC. \n",
      " \n",
      "It is expressly understood and\n",
      "agreed that the control of decision-making authority by a Party so as to resolve a disagreement or deadlock at the JDC for any matter will not relieve such Party from any of its representations, warranties, or covenants in this Agreement, nor will\n",
      "it enable such Party to unilaterally modify or amend the terms of this Agreement. \n",
      " \n",
      "6.3 Joint Commercialization Committee.\n",
      " \n",
      "(a) Formation; Composition. Promptly following the Effective Date but in no event later than thirty (30) days after the\n",
      "Effective Date, the Parties shall form a committee to, in the first instance agree upon and approve the Sales Tracking Methodology, and, following exercise by an Opt-In Party of its Co-Promotion Option or Sole Promotion Option, coordinate and\n",
      "oversee the Parties’ respective commercialization activities with respect to a Product for the treatment of any Permitted Indications (the “JCC”). Tercica and Insmed each shall initially appoint two (2) representatives to\n",
      "the JCC, and GNE may initially appoint up to two (2) representatives to the JCC. Following any exercise of its Opt-In rights, GNE shall appoint at least one (1), but no more than two (2), representatives to JCC. The JCC may change its size from\n",
      "time to time by mutual consent of its members, provided that the JCC shall include at all times of an equal number of representatives of each of Tercica, Insmed, and where GNE so \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "26 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "elects, of GNE. Each Party may replace its JCC representatives at any time upon written notice to the other Party(ies). The JCC may invite non-members to\n",
      "participate in the discussions and meetings of the JCC, provided that such participants shall have no voting authority at the JCC. The JCC will be chaired initially by Insmed. The chairperson shall be responsible for administering JCC meetings, but\n",
      "shall have no additional powers or rights beyond those held by the other representatives on the JCC. \n",
      " \n",
      "(b) Meetings. The JCC shall\n",
      "meet at least twice per year after its formation pursuant to Section 6.3(a) unless the Parties mutually agree in writing to a different frequency. The JCC may meet in person, by videoconference, or by teleconference. The location of in-person\n",
      "JCC meetings will be held at locations alternately selected by Tercica, Insmed and GNE. Meetings of the JCC shall be effective only if at least one representative of each Party is present or participating in such meeting. Each Party shall report to\n",
      "the JCC on all material issues relating to the commercialization of Products promptly after such issues arise. Each Party will bear the expense of its respective JCC members’ participation in JCC meetings. The chairperson will be responsible\n",
      "for preparing reasonably detailed written minutes of JCC meetings that reflect, without limitation, material decisions made at such meetings. Such meeting minutes will be sent to each member of the JCC for review and approval within ten\n",
      "(10) business days after a meeting. \n",
      " \n",
      "(c) Decision-Making. The JCC shall act by consensus. The representatives from each Party\n",
      "will have, collectively, one (1) vote on behalf of that Party. If the JCC cannot reach consensus on any issue that comes before the JCC, then: \n",
      " \n",
      "(i) prior to the date when, and if, an Opt-In Party exercises its Sole Promotion Rights with respect to a particular Opt-In Indication pursuant to Section 5.4, and other than with respect to Sales Tracking Methodology matters,\n",
      "Insmed shall have the deciding vote for all issues to be determined by the JCC; and \n",
      " \n",
      "(ii) following the date when an Opt-In Party\n",
      "exercises its Sole Promotion Rights with respect to a particular Opt-In Indication pursuant to Section 5.4, such Opt-In Party shall have the deciding vote for all issues to be determined by the JCC with respect to the commercialization of a\n",
      "Product for such Opt-In Indication. \n",
      " \n",
      "It is expressly understood and agreed that the control of decision-making authority by a Party so as to resolve a\n",
      "disagreement or deadlock at the JCC for any matter will not relieve such Party from any of its representations, warranties, or covenants in this Agreement, nor will it enable such Party to unilaterally modify or amend the terms of this Agreement.\n",
      " \n",
      "6.4 General Committee Authority. Each Committee shall have solely the powers assigned to it in this Article 6 and elsewhere in this\n",
      "Agreement. No Committee shall have any power to amend, modify, or waive compliance with this Agreement. \n",
      " \n",
      "6.5 Discontinuation of\n",
      "Participation on a Committee. Each Committee shall continue to exist until the first to occur of (a) the Parties mutually agreeing to disband the Committee, or (b) Tercica providing to Insmed written notice of its intention to disband\n",
      "and no longer participate in such Committee. In any event, at any time Tercica and/or GNE may \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "27 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "terminate its participation on any Committee, on thirty (30) days’ written notice. Unless the Parties agree otherwise in writing at the time, upon\n",
      "dissolution of a Committee, such Committee’s powers and duties shall automatically be assumed by Insmed; provided, however, the Opt-In Party’s approval shall be required for any decisions made by Insmed after the dissolution of a\n",
      "Committee, such approval not to be unreasonably withheld or delayed. \n",
      " \n",
      "ARTICLE 7 \n",
      " \n",
      "FINANCIALS \n",
      " \n",
      "7.1 Royalty Payments\n",
      "for Non-Profit Share Indications. \n",
      " \n",
      "(a) Insmed’s Royalty Obligations to Tercica and GNE. \n",
      " \n",
      "(i) Royalties for Insmed’s Sales to Existing Patients Under Section 3.1(a). Insmed shall pay to Tercica a royalty equal to [ * ] of its\n",
      "Net Sales made pursuant to its license under Section 3.1(a) to Existing Patients and which are booked after the end of the three (3) month period after the Effective Date, as set forth in Section 3.1(a). \n",
      " \n",
      "(ii) Royalties for Insmed’s Sales Pursuant to its License under Section 3.1(c). Insmed shall pay to Tercica a royalty equal to four\n",
      "percent (4%) of its Net Sales arising from use of a Product for all Permitted Indications for which (A) neither GNE nor Tercica has exercised its Opt-In right pursuant to Section 4.2 above; or (B) subsequent to Tercica’s or\n",
      "GNE’s exercise of its Opt-In right, such Party exercised its Opt-Out right with respect to such Permitted Indication (but where such Opt-Out was exercised only as to a specific region or country, only Net Sales from such region or country shall\n",
      "be subject to such royalty). \n",
      " \n",
      "(iii) Royalties for ALS Named Patient Sales in Italy. Insmed shall pay directly to GNE a royalty on\n",
      "all sales made on a Named Patient Basis for the treatment of ALS in accordance with Section 3.1(d) as follows (such Net Sales referred to herein as the “ALS Portion,” and such royalty paid thereon referred to as the\n",
      "“ALS Royalty”): \n",
      " \n",
      " \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "ALS Portion\n",
      "  \n",
      "Royalty Rates Applicable to ",
      "ALS Portion\n",
      "[ * ]\n",
      "  \n",
      "4%\n",
      "[ * ]\n",
      "  \n",
      "[ * ]\n",
      "[ * ]\n",
      "  \n",
      "[ * ]\n",
      "[ * ]\n",
      "  \n",
      "15%\n",
      " \n",
      "(iv) Royalties for Other Named Patient Sales Pursuant to Section 3.1(b) and All Off-Label\n",
      "Sales. \n",
      " \n",
      "(1) For Named Patient Indications. Insmed shall pay to Tercica a royalty on all sales made on a Named Patient Basis for\n",
      "the treatment of indications other than ALS in accordance with Section 3.1(b) pursuant to subsection (3) below. \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "28 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "(2) For All Off Label Sales. Insmed shall pay to Tercica a royalty on its Net Sales attributable\n",
      "to use of a Product in the treatment of one or more Permitted Indications, which, at the time of such sale: (A) Insmed does not have Marketing Authorization for such Product for such Permitted Indication in the country of sale, and\n",
      "(B) either (i) Insmed has not yet commenced any development of such Product for such Permitted Indication so that there was not an opportunity for Tercica or GNE to exercise the Opt-In right pursuant to Section 4.2, or\n",
      "(ii) Insmed has commenced such development of such Product but the Opt-In right described in Section 4.2 has not yet been exercised (“Off-Label Sales”). In such event, the royalty owed to Tercica on such Off-Label Sales\n",
      "will be paid pursuant to subsection (3) below. If, following commencement of payment of royalties for such Permitted Indication to Tercica pursuant to subsection (3) below, neither Tercica nor GNE exercises the Opt-In right described in\n",
      "Section 4.2 for such Permitted Indication, then upon grant of Marketing Authorization for such Product in the treatment of such Permitted Indication in a given country, the royalty for sales of Product for such Permitted Indication in such\n",
      "country shall be [ * ]. \n",
      " \n",
      "(3) Calculation of Royalties Due under Subsections (1) and (2) Above. For the purpose of this\n",
      "subsection (3), “Aggregated Named Patient and Off-Label Sales” shall mean collectively, (A) the ALS Portion; (B) the annual Net Sales of all Products aggregated across all countries which result from Named Patient Basis\n",
      "sales other than ALS pursuant to Section 3.1(b); and (C) the annual Net Sales of all Products aggregated across all countries which are Off-Label Sales. The Aggregated Named Patient and Off-Label Sales described in (B) and\n",
      "(C) shall be referred to as the “Non-ALS Portion”. In calculating royalties due under this subsection (3), the following rules shall apply: \n",
      " \n",
      "(a) Determining Royalties Due for the Non-ALS Portion: The royalties due for the Non-ALS Portion shall equal the “Aggregated Royalty Amount” less the “ALS Credit”. \n",
      "\n",
      "(i) The Parties shall determine the Aggregated Royalty Amount by applying the applicable royalty rates set forth in Table A below to the\n",
      "Annual Aggregated Named Patient and Off-Label Sales; \n",
      " \n",
      "Table A for Calculating Aggregated Royalty Amount: \n",
      " \n",
      " \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Annual Aggregated Named Patient and Off-Label Sales\n",
      "  \n",
      "Royalty Rates Applicable to ",
      "Annual Aggregated Named ",
      "Patient and Off-Label Sales\n",
      "[ * ]\n",
      "  \n",
      "4%\n",
      "[ * ]\n",
      "  \n",
      "[ * ]\n",
      "[ * ]\n",
      "  \n",
      "[ * ]\n",
      "[ * ]\n",
      "  \n",
      "[ * ]\n",
      "[ * ]\n",
      "  \n",
      "[ * ]\n",
      "[ * ]\n",
      "  \n",
      "15%\n",
      " \n",
      " \n",
      "\n",
      " \n",
      "29 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "(ii) The Parties shall then determine the ALS Credit by applying the applicable royalty rates set\n",
      "forth in Table B below to the ALS Portion: \n",
      " \n",
      "Table B for Calculating the ALS Credit: \n",
      " \n",
      " \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "ALS Portion\n",
      "  \n",
      "Royalty Rates Applicable ",
      "to ALS Portion\n",
      "[ * ]\n",
      "  \n",
      "4%\n",
      "[ * ]\n",
      "  \n",
      "[ * ]\n",
      "[ * ]\n",
      "  \n",
      "[ * ]\n",
      "[ * ]\n",
      "  \n",
      "[ * ]\n",
      "[ * ]\n",
      "  \n",
      "[ * ]\n",
      "[ * ]\n",
      "  \n",
      "15%\n",
      " \n",
      "(b) Example. By way of illustration, if, for a given year, the ALS Portion is [ * ], and\n",
      "the Non-ALS Portion is [ * ], then the Aggregated Named Patient and Off-Label Sales shall be [ * ]. The royalties payable shall be calculated as follows: \n",
      " \n",
      "(i) For the ALS Portion: As set forth in Section 7.1(a)(iii), the first [ * ] of the ALS Portion shall bear royalties at a rate of [ * ], resulting in a royalty obligation of [ * ]; and the next [ * ] of\n",
      "the ALS Portion shall bear royalties at a rate of [ * ], resulting in a royalty obligation of [ * ]. The total royalty obligation for the ALS Portion shall be [ * ] and shall be paid directly to GNE \n",
      " \n",
      "(ii) For the Non-ALS Portion: As set forth in Section 7.1(a)(iv), such royalty is equal to the Aggregated Royalty Amount minus the ALS\n",
      "Credit, calculated as follows: \n",
      " \n",
      "Aggregated Royalty Amount: \n",
      " \n",
      " \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Aggregated Named Patient\n",
      "and Off-Label Sales ([ * ])\n",
      "  \n",
      "Royalties Per Table A\n",
      "\n",
      "\n",
      "[ * ]\n",
      "  \n",
      " \n",
      "Aggregated Royalty Amount\n",
      "  \n",
      "[ * ]\n",
      " \n",
      " \n",
      "\n",
      " \n",
      "30 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "ALS Credit: \n",
      " \n",
      " \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "ALS Portion ([ * ])\n",
      "[ * ]\n",
      "  \n",
      "Royalties Per Table B\n",
      " \n",
      "ALS Credit\n",
      "  \n",
      "[ * ]\n",
      " \n",
      "Royalties Due for Non-ALS Portion: The royalty payments for Non-ALS Portion shall be: [ * ]\n",
      "and shall be paid directly to Tercica. \n",
      " \n",
      "(b) Royalty Obligations to GNE with Respect to Tercica’s Opt-In Indication(s). In the\n",
      "event GNE does not elect to exercise its Opt-In rights for a given Permitted Indication, but Tercica does so exercise its Opt-In rights for such Permitted Indication, for so long as Tercica has not exercised its Opt-Out right, Insmed or Tercica, as\n",
      "the case may be and whichever is the Booking Party, shall pay to GNE the incremental rates set forth below, on annual Net Sales of all Products used in the treatment of such Permitted Indication, aggregated across all such Permitted Indications as\n",
      "to which this Section 7.1(b) applies: \n",
      " \n",
      " \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Aggregate Annual Net Sales for all Products for all such Indications\n",
      "  \n",
      "Royalty Rate Applicable\n",
      "[ * ]\n",
      "  \n",
      "6%\n",
      "[ * ]\n",
      "  \n",
      "[ * ]\n",
      "[ * ]\n",
      "  \n",
      "[ * ]\n",
      "[ * ]\n",
      "  \n",
      "[ * ]\n",
      "[ * ]\n",
      "  \n",
      "[ * ]\n",
      "[ * ]\n",
      "  \n",
      "15%\n",
      " \n",
      "Such royalties owed GNE shall be deducted from Actual Sales in calculating Operating Profit (Loss). \n",
      " \n",
      "(c) Royalties for Mass Sales. Notwithstanding any other provision in this Section 7.1, Insmed shall pay to Tercica a royalty at the rate\n",
      "equal to [ * ] of its Net Sales of any mass sales of a Product to a buyer who is governmental agency, quasi governmental agency, institution, foundation or other organization or entity and pursuant to a bulk sales contract or other arrangement, but\n",
      "excluding any sales of a Product pursuant to contract or purchase order to distributors in the normal course of business for any intended use.  \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "31 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "(d) Royalty Report and Payment. All royalty amounts payable to Tercica (or GNE as applicable)\n",
      "pursuant to this Section 7.1 shall be paid in Dollars within thirty (30) days after the end of each calendar quarter with respect to Net Sales in such calendar quarter. Each payment of royalties due to Tercica (or GNE as applicable) shall\n",
      "be accompanied by a statement, on a country-by-country basis, of the amount of gross sales of Product for the applicable indication during the applicable calendar quarter, an itemized calculation of Net Sales in the Territory showing deductions\n",
      "provided for in the definition of Net Sales during such calendar quarter, and a calculation of the amount of royalty payment due on such sales for such calendar quarter in accordance with Sections 7.1(a)(i), 7.1(a)(ii), 7.1(a)(iii), 7.1(a)(iv) and\n",
      "7.1(b). \n",
      " \n",
      "(e) Royalty Payment Term. All royalty obligations that apply to sales of Product for use in an indication in a Sale Country\n",
      "pursuant to this Section 7.1 shall extend, on a Product-by-Product, Permitted Indication-by-Permitted Indication, and Sale Country-by-Sale Country basis, until the later of (a) the expiration of the last to expire Licensed Patents existing\n",
      "in such Sale Country that would, but for the license grant in Section 3.1, be infringed by the use, sale, offer for sale, or importation of such Product for use in such Permitted Indication in such Sale Country and (b) the expiration of\n",
      "the last to expire Licensed Patents existing in such Sale Country or other country, that would, but for the license grant in Section 3.1, be infringed by the actual method of manufacture or use of such Product (or a component thereof) as\n",
      "practiced by Insmed in the manufacture of such Product in such Sale Country or such other country that is subsequently sold for use in such Permitted Indication in such Sale Country. \n",
      " \n",
      "(f) Minimum Royalty. The Parties acknowledge that there may be dispute between the Parties with respect to which Net Sales are attributable to\n",
      "which Permitted Indication, or the calculation of any royalties due thereunder, which may be ongoing as of the end of a given calendar quarter (the “Sales Tracking Dispute”). The Parties agree that Insmed’s royalty payment\n",
      "obligations under Section 7.1(a)(i) for sales of a Product to Existing Patients and under Section 7.1(c) for mass sales shall not be affected by any Sales Tracking Dispute, and shall be due and owing at the end of the relevant quarter in\n",
      "accordance with Section 7.1(d) above regardless of any then existing Sales Tracking Dispute. With respect to Insmed’s royalty payment obligations under Sections 7.1(a)(ii) through 7.1(a)(iv), or 7.1(b) or the payment of Operating Profit\n",
      "(Loss), any such Sales Tracking Dispute shall only affect the payment of the portion of the royalties in dispute, and the remainder of the royalties (which shall at all times be at least [ * ] of all Net Sales for each Permitted Indication) shall\n",
      "nevertheless be due and owing at the end of the relevant quarter in accordance with Section 7.1(d) above. \n",
      " \n",
      "7.2 Sharing of Operating\n",
      "Profit of Product for an Opt-In Indication. \n",
      " \n",
      "(a) Profit Share. The Parties shall share the Operating Profit (Loss) for each\n",
      "Opt-In Indication based on the applicable Percentage Interest for such Opt-In Indication. \n",
      " \n",
      "(b) Quarterly Calculations. Each\n",
      "Party’s share of Operating Profit (Loss) will be determined on a calendar quarterly basis, using a weighted average based on forecasted Actual Sales (as defined in Exhibit A) for a Product for the Opt-In Indication for the then current\n",
      "calendar year and actual Operating Profit (Loss) for the completed calendar quarter. \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "32 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "(c) Quarterly Reconciliation. On a calendar quarterly basis after the end of each calendar\n",
      "quarter, each Party’s actual share of Operating Profit (Loss) will be calculated and reconciled as follows: the forecasted Actual Sales for a Product for such Opt-In Indication for the then current calendar year will be adjusted based on the\n",
      "actual sales booked for the recently-completed calendar quarter and the forecasted Actual Sales for all remaining calendar quarters. Then, each Party’s share of cumulative Operating Profit (Loss) for all of the completed calendar quarter(s) for\n",
      "such calendar year will be determined using a weighted average based on such newly-calculated Actual Sales and the actual Operating Profit (Loss) for all such completed calendar quarter(s) for such calendar year. The payment to be made by one Party\n",
      "to the other Party for such recently-completed calendar quarter shall reflect such reconciliation, so that each Party will receive its share of then-current cumulative Operating Profit (Loss). \n",
      " \n",
      "(d) Reconciliation Payments. If the Opt-In Party does not exercise its Sole Promotion Option, then, as between the Parties, Insmed shall be the\n",
      "Booking Party for such Product for the Opt-In Indication. If the Opt-In Party exercises its Sole Promotion Option, then such Opt-In Party shall be the Booking Party for such Product for the Opt-In Indication. In accordance with the timeline set\n",
      "forth in Exhibit A, for as long as any Product is being commercialized for an Opt-In Indication, the Non-Booking Party shall submit to the Booking Party a statement setting forth any expenditures incurred in any of the elements of calculation\n",
      "of the Operating Profit (Loss) by such Non-Booking Party for the sale of Product for the Opt-In Indication during such calendar quarter, together with the information detailing the basis for the calculation of such expenditures, in detail and by\n",
      "category of expenditure. The Booking Party shall consolidate any such Operating Profit (Loss) expenditures reported by such Non-Booking Party with those obtained directly by the Booking Party. The Booking Party shall, in accordance with the time\n",
      "periods set forth in Exhibit A, notify such Non-Booking Party whether a reconciliation payment is due from one Party to the other based on its calculation pursuant to Section 7.2(c) above, and if so, the amount of such reconciliation\n",
      "payment, so that the Parties will share the Operating Profit (Loss) for such calendar quarter in the ratio set forth in Section 7.2(a). The Party required to pay such reconciliation payment shall submit such payment to the other Party within\n",
      "the time period set forth in Exhibit A. \n",
      " \n",
      "7.3 GNE License Fee. Upon receipt of invoice from Tercica, Insmed shall reimburse\n",
      "Tercica for license payments made to GNE pursuant to Section G.1(a)(x) of Exhibit G to the GNE US License. For clarity, Insmed shall have no further obligation under this Section 7.3 upon Insmed’s reimbursement of Tercica for the final\n",
      "license payment made by Tercica to GNE pursuant to Section G.1(a)(x) of Exhibit G to the GNE US License, which final license payment is the last payment made to GNE by Tercica under such section of the GNE US License before the expiration of the\n",
      "last to expire patent in the BP3 Patents (as that term is defined in Section 1.7 of the GNE US License) existing in the United States. For additional clarity, nothing in this Section 7.3 shall be construed to limit or amend Tercica’s\n",
      "obligation to pay GNE any license payments due pursuant to Section G.1(a)(x) of Exhibit G to the GNE US License. \n",
      " \n",
      "7.4 Taxes. A Party\n",
      "receiving a payment pursuant to this Article 7 shall pay any and all taxes levied on such payment. If applicable law requires that taxes be deducted and withheld from a payment made pursuant to this Article 7, the remitting Party shall\n",
      "(i) deduct those taxes from the payment; (ii) pay the taxes to the proper taxing authority; and (iii) send evidence of the \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "33 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "obligation together with proof of payment to the other Party within sixty (60) days following that payment. \n",
      " \n",
      "7.5 Blocked Currency. In each country where the local currency is blocked and cannot be removed from the country, royalties accrued in that\n",
      "country shall be paid to the other Party in the country in local currency by deposit to a local bank designated by such Party, unless the Parties otherwise agree. \n",
      " \n",
      "7.6 Foreign Exchange. The rate of exchange to be used in computing the amount of currency equivalent in Dollars owed to a Party under this Agreement shall be made at the period-end rate of exchange quoted on\n",
      "the last business day of the applicable calendar quarter by Citibank in New York City. \n",
      " \n",
      "7.7 Late Payments. If a Party does not\n",
      "receive payment of any sum due to it on or before the due date, simple interest shall thereafter accrue on the sum due to such Party until the date of payment at the per annum rate of two percent (2%) over the then-current prime rate quoted by\n",
      "Citibank in New York City or the maximum rate allowable by applicable law, whichever is greater. All payments made hereunder shall be made net of any withholding taxes. \n",
      " \n",
      "7.8 Financial Records; Audits. Each Party will maintain complete and accurate records in sufficient detail to permit the other Parties to confirm the accuracy of the Development Costs incurred by such Party and\n",
      "the calculation of royalty payments, Operating Profit (Loss), and other compensation payable under this Agreement. In addition, Insmed will maintain complete and accurate records of its Named Patient Basis sales under Sections 3.1(b) and (d) in\n",
      "sufficient detail to permit GNE or Tercica to confirm the accuracy of such sales. Upon reasonable prior notice, such records shall be open during regular business hours for a period of three (3) years from the creation of individual records for\n",
      "examination at the auditing Party’s expense, and not more often than once each calendar year, by an independent certified public accountant selected by the auditing Party and reasonably acceptable to the audited Party for the sole purpose of\n",
      "verifying for the auditing Party the accuracy of the financial reports furnished by the audited Party pursuant to this Agreement or of any payments made by the audited Party to the non-audited Party pursuant to this Agreement. Any such auditor shall\n",
      "not disclose the audited Party’s Confidential Information to the auditing Party, except to the extent such disclosure is necessary to verify the accuracy of the financial reports furnished by the audited Party or the amount of payments due by\n",
      "the audited Party under this Agreement. Any amounts shown to be owed but unpaid shall be paid within thirty (30) days from the accountant’s report, plus interest (as set forth in Section 7.6) from the original due date. The auditing\n",
      "Party shall bear the full cost of such audit unless such audit discloses an underpayment of the amount actually owed during the applicable calendar year of more than five percent (5%), in which case the audited Party shall bear the full cost of such\n",
      "audit. \n",
      " \n",
      "ARTICLE 8 \n",
      " \n",
      "INTELLECTUAL PROPERTY \n",
      " \n",
      "8.1 Prosecution of Patents. \n",
      " \n",
      "(a) Licensed Patents. Tercica or GNE (as such rights and obligations are allocated between Tercica and GNE under the GNE Licenses) shall have the\n",
      "sole right and authority to prepare, file, prosecute (including any interferences, reissue proceedings and reexaminations) and maintain the Licensed Patents on a worldwide basis. Tercica or GNE (as such rights and obligations are allocated between\n",
      "Tercica and GNE under the GNE Licenses) shall be responsible for all costs and expenses related to such preparation, filing, prosecution and maintenance of such Licensed Patents. \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "34 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "(b) Insmed Patents. Except as otherwise provided in this Section 8.1(b), Insmed shall have\n",
      "the sole right and authority to prepare, file, prosecute (including any interferences, reissue proceedings and reexaminations) and maintain the patents within the Insmed Patents on a worldwide basis. Except as set forth in this Section 8.1(b),\n",
      "Insmed shall be responsible for all costs and expenses related to such preparation, filing, prosecution and maintenance of such patents within the Insmed Patents. In the event that Tercica or GNE is the Opt-In Party for any Product for an Opt-In\n",
      "Indication, after the proper exercise of the Opt-In, and unless and until such Party exercises the Opt-Out with respect to such Permitted Indication: (i) Insmed shall provide such Opt-In Party reasonable opportunity to review and comment on\n",
      "such prosecution efforts regarding such patents relating to a Product for the Opt-In Indication within the Insmed Patents, (ii) Insmed shall provide such Opt-In Party with a copy of material communications from any patent authority in the\n",
      "Territory regarding such patents within the Insmed Patents, and shall provide drafts of any material filings or responses to be made to such patent authorities a reasonable amount of time in advance of submitting such filings or responses, and\n",
      "(iii) if Insmed determines in its sole discretion to abandon or not maintain any patent within such patents within the Insmed Patents anywhere in the Territory, then Insmed shall provide such Opt-In Party with thirty (30) days prior\n",
      "written notice of such determination (or such other period of time reasonably necessary to allow such Opt-In Party to assume such responsibilities) and shall provide such Opt-In Party with the opportunity to prepare, file, prosecute and maintain\n",
      "such patent in the Territory on behalf of Insmed at such Opt-In Party’s sole expense. \n",
      " \n",
      "(c) Cooperation in Prosecution. Each\n",
      "Party shall provide the other Parties all reasonable assistance and cooperation in the patent prosecution efforts to the extent necessary or useful for the exercise of the other Parties’ right to control patents as provided above in this\n",
      "Section 8.1, including providing any necessary powers of attorney and executing any other required documents or instruments for such prosecution. \n",
      " \n",
      "8.2 Infringement of Patents by Third Parties. \n",
      " \n",
      "(a) Notification. Each Party shall promptly\n",
      "notify the other Parties in writing of any existing or threatened infringement of the Licensed Patents or any patents within the Insmed Patents of which it becomes aware, and shall provide evidence in such Party’s possession demonstrating such\n",
      "infringement. \n",
      " \n",
      "(b) Infringement of Licensed Patents. Tercica or GNE (as such rights and obligations are allocated between Tercica\n",
      "and GNE under the GNE Licenses) shall have the exclusive right, but not the obligation, to bring, at Tercica’s or GNE’s (as applicable) expense \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "35 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "and in its sole control, an appropriate suit or other action against any person or entity engaged in such infringement of a Licensed Patent. \n",
      " \n",
      "(c) Infringement of Insmed Patents. Insmed shall have the exclusive right, but not the obligation, to bring, at Insmed’s expense and in its\n",
      "sole control, an appropriate suit or other action against any person or entity engaged in such infringement of a patent within the Insmed Patents. \n",
      " \n",
      "8.3 Infringement of Third Party Rights. \n",
      " \n",
      "(a) Notice. If any Product manufactured, used or sold by either Party, its\n",
      "Affiliates, licensees or sublicensees becomes the subject of a Third Party’s claim or assertion of infringement of a patent granted by a jurisdiction within the Territory relating to the manufacture, use, sale, offer for sale or importation of\n",
      "a Product, and if Tercica or GNE is the Opt-In Party for a Product for any Opt-In Indication implicated in such claim or assertion, then: (i) if the Opt-In Party first has notice of the claim or assertion, it shall promptly notify Insmed; and\n",
      "(ii) if Insmed first has notice of the claim or assertion, it shall promptly notify such Opt-In Party. The Parties shall then promptly meet to consider the claim or assertion and the appropriate course of action. \n",
      " \n",
      "(b) Defense. Insmed shall have the first right, but not the obligation, to defend any such claim, the costs to conduct such defense being at\n",
      "Insmed’s sole expense. If Insmed does not commence actions to defend such claim within five (5) business days after it had notice thereof, then such Opt-In Party shall have the right, but not the obligation, to control the defense of such\n",
      "claim by counsel of its choice, at such Opt-In Party’s sole expense. Each of Insmed and the Opt-In Party shall reasonably cooperate with the other Party and shall give reasonable consideration to the other Party’s input, including if\n",
      "required to conduct such defense, furnishing a power of attorney. \n",
      " \n",
      "(c) Settlement. Neither Party shall enter into any settlement of\n",
      "any claim described in this Section 8.3 that affects the other Parties’ rights or interests without such other Parties’ written consent, which consent shall not be unreasonably withheld or delayed. \n",
      " \n",
      "ARTICLE 9 \n",
      " \n",
      "CONFIDENTIALITY\n",
      " \n",
      "9.1 Confidential Information. All information, whether in oral, written, graphic or electronic form, disclosed by either Party\n",
      "(“Disclosing Party”) to the other and/or any of its subsidiaries, subdivisions, parent companies, affiliates agents or consultants (“Receiving Party”), and all notes, documents and materials prepared by or for\n",
      "either Party which reflect, interpret, evaluate, include or are derived therefrom, shall be deemed to be “Confidential Information.” In particular, Confidential Information shall include, without limitation, any trade secret,\n",
      "proprietary information, invention, research and development work, work-in-process, technology, technique, know-how, design, specification, program, unpublished data, procedure (including operating procedures), computer software, data base or\n",
      "programming, idea, sample, strategy, budget, projection, development, process, formulation, method, guideline, \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "36 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "policy, proposal, contract, test data or data file, or any engineering, manufacturing, marketing, servicing, financing, pricing, cost, profit, personnel or\n",
      "salary structure/compensation information relating to the past, present or future operations, products, services, technology, sales, suppliers, clients, customers, employees, investigators, investors or business of Disclosing Party. In addition,\n",
      "“Confidential Information” includes any trade secrets, data (technical or non-technical) or confidential information relating to the past, present or future operations, organization, business, projects or finances of any Third Party\n",
      "to which Disclosing Party owes a duty of confidentiality including, without limitation, the mere fact that Disclosing Party is or may be working with or for any client. \n",
      " \n",
      "9.2 Non-use; Nondisclosure of Confidential Information. Receiving Party shall not use or disclose such Confidential Information to others (except its employees, Affiliates and sublicensees who reasonably\n",
      "require same for the purposes hereof and who are bound to it by a like obligation as to confidentiality except as required by law) without the express written permission of Disclosing Party, except for Confidential Information that (a) can be\n",
      "demonstrated by written records to be known to Receiving Party from a source other than Disclosing Party at the time of receipt; or (b) was subsequently otherwise legally acquired by Receiving Party from a Third Party having an independent\n",
      "right to disclose the information; or (c) is now or later becomes publicly known without breach of this Agreement by Receiving Party or any Party that received such Confidential Information from Receiving Party. \n",
      " \n",
      "9.3 Permitted Disclosure of Confidential Information. Any Party may disclose the other Party’s Confidential Information to the extent such\n",
      "disclosure is required by law, regulations (including without limitation the rules and regulations promulgated by the United States Securities Exchange Commission) and valid court order, provided that such Party gives the other Party reasonable\n",
      "notice of such disclosure and uses reasonable efforts to obtain confidential treatment or a protective order for such information. Tercica shall have the right to disclose Insmed’s Confidential Information to the extent such disclosure is\n",
      "required to satisfy its obligations under the GNE Licenses or any agreements with Ipsen, provided that such persons undertake to keep confidential such Confidential Information. \n",
      " \n",
      "9.4 Other Permitted Disclosure. Except as otherwise expressly provided herein or as otherwise set forth in Section 9.3, to the extent\n",
      "reasonably necessary to carry on the activities contemplated in this Agreement, a Party shall be permitted to (a) disclose or grant use of Confidential Information received under this Agreement to any of its permitted sublicensees, agents,\n",
      "consultants, clinical investigators, collaborators or contractors, under confidentiality and non-use obligations at least as stringent as those set forth in this Article 9; (b) disclose Confidential Information received under this Agreement to\n",
      "actual or potential professional investors, acquirers, merger or other business partners or retained professional advisors (e.g. attorneys, accountants and investment bankers), under confidentiality and non-use obligations at least as stringent as\n",
      "those set forth in this Article 9; and (c) to a Regulatory Authority to the extent necessary for obtaining Marketing Authorization for a Product. \n",
      " \n",
      "9.5 Press Release. The Parties agree that the material terms of this Agreement are included within the Confidential Information of all Parties, subject to the special authorized disclosure set forth in this\n",
      "Section 9.5. Tercica and Insmed have agreed to make a joint public \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "37 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "announcement of the execution of this Agreement substantially in the form of the press release attached as Exhibit F on or after the Effective Date.\n",
      " \n",
      "9.6 Publication. \n",
      " \n",
      "(a) If Opt-In Rights Have Not Been Exercised. In the event that (i) neither Tercica nor GNE has exercised its Opt-In rights under Section 4.2 when they became due, or (ii) the Opt-In Party has subsequently exercised\n",
      "its Opt-Out right under Section 4.4, then Insmed shall have the right to publish or orally deliver a scientific article or speech relating to the development of Product for the Permitted Indication subject to the confidentiality restrictions\n",
      "described in Sections 9.1 through 9.4. \n",
      " \n",
      "(b) If Opt-In Rights Have Been Exercised. In the event that either Tercica or GNE has\n",
      "exercised its Opt-In rights under Section 4.2, or during such time period as such rights are ongoing, and provided such Opt-In Party has not yet exercised its Opt-Out right under Section 4.4, then if Insmed or the Opt-In Party (or\n",
      "potential Opt-In Party) wishes to publish or orally deliver a scientific article or speech relating to the development of Product for the Opt-In Indication, then the following shall apply: The Party wishing to make such proposed oral disclosure or\n",
      "written publication shall submit to the other Party a draft of each such proposed oral disclosure or written publication at least thirty (30) days prior to the anticipated oral disclosure or the submission of the written publication. As soon as\n",
      "reasonably possible, but in no event more than thirty (30) days after receipt of an advance copy of a publishing Party’s proposed oral disclosure or written publication, the reviewing Party shall inform the publishing Party if the proposed\n",
      "oral disclosure or written publication contains any of the reviewing Party’s Confidential Information or could be expected to have a material adverse effect on any patent rights of the reviewing Party. If so requested by the reviewing Party,\n",
      "the publishing Party shall amend any proposed oral disclosure or written publication to the extent necessary to protect the Confidential Information of the reviewing Party of which the publishing Party is made aware by the reviewing Party and, if so\n",
      "requested by the reviewing Party, shall delay such proposed oral disclosure or written publication for a reasonable period of time to permit the timely preparation of a patent application by the reviewing Party. \n",
      " \n",
      "ARTICLE 10 \n",
      " \n",
      "REPRESENTATIONS AND\n",
      "WARRANTIES \n",
      " \n",
      "10.1 Representations and Warranties of Tercica. Tercica makes the following covenants, representations and\n",
      "warranties to each of the other Parties, as of the Effective Date, and does so in full understanding and acknowledgement that each of the other Parties is relying on the said representations and warranties in entering into the present Agreement:\n",
      " \n",
      "(a) Status. Tercica is a corporation organized and existing under the laws of the State of Delaware. No action has been taken by the\n",
      "directors, officers or shareholders of Tercica to dissolve Tercica. Tercica has the corporate power and authority to enter into the present Agreement and to perform all its obligations hereunder. \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "38 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "(b) All Necessary Proceedings. Tercica has taken all necessary corporate actions and proceedings\n",
      "to enable it to enter into the present Agreement. \n",
      " \n",
      "(c) No Violation. The execution, delivery and performance of this Agreement by it\n",
      "(i) does not and will not violate or conflict with any provision of law or any provision of its articles of incorporation or by-laws; and (ii) does not and will not, with or without the passage of time or the giving of notice, result in\n",
      "the breach of, or constitute a default, cause the acceleration of performance, or require any consent under, or result in the creation of any lien, charge or encumbrance upon any of its property or assets pursuant to any material instrument or\n",
      "agreement to which it is a party or by which it or its properties may be bound or affected. \n",
      " \n",
      "(d) GNE Licenses. As of the Effective\n",
      "Date, (i) the GNE Licenses are in full force and in effect in accordance with their terms, (ii) Tercica is not in default or breach in any material respect of the GNE Licenses, (iii) to Tercica’s knowledge, there is no cause for\n",
      "early termination of the GNE Licenses, (iv) Tercica has provided to Insmed a copy of the GNE Licenses; and (v) the terms under this Agreement are not in conflict with the terms in the GNE Licenses. Tercica shall (A) comply with and\n",
      "observe in all material respects its obligations under the GNE Licenses and (B) not terminate or otherwise modify any terms or conditions of the GNE Licenses in any manner that would materially adversely affect Insmed’s rights under this\n",
      "Agreement without the prior written consent of Insmed. \n",
      " \n",
      "10.2 Representations and Warranties of Insmed. Insmed makes the following\n",
      "covenants, representations and warranties to each of the other Parties, as of the Effective Date, and does so in full understanding and acknowledgement that each of the other Parties is relying on the said representations and warranties in entering\n",
      "into the present Agreement: \n",
      " \n",
      "(a) Status. Insmed is a corporation organized and existing under the laws of Virginia. No action has\n",
      "been taken by the directors, officers or shareholders of Insmed to dissolve Insmed. Insmed has the corporate power and authority to enter into the present Agreement and to perform all its obligations hereunder. \n",
      " \n",
      "(b) All Necessary Proceedings. Insmed has taken all necessary corporate actions and proceedings to enable it to enter into the present Agreement.\n",
      " \n",
      "(c) No Violation. The execution, delivery and performance of this Agreement by it (i) does not and will not violate or\n",
      "conflict with any provision of law or any provision of its articles of incorporation or by-laws; and (ii) does not and will not, with or without the passage of time or the giving of notice, result in the breach of, or constitute a default,\n",
      "cause the acceleration of performance, or require any consent under, or result in the creation of any lien, charge or encumbrance upon any of its property or assets pursuant to any material instrument or agreement to which it is a party or by which\n",
      "it or its properties may be bound or affected. \n",
      " \n",
      "(d) Existing Patients. Insmed has provided to Tercica and GNE the accurate maximum\n",
      "number of all Existing Patients as of the Execution Date as such number is set forth in Section 3.1(a) above. \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "39 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "(e) No Other Agreements. As of the Effective Date, Insmed has neither entered into nor is a party\n",
      "to any agreement with either Tercica or GNE that relates to the subject matter of the Lawsuit, with the sole exception of this Agreement, the UK Proceedings Settlement Agreement, and the Permanent Injunction. \n",
      " \n",
      "10.3 Representations and Warranties of GNE. GNE makes the following covenants, representations and warranties to each of the other Parties, as of\n",
      "the Effective Date, and does so in full understanding and acknowledgement that each of the other Parties is relying on the said representations and warranties in entering into the present Agreement: \n",
      " \n",
      "(a) Status. GNE is a corporation organized and existing under the laws of the State of Delaware. No action has been taken by the directors,\n",
      "officers or shareholders of GNE to dissolve GNE. GNE has the corporate power and authority to enter into the present Agreement and to perform all its obligations hereunder. \n",
      " \n",
      "(b) All Necessary Proceedings. GNE has taken all necessary corporate actions and proceedings to enable it to enter into the present Agreement.\n",
      " \n",
      "(c) No Violation. The execution, delivery and performance of this Agreement by it (i) does not and will not violate or\n",
      "conflict with any provision of law or any provision of its articles of incorporation or by-laws; and (ii) does not and will not, with or without the passage of time or the giving of notice, result in the breach of, or constitute a default,\n",
      "cause the acceleration of performance, or require any consent under, or result in the creation of any lien, charge or encumbrance upon any of its property or assets pursuant to any material instrument or agreement to which it is a party or by which\n",
      "it or its properties may be bound or affected. \n",
      " \n",
      "10.4 THE WARRANTIES SET OUT ABOVE ARE THE ONLY WARRANTIES GIVEN BY ANY PARTY AND ARE\n",
      "MADE IN LIEU OF ALL OTHER WARRANTIES, EXPRESS OR IMPLIED. THERE IS NO OTHER CONDITION OR WARRANTY RELATING TO PRODUCT MERCHANTABILITY OR FIT FOR ANY PARTICULAR PURPOSE, ALL OF WHICH ARE HEREBY EXCLUDED AND DISCLAIMED. \n",
      " \n",
      "ARTICLE 11 \n",
      " \n",
      "INDEMNIFICATION\n",
      " \n",
      "11.1 Indemnification by Tercica. Tercica shall defend, indemnify, and hold Insmed and GNE and each of Insmed’s and\n",
      "GNE’s respective officers, directors, employees, and agents harmless from and against any and all Third Party claims, suits, proceedings, damages, expenses (including court costs and reasonable attorneys’ fees and expenses), and recoveries\n",
      "(collectively, “Claims”) to the extent that such Claims arise out of, are based on, or result from (a) the development, manufacture, storage, handling, use, promotion, sale, offer for sale, and importation of Products by\n",
      "Tercica or its sublicensees or Affiliates; (b) a breach of any of Tercica’s representations, warranties, and obligations under the Agreement; or (c) the willful misconduct or negligent acts of Tercica, its Affiliates, or the officers,\n",
      "directors, employees, or agents of Tercica or its Affiliates. The foregoing indemnity obligation shall not apply if the \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "40 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "indemnifiable Party fails to comply with the indemnification procedures set forth in Section 11.4, or to the extent that any Claim arises from, is based\n",
      "on, or results from (i) the development, manufacture, storage, handling, use, promotion, sale, offer for sale, and importation of Products by Insmed or GNE or their respective Affiliates, sublicensees, or distributors; (ii) a breach of any\n",
      "of Insmed’s or GNE’s respective representations, warranties, and obligations under the Agreement; or (iii) the willful misconduct or negligent acts of Insmed or GNE or their respective Affiliates, or the officers, directors,\n",
      "employees, or agents thereof. \n",
      " \n",
      "11.2 Indemnification by Insmed. Insmed shall defend, indemnify, and hold Tercica and GNE and each of\n",
      "Tercica’s and GNE’s respective officers, directors, employees, and agents harmless from and against any and all Claims to the extent that such Claims arise out of, are based on, or result from (a) the development, manufacture,\n",
      "storage, handling, use, promotion, sale, offer for sale, and importation of Products by Insmed or its Affiliates, sublicensees, or distributors; (b) a breach of any of Insmed’s representations, warranties, and obligations under the\n",
      "Agreement; or (c) the willful misconduct or negligent acts of Insmed or its Affiliates, or the officers, directors, employees, or agents of Insmed or its Affiliates. The foregoing indemnity obligation shall not apply if the indemnifiable Party\n",
      "fails to comply with the indemnification procedures set forth in Section 11.4, or to the extent that any Claim arises from, is based on, or results from (i) the development, manufacture, storage, handling, use, promotion, sale, offer for\n",
      "sale, and importation of Products by Tercica or GNE or their respective Affiliates or sublicensees for the treatment of Permitted Indications; (ii) a breach of any of Tercica’s or GNE’s respective representations, warranties, and\n",
      "obligations under the Agreement; or (iii) the willful misconduct or negligent acts of Tercica or GNE or their respective Affiliates, or the officers, directors, employees, or agents thereof. \n",
      " \n",
      "11.3 Indemnification by GNE. GNE shall defend, indemnify, and hold Tercica and Insmed and each of Tercica’s and Insmed’s respective\n",
      "officers, directors, employees, and agents harmless from and against any and all Claims to the extent that such Claims arise out of, are based on, or result from (a) the development, manufacture, storage, handling, use, promotion, sale, offer\n",
      "for sale, and importation of Products by GNE or its Affiliates, sublicensees, or distributors; (b) a breach of any of GNE’s representations, warranties, and obligations under the Agreement; or (c) the willful misconduct or negligent\n",
      "acts of GNE or its Affiliates, or the officers, directors, employees, or agents of GNE or its Affiliates. The foregoing indemnity obligation shall not apply if the indemnifiable Party fails to comply with the indemnification procedures set forth in\n",
      "Section 11.4, or to the extent that any Claim arises from, is based on, or results from (i) the development, manufacture, storage, handling, use, promotion, sale, offer for sale, and importation of Products by Tercica or Insmed or their\n",
      "respective Affiliates or sublicensees; (ii) a breach of any of Tercica’s or Insmed’s respective representations, warranties, and obligations under the Agreement; or (iii) the willful misconduct or negligent acts of Tercica or\n",
      "Insmed or their respective Affiliates, or the officers, directors, employees, or agents thereof. \n",
      " \n",
      "11.4 Indemnification Procedures.\n",
      "The Party claiming indemnity under this Article 10 (the “Indemnified Party”) shall give written notice to the Party from whom indemnity is being sought (the “Indemnifying Party”) promptly after learning of such\n",
      "Claim. The Indemnified Party shall provide the Indemnifying Party with reasonable assistance, at the Indemnifying Party’s expense, in connection with the defense of the Claim for which indemnity is being sought. The Indemnified Party may\n",
      "participate in and monitor such defense with \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "41 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "counsel of its own choosing at its sole expense; provided, however, the Indemnifying Party shall have the right to assume and conduct the defense of the\n",
      "Claim with counsel of its choice. The Indemnifying Party shall not settle any Claim without the prior written consent of the Indemnified Party, not to be unreasonably withheld, unless the settlement involves only the payment of money by the\n",
      "Indemnifying Party. So long as the Indemnifying Party is actively defending the Claim in good faith, the Indemnified Party shall not settle any such Claim without the prior written consent of the Indemnifying Party. If the Indemnifying Party does\n",
      "not assume and conduct the defense of the Claim as provided above, (a) the Indemnified Party may defend against, and consent to the entry of any judgment or enter into any settlement with respect to the Claim in any manner the Indemnified Party\n",
      "may deem reasonably appropriate (and the Indemnified Party shall be given written notice to the Indemnifying Party of any settlement thereof and shall not settle without the consent of the Indemnifying Party), and (b) the Indemnifying Party\n",
      "will remain responsible to indemnify the Indemnified Party as provided in this Article 11. \n",
      " \n",
      "11.5 Limitation of Liability. NONE OF\n",
      "THE PARTIES SHALL BE LIABLE TO ANY OTHER PARTY FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR INDIRECT DAMAGES ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES.\n",
      "NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 11.5 IS INTENDED TO OR SHALL LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER SECTIONS 11.1, 11.2 OR 11.3, OR DAMAGES AVAILABLE FOR A PARTY’S BREACH OF ITS\n",
      "CONFIDENTIALITY OBLIGATIONS IN ARTICLE 9. \n",
      " \n",
      "11.6 Insurance. Each Party shall procure and maintain insurance, including product\n",
      "liability insurance, adequate to cover its obligations hereunder and which are consistent with normal business practices of prudent companies similarly situated at all times during which any Product is being clinically tested in human subjects or\n",
      "commercially distributed or sold. It is understood that such insurance shall not be construed to create a limit of either Party’s liability with respect to its indemnification obligations under this Article 11. Each Party shall provide the\n",
      "other with written evidence of such insurance upon request. Each Party shall provide the other with written notice at least thirty (30) days prior to the cancellation, non renewal or material change in such insurance or self-insurance which\n",
      "materially adversely affects the rights of the other Party hereunder. \n",
      " \n",
      "ARTICLE 12 \n",
      " \n",
      "TERM AND TERMINATION \n",
      " \n",
      "12.1 Term and\n",
      "Overview of Termination Rights. \n",
      " \n",
      "(a) Term. The term of the Agreement shall commence on the Effective Date and, unless sooner\n",
      "terminated as provided herein, shall continue in full force and effect on a country-by-country basis until the later of (a) the expiration of all payment obligations described in Article 7 in such country; and (b) the expiration of Tercica\n",
      "and GNE’s Opt-In rights under Section 4.2 (the “Term”). Articles 1, 2, 9, 11 (to the extent the Claims arise from actions or \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "42 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "omissions under this Agreement), 13 and 14 and Sections 3.2, 3.4, 3.5, 3.6, 7.8 and 12.6 shall survive the expiration of this Agreement. In addition and\n",
      "pursuant to their terms, the Permanent Injunction and UK Proceedings Settlement Agreement shall remain in full force and effect following expiration of this Agreement. \n",
      " \n",
      "(b) Overview of Termination. As further described in Sections 12.3 and 12.4, each Party has certain rights to terminate the Agreement in its entirety or on an indication-by-indication basis depending on whether\n",
      "another Party has breached this Agreement generally or with respect to a specific Permitted Indication or Non-Permitted Indication. Section 12.2 sets forth the general procedures applicable in the event that a Party commits a Material Breach of\n",
      "the Agreement. Sections 12.3 and 12.4 describe the specific rights of GNE, Tercica and Insmed to terminate the Agreement in its entirety or on an indication-by-indication basis due to the breach by another Party. \n",
      " \n",
      "12.2 Material Breach; Procedures Applicable in Event of a Material Breach by a Party. If a Party is in material breach or default with respect to\n",
      "any term or provision hereof and as specified below (such breach, a “Material Breach”), then the non-breaching Party(ies) shall have the right to terminate this Agreement, either in its entirety or on an indication-by-indication\n",
      "basis (as further set forth in Sections 12.3 and 12.4 below), by providing such breaching Party written notice of termination detailing such Material Breach, provided that such notice of termination shall only become effective at the end of a ninety\n",
      "(90) day period (however, termination shall become effective at the end of ten (10) days if Insmed or its Affiliates or Sublicensees challenge(s) the validity or enforceability of any patent or patent application that is included in the\n",
      "Licensed Patents anywhere in the Territory and at the end of thirty (30) days in the case of failure to pay) after such notice is received by the breaching Party, and only if such breaching Party fails to cure such Material Breach during the\n",
      "same period. Notwithstanding anything to the contrary in this Section 12.2, each of Tercica, Insmed, and GNE may elect not to exercise its right to terminate this Agreement in its entirety or an indication-by-indication basis pursuant to this\n",
      "Article 12 for another Party’s uncured Material Breach, but instead elect to allow this Agreement to continue in effect, in which case, the breaching Party shall continue to be liable to the non-breaching Party(ies) for such Material Breach.\n",
      "The non-breaching Party(ies) shall be entitled to pursue legal and equitable remedies arising from such Material Breach that are available to it or them (as applicable), regardless of whether such non-breaching Party(ies) terminates this Agreement\n",
      "for such Material Breach. \n",
      " \n",
      "12.3 Termination by GNE and/or Tercica for Insmed’s Material Breach. \n",
      " \n",
      "(a) General Right to Terminate for Material Breach by Insmed. \n",
      " \n",
      "(i) Tercica’s and GNE’s Right to Terminate. \n",
      " \n",
      "(1) Right to Terminate with Consent.\n",
      "Subject to Section 12.3(a)(i)(2) below, each of Tercica and GNE shall have the right to terminate this Agreement in its entirety pursuant to Section 12.2 above, with the other non-breaching Party’s consent if: (A) Insmed commits\n",
      "a Material Breach with respect to a Non-Permitted Indication or ALS Indication (including without limitation, Insmed’s sales of a Product beyond the scope of its license under Section 3.1(a) or Section 3.1(d) for the Non-Permitted\n",
      "Indication or the ALS Indication, \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "43 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "respectively); (B) Insmed breaches any of its representations, warranties, obligations, or covenants under this Agreement which are not specific to a\n",
      "particular Permitted Indication; (C) Insmed breaches the terms of the Permanent Injunction; (D) Insmed breaches the terms of the UK Proceedings Settlement Agreement; or (E) Insmed commits a Material Breach with respect to more than\n",
      "one Permitted Indication. \n",
      " \n",
      "(2) Unilateral Right to Terminate. Notwithstanding Section 12.3(a)(i)(1) above, GNE shall have the\n",
      "right to terminate this Agreement in its entirety pursuant to Section 12.2 above, without Tercica’s consent if: (A) Insmed or its Affiliates or Sublicensees challenge(s) the validity or enforceability of any patent or patent\n",
      "application that is included in the GNE Patents anywhere in the Territory (whether or not with respect to a particular Permitted Indication); or (B) Insmed breaches its payment obligations to GNE under Article 7. Notwithstanding\n",
      "Section 12.3(a)(i)(1) above, Tercica shall have the right to terminate this Agreement in its entirety pursuant to Section 12.2 above, without GNE’s consent if: (Y) Insmed or its Affiliates or Sublicensees challenge(s) the\n",
      "validity or enforceability of any patent or patent application that is included in the Licensed Patents and that is not a GNE Patent anywhere in the Territory (whether or not with respect to a particular Permitted Indication); or (Z) Insmed\n",
      "breaches its payment obligations to Tercica under Article 7. \n",
      " \n",
      "(ii) Consequences of Termination by Tercica or GNE. If Tercica or GNE\n",
      "terminates this Agreement in its entirety pursuant to Section 12.3(a)(i) above, then: \n",
      " \n",
      "(1) the licenses granted to Insmed in\n",
      "Section 3.1 shall immediately terminate; \n",
      " \n",
      "(2) the Permanent Injunction and the UK Proceedings Settlement Agreement shall each\n",
      "remain in full force and effect; \n",
      " \n",
      "(3) Insmed shall immediately cease to make, have made, use, sell, offer for sale or import any\n",
      "Product, either by itself or through an Affiliate, Sublicensee or subcontractor, in all countries of the Other Territory where an unexpired claim included in the Licensed Patents covers the composition of matter of, or the method of making or using,\n",
      "any component contained in such Product; \n",
      " \n",
      "(4) within five (5) business days after the effective date of such termination, in\n",
      "the event and to the extent of any Infringing Activity, Insmed shall be automatically enjoined from engaging in and from inducing any Third Party to engage in any such Infringing Activity, such injunction to remain and continue in full force and\n",
      "effect until the expiration of the last to expire of such GNE Patents covering such Infringing Activity, on a country-by-country basis; and \n",
      " \n",
      "(5) all rights and obligations under this Agreement shall terminate except for the Parties’ rights and obligations under Sections 3.2, 3.4, 3.5, 3.6, 7.8 and 12.6, and Articles 1, 2, 9, 11 (to the extent the Claims arise from\n",
      "actions or omissions under this Agreement), 13 and 14. \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "44 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "(b) Additional Rights to Terminate for Insmed’s Material Breach Where Such Material Breach is\n",
      "with Respect to a Specific Permitted Indication that is an Opt-In Indication.  \n",
      " \n",
      "(i) Opt-In Party’s Right to\n",
      "Terminate. If Insmed commits a Material Breach with respect to a Permitted Indication that is an Opt-In Indication, then the Opt-In Party shall have the right, without the other, non-Opt-In Party’s consent, to terminate this Agreement only\n",
      "with respect to such Opt-In Indication, pursuant to Section 12.2 above. Notwithstanding the foregoing sentence, and as further described in Section 12.3(b)(iii), under certain circumstances, GNE shall also have the right to terminate this\n",
      "Agreement with respect to an Opt-In Indication even if GNE is not the Opt-In Party for such Opt-In Indication. \n",
      " \n",
      "(ii) Consequences of\n",
      "Termination by an Opt-In Party. If an Opt-In Party terminates this Agreement with respect to a particular Opt-In Indication pursuant to Section 12.3(b)(i) above, then: \n",
      " \n",
      "(1) the licenses granted to Insmed in Section 3.1 shall immediately terminate with respect to such Opt-In Indication; \n",
      " \n",
      "(2) the Permanent Injunction and the UK Proceedings Settlement Agreement shall each remain in full force and effect; \n",
      " \n",
      "(3) the Opt-In Party shall have the right to take over development of such Opt-In Indication in its entirety, at its own expense, in accordance\n",
      "with the financial consequences as described in the remainder of this Section 12.3(b)(ii)(3). If the Opt-In Party elects to take over development of such Opt-In Indication in its entirety, then the Percentage Interest of Insmed in such Opt-In\n",
      "Indication shall be reduced to a portion equal to the result of the following formula: \n",
      " \n",
      " \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "50%  x\n",
      " \n",
      "[\n",
      "  \n",
      "Total Development Costs actually funded by Insmed prior to the date of the Material Breach\n",
      "  \n",
      "]\n",
      "\n",
      " \n",
      "\n",
      "  \n",
      "50% x (Total Development Costs incurred by Insmed and the Opt-In Party to obtain regulatory approval of such Product in the given country at issue)\n",
      "  \n",
      "\n",
      " \n",
      "The profit-sharing arrangement (as adjusted pursuant to the formula in this Section 12.3(b)(ii)(3)) shall\n",
      "continue only until the payments so received by Insmed equal the Development Costs actually incurred by Insmed for the Product for such Opt-In Indication, after which the profit share arrangement for such Opt-In Indication shall terminate. For\n",
      "illustration, if Insmed has actually funded $4 million of the total Development Costs prior to the date of the Material Breach, and the total Development Costs incurred by Insmed and such Opt-In Party to obtain regulatory approval of the Product in\n",
      "a given country at issue is $20 million, then Insmed’s newly calculated Percentage Interest after such termination shall be 50% x ($4 million/(50% x $20 million)) = 20%. The Opt-In Party shall share Operating Profit (Loss) with Insmed for such\n",
      "Product for such Permitted Indication in such country on a 80:20 basis until Insmed receives a total of $4 million in proceeds from such Operating Profit (Loss) sharing, after which the profit share arrangement shall terminate. The principle of this\n",
      "illustration shall also apply to Sections 12.3(b)(iii)(3), 12.4(b)(ii)(2)(b), and 12.5(b). \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "45 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "After the termination of the profit share arrangement for such Opt-In Indication pursuant to subsection (3) above,\n",
      "the Opt-In Party shall pay to Insmed royalties on the Net Sales for such Opt-In Indication at a rate of [ * ], and such royalty payment obligation shall expire in a given Sale Country on a Sale Country-by-Sale Country basis, upon the later of\n",
      "(A) the expiration of the last to expire Insmed Patents existing in such Sale Country that would be infringed by the use, sale, offer for sale, or importation of such Product for use in such Opt-In Indication in such Sale Country but for the\n",
      "license grant in Section 3.2(b), and (B) the expiration of the last to expire Insmed Patents existing in such Sale Country or other country that covers the actual method of manufacture or use of the Product (or a component thereof) as\n",
      "practiced by Insmed in the manufacture of the Product in such Sale Country or such other country that is subsequently sold for use in such Opt-In Indication in such Sale Country; \n",
      " \n",
      "(4) the Opt-In Party (a) shall become, if not already, the Booking Party for such Opt-In Indication; and (b) shall have the final\n",
      "decision making authority in the commercialization of such Product for such Opt-In Indication. \n",
      " \n",
      "(iii) Right and Consequences of\n",
      "Termination by GNE When It is Not the Opt-In Party for the Permitted Indication. Notwithstanding anything to the contrary in this Section 12.3(b), if Insmed commits a Material Breach with respect to an Opt-In Indication when Tercica is the\n",
      "Opt-In Party for such Opt-In Indication, then GNE shall have the right to terminate this Agreement with respect to such Opt-In Indication only in the event that Insmed’s Material Breach is an underpayment to GNE of the royalties under\n",
      "Section 7.1(b). In the event of such termination: \n",
      " \n",
      "(1) the licenses granted to Insmed in Section 3.1 shall immediately\n",
      "terminate with respect to such Permitted Indication; \n",
      " \n",
      "(2) the Permanent Injunction and the UK Proceedings Settlement Agreement\n",
      "shall each remain in full force and effect; \n",
      " \n",
      "(3) Tercica shall have the right to take over development of such Permitted Indication\n",
      "in its entirety, at its own expense, in accordance with the financial consequences as described in remainder of this Section 12.3(b)(iii)(3). If Tercica elects to take over development of such Permitted Indication in entirety, then the\n",
      "Percentage Interest of Insmed in such Permitted Indication shall be reduced to a portion equal to the result of the following formula: \n",
      " \n",
      " \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "50%  x\n",
      " \n",
      "[\n",
      "  \n",
      "Total Development Costs actually funded by Insmed prior to the date of the Material Breach\n",
      "  \n",
      "]\n",
      "\n",
      " \n",
      "\n",
      "  \n",
      "50% x (Total Development Costs incurred by Insmed and the Opt-In Party to obtain regulatory approval of such Product in the given country at issue)\n",
      "  \n",
      "\n",
      " \n",
      "The profit-sharing arrangement (as adjusted pursuant to the formula in this Section 12.3(b)(iii)(3)) shall\n",
      "continue only until the payments so received by Insmed equal the Development Costs actually incurred by Insmed for a Product for such indication. The formula provided in this Section 12.3(b)(iii)(3) shall be interpreted based on the same\n",
      "principle set forth in the illustration in Section 12.3(b)(ii)(3). Thereafter the profit share arrangement for such indication shall terminate and Tercica shall pay to Insmed royalties on the Net Sales for such \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "46 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "Opt-In Indication at a rate of [ * ], and such royalty payment obligation shall expire in a given Sale Country on a Sale Country-by-Sale Country basis, upon\n",
      "the later of (A) the expiration of the last to expire Insmed Patents existing in such Sale Country that would be infringed by the use, sale, offer for sale, or importation of such Product for use in such Opt-In Indication in such Sale Country\n",
      "but for the license grant in Section 3.2(b), and (B) the expiration of the last to expire Insmed Patents existing in such Sale Country or other country that covers the actual method of manufacture or use of such Product (or a component\n",
      "thereof) as practiced by Insmed in the manufacture of such Product in such Sale Country or such other country that is subsequently sold for use in such Opt-In Indication in such Sale Country; \n",
      " \n",
      "(4) Tercica (a) shall become, if not already, the Booking Party for such Opt-In Indication; (b) shall have the final decision making\n",
      "authority in the commercialization of such Product for such Opt-In Indication; (c) shall make payments to GNE from the proceeds received from such future sales of a Product for such Opt-In Indication to cover both the royalties otherwise due\n",
      "for such future sales and the unpaid royalties from sales booked prior to such termination; and (d) shall reserve all rights to seek recovery from Insmed for such royalty payments made to GNE by Tercica that account for the unpaid royalties\n",
      "from sales booked prior to such termination and Insmed shall have the obligation to reimburse Tercica for all such payments, together with all costs and expenses incurred by Tercica in seeking such recovery from Insmed. \n",
      " \n",
      "(c) Additional Rights to Terminate for Insmed’s Material Breach Where Such Material Breach is with Respect to a Permitted Indication other than\n",
      "an Opt-In Indication. \n",
      " \n",
      "(i) Tercica’s and GNE’s Right to Terminate. If Insmed commits a Material Breach with respect\n",
      "to a Permitted Indication other than an Opt-In Indication, then each of Tercica and GNE shall have the right to terminate this Agreement with respect to such Permitted Indication pursuant to Section 12.2 above, provided that, if at the time of\n",
      "such proposed termination, the Opt-In rights of Tercica and GNE with respect to such Permitted Indication under Section 4.2 have not expired or lapsed, then the Party seeking to terminate this Agreement with respect to such Permitted Indication\n",
      "shall obtain the written consent of the other non-breaching Party prior to such termination. \n",
      " \n",
      "(ii) Consequences of Termination by\n",
      "Tercica or GNE. If Tercica or GNE terminates this Agreement with respect to a particular Permitted Indication pursuant to Section 12.3(c)(i) above, then: \n",
      " \n",
      "(1) such Permitted Indication shall thereafter be deemed, for all purposes under this Agreement to be a Non-Permitted Indication; and \n",
      " \n",
      "(2) the remaining provisions set forth in this Agreement shall otherwise remain in full force and effect. \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "47 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "12.4 Termination by Insmed for GNE’s and/or Tercica’s Material Breach. \n",
      " \n",
      "(a) Termination of the Agreement in its Entirety by Insmed for Tercica’s and/or GNE’s Material Breach of More Than One Permitted Indication.\n",
      " \n",
      "(i) Insmed’s Right to Terminate. Insmed shall have the right to terminate this Agreement in its entirety pursuant to\n",
      "Section 12.2 above only in the event of an uncured Material Breach by Tercica and/or GNE with respect to more than one (1) Permitted Indications. \n",
      " \n",
      "(ii) Consequences of Termination by Insmed. If Insmed terminates this Agreement in its entirety pursuant to Section 12.4(a)(i), then: \n",
      " \n",
      "(1) the licenses granted to Insmed in Section 3.1 shall immediately terminate; \n",
      " \n",
      "(2) the Permanent Injunction and the UK Proceedings Settlement Agreement shall each remain in full force and effect; \n",
      " \n",
      "(3) Insmed shall immediately cease to make, have made, use, sell, offer for sale or import any Product, either by itself or through an Affiliate,\n",
      "Sublicensee or subcontractor, in any country in the Other Territory to the extent any unexpired Licensed Patents existing in such country would be infringed by such manufacture, having manufactured, use, sale, offer for sale or importation of such\n",
      "Product in such country; \n",
      " \n",
      "(4) within five (5) business days after the effective date of such termination, in the event and to\n",
      "the extent of any Infringing Activity, Insmed shall be automatically enjoined from engaging in and from inducing any Third Party to engage in any such Infringing Activity, such injunction to remain and continue in full force and effect until the\n",
      "expiration of the last to expire of such GNE Patents covering such Infringing Activity; and \n",
      " \n",
      "(5) all rights and obligations under\n",
      "this Agreement shall terminate except for the Parties’ rights and obligations under Sections 3.2(a), 3.4, 3.5, 3.6, 7.8 and 12.6, and Articles 1, 2, 9, 11 (to the extent the Claims arise from actions or omissions under this Agreement), 13 and\n",
      "14. \n",
      " \n",
      "(b) Termination of the Agreement for a Permitted Indication by Insmed. \n",
      " \n",
      "(i) Insmed’s Right to Terminate. Insmed shall have the right to terminate this Agreement pursuant to Section 12.2 only with respect to\n",
      "a given Permitted Indication upon an uncured Material Breach by Tercica and/or GNE with respect to such Permitted Indication. \n",
      " \n",
      "(ii)\n",
      "Consequences of Termination by Insmed. If Insmed terminates this Agreement with respect to a particular Permitted Indication pursuant to Section 12.4(b)(i), then: \n",
      " \n",
      "(1) the Permanent Injunction and the UK Proceedings Settlement Agreement shall each remain in full force and effect; and \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "48 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "(2) this Agreement shall continue in full force and effect except as follows (as applicable):\n",
      " \n",
      "(a) if the Opt-In right for such Permitted Indication has not been exercised by the breaching Party, then it shall be cancelled and\n",
      "shall be of no force or effect with respect to such Party; or \n",
      " \n",
      "(b) where an Opt-In Party has exercised the Opt-In right with\n",
      "respect to such Permitted Indication, Insmed shall have the right to take over development of such Opt-In Indication in its entirety, in accordance with the financial consequences as described in remainder of this Section 12.4(b)(ii)(2)(b). If\n",
      "Insmed elects to take over development of such Opt-In Indication in entirety, then the Percentage Interest of such Opt-In Party in such Opt-In Indication shall be reduced to a portion equal to the result of the following formula: \n",
      " \n",
      " \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "50%  x\n",
      " \n",
      "[\n",
      "  \n",
      "Total Development Costs actually funded by Opt-In Party prior to the date of the Material Breach\n",
      "  \n",
      "]\n",
      "\n",
      " \n",
      "\n",
      "  \n",
      "50% x (Total Development Costs incurred by the Opt-In Party and Insmed to obtain regulatory approval of such Product in the given country at issue)\n",
      "  \n",
      "\n",
      " \n",
      "The profit-sharing arrangement (as adjusted pursuant to the formula in this Section 12.3(b)(ii)(2)(b)) shall\n",
      "continue only until the payments so received by the Opt-In Party equal the Development Costs actually incurred by the Opt-In Party for a Product for such Opt-In Indication. The formula provided in this Section 12.4(b)(ii)(2)(b) shall be\n",
      "interpreted based on the same principle set forth in the illustration in Section 12.3(b)(ii)(3). Thereafter the profit share arrangement for such Opt-In Indication shall terminate and Insmed shall pay to the Opt-In Party royalties on the Net\n",
      "Sales for such Opt-In Indication at a rate of 4%, and such royalty payment obligation shall expire in a given Sale Country on a Sale Country-by-Sale Country basis, upon the later of (A) the expiration of the last to expire Licensed Patents\n",
      "existing in such Sale Country that would be infringed by the use, sale, offer for sale, or importation of such Product for use in such Opt-In Indication in such Sale Country but for the license grant in Section 3.1(c), and (B) the\n",
      "expiration of the last to expire Licensed Patents existing in such Sale Country or other country that would, but for the license grant in Section 3.1(c), be infringed by the actual method of manufacture or use of such Product (or a component\n",
      "thereof) as practiced by Insmed in the manufacture of such Product in such Sale Country or such other country that is subsequently sold for use in such Opt-In Indication in such Sale Country. \n",
      " \n",
      "(c) all Committees relating to such Permitted Indication shall be disbanded and Insmed shall have the full authority over all subsequent\n",
      "development and commercialization activities relating to such Product for such Permitted Indication; and \n",
      " \n",
      "(d) the breaching Party\n",
      "shall transfer to Insmed all materials obtained or developed in connection with the commercialization of a Product in such Permitted Indication, including without limitation, all Product (including samples), Product Labeling and Promotional\n",
      "Materials. \n",
      " \n",
      "12.5 Election to Keep Agreement or Indication in Effect Despite Right to Terminate and Consequences Thereof. If a\n",
      "non-breaching Party has the right to terminate this \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "49 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "Agreement in its entirety pursuant to this Article 12 due to an uncured Material Breach with respect to more than one (1) Permitted Indications by a\n",
      "breaching Party, such non-breaching Party may nonetheless elect not to terminate the Agreement in its entirety, in which event: \n",
      " \n",
      "(a)\n",
      "the Permanent Injunction shall remain in full force and effect; and \n",
      " \n",
      "(b) the Agreement shall continue in full force and effect\n",
      "except that to the extent the breaching Party is an Opt-In Party who has materially breached the Agreement by failing to co-fund the Development Costs of a Product for a particular Opt-In Indication, such Opt-In Party shall no longer have such right\n",
      "to continue to co-fund such Development Costs, and the Percentage Interest of such Opt-In Party in such Opt-In Indication shall be reduced to a portion equal to the result of the following formula: \n",
      " \n",
      " \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "50%  x\n",
      " \n",
      "[\n",
      "  \n",
      "Development Costs actually funded by Opt-In Party prior to the date of the Material Breach\n",
      "  \n",
      "]\n",
      "\n",
      " \n",
      "\n",
      "  \n",
      "50% x (Total Development Costs incurred by the Opt-In Party and Insmed to obtain regulatory approval of such Product in the given country at issue)\n",
      "  \n",
      "\n",
      " \n",
      "The profit-sharing arrangement (as adjusted pursuant to the formula in this Section 12.5(b) shall continue\n",
      "only until the payments so received by the Opt-In Party equal the Development Costs actually incurred by such breaching Opt-In Party for a Product for such Opt-In Indication (the formula provided in this Section 12.5(b) shall be interpreted\n",
      "based on the same principle set forth in the illustration in Section 12.3(b)(ii)(3)), and thereafter the profit share arrangement for such Opt-In Indication shall terminate and the sales for such Opt-In Indication shall be subject to the\n",
      "royalty payments set forth in Section 7.1(a)(ii) as if such Opt-In Indication was not an Opt-In Indication. \n",
      " \n",
      "In addition, such election not to so\n",
      "terminate the Agreement shall not constitute a waiver or release of, or otherwise be deemed to prejudice or adversely affect, any rights, remedies or claims, whether for damages or otherwise, that the non-breaching Party may have hereunder or that\n",
      "may arise out of or in connection with such Material Breach by the breaching Party. \n",
      " \n",
      "12.6 Other Remedies. Termination or expiration\n",
      "of this Agreement for any reason shall not release any Party from any liability or obligation that already has accrued prior to such expiration or termination, nor affect the survival of any provision hereof to the extent it is expressly stated to\n",
      "survive such termination. Termination or expiration of this Agreement for any reason shall not constitute a waiver or release of, or otherwise be deemed to prejudice or adversely affect, any rights, remedies or claims, whether for damages or\n",
      "otherwise, that a Party may have hereunder or that may arise out of or in connection with such termination or expiration. \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "50 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "ARTICLE 13 \n",
      " \n",
      "DISPUTE RESOLUTION \n",
      " \n",
      "Any dispute, controversy or claim arising out of or relating to this Agreement,\n",
      "or the breach or termination thereof, shall be settled as follows: \n",
      " \n",
      "13.1 Reference to Executives. Except as set forth in\n",
      "Section 5.5(d) with respect to disputes involving sales tracking, in the event of a significant controversy, claim, or dispute arising out of or relating to this Agreement or any significant breach thereof (hereinafter collectively referred to\n",
      "as a “Dispute”), the Parties agree that the Dispute shall be described in writing by one or all of the Parties and copies of the description(s) shall be sent to the General Counsel of Insmed, the General Counsel of Tercica, and the\n",
      "General Counsel of GNE. These General Counsels (or their designees or equivalents who have decision-making authority) will then have thirty (30) days from receipt of such Dispute description to attempt in good faith to resolve the Dispute. In\n",
      "the event that the Dispute is not resolved within this thirty (30) day time period, then any Party can proceed to arbitration of the Dispute, as described in Section 13.2, or to litigation, as described in Section 13.3. \n",
      " \n",
      "13.2 Arbitration. Subject to Section 13.3, the Parties agree that any Dispute shall be resolved through negotiation. If a Dispute arises\n",
      "between the Parties, and if said Dispute cannot be resolved pursuant to Section 13.1 (and such Dispute does not relate to a patent) then any such Dispute, including, without limitation, the interpretation, enforceability, performance, breach,\n",
      "termination or validity hereof, including, without limitation, this arbitration clause, shall be solely and finally settled by arbitration in the manner specified in this Section 13.2. All arbitration proceedings shall be conducted in the San\n",
      "Francisco Bay Area or such other location as is mutually agreed to by the Parties. The arbitration proceedings shall be conducted under the procedural rules of the American Arbitration Association or such other forum as is mutually agreed to by the\n",
      "Parties. The Party requesting arbitration shall serve upon the other Party a written demand for arbitration stating the substance of the Dispute, and the contention of the Party requesting arbitration. Within sixty (60) days after the demand,\n",
      "the Parties shall select three (3) arbitrators as follows: each Party shall designate one arbitrator, and those two arbitrators shall designate a third. The decision of the arbitrators shall be in writing setting forth the basis therefor. The\n",
      "arbitrators shall have the authority to award such remedies as they believe are appropriate in the circumstances, including, but not limited to, compensatory damages, interest, tort damages (but not consequential and incidental damages or punitive\n",
      "or similar damages) and specific performance and other equitable relief. The Parties shall abide by the award rendered in such arbitration proceeding, and such award may be entered, enforced and executed upon in the United States District Court for\n",
      "the Northern District of California. The Parties shall divide equally the administrative charges, arbitrators’ fees and related expenses of arbitration, but each Party shall pay its own attorney’s fees incurred in connection with such\n",
      "arbitration; provided however, if the arbitrators specifically determine that one Party prevailed clearly and substantially over the other Party, then the arbitrators may require that the non-prevailing Party shall also pay the prevailing\n",
      "Party’s reasonable attorney’s fees and expert witness costs and arbitration costs. \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "51 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "13.3 Patent Dispute Resolution. Any dispute, controversy or claim relating to the scope, validity,\n",
      "enforceability or infringement of any Licensed Patents or Insmed Patents covering the manufacture, use or sale of any Product shall be submitted to a court of competent jurisdiction. \n",
      " \n",
      "13.4 Governing Law. In the event that a Dispute is not resolved though discussion of the executives pursuant to Section 13.1, as provided\n",
      "above, the laws of California shall apply to any arbitration or litigation under this Agreement (regardless of its or any other jurisdiction’s choice of law principles), provided that matters of intellectual property law shall be\n",
      "determined in accordance with the national intellectual property laws relevant to the intellectual property in question. For any disputes, arbitrations or litigation under this Agreement, each Party hereby consents to personal jurisdiction and venue\n",
      "in the United States District Court for the Northern District of California, and agrees to service of process issued or authorized by such Court. \n",
      " \n",
      "13.5 Restraining Order. The dispute resolution procedures set forth herein shall not limit a court from granting a temporary restraining order or a preliminary injunction in order to preserve the status quo of the Parties’\n",
      "pending arbitration or to protect a Party’s trademark or confidential or proprietary information. Further, the arbitrator shall have power to enter such orders by way of interim award, and such orders shall be enforceable in court. \n",
      "\n",
      "ARTICLE 14 \n",
      " \n",
      "MISCELLANEOUS\n",
      " \n",
      "14.1 Entire Agreement; Amendment. This Agreement, including the Exhibits hereto, sets forth the complete, final and exclusive\n",
      "agreement and all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties hereto with respect to the subject matter hereof and supersedes, as of the Effective Date, all prior agreements and\n",
      "understandings between the Parties with respect to the subject matter hereof. There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties other than as are set\n",
      "forth herein and therein. Notwithstanding the foregoing, and for the avoidance of doubt, the Permanent Injunction and the UK Proceedings Settlement shall remain in full force and effect and shall not be superseded by this Agreement. No subsequent\n",
      "alteration, amendment, change or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by an authorized officer of each Party. \n",
      " \n",
      "14.2 Notices. Any notice required or permitted to be given under this Agreement shall be in writing, shall specifically refer to this Agreement, and shall be addressed to the appropriate Party at the address\n",
      "specified below or such other address as may be specified by such Party in writing in accordance with this Section 14.2, and shall be deemed to have been given for all purposes (a) when received, if hand-delivered or sent by a reputable\n",
      "overnight delivery service, or (b) five (5) business days after mailing, if mailed by first class certified or registered mail, postage prepaid, return receipt requested. \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "52 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "If to Tercica:\n",
      "    \n",
      "Tercica, Inc.\n",
      "\n",
      "    \n",
      "2000 Sierra Point Parkway\n",
      "\n",
      "    \n",
      "Suite 400\n",
      "\n",
      "    \n",
      "Brisbane, CA 94005\n",
      "\n",
      "    \n",
      "Attention: General Counsel\n",
      "\n",
      "\n",
      "With a copy to:\n",
      "    \n",
      "Cooley Godward Kronish LLP\n",
      "\n",
      "    \n",
      "Five Palo Alto Square\n",
      "\n",
      "    \n",
      "3000 El Camino Real\n",
      "\n",
      "    \n",
      "Palo Alto, CA 94306\n",
      "\n",
      "    \n",
      "Attention: Barbara A. Kosacz, Esq.\n",
      "\n",
      "\n",
      "With a copy to:\n",
      "    \n",
      "McDermott Will & Emery LLP\n",
      "\n",
      "    \n",
      "3150 Porter Drive\n",
      "\n",
      "    \n",
      "Palo Alto, CA 94304-1212\n",
      "\n",
      "    \n",
      "Attention: William G. Gaede III, Esq.\n",
      "\n",
      "\n",
      "If to Insmed:\n",
      "    \n",
      "Insmed Incorporated\n",
      "\n",
      "    \n",
      "8720 Stony Point Parkway\n",
      "\n",
      "    \n",
      "Suite 200\n",
      "\n",
      "    \n",
      "Richmond, VA 23235\n",
      "\n",
      "    \n",
      "Attention: Chief Executive Officer\n",
      "\n",
      "\n",
      "With a copy to:\n",
      "    \n",
      "Goodwin Procter LLP\n",
      "\n",
      "    \n",
      "Exchange Place\n",
      "\n",
      "    \n",
      "53 State Street\n",
      "\n",
      "    \n",
      "Boston, MA 02109\n",
      "\n",
      "    \n",
      "Attention: Mitchell Bloom, Esq.\n",
      "\n",
      "\n",
      "If to GNE:\n",
      "    \n",
      "Genentech, Inc.\n",
      "\n",
      "    \n",
      "1 DNA Way\n",
      "\n",
      "    \n",
      "South San Francisco, CA 94080\n",
      "\n",
      "    \n",
      "Attention: General Counsel\n",
      "\n",
      "\n",
      "With a copy to:\n",
      "    \n",
      "Heller Ehrman LLP\n",
      "\n",
      "    \n",
      "333 Bush Street\n",
      "\n",
      "    \n",
      "San Francisco, CA 94104\n",
      "\n",
      "    \n",
      "Attention: M. Patricia Thayer, Esq.\n",
      " \n",
      "14.3 No Strict Construction; Headings. This Agreement has been prepared jointly and shall\n",
      "not be strictly construed against any Party. Ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision. Wherever used herein, the terms\n",
      "“includes” and “including” mean includes without limitation and including without limitation, respectively. The headings of each Article and Section in this Agreement have been inserted for convenience of reference only and are\n",
      "not intended to limit or expand on the meaning of the language contained in the particular Article or Section. \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "53 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "14.4 Assignment. None of the Parties may assign or transfer this Agreement or any rights or\n",
      "obligations hereunder without the prior written consent of the other Parties, except that a Party may make such an assignment without the other Parties’ consent to Affiliates or to a successor to substantially all of the business of such Party\n",
      "in the field to which this Agreement relates, whether in a merger, sale of stock, sale of assets or other transaction. Any permitted successor or assignee of rights and/or obligations hereunder shall, in a writing to each of the other Parties,\n",
      "expressly assume performance of such rights and/or obligations. Any permitted assignment shall be binding on the successors of the assigning Party. Any assignment or attempted assignment by any Party in violation of the terms of this\n",
      "Section 14.4 shall be null, void and of no legal effect. Notwithstanding the aforesaid, to the extent such assignment of rights is permitted in any section of this Agreement other than this Section 14.4, Ipsen shall be considered a\n",
      "permitted assignee of Tercica. \n",
      " \n",
      "14.5 Performance by Affiliates. Each Party may discharge any obligations and exercise any right\n",
      "hereunder through any of its Affiliates. Each Party hereby guarantees the performance by its Affiliates of such Party’s obligations under this Agreement, and shall cause its Affiliates to comply with the provisions of this Agreement in\n",
      "connection with such performance. Any breach by a Party’s Affiliate of any of such Party’s obligations under this Agreement shall be deemed a breach by such Party, and the other Party may proceed directly against such Party without any\n",
      "obligation to first proceed against such Party’s Affiliate. \n",
      " \n",
      "14.6 Further Actions. Each Party agrees to execute, acknowledge\n",
      "and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. \n",
      " \n",
      "14.7 Severability. If any one or more of the provisions of this Agreement is held to be invalid or unenforceable by any court of competent jurisdiction from which no appeal can be or is taken, the provision\n",
      "shall be considered severed from this Agreement and shall not serve to invalidate any remaining provisions hereof. The Parties shall make a good faith effort to replace any invalid or unenforceable provision with a valid and enforceable one such\n",
      "that the objectives contemplated by the Parties when entering this Agreement may be realized. \n",
      " \n",
      "14.8 No Waiver. Any delay in\n",
      "enforcing a Party’s rights under this Agreement or any waiver as to a particular default or other matter shall not constitute a waiver of such Party’s rights to the future enforcement of its rights under this Agreement, except with respect\n",
      "to an express written and signed waiver relating to a particular matter for a particular period of time. \n",
      " \n",
      "14.9 Independent\n",
      "Contractors. Each Party shall act solely as an independent contractor, and nothing in this Agreement shall be construed to give any Party the power or authority to act for, bind, or commit any other Party in any way. Nothing herein shall be\n",
      "construed to create the relationship of partners, principal and agent, or joint-venture partners between the Parties. \n",
      " \n",
      "14.10\n",
      "Counterparts. This Agreement may be executed in one (1) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "54 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "Signature Page To Follow \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "55 \n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED\n",
      "BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES\n",
      "AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE\n",
      "ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "IN WITNESS WHEREOF, the Parties have executed this\n",
      "Settlement, License and Development Agreement in duplicate originals by their duly authorized officers as of the Effective Date. \n",
      " \n",
      " \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "TERCICA, INC.\n",
      " \n",
      "\n",
      " \n",
      "INSMED INCORPORATED\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "By:\n",
      " \n",
      "/s/ Stephen N. Rosenfield\n",
      " \n",
      "\n",
      " \n",
      "By:\n",
      " \n",
      "/s/ Geoffrey Allan\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Name: \n",
      " \n",
      "Stephen N. Rosenfield\n",
      " \n",
      "\n",
      " \n",
      "Name: \n",
      " \n",
      "Geoffrey Allan\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Title:\n",
      " \n",
      "Executive Vice President Legal Affairs, General Counsel and Secretary\n",
      " \n",
      "\n",
      " \n",
      "Title:\n",
      " \n",
      "President and CEO\n",
      "\n",
      "\n",
      "\n",
      "GENENTECH, INC.\n",
      " \n",
      "\n",
      " \n",
      "INSMED THERAPEUTIC PROTEINS, INC.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "By:\n",
      " \n",
      "/s/ Joseph S. McCracken\n",
      " \n",
      "\n",
      " \n",
      "By:\n",
      " \n",
      "/s/ Geoffrey Allan\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Name: \n",
      " \n",
      "Joseph S. McCracken\n",
      " \n",
      "\n",
      " \n",
      "Name: \n",
      " \n",
      "Geoffrey Allan\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Title:\n",
      " \n",
      "VP Business Development\n",
      " \n",
      "\n",
      " \n",
      "Title:\n",
      " \n",
      "President and CEO\n",
      "\n",
      "\n",
      "\n",
      "CELTRIX PHARMACEUTICALS, INC.\n",
      " \n",
      "\n",
      " \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "By:\n",
      " \n",
      "/s/ Geoffrey Allan\n",
      " \n",
      "\n",
      " \n",
      "\n",
      " \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Name: \n",
      " \n",
      "Geoffrey Allan\n",
      " \n",
      "\n",
      " \n",
      "\n",
      " \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Title:\n",
      " \n",
      "President and CEO\n",
      " \n",
      "\n",
      " \n",
      "\n",
      " \n",
      "\n",
      " \n",
      "Signature Page to Settlement, License and Development Agreement \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL\n",
      "INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED\n",
      "AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO\n",
      "RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "EXHIBITS \n",
      " \n",
      "Exhibit A – Financial Appendix \n",
      " \n",
      "Exhibit B – Form of Consent Judgment and Permanent Injunction \n",
      " \n",
      "Exhibit C – Form of UK Proceedings Settlement Agreement \n",
      " \n",
      "Exhibit D – Joint Letter to Physicians \n",
      " \n",
      "Exhibit E – Co-Promotion Agreement Terms and Conditions \n",
      " \n",
      "Exhibit F – Joint Press Release \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL\n",
      "INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED\n",
      "AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO\n",
      "RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "EXHIBIT A \n",
      " \n",
      "FINANCIAL APPENDIX \n",
      " \n",
      "This Exhibit A to the Agreement sets forth\n",
      "financial planning, accounting policies and procedures to be followed in determining Operating Profit (Loss) and related sharing of revenue and expenses for a Product for an Opt-In Indication and for calculating Net Sales for purposes of\n",
      "Section 7.1. Except as required for calculating Net Sales for purposes of Section 7.1, the terms and conditions set forth in this Exhibit A shall apply following the exercise of a Party’s Opt-In rights until the exercise by the Opt-In\n",
      "Party of the Opt-In Party’s Opt-Out rights, if any, to the sales of a Product for the Opt-In Indication in the Territory. \n",
      " \n",
      "The contents of this\n",
      "Exhibit A are hereby incorporated into the Agreement and are governed by the terms and conditions of the Agreement, including the confidentiality provisions set forth therein. \n",
      " \n",
      "A.1 Principles of Reporting. \n",
      " \n",
      "The presentation of budgets and results of operations of Insmed and the Opt-In Party\n",
      "in the Territory will be based on each Party’s respective financial information presented separately and on a consolidated basis using the following schema (financial terms are defined further below): \n",
      " \n",
      "Gross Sales \n",
      " \n",
      "less Sales Returns &\n",
      "Allowances \n",
      " \n",
      "= Actual Sales \n",
      " \n",
      "less Cost of Sales (which includes FBMC) \n",
      " \n",
      "less Distribution Costs (which includes Allocable Overhead) \n",
      " \n",
      "less G&A Costs \n",
      " \n",
      "less Other Operating\n",
      "Income/Expense \n",
      " \n",
      "less Development Costs (which includes Allocable Overhead) \n",
      " \n",
      "less Selling and Marketing Costs (which includes Allocable Overhead) \n",
      " \n",
      "= Operating Profit (Loss) \n",
      " \n",
      "The types of costs in this schema are to be grouped together as follows: \n",
      " \n",
      " \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "DIRECT COSTS\n",
      " \n",
      "NON-DIRECT COSTS\n",
      " \n",
      "TERMS FOR CALCULATING\n",
      "Cost of Sales\n",
      " \n",
      "Allocable Overhead\n",
      " \n",
      "Operating Profit (Loss)\n",
      "Development Costs\n",
      " \n",
      "G&A Costs\n",
      " \n",
      "Gross Sales\n",
      "Distribution Costs\n",
      " \n",
      "\n",
      " \n",
      "Sales Returns & Allowances\n",
      "FBMC\n",
      " \n",
      "\n",
      " \n",
      "\n",
      "Other Operating Income/Expense\n",
      " \n",
      "\n",
      " \n",
      "\n",
      "Selling and Marketing Costs\n",
      " \n",
      "\n",
      " \n",
      "\n",
      " \n",
      " \n",
      "\n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL\n",
      "INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED\n",
      "AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO\n",
      "RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "If necessary, a Party will make the appropriate adjustments to the financial information it supplies under the Agreement\n",
      "to conform to the above format of reporting results of operations. \n",
      " \n",
      "Accounting and Cost Categories. Definitions of the various categories of\n",
      "revenues, costs and expenses included in Operating Profit (Loss) shall be interpreted in accordance with GAAP. Any costs included in the calculation under one cost category may not be included in the calculation of another cost category. Where the\n",
      "terms of this Financial Appendix would permit inclusion of a cost within more than one cost category, that cost will be allocated to a single cost category consistent with GAAP and the other provisions of this Agreement. Any cost included in this\n",
      "calculation shall only include costs directly or indirectly (to the extent allowed and consistent with the definitions for this Financial Appendix) allocable to a Product for the Opt-In Indication in accordance with GAAP. \n",
      " \n",
      "References to “Collaboration.” References in this Financial Appendix to the “Collaboration” are references to those activities related\n",
      "to a Product that would form the basis for Operating Profit (Loss) under this Agreement. The Parties may consolidate accounting of operations related to Product for the specific Opt-In Indication, and the activities subject to that consolidated\n",
      "accounting also will be referred to as the “Collaboration.” Where the same Parties are Collaborating on more than one Opt-In Indication, the accounting of operations related to a Product for all such Opt-In Indications may be consolidated.\n",
      "However, the Collaboration is not a legal entity for financial accounting, income tax reporting or any other purposes \n",
      " \n",
      "A.2 Frequency of\n",
      "Reporting. \n",
      " \n",
      "The fiscal year for the Collaboration will be a calendar year. \n",
      " \n",
      "Each of Insmed and the Opt-In Party is responsible for providing the other Party reports as set forth in the table below, for activities for which it is\n",
      "responsible and costs it incurred and revenue obtained that forms a component of Operating Profit (Loss) for Product for the Opt-In Indication(s). \n",
      " \n",
      "Reporting will be at the times set forth in the following Report Table, with submissions due on the date indicated or the next business day if such date is a weekend or U.S. holiday: \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL\n",
      "INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED\n",
      "AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO\n",
      "RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Report\n",
      "  \n",
      "Frequency\n",
      "  \n",
      "Responsible Party\n",
      "  \n",
      "Timing of Submission\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Non-Booking Party monthly Actual Sales (actual numbers)\n",
      "  \n",
      "Monthly\n",
      "  \n",
      "Non-Booking Party\n",
      "  \n",
      "+ 5 days after the end of such month\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Non-Booking Party quarterly Operating Profit (Loss)\n",
      "•   For the first three quarters in the calendar year: report to include actual numbers for the first two months of the then current calendar quarter, and forecasted numbers for the last month of the then current calendar quarter for planning.\n",
      "•   For the last quarter of the calendar year, the report should include the actual numbers for the first 11 months of such calendar year and the forecasted numbers for the last month of such calendar year for planning\n",
      "  \n",
      "Quarterly\n",
      "  \n",
      "Non-Booking Party\n",
      "  \n",
      "Q1-Q4: + 75 days after the beginning of such calendar quarter\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Consolidated quarterly Operating Profit (Loss)\n",
      "•   For the first three quarters in the calendar year: report to include actual numbers for the first two months of the then current calendar quarter, and forecasted numbers for the last month of the then current calendar quarter for planning.\n",
      "•   For the last quarter of the calendar year, the report should include the actual numbers for the first 11 months of such calendar year and the forecasted numbers for the last month of such calendar year for planning\n",
      "  \n",
      "Quarterly\n",
      "  \n",
      "Booking Party\n",
      "  \n",
      "Q1-Q4: + 85 days after the beginning of such calendar quarter (for the last quarter, the report should reflect the actual numbers for the first 11 months of such calendar year and the forecasted numbers for the last month of such calendar year)\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Non-Booking Party quarterly Operating Profit (Loss) (actual numbers)\n",
      "  \n",
      "Quarterly\n",
      "  \n",
      "Non-Booking Party\n",
      "  \n",
      "Q1-Q4: + 15 days after the end of such calendar quarter\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Draft of consolidated Operating Profit (Loss) (based on actual numbers)\n",
      "  \n",
      "Quarterly\n",
      "  \n",
      "Booking Party\n",
      "  \n",
      "Quarter end +30 days\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Final of consolidated Operating Profit (Loss) (based on actual numbers)\n",
      "  \n",
      "Quarterly\n",
      "  \n",
      "Booking Party\n",
      "  \n",
      "Quarter end +60 days\n",
      " \n",
      "The Parties may agree to modify the foregoing reporting cycles and deadlines. In the event that a Party\n",
      "substantially or materially changes its internal reporting cycles and deadlines generally, then the Parties shall discuss, in good faith, appropriate revisions to the foregoing reporting cycles and deadlines to reasonably accommodate such change.\n",
      " \n",
      "The Party responsible for booking sales (the “Booking Party”) for the Opt-In Indications(s) at issue in accordance with Section 7.2(d)\n",
      "shall be responsible for the consolidated accounting of \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL\n",
      "INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED\n",
      "AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO\n",
      "RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "Operating Profit (Loss) for the Collaboration. Without limiting the Parties’ reporting obligations as set forth in the Report Table above, on a calendar\n",
      "quarterly basis, the Party that is not responsible for booking sales (the “Non-Booking Party”) in accordance with Section 7.2(d) will supply the Booking Party with a statement setting forth that quarter’s Operating Profit (Loss)\n",
      "obtained by the Non-Booking Party for the applicable Product for the Opt-In Indication, including the basis for calculation of such amounts. The Booking Party shall consolidate any Operating Profit (Loss) reported by the Non-Booking Party with those\n",
      "obtained directly by the Booking Party. Each such report shall be provided as early as possible, on the schedule in the chart above. \n",
      " \n",
      "Each Party will make\n",
      "available a financial representative to coordinate regarding financial aspects of planning, reporting and information sharing, at the request of the other Party. Upon the reasonable request of either Party, the other Party shall answer any question\n",
      "and address any comment from the other Party pertaining to such financial planning and reporting. \n",
      " \n",
      "A.3 Budgets. \n",
      " \n",
      "The Booking Party, through the JDC, will prepare a consolidated budget for Operating Profit (Loss) for the Collaboration on an annual basis; the\n",
      "Non-Booking Party, through the JDC, shall provide input for that budget regarding its sales force activities. \n",
      " \n",
      "Budgets are provided for information and\n",
      "planning purposes, including establishing the initial profit share ratio for the forthcoming calendar year; final sharing of Operating Profit (Loss) on a calendar year basis are based on actual amounts. The Party that is the Non-Booking Party shall\n",
      "not be required to fund an amount which is more than half of 110% of the budgeted amount for such expenditure without its prior written consent to such variance from budget. \n",
      " \n",
      "A.4 Financial Appendix Definitions. \n",
      " \n",
      "[ * ] \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL\n",
      "INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED\n",
      "AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO\n",
      "RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "EXHIBIT B \n",
      " \n",
      "FORM OF CONSENT JUDGMENT AND PERMANENT INJUNCTION \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL\n",
      "INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED\n",
      "AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO\n",
      "RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "MCDERMOTT WILL & EMERY LLP \n",
      " \n",
      "WILLIAM G. GAEDE, III (136184) \n",
      " \n",
      "wgaede@mwe.com \n",
      " \n",
      "TERRENCE P. McMAHON (71910) \n",
      " \n",
      "tmcmahon@mwe.com \n",
      " \n",
      "ANDREW\n",
      "A. KUMAMOTO (178541) \n",
      " \n",
      "akumamoto@mwe.com \n",
      " \n",
      "DAVID L. LARSON\n",
      "(112342) \n",
      " \n",
      "dlarson@mwe.com \n",
      " \n",
      "3150 Porter Drive \n",
      " \n",
      "Palo Alto, CA 94304-1212 \n",
      " \n",
      "Telephone: (650) 813-5000 \n",
      " \n",
      "Facsimile: (650) 813-5100 \n",
      " \n",
      "Attorneys for Tercica, Inc.\n",
      " \n",
      "HELLER EHRMAN LLP \n",
      " \n",
      "M. PATRICIA THAYER (90818) \n",
      "\n",
      "patricia.thayer@hellerehrman.com \n",
      " \n",
      "ETHAN C. GLASS (216159) \n",
      " \n",
      "ethan.glass@hellerehrman.com \n",
      " \n",
      "333 Bush Street \n",
      " \n",
      "San Francisco, CA 94104-2878 \n",
      " \n",
      "Telephone: (415) 772-6794 \n",
      " \n",
      "Facsimile: (415) 772-6268 \n",
      " \n",
      "Attorneys for Genentech, Inc.\n",
      " \n",
      "UNITED STATES DISTRICT COURT \n",
      " \n",
      "NORTHERN DISTRICT OF CALIFORNIA \n",
      " \n",
      "OAKLAND DIVISION \n",
      " \n",
      " \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "GENENTECH, INC., a Delaware corporation,\n",
      "and TERCICA, INC., a Delaware corporation,\n",
      " \n",
      "Plaintiffs,\n",
      " \n",
      "v.\n",
      " \n",
      "INSMED INCORPORATED, a Virginia corporation, CELTRIX ",
      "PHARMACEUTICALS, INC., a Delaware corporation, and ",
      "INSMED THERAPEUTIC PROTEINS, a Colorado corporation,\n",
      " \n",
      "Defendants.\n",
      " \n",
      "  \n",
      "No. C-04-5429 CW (EMC)\n",
      " \n",
      "CONSENT JUDGMENT AND\n",
      "PERMANENT INJUNCTION\n",
      " \n",
      "AND RELATED COUNTERCLAIMS.\n",
      " \n",
      "  \n",
      "\n",
      " \n",
      " \n",
      "\n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL\n",
      "INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED\n",
      "AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO\n",
      "RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "RECITALS \n",
      " \n",
      "Whereas, Plaintiff Tercica, Inc. is the exclusive licensee of U.S. Patent No. 6,331,414 entitled “Preparation of Human IGF via Recombinant DNA Technology,” which issued to Plaintiff Genentech,\n",
      "Inc. as assignee of the inventors on December 18, 2001; \n",
      " \n",
      "Whereas, Plaintiff Tercica, Inc. is the exclusive licensee of U.S.\n",
      "Patent No. 5,187,151 entitled “Use of Binding Protein with IGF-1 as an Anabolic Growth Promoting Agent,” which issued to Plaintiff Genentech, Inc. as assignee of the inventors on February 16, 1993; \n",
      " \n",
      "Whereas, Plaintiff Tercica, Inc. is the exclusive licensee of U.S. Patent No. 5,258,287 entitled “DNA Encoding and Methods of Production\n",
      "of Insulin Like Growth Factor Binding Protein BP53,” which issued to, inter alia, Plaintiff Genentech, Inc., as assignee of the inventors on November 2, 1993; \n",
      " \n",
      "Whereas, on December 23, 2004, Plaintiffs Genentech, Inc. (GNE) and Tercica, Inc. (Tercica) filed this action against Insmed Incorporated\n",
      "Genentech Inc., et al. v. Insmed Incorporated, et al., United States District Court for the Northern District of California, Case No. 04-CV-05429-CW (EMC) (the “Lawsuit”). By operation of the Second Amended Complaint, Defendant\n",
      "Celtrix Pharmaceuticals, Inc. was added as a named defendant in the lawsuit. By operation of the Third Amended Complaint, Defendant Insmed Therapeutic Proteins was added as a named defendant to the Lawsuit. Plaintiffs alleged that Defendants’\n",
      "making, using, selling, offering to sell, import or export of the product known as IPLEX™, infringed or will infringe under 35 U.S.C. § 271(a) – (c) and (g) certain asserted claims of United States Patent Nos. 5,187,151 (the\n",
      "“‘151 Patent”), 5,258,287 (the “‘287 Patent”) and 6,331,414 (the “‘414 Patent”) (collectively, the “Asserted Patents”). \n",
      " \n",
      "Whereas, Defendants denied such allegations and further alleged, among other defenses, that the asserted claims of the Asserted Patents were\n",
      "invalid under various theories, including those arising under 35 U.S.C. §§ 102, 103, 112 and 135. Defendants further asserted that the ‘151 Patent was unenforceable for alleged inequitable conduct. \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL\n",
      "INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED\n",
      "AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO\n",
      "RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "Whereas, the parties had a full and fair opportunity to litigate the case, including full fact and\n",
      "expert discovery, and motion process, including claim construction, motions for summary judgment and other pretrial motions as reflected in the docket sheet. \n",
      " \n",
      "Whereas, the Court adjudicated as a matter of law on June 30, 2006 that Defendants’ method of making the rhIGF-I component of IPLEX™ literally infringed Claims 1 and 9 of the ‘414 Patent\n",
      "(Docket No. 510), and Defendants subsequently stipulated, subject to an appeal of the Court’s claim construction, that their method also literally infringed Claims 2, 3, 4 and 10 of the ‘414 Patent. \n",
      " \n",
      "Whereas, a jury trial commenced on November 6, 2006, that resulted in the Verdict Form (Docket No. 1006), filed December 6, 2006.\n",
      "The Jury found that Defendants Insmed and Insmed Therapeutic Proteins (“Insmed”) induced infringement of Claims 1, 4 and 5 of the ‘151 Patent, contributorily infringed Claims 1, 4 and 5 of the ‘151 Patent, and literally infringed\n",
      "Claims 1, 6-8 and 17 of the ‘287 Patent through the manufacture, distribution, sale, and/or offering to sell IPLEX™ in the United States as approved by the Food and Drug Administration. The Jury further found that Insmed had not proven\n",
      "that Claims 1-4, 9-10 of the ‘414 Patent were invalid under the enablement or written description requirement. The Jury further found that Insmed’s infringement of the ‘151 Patent was willful, and awarded damages to Tercica and GNE of\n",
      "$7.5 million plus the royalty rates assessed in the Verdict Form on sales of IPLEX™ through December 6, 2006 (the “Awarded Damages”). \n",
      " \n",
      "Whereas, following the verdict, Plaintiffs and Defendants made various post-trial motions, including Plaintiffs’ motion for a permanent injunction. \n",
      " \n",
      "Whereas, Plaintiffs and Defendants (the “Parties”) have entered into a Settlement, License and Development Agreement (“Settlement\n",
      "Agreement”), which is incorporated herein by reference, have withdrawn all pending motions, and have agreed to entry of this Consent Judgment and Permanent Injunction, subject to the Court’s approval. \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL\n",
      "INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED\n",
      "AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO\n",
      "RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "IT IS HEREBY FOUND, ADJUDICATED AND ORDERED: \n",
      " \n",
      "I. STIPULATED FINDINGS OF FACT/CONCLUSIONS OF LAW \n",
      " \n",
      "1. The Parties stipulate this is an action\n",
      "for patent infringement arising under the patent laws of the United States. \n",
      " \n",
      "2. The Parties stipulate jurisdiction of this Court is proper\n",
      "pursuant to 28 U.S.C. §§ 1331, 1332, and 1338(a). \n",
      " \n",
      "3. The Parties stipulate this Court has personal jurisdiction over\n",
      "Defendants, and each of them, and that venue is proper in this district. \n",
      " \n",
      "4. The Parties stipulate that all claims of the ‘414 Patent,\n",
      "the ‘151 Patent, and the ‘287 Patent are valid and enforceable. \n",
      " \n",
      "5. The Parties stipulate Defendants have infringed the\n",
      "above-recited asserted claims of the Asserted Patents. \n",
      " \n",
      "6. Defendants forever waive the right to assert and agree that they shall not ever\n",
      "assert in any court or administrative tribunal that any claim of the Asserted Patents is invalid and/or not enforceable. Defendants further agree that they will not voluntarily directly or indirectly aid, assert or participate in any action\n",
      "contesting the validity or enforceability of any of the Asserted Patents. \n",
      " \n",
      "7. The Parties stipulate that the ‘414 Patent is\n",
      "enforceable until December 18, 2018; that the ‘151 Patent is enforceable until February 12, 2011; and that the ‘287 Patent is enforceable until November 2, 2010. \n",
      " \n",
      "8. The Parties stipulate that Plaintiffs are irreparably harmed by, and have no adequate remedy at law for, Defendants’ infringement, and are\n",
      "entitled to a permanent injunction. \n",
      " \n",
      "9. The Parties stipulate that the balance of hardships regarding an injunction weighs in\n",
      "Plaintiffs’ favor. \n",
      " \n",
      "10. The Parties stipulate that the public interest does not preclude entry of a permanent injunction in this case.\n",
      " \n",
      " \n",
      "\n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL\n",
      "INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED\n",
      "AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO\n",
      "RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "11. The Parties stipulate to waive any right to appeal from this Consent Judgment and Permanent\n",
      "Injunction and agree to the exclusive and continuing jurisdiction of this Court to enforce this Consent Judgment and Permanent Injunction. \n",
      " \n",
      "12. The Parties stipulate that the Stipulated Protective Order (Docket No. 169) shall remain in force and effect with the exception of Paragraph 18(f), which is no longer effective. \n",
      " \n",
      "13. The Parties have voluntarily entered into the Settlement Agreement dated March 5, 2007 (which is incorporated herein by reference), subject to\n",
      "this Court’s approval. \n",
      " \n",
      "II. STIPULATED ORDER FOR PERMANENT INJUNCTION \n",
      " \n",
      "1. Except as expressly permitted below, and as set forth in the Settlement Agreement, Defendants INSMED INCORPORATED, CELTRIX PHARMACEUTICALS, INC., and\n",
      "INSMED THERAPEUTIC PROTEINS (collectively, “Defendants”), as well as each of their employees, agents, other representatives, officers, directors, stockholders, partners, members, subsidiaries, predecessors, successors, licensees,\n",
      "distributors, resellers, and assigns, and any persons acting in concert with any of them, are permanently enjoined, as of the date of this Order, from: \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "(a)\n",
      "making, using, selling, offering to sell, importing into, or exporting from, the United States, during the patent term of the ‘414 Patent, any product containing rhIGF-1 that is made using any of the methods claimed in the ‘414 Patent, including without limitation, the current manufacturing method for the rhIGF-I component of the product known as IPLEX™ (mecasermin rinfabate) that employs the plasmid identified as pPoP/tr41UQ-3c-rhIGF-I;\n",
      " \n",
      " \n",
      "\n",
      " \n",
      "(b)\n",
      "making, using, selling, offering to sell, importing into, or exporting from, the United States, during the patent term of the ‘287 Patent, any product containing rhIGFBP-3 that is made using any of the compositions and methods claimed in the ‘287 Patent, including without limitation, the DNA sequence Defendants currently use to manufacture the rhIGFBP-3 component of the product known as IPLEX™ (mecasermin rinfabate) found in the plasmid identified as pPop/met-rhIGFBP3; and\n",
      " \n",
      " \n",
      "\n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL\n",
      "INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED\n",
      "AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO\n",
      "RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "(c)\n",
      "using, or otherwise selling, offering to sell, distributing, inducing or otherwise contributing to the use of, in the United States during the term of the ‘151 Patent, any product or formulation that is administered in accordance with any of the claims of the ‘151 Patent, including, without limitation, IPLEX™ (mecasermin rinfabate), as currently approved by the Food and Drug Administration for commercial sale in the United States to treat severe primary IGFD.\n",
      " \n",
      "2. Notwithstanding the foregoing, Defendants may: \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "(a)\n",
      "conduct research and development or other activity involving mecasermin rinfabate, or any other product, that is protected from claims of patent infringement under 35 U.S.C. § 271(e)(1), unless otherwise prohibited in the Settlement Agreement;\n",
      " \n",
      " \n",
      "\n",
      " \n",
      "(b)\n",
      "make, use, sell, offer to sell, import into, or export from, the United States, mecasermin rinfabate to the extent expressly permitted pursuant to (and in accordance with the requirements of) the grants in Article 3 of the Settlement Agreement.\n",
      " \n",
      "3. Any violation of this Order for Permanent\n",
      "Injunction may be punishable by civil contempt or other appropriate proceedings, and the Court retains jurisdiction over this matter and over the Parties with the power to adjudicate any such alleged violation. \n",
      " \n",
      "III. STIPULATED FINAL JUDGMENT \n",
      " \n",
      "1. Based on\n",
      "the Parties’ stipulated findings above, the Court finds as fact and/or conclusions of law the statements in Paragraphs 1 through 13 of Section I above. \n",
      " \n",
      "2. Judgment is hereby entered for Plaintiffs and against Defendants. \n",
      " \n",
      "3. Defendants are permanently\n",
      "enjoined in accordance with Section II above. \n",
      " \n",
      "4. In accordance with the terms of the Settlement Agreement, none of the Parties shall\n",
      "recover any damages, including the Awarded Damages, costs, or attorney’s fees, and each side shall bear its own costs and attorney’s fees. Any further costs associated with obtaining this Judgment shall be assumed by the side incurring\n",
      "them. \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL\n",
      "INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED\n",
      "AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO\n",
      "RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "5. This Judgment constitutes a final judgment that fully concludes and disposes of the claims and\n",
      "defenses in this litigation, and Plaintiffs and Defendants shall be subject to the full legal effects of issue preclusion, claim preclusion, res judicata, and collateral estoppel. The Parties and this Court explicitly intend such issue\n",
      "preclusion, claim preclusion, res judicata, and collateral estoppel to extend and apply to any issues of infringement, validity, inventorship, and enforceability regarding any of the claims of the ‘414 Patent, the ‘151 Patent and\n",
      "the ‘287 Patent raised in any subsequent court or administrative proceeding and regardless of the product or process at issue. \n",
      " \n",
      "6.\n",
      "This Court retains exclusive jurisdiction over the parties and over this action for purposes of ensuring compliance with this Consent Judgment and Permanent Injunction, and to enforce the Settlement Agreement. The Settlement Agreement, incorporated\n",
      "herein by reference, shall be filed with the Court under seal. \n",
      " \n",
      "7. No appeal shall be taken by any party from this Consent Judgment and\n",
      "Permanent Injunction, the right to appeal having been expressly waived by all parties. \n",
      " \n",
      "8. This Consent Judgment and Permanent Injunction\n",
      "may be modified by written agreement of the parties, subject to Court approval. \n",
      " \n",
      "The Clerk is directed to enter this Consent Judgment and\n",
      "Permanent Injunction forthwith. \n",
      " \n",
      "IT IS SO ORDERED. \n",
      " \n",
      " \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "DATED:\n",
      " \n",
      "                            , 2007.\n",
      " \n",
      "\n",
      " \n",
      "\n",
      "\n",
      " \n",
      "\n",
      " \n",
      "\n",
      " \n",
      "HONORABLE CLAUDIA WILKEN\n",
      "\n",
      " \n",
      "\n",
      " \n",
      "\n",
      " \n",
      "United States District Court Judge\n",
      " \n",
      " \n",
      "\n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL\n",
      "INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED\n",
      "AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO\n",
      "RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Consented to on behalf of Plaintiffs:\n",
      " \n",
      "\n",
      " \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "DATED:\n",
      " \n",
      "March 5, 2007\n",
      " \n",
      "\n",
      " \n",
      "\n",
      " \n",
      "MCDERMOTT WILL & EMERY LLP\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      " \n",
      "\n",
      " \n",
      "By:\n",
      " \n",
      "  \n",
      "\n",
      " \n",
      "\n",
      " \n",
      "\n",
      " \n",
      "\n",
      " \n",
      "William G. Gaede, III\n",
      " \n",
      "Attorneys for Tercica, Inc.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      " \n",
      "\n",
      " \n",
      "HELLER EHRMAN LLP\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      " \n",
      "\n",
      " \n",
      "By:\n",
      " \n",
      "  \n",
      "\n",
      " \n",
      "\n",
      " \n",
      "\n",
      " \n",
      "\n",
      " \n",
      " \n",
      "M. Patricia Thayer\n",
      " \n",
      "Attorneys for Genentech, Inc\n",
      "\n",
      "\n",
      "\n",
      "Consented to on behalf of Defendants:\n",
      " \n",
      "\n",
      " \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "DATED:\n",
      " \n",
      "March 5, 2007\n",
      " \n",
      "\n",
      " \n",
      "\n",
      " \n",
      "FOLEY & LARDNER LLP\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      " \n",
      "\n",
      " \n",
      "By:\n",
      " \n",
      "  \n",
      "\n",
      " \n",
      "\n",
      " \n",
      "\n",
      " \n",
      "\n",
      " \n",
      "Larry L. Shatzer\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      " \n",
      "\n",
      " \n",
      "HOWREY LLP\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      " \n",
      "\n",
      " \n",
      "By:\n",
      " \n",
      "  \n",
      "\n",
      " \n",
      "\n",
      " \n",
      "\n",
      " \n",
      "\n",
      " \n",
      " \n",
      "Henry Bunsow\n",
      " \n",
      " \n",
      "\n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL\n",
      "INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED\n",
      "AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO\n",
      "RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "Attorneys for Insmed Incorporated, Celtrix Pharmaceuticals, Inc., and Insmed\n",
      "Therapeutic Proteins, Inc \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL\n",
      "INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED\n",
      "AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO\n",
      "RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "EXHIBIT C \n",
      " \n",
      "FORM OF UK PROCEEDINGS SETTLEMENT AGREEMENT \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL\n",
      "INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED\n",
      "AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO\n",
      "RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "SETTLEMENT AGREEMENT \n",
      " \n",
      "THIS AGREEMENT is made on the            day of March 2007 \n",
      " \n",
      "BETWEEN: \n",
      " \n",
      " \n",
      "\n",
      "(1)\n",
      "Tercica, Inc., a company incorporated under the laws of Delaware with offices at 2000 Sierra Point Parkway, Suite 400, Brisbane, CA 94005, United States of America (“Tercica”);\n",
      " \n",
      " \n",
      "\n",
      "(2)\n",
      "Genentech, Inc., a company incorporated under the laws of Delaware with offices at 1 DNA Way, South San Francisco, California 94080 (“Genentech”);\n",
      " \n",
      " \n",
      "\n",
      "(3)\n",
      "Insmed Incorporated, a company incorporated under the laws of Virginia with offices at 8720 Stony Point Parkway, Suite 200, Richmond, VA 23235 (“Insmed”);\n",
      " \n",
      " \n",
      "\n",
      "(4)\n",
      "Avecia Limited, a company incorporated under the laws of England and Wales, whose registered office is at PO Box 42, Hexagon Tower, Blackley, Manchester M9 8ZS, United Kingdom (“Avecia”); and\n",
      " \n",
      " \n",
      "\n",
      "(5)\n",
      "Avecia Biologics Limited, a company incorporated under the laws of England and Wales, whose registered office is at PO Box 42, Hexagon Tower, Blackley, Manchester M9 8ZS, United Kingdom (“Avecia Biologics”).\n",
      " \n",
      "RECITALS \n",
      " \n",
      " \n",
      "\n",
      "(A)\n",
      "Legal proceedings have been commenced in England between the parties relating to European Patent (UK) No. 0 571 417 in the High Court of Justice under action numbers HC 04 C 03940 and HC 05 C 00415 (the “UK Proceedings”).\n",
      " \n",
      " \n",
      "\n",
      "(B)\n",
      "Related legal proceedings in the United States between Tercica, Genentech and Insmed have been settled by an agreement of even date, pursuant to which Tercica, Genentech and Insmed have agreed to discontinue the UK Proceedings and Insmed has agreed to procure on the part of Avecia such acts as may be necessary or desirable to achieve this.\n",
      " \n",
      " \n",
      "\n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL\n",
      "INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED\n",
      "AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO\n",
      "RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "(C)\n",
      "The parties have determined that it is in their mutual interest to avoid the expense, distraction, and uncertainty of further litigation and have therefore agreed to conclude and resolve all of their disputes under the UK Proceedings pursuant to the terms and conditions of this Agreement.\n",
      " \n",
      " \n",
      "\n",
      "(D)\n",
      "Avecia undertook a re-organisation of its group corporate structure in the UK, effective on 1st January 2007, which resulted in the transfer of the group’s biologics business (to which the UK Proceedings relate) from Avecia to Avecia Biologics.\n",
      " \n",
      "In consideration of the mutual covenants and promises set forth in this Agreement the parties AGREE as\n",
      "follows: \n",
      " \n",
      " \n",
      "\n",
      "1.\n",
      "Discontinuance of the UK Proceedings\n",
      " \n",
      " \n",
      "\n",
      "1.1\n",
      "The parties agree to discontinue the UK Proceedings with no order as to costs. The parties shall forthwith instruct their respective solicitors to approve, sign and then apply to the Court for a consent order in the form of the draft order attached as the Schedule to this Agreement (the “Consent Order”).\n",
      " \n",
      " \n",
      "\n",
      "1.2\n",
      "For the avoidance of doubt the Consent Order is without prejudice to costs which have already been paid by one party to another pursuant to any Order of the Court made prior to the date of this Agreement.\n",
      " \n",
      " \n",
      "\n",
      "1.3\n",
      "The parties shall do all such acts as may be necessary or desirable to obtain and give effect to the Consent Order.\n",
      " \n",
      " \n",
      "\n",
      "2.\n",
      "Settlement\n",
      " \n",
      " \n",
      "\n",
      "2.1\n",
      "This Agreement is in full and final settlement of the claims and counterclaims in the UK Proceedings.\n",
      " \n",
      " \n",
      "\n",
      "2.2\n",
      "Each party to this Agreement warrants to the others that it has not before the date of this Agreement assigned or transferred or purported to assign or transfer any claim or counterclaim (or any part thereof) relating to the UK Proceedings save in respect of the transfer from Avecia to Avecia Biologics referred to in Recital D.\n",
      " \n",
      " \n",
      "\n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL\n",
      "INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED\n",
      "AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO\n",
      "RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "2.3\n",
      "Without prejudice to the provisions of clause 2.1, Tercica and Genentech undertake to Avecia and Avecia Biologics that, in the event that Tercica and/or Genentech issues proceedings in respect of facts or matters not pleaded in the Particulars of Infringement in the UK Proceedings against Avecia and/or Avecia Biologics alleging infringement of European Patent (UK) No. 0 571 417, neither Tercica nor Genentech shall object, by reason of Avecia and Avecia Biologics having entered into this Agreement, to Avecia or Avecia Biologics alleging that European Patent (UK) No. 0 571 417 is invalid as a defence to or counterclaim for revocation in such infringement proceedings, or to Avecia or Avecia Biologics relying in any such defence or counterclaim on any of the objections raised in the Grounds of Invalidity served in the UK Proceedings.\n",
      " \n",
      " \n",
      "\n",
      "2.4\n",
      "Without prejudice to the provisions of clause 2.1, Avecia and Avecia Biologics undertake to Tercica and Genentech that they shall not object, by reason of Tercica and Genentech having entered into this Agreement, to Tercica and/or Genentech bringing proceedings in respect of facts or matters not pleaded in the Particulars of Infringement in the UK Proceedings against Avecia and/or Avecia Biologics alleging infringement of European Patent (UK) No. 0 571 417.\n",
      " \n",
      " \n",
      "\n",
      "2.5\n",
      "For the avoidance of doubt, neither Avecia nor Avecia Biologics shall commence revocation proceedings in respect of European Patent (UK) No. 0 571 417 other than as a defence to or counterclaim for revocation in the infringement proceedings described in clause 2.3.\n",
      " \n",
      " \n",
      "\n",
      "3.\n",
      "Confidentiality\n",
      " \n",
      " \n",
      "\n",
      "    \n",
      "The terms of this Agreement and the discussions, correspondence and negotiations leading to the making of this Agreement shall remain confidential to the parties who, save as expressly permitted by the terms of this Agreement, shall not disclose the terms of settlement to any other person except:\n",
      " \n",
      " \n",
      "\n",
      " \n",
      "(a)\n",
      "to the auditors and to the legal and other professional advisers of that party;\n",
      " \n",
      " \n",
      "\n",
      " \n",
      "(b)\n",
      "to the Court in connection with any future legal proceedings between the parties (or any of them);\n",
      " \n",
      " \n",
      "\n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL\n",
      "INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED\n",
      "AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO\n",
      "RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "(c)\n",
      "where that party is under a legal or regulatory obligation to make such disclosure, but limited to the extent of that obligation;\n",
      " \n",
      " \n",
      "\n",
      " \n",
      "(d)\n",
      "with the prior written consent of the other parties to this Agreement;\n",
      " \n",
      " \n",
      "\n",
      " \n",
      "(e)\n",
      "by a party to its employees or agents provided that the party making such disclosure ensures that the employees/agents (as the case may be) are made aware of and required to observe the provisions of this clause.\n",
      " \n",
      " \n",
      "\n",
      "4.\n",
      "General Provisions\n",
      " \n",
      " \n",
      "\n",
      "4.1\n",
      "The headings in this Agreement are solely for reference and shall not affect its interpretation.\n",
      " \n",
      " \n",
      "\n",
      "4.2\n",
      "This Agreement sets out the entire agreement and understanding between the parties in relation to its subject matter. Each of the parties acknowledges that no representation has been relied upon by that party in connection with or in relation to the settlement to which this Agreement gives effect.\n",
      " \n",
      " \n",
      "\n",
      "4.3\n",
      "This Agreement shall be binding on the parties, their successors and assigns and the name of a party appearing herein shall be deemed to include the names of any such successor or assign.\n",
      " \n",
      " \n",
      "\n",
      "4.4\n",
      "This Agreement may be executed in any number of counterparts, all of which, taken together, shall constitute one and the same agreement and any party may enter into this Agreement by executing a counterpart.\n",
      " \n",
      " \n",
      "\n",
      "4.5\n",
      "This Agreement shall be governed by and shall be construed in accordance with English law and the courts of England shall have exclusive jurisdiction to determine any dispute between the parties regarding the construction and application of this Agreement.\n",
      " \n",
      "IN WITNESS of which this Agreement has been signed\n",
      "by and on behalf of the parties effective as of the date first written above. \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL\n",
      "INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED\n",
      "AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO\n",
      "RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "SCHEDULE \n",
      " \n",
      "DRAFT CONSENT ORDER \n",
      " \n",
      " \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "                            (i)\n",
      "  \n",
      "\n",
      "IN THE HIGH COURT OF JUSTICE\n",
      "  \n",
      "HC 04 C 03940    \n",
      " \n",
      "CHANCERY DIVISION \n",
      " \n",
      "PATENTS COURT \n",
      " \n",
      "{The Honourable Mr Justice\n",
      "                        } \n",
      " \n",
      "{Date} \n",
      " \n",
      "B E T W E E N:- \n",
      " \n",
      "TERCICA, INC \n",
      " \n",
      "Claimant \n",
      " \n",
      "-and- \n",
      " \n",
      "(1) AVECIA LIMITED \n",
      " \n",
      "(2) INSMED, INC \n",
      " \n",
      "(3) GENENTECH,\n",
      "INC \n",
      " \n",
      "Defendants \n",
      " \n",
      " \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "                            (ii)\n",
      "  \n",
      "\n",
      "AND\n",
      "  \n",
      "HC 05 C 00415    \n",
      " \n",
      "B E T W E E N:- \n",
      " \n",
      "(1) AVECIA LIMITED \n",
      " \n",
      "(2) INSMED, INC \n",
      " \n",
      "Claimants \n",
      " \n",
      "-and- \n",
      " \n",
      "GENENTECH, INC \n",
      " \n",
      "1.2     Defendant \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "draft/\n",
      "CONSENT ORDER \n",
      " \n",
      " \n",
      "\n",
      " \n",
      " \n",
      "\n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL\n",
      "INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED\n",
      "AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO\n",
      "RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "UPON THE APPLICATION of the parties \n",
      " \n",
      "AND UPON reading the documents recorded in the court file as having been read \n",
      " \n",
      "IT IS BY CONSENT ORDERED THAT\n",
      "the claims and counterclaims in these proceedings be hereby discontinued and that upon the discontinuance of such claims and counterclaims there shall be no order as to costs. \n",
      " \n",
      " \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "..........................................................\n",
      "Marks & Clerk Solicitors\n",
      "Solicitors for Tercica, Inc\n",
      "90 Long Acre\n",
      "London\n",
      "WC2E 9RA\n",
      "  \n",
      "..........................................................\n",
      "Howrey LLP\n",
      "Solicitors for Insmed Incorporated and Avecia Limited\n",
      "22 Tudor Street\n",
      "London\n",
      "EC4Y 0AY\n",
      "\n",
      "\n",
      "Ref: MG/GBH/L2297\n",
      "  \n",
      "Ref: RW/CPS/04378.0002\n",
      "\n",
      "\n",
      "Date: March 2007\n",
      "  \n",
      "Date: March 2007\n",
      "\n",
      "\n",
      "..........................................................\n",
      "Wragge & Co LLP\n",
      "Solicitors for Genentech, Inc\n",
      " \n",
      "3 Waterhouse Square\n",
      "142 Holborn\n",
      "London EC1N 2SW\n",
      " \n",
      "Ref: ANC/YMA\n",
      " \n",
      "Date: March 2007\n",
      "  \n",
      "\n",
      " \n",
      " \n",
      "\n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL\n",
      "INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED\n",
      "AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO\n",
      "RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "SIGNED for and on behalf of\n",
      "  \n",
      ")                \n",
      "  \n",
      "\n",
      "TERCICA, INC\n",
      "  \n",
      ")\n",
      "  \n",
      "\n",
      "By Stephen N. Rosenfield, its\n",
      "  \n",
      ")\n",
      "  \n",
      "\n",
      "General Counsel and Executive Vice-\n",
      "  \n",
      ")\n",
      "  \n",
      "\n",
      "President of Legal Affairs\n",
      "  \n",
      ")\n",
      "  \n",
      "………………………………………..\n",
      "\n",
      "  \n",
      "\n",
      "  \n",
      "Director\n",
      "\n",
      "\n",
      "\n",
      "SIGNED for and on behalf of\n",
      "  \n",
      ")\n",
      "  \n",
      "\n",
      "GENENTECH, INC\n",
      "  \n",
      ")\n",
      "  \n",
      "\n",
      "by\n",
      "  \n",
      ")\n",
      "  \n",
      "………………………………………..\n",
      "\n",
      "  \n",
      "\n",
      "  \n",
      "Director\n",
      "\n",
      "\n",
      "\n",
      "SIGNED for and on behalf of\n",
      "  \n",
      ")\n",
      "  \n",
      "\n",
      "INSMED INCORPORATED\n",
      "  \n",
      ")\n",
      "  \n",
      "\n",
      "by\n",
      "  \n",
      ")\n",
      "  \n",
      "………………………………………..\n",
      "\n",
      "  \n",
      "\n",
      "  \n",
      "Director\n",
      "\n",
      "\n",
      "\n",
      "SIGNED for and on behalf of\n",
      "  \n",
      ")\n",
      "  \n",
      "\n",
      "AVECIA LIMITED\n",
      "  \n",
      ")\n",
      "  \n",
      "\n",
      "by\n",
      "  \n",
      ")\n",
      "  \n",
      "………………………………………..\n",
      "\n",
      "  \n",
      "\n",
      "  \n",
      "Director\n",
      "\n",
      "\n",
      "\n",
      "SIGNED for and on behalf of\n",
      "  \n",
      ")\n",
      "  \n",
      "\n",
      "AVECIA BIOLOGICS LIMITED\n",
      "  \n",
      ")\n",
      "  \n",
      "\n",
      "by\n",
      "  \n",
      ")\n",
      "  \n",
      "………………………………………..\n",
      "\n",
      "  \n",
      "\n",
      "  \n",
      "Director\n",
      " \n",
      " \n",
      "\n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL\n",
      "INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED\n",
      "AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO\n",
      "RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "EXHIBIT D \n",
      " \n",
      "JOINT LETTER TO PHYSICIANS \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL\n",
      "INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED\n",
      "AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO\n",
      "RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "  \n",
      "\n",
      " \n",
      "February 20, 2007 \n",
      " \n",
      "Dear                         , \n",
      " \n",
      "Today, Insmed, Tercica and Genentech concluded a Settlement, Development and Licensing Agreement which lays out the future development and commercialization of IPLEX. As part of the agreement, the companies settled\n",
      "the outstanding patent infringement suit filed with the Federal Court of the Northern District of California pertaining to IPLEX. As a consequence of the court’s finding of Tercica’s patents having been infringed, Insmed will no longer be\n",
      "able to provide IPLEX commercially to patients with severe primary IGF-1 deficiency and other short stature indications. It has been agreed that all patients will be transitioned off IPLEX as soon as the patient’s current supply of IPLEX is\n",
      "exhausted. \n",
      " \n",
      "Insmed and Tercica are fully committed to assisting you during this transition period. For children currently treated with IPLEX whom you\n",
      "consider suitable for INCRELEX therapy, Tercica will supply INCRELEX free of charge while working with your office to secure reimbursement. \n",
      " \n",
      "Tercica’s\n",
      "pediatric endocrinologists, Dr. George Bright and Dr. Sandra Blethen, would be pleased to discuss this transition and any medical questions you may have. You can reach them at (650) 624-4900 or 1-866-TERCICA. \n",
      " \n",
      "Best regards, \n",
      " \n",
      " \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "/s/ Ronald D. Gunn\n",
      "  \n",
      "/s/ Thorsten von Stein\n",
      "\n",
      "\n",
      "Ronald D. Gunn, M.S., M.B.A.\n",
      "Executive Vice President and\n",
      "Chief Operating Officer\n",
      "Insmed Incorporated\n",
      "  \n",
      "Thorsten von Stein, MD, PhD\n",
      "Senior Vice President and\n",
      "Chief Medical Officer\n",
      "Tercica, Inc.\n",
      " \n",
      " \n",
      "\n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL\n",
      "INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED\n",
      "AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO\n",
      "RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "EXHIBIT E \n",
      " \n",
      "CO-PROMOTION AGREEMENT TERMS AND CONDITIONS \n",
      " \n",
      "If Tercica or GNE (as the case may be) exercises its Co-Promotion Option pursuant to Section 5.3 of the Agreement, the following terms and conditions shall be\n",
      "incorporated into a definitive Co-Promotion Agreement for the co-promotion of Product for the treatment of the Permitted Indication by Insmed and the Opt-In Party. \n",
      " \n",
      " \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Provision\n",
      "  \n",
      "Details\n",
      "\n",
      "\n",
      "General:\n",
      "  \n",
      "The Opt-In Party shall the right to provide up to fifty percent (50%) of the selling effort of a Product for the treatment of such Permitted Indication.\n",
      "\n",
      "\n",
      "Oversight of Co-Promotion:\n",
      "  \n",
      "The JCC shall oversee the co-promotion effort and shall allocate all co-promotion responsibilities between the Parties in accordance with a Commercialization Plan that shall be prepared by the JCC.\n",
      "\n",
      "\n",
      "Sales Contribution by Tercica and Insmed:\n",
      "  \n",
      "TBD\n",
      "\n",
      "\n",
      "Compensation to Tercica:\n",
      "  \n",
      "TBD\n",
      "\n",
      "\n",
      "Product Sales:\n",
      "  \n",
      "The Opt-In Party shall be responsible for receiving and filling orders, controlling invoicing, collection of payments, returns, charge-backs and rebates on sales of a Product for such Permitted Indication for a Product that it markets.\n",
      " \n",
      "Insmed shall be responsible for receiving and filling orders, controlling invoicing, collection of payments, returns, charge-backs and rebates on sales of a Product for such Permitted Indication for a Product that it markets.\n",
      " \n",
      "Insmed shall have sole control over pricing strategies and distribution of a Product for such Permitted Indication.\n",
      "\n",
      "\n",
      "Use and Distribution of Promotional Materials:\n",
      "  \n",
      "Insmed shall have responsibility for preparing and producing all Promotional Materials for a Product for such Permitted Indication, provided, however, that the JCC shall approve all such Promotional Materials to ensure consistency across the entire field of effort of both Parties.\n",
      " \n",
      "Insmed shall provide such JCC-approved Promotional Materials to Tercica in accordance with the Commercialization Plan. Each Party’s sales force shall use, and if applicable, distribute Promotional Materials to physicians to whom it details a Product. Promotional\n",
      " \n",
      " \n",
      "\n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL\n",
      "INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED\n",
      "AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO\n",
      "RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Provision\n",
      "  \n",
      "Details\n",
      "\n",
      "\n",
      "\n",
      "  \n",
      "Materials shall not be used unless approved by the JCC.\n",
      " \n",
      "The Parties shall share equally the cost of developing and producing such Promotional Materials.\n",
      "\n",
      "\n",
      "Samples:\n",
      "  \n",
      "The Parties shall use and distribute any samples of a Product in accordance with the Commercialization Plan and all applicable laws.\n",
      "\n",
      "\n",
      "Sales Force Training:\n",
      "  \n",
      "Insmed shall develop and provide training programs and materials for a Product for such Permitted Indication to ensure a consistent, focused promotional strategy. Insmed shall treat the Opt-In Party and Insmed sales representatives as a combined sales force and shall provide the Opt-In Party representatives with the same support and assistance it provides its own representatives. The Opt-In Party shall reimburse Insmed for all training, support and assistance it shall provide for such Opt-In Party’s representatives.\n",
      "\n",
      "\n",
      "Termination:\n",
      "  \n",
      "The Opt-In Party may terminate its co-promotion of a Product for the treatment of the Permitted Indication upon not less than one hundred eighty (180) days prior written notice to Insmed. Insmed and the Opt-In Party shall reasonably cooperate to transition to Insmed the Opt-In Party’s co-promotion activities with respect to a Product so as to minimize disruption to sales activity and the Opt-In Party shall withdraw its sales representatives from such co-promotion activities in a professional manner.\n",
      "\n",
      "\n",
      "Compliance and Performance:\n",
      "  \n",
      "Each Party shall be responsible for its own compliance with all applicable laws and Regulatory Authority policies and guidelines relating to the co-promotion of a Product for the treatment of the Permitted Indication. Each Party’s sales representatives shall be held to the same standards of performance. The Co-Promotion Agreement shall include an audit provision for purposes of measuring each Party’s sales force effectiveness and performance.\n",
      "\n",
      "\n",
      "Regulatory:\n",
      "  \n",
      "Insmed shall be solely responsible for communicating with the applicable regulatory authorities, including any adverse event reporting, recall notifications and safety updates. The Opt-In Party shall reasonably cooperate with Insmed regarding co-promotion activities so that Insmed can meet its regulatory obligations.\n",
      " \n",
      " \n",
      "\n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL\n",
      "INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED\n",
      "AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO\n",
      "RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "EXHIBIT F \n",
      " \n",
      "JOINT PRESS RELEASE \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL\n",
      "INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED\n",
      "AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO\n",
      "RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Tercica Logo\n",
      "  \n",
      "INSM Logo\n",
      " \n",
      "Investor & Media Contacts for Tercica and Insmed: \n",
      " \n",
      "Litigation Settlement Reached between Tercica, Genentech and Insmed \n",
      " \n",
      "Companies Partner through License and Development Agreement \n",
      " \n",
      "Brisbane, California and Richmond, Virginia. –\n",
      "March 6, 2007 – Tercica, Inc., (Nasdaq: TRCA) and Insmed Incorporated (Nasdaq: INSM) today announced that Tercica, Insmed and Genentech, Inc. (NYSE: DNA) have entered a Settlement, License and Development Agreement that resolves all\n",
      "outstanding litigation between the companies, including the patent infringement suits brought by Tercica and Genentech against Insmed in the United States (N.D. Cal.) and United Kingdom, and the unfair business practices suit (E.D. Virginia). The\n",
      "key elements of this settlement are: \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "•\n",
      " \n",
      "Insmed will no longer provide IPLEX to patients with severe Primary IGF-1 Deficiency and other short stature indications and will withdraw its IPLEX marketing authorization application for severe Primary IGF-1 Deficiency in the European Union\n",
      " \n",
      " \n",
      "\n",
      " \n",
      "•\n",
      " \n",
      "Through licensing and development rights granted by Tercica and Genentech, Insmed will have freedom to operate regarding the manufacture, development and commercialization of IPLEX for certain non short stature indications including severe insulin resistance, myotonic muscular dystrophy and HIV associated adipose redistribution syndrome (HARS), subject to opt-in rights and royalty provisions for Tercica and Genentech\n",
      " \n",
      " \n",
      "\n",
      " \n",
      "•\n",
      " \n",
      "Tercica and Genentech have waived the damages award by the jury in the U.S. patent infringement litigation.\n",
      " \n",
      "In a joint statement, Dr. John A. Scarlett, Tercica’s President and Chief Executive Officer, and Dr. Geoffrey Allan, Insmed’s President,\n",
      "Chief Executive Officer and Chairman of the Board of Directors stated, “We are very pleased with our new licensing and development relationship. It allows Tercica to focus its efforts in the short stature market and allows Insmed, in\n",
      "cooperation with Tercica and \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL\n",
      "INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED\n",
      "AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO\n",
      "RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "Genentech, to focus its IPLEX development efforts in valuable non-short stature indications.” \n",
      " \n",
      "U.S./Canada IPLEX Sales for Tercica/Genentech Indications \n",
      " \n",
      "As a\n",
      "consequence of the court’s finding that Tercica’s patents were infringed, Insmed will no longer be able to provide IPLEX in the U.S. for severe Primary IGF-1 Deficiency and the following indications: Primary IGF-1 Deficiency, Noonan’s\n",
      "Syndrome, Laron Syndrome, Growth Hormone Deficiency, and all other short stature indications; and Adult Growth Hormone Deficiency. These indications are collectively referred to as “the TRCA/Genentech Indications.” Insmed and Tercica will\n",
      "work closely together with pediatric endocrinologists to identify therapeutic alternatives for children currently receiving IPLEX, and where appropriate, to transition patients to Increlex. \n",
      " \n",
      "IPLEX Worldwide License and Development Agreement \n",
      " \n",
      "The parties will\n",
      "form a joint development (and subsequently, a joint commercialization) committee to guide the development and commercialization of IPLEX in non-Tercica/Genentech Indications. Tercica (along with Ipsen, for Ipsen’s Increlex territory) and\n",
      "Genentech will have the right to opt into Insmed’s development and commercialization of each non-Tercica/Genentech Indication up to 90 days after Insmed provides “Phase III-enabling” clinical data. Tercica will have the first right to\n",
      "opt into orphan indications, and Genentech will have the first right to opt into non-orphan indications. If Tercica does not opt into an orphan indication, Genentech will have the right to opt-in. Similarly, if Genentech does not opt into a\n",
      "non-orphan indication, Tercica will have the right to opt-in. In the case of an opt-in, Insmed will retain development control prior to approval, and Tercica or Genentech would gain commercial control after approval. \n",
      " \n",
      "If the opt-in is exercised by Tercica, Insmed would be reimbursed 50% of its incurred development costs for the indication and further development costs would be shared\n",
      "50:50. Upon subsequent commercialization, Insmed and Tercica will split \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL\n",
      "INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED\n",
      "AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO\n",
      "RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "profits 50:50 after accounting for relevant expenses including sales-based tiered royalties of 6%-15% to Genentech. \n",
      " \n",
      "If the opt-in is exercised by Genentech, Insmed would be reimbursed 50% of its incurred development costs for the indication. Subsequent development costs and profits\n",
      "will be split 50:50, but no royalty will be owed to Tercica. \n",
      " \n",
      "If neither Tercica nor Genentech opts in, Insmed will pay a 4% royalty on all commercial\n",
      "sales of the approved drug to Genentech. \n",
      " \n",
      "Worldwide pre-Approval IPLEX Sales \n",
      " \n",
      "Outside the U.S. and Canada, Insmed will be permitted to continue to provide IPLEX to physicians through its Expanded Access Program for non Tercica/Genentech indications (excluding severe insulin resistance) and ALS\n",
      "in Italy. Any cost reimbursement obtained from this program would be subject to a tiered royalty of 4% to 15% shared between Tercica, Genentech and Ipsen. \n",
      " \n",
      "The Settlement, License and Development Agreement is in effect until the later of 2018 or the expiration of any subsequent Tercica/Genentech issued patents that cover IPLEX or its indications. \n",
      " \n",
      "About Tercica \n",
      " \n",
      "Tercica is a biopharmaceutical company\n",
      "committed to improving endocrine health by partnering with the endocrine community to develop and commercialize new therapeutics for short stature and other metabolic disorders. For further information on Tercica, please visit www.tercica.com.\n",
      " \n",
      "Tercica Safe Harbor Statement \n",
      " \n",
      "Except for the\n",
      "historical statements contained herein, this press release contains forward-looking statements concerning prospects and results, including statements concerning a worldwide partnership with opt-in rights for Tercica on non-Tercica/Genentech\n",
      "Indications and settlement of all outstanding litigation between Tercica, Genentech and Insmed. Because Tercica’s forward-looking statements are subject to risks and uncertainties, there are important factors that could cause actual results to\n",
      "differ materially from those in the forward-looking statements. \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL\n",
      "INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED\n",
      "AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO\n",
      "RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "These factors include, without limitation, the risk that none of the non-Tercica/Genentech Indications demonstrate\n",
      "clinically meaningful efficacy and safety, and the risks and uncertainties disclosed from time to time in reports filed by Tercica with the SEC, including most recently Tercica’s Form 10-Q for the quarter ended September 30, 2006 filed\n",
      "with the SEC on November 3, 2006 \n",
      " \n",
      " \n",
      "\n",
      " \n",
      "[  *  ] = CERTAIN CONFIDENTIAL\n",
      "INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED\n",
      "AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO\n",
      "RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Bottom of Form\n",
      "© Copyright 2000 - 2016 RoyaltyStat.\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "file_path = '/home/kprasath/DS/NLPInternship/txt_data/ref_1_txt/11206.txt' # Replace with the actual path to your TXT file\n",
    "text = read_txt(file_path)\n",
    "print(text)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.9"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
